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 Processes for the synthesis of seven-membered N-heterocycles, involving intramolecular 
nucleophilic addition to rhodacyclopentanones have been developed. Initially, a (6+1) carbonylative 
cyclisation of cyclopropylureas, discovered by Dr. McCreanor at Bristol, was optimised and its scope 
examined. Mechanistic studies were carried out to explain unexpected aspects of this reaction. 
Subsequently, investigations were directed towards the discovery of other processes involving 
nucleophilic addition to rhodacyclopentanones, which resulted in the identification of a (6+1) 
carbonylative cyclisation of cyclopropylmethylamides to form azepanes.  
 Later, studies were directed towards the asymmetric total synthesis of (R)-otonecine and related 
pyrrolizidine alkaloids. This built upon the (7+1) carbonylative cycloaddition of 
cyclopropylacrylamides to form azocanes, developed at Bristol. Further optimisation of the (7+1) 
reaction conditions identified several beneficial amide and carboxylic acid additives, and an improved 
reaction set-up, which allowed the cycloaddition of a challenging silylmethylcyclopropane-based 
substrate. Investigations into the four proposed post-cycloaddition transformations identified suitable 
conditions for three of these. A Rubottom oxidation and Tamao-Fleming oxidation installed the C7- 
and C9-alcohols of otonecine. The C2 to C1 alkene isomerisation was achieved under kinetic conditions 
using newly developed conditions for the hydrobromination of enelactams. The penultimate lactam 
reduction step failed under various chemoselective conditions.  
 In parallel studies, a short, asymmetric and diastereodivergent synthesis of the C10 dicarboxylic 
necic acids was designed. Unoptimised conditions for the asymmetric crotylation of a pyruvate ester 
formed the C12,C13-vicinal stereocentres of the necic acid targets. Finally, model studies into a sp2-sp3 
Negishi cross-coupling suggest that this transformation might be applicable to the proposed synthesis. 
Realisation of the asymmetric total synthesis of (R)-otonecine and the C10 dicarboxylic necic acids pave 
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Chapter 1 – Introduction 
1.1 Tackling the declining rate of drug discovery 
Since the 1990s, the pharmaceutical industry has suffered a steady decline in productivity as 
measured by the number of novel drugs released onto the market each year.1-3 This observation is starkly 
illustrated by the fact that in the period from 2010 to 2017, greater than 93% of drug candidates entering 
Phase 1 clinical trials failed to reach the market.4 The remarkable inefficiency of the drug discovery 
process has forced pharmaceutical companies to adopt cost saving measures, which are not conducive 
to developing treatments for many diseases.1 For example, less money is being reinvested into basic 
(but high risk) research and development, which is necessary to address so far untreatable diseases. 
Instead, research focus is gradually shifting towards low risk therapeutic areas, for which effective 
treatments may already exist. Furthermore, the need to recoup costs, which were lost to failed drug 
candidates, is a factor in rising drug prices. 
The underlying causes of declining drug approval rates have been studied. In the 1990s, 
approximately 40% of failures were due to compounds having poor pharmacokinetic properties and 
bioavailability, which was in part a result of the adoption of high-throughput screening (HTS) methods 
in the early stages of the drug discovery process.1 The compound libraries employed in these HTS 
efforts were heavily skewed towards sp2-rich compounds as a result of the explosive development and 
uptake of transition metal-catalysed cross-coupling methodologies, such as the Suzuki coupling.5 In 
response, several new compound metrics (e.g. MW, clogP, Lipinski’s rule of 5) were introduced to help 
measure the drug-likeness of a molecule.6-9 These metrics were successful in improving the physical 
properties of drug libraries, but did not result in an increase in drug approvals. Instead, toxicity became 
the number one reason why drug candidates failed in clinical trials.10 Modern drug discovery 
programmes now put a large emphasis on investigating the toxicity of compounds prior to their 
introduction into the clinic, but the causes of toxicity are poorly understood.11 
In 2008, Lovering and co-workers introduced fractional sp3 character (Fsp3, the fraction of sp3 
carbons out of the total number of carbon atoms in a molecule) as a measure of a molecule’s degree of 
saturation, which is related to the “chirality” of that molecule.12 The authors observed that the average 
Fsp3 character of clinical candidates increased at each stage of the drug discovery process (31% increase 
from preclinical to market) indicating that sp3-rich molecules were more successful in the clinic. In 
2013, Lovering furthered this analysis of small molecules in clinical trials, and concluded that 
compounds with greater Fsp3 values were less likely to cause off-target toxicity.13 It was concluded 
from these two studies that compounds with greater Fsp3 values (and therefore more stereocentres) are 
better suited to binding to the 3-dimensional binding sites of their biological target, resulting in a high 




binding affinity. Furthermore, these molecules are innately more specific to a single binding site, which 
reduces the chances that they will exhibit off-target toxicity.  
In order to increase the average Fsp3 value of molecules produced by medicinal chemists, it is 
desirable to develop new catalytic methodologies that are as appealing to medicinal chemists as, for 
example, the Suzuki reaction.5, 14 The success of Pd(0)-catalysed cross couplings is partly due to the 
accessibility and utility of Pd(II)-intermediates  (Scheme 1). These can be reliably generated by 
oxidative addition of a Pd(0)-catalyst to readily available aryl (or alkenyl) (pseudo)halides. The 
resulting Pd(II)-intermediate can be directed to several different catalytic steps giving access to many 
product types. Therefore, one way of improving the average Fsp3 value of drug libraries would be to 
develop analogous sp3-rich organometallic intermediates, which are as easy to access and as versatile 
as Pd(II)-intermediates. Towards this end, several research groups have developed catalytic 
methodologies that exploit oxidative addition to highly strained C-C bonds of small rings (cyclopropane 
or cyclobutane derivatives) to generate sp3-rich intermediates, which can then be converted to sp3-rich 
products. In particular, oxidative addition of transition metals to C-C bonds of small rings initially forms 
cyclic intermediates, which are particularly suited to the synthesis of (hetero)cyclic molecules. Research 
at Bristol has contributed to this field with the development of a directing-group strategy for the 
formation of rhodacyclopentanones from cyclopropane derivatives (see Section 1.3). 
Rhodacyclopentanones formed in this way have been shown to be useful for the synthesis of complex 
sp3-rich heterocyclic structures. 
 
Scheme 1: Comparison of a Pd(II)-intermediate with strained ring-derived organometallics. 
The following sections will introduce the field of transition metal-catalysed C-C oxidative 
addition to strained small rings, and how this basic step has been incorporated into the synthesis of 
sp3-rich products. The discussion will focus on recent developments (from mid-2009 to mid-2019) in 
order to present the state of the art, but seminal contributions from before this time period will be 
included where informative. Transition metal-catalysed C-C cleavage of small rings can also be 
achieved via redox neutral -carbon elimination processes, but these will not be discussed here because 




they are not pertinent to the research contained within this dissertation. This area has been reviewed 
recently.15 In Section 1.3, a strategy for directed C-C oxidative addition to cyclopropanes, developed at 
Bristol, is described. Finally, the aims of the research project will be presented.  
1.2 Oxidative addition of transition metals to strained C-C bonds 
Aspects of this Chapter have been adapted from a review article. 
(Fumagalli, G.; Stanton, S.; Bower, J. F. Chem. Rev. 2017, 117, 9404) 
 Oxidative addition of transition metals to strained C-C bonds (herein also termed as 
“transition-metal”-addition) is an established process.16-17 Cyclopropanes are particularly suited to C-C 
oxidative addition by transition metals because of two main reasons. Firstly, C-C oxidative insertion is 
promoted by the release of ring strain, which acts as a thermodynamic and kinetic driving force.18 
Secondly, the HOMO and LUMO orbitals of cyclopropanes (and to a lesser extent cyclobutanes) have 
significant p-character, which makes them suited to bonding with transition metal HOMOs and LUMOs 
(Figure 1A).18 The p-orbital character is a result of the narrow bond angles within the cyclopropane ring 
causing the C-C bonds to be twisted out of linearity giving them the appearance of “banana bonds”. 
The first example of C-C oxidative addition to a cyclopropane was achieved in 1955 by Tipper and 
Lawrence who reported the oxidative addition of PtCl2 to cyclopropane to form a platinacyclobutane.19-
20 Since then, several categories of strained, small rings have been employed in C-C oxidative addition-
based methodologies (Figure 1B). Cyclopropenes (approximate strain energies of 55 kcal/mol)21-22 and 
alkylidenecyclopropanes (approximate strain energies of 39 kcal/mol)21 possess the greatest ring strain 
of the three-membered rings as they contain sp2-hybridised ring carbons, and therefore readily undergo 
C-C oxidative addition by transition metals. Less strained cyclopropanes, such as vinyl cyclopropanes, 
and cyclopropyl ketones and their derivatives, have also proved viable. C-C oxidative addition to less 
Figure 1 




activated cyclopropanes (approximate strain energies of 28 kcal/mol)22 is more challenging, but 
strategies have emerged in the recent decades. Four-membered rings are challenging in this context 
because these are typically less strained than three-membered rings,22 but strained cyclobutane 
analogues possessing sp2-hybridised ring atoms, such as biphenylenes and cyclobutanones, have found 
use in a number of contexts.  
1.2.1 Cyclopropane-based processes 
1.2.1.1 Cyclopropenes 
 Cyclopropenes are among the most strained (approximate strain energy 55 kcal/mol) of the 
cyclopropane-based systems and are therefore highly susceptible to C-C activation by transition-
metals.21 However, few examples of cyclopropene-based methodologies exist, perhaps due to the lack 
of methods for the synthesis of cyclopropenes. Wang and co-workers have published Rh(I)-catalysed 
methodologies based on C-C addition to cyclopropenes.23 One example, published in 2010, describes a 
Rh(I)-catalysed carbonylative (3+1+2) cycloaddition of cyclopropenes 1, which forms 5,6-
heterobicycles (e.g. 2 and 3) (Scheme 2A).24 The transformation is initiated by oxidative addition to the 
C-C single bond of the cyclopropene, followed by migratory insertion of carbon monoxide (CO) to 
form rhodacyclopentenones 4. Migratory insertion of the tethered -unsaturate and C-C reductive 
elimination forms the products. Carbon monoxide has been incorporated as a one-carbon component in 
many related C-C activation-based methodologies described herein. More recently, Li and co-workers 
demonstrated that rhodacyclopentenones (cf. 4) could also undergo reductive elimination to form 
cyclobutenones (e.g. 5a and 5b) (Scheme 2B).25 These examples show how organometallic 
intermediates can be redirected to different mechanistic pathways resulting in the synthesis of 
structurally diverse products.  
 
Scheme 2 





 Alkylidenecyclopropanes (ACPs) are another class of highly strained (approximate strain 
energy 39 kcal/mol) cyclopropane-based system, which undergo facile C-C oxidative addition by 
transition metals.21 Metal addition can occur to either the distal (bond “d”) or proximal (bond “p”) C-C 
bond leading to regioisomeric metallacyclobutanes 6 or 8, respectively (Scheme 3A). 
Metallacyclobutane 6, resulting from addition to the distal C-C bond, undergoes allylic rearrangement 
to form the more stable isomer 7. Both 6 and 8 have been implicated in processes described herein. The 
regioselectivity of C-C oxidative addition to ACPs is influenced by the transition metal and by other 
factors such as the ligand. As a result, distinct product scaffolds can be accessed from ACP-based 
substrates depending on the catalyst system employed. 
The Mascareñas group have developed a suite of ACP-based methodologies, which 
demonstrate how a single organometallic intermediate (see 12a) can give rise to multiple product 
scaffolds by controlling the subsequent catalytic steps. In 2003, a protocol for the Pd(0)-catalysed (3+2) 
cycloaddition of ACPs 9 to form 5,5-bicycles (e.g. 10a and 10b) was published (Scheme 3B).26 
Computational studies support the proposed mechanism, which involves initial Pd(0)-addition to the 
distal C-C bond of ACPs 9 and rearrangement to give isomer 11.27 Carbopalladation of the tethered 
alkyne forms six-membered palladacycle 12a, from which reductive elimination affords the observed 
products. It has since been shown that palladacycle 12a can be generated enantioselectively by using a 
chiral phosphoramidite ligand.28 Several further developments were reported,29-30 including the use of 
Scheme 3 Sch me 3 




substrates bearing tethered alkenes,31 allenes32 and 1,3-dienes,33 each of which resulted in the formation 
of a different product scaffold.  
Mascareñas and co-workers later demonstrated that six-membered palladacycle 12b (cf. 12a) 
could be redirected to undergo further complexity generating steps instead of C-C reductive elimination. 
For example, ACPs 13, bearing two tethered -unsaturates, underwent (3+2+2) cycloaddition when 
treated with a phosphine-ligated Pd(0)-catalyst to form 5,7,5-tricycles (e.g. 14a and 14b) (Scheme 4).34 
Here, palladacycle 12b undergoes carbopalladation of the tethered alkene (instead of C-C reductive 
elimination) to form eight-membered intermediate 15. Reductive elimination then provided the 
observed 5,7,5-tricycles. The Pd(0)-catalysed conditions suffered from competing formation of (3+2) 
side-products (via reductive elimination from 12b); this prompted the development of Rh(I)-catalysed 
conditions, which completely favoured the formation of the (3+2+2) cycloaddition products.35-36 
 
Scheme 4: Pd(0)-catalysed (3+2+2) cycloaddition of ACPs. 
 In 2008, Evans and Inglesby published a Rh(I)-catalysed intermolecular (3+2+2) cycloaddition 
of ACPs 16 with external electron-deficient alkynes to form 5,7-bicycles (e.g. 17a and 17b) (Scheme 
5).37 In this case, the Rh(I)-catalyst inserts into the distal C-C bond of ACP 16 to form rhodacyclobutane 
18, which rearranges to 19. Next, an undetermined order of consecutive carbometallations of the alkene 
and alkyne (the regiodetermining step) is followed by reductive elimination to give the observed 
products with moderate to good levels of regioselectivity (4:1 to >19:1 r.r.). Later, trialkoxysilane-
substituted alkenes were identified as efficient substrates in this transformation,38 and the methodology 
was incorporated into a three step total synthesis of the sesquiterpene, pyrovellerolactone.39 
In the absence of an external alkyne, ACPs can undergo (3+2) ene-cycloadditions to form 
substituted pyrrolidines. This transformation was demonstrated by the Evans group in the total synthesis 
of (-)--kainic acid (Scheme 6).40 Treatment of ACP 20 (prepared in three steps from serine) with a 
phosphite-ligated Rh(I)-catalyst afforded pyrrolidine 21 in 69% yield and as a single diastereomer via 
a (3+2) ene-cycloaddition. The mechanism of the Rh(I)-catalysed (3+2) ene-cycloaddition begins with 
the formation of rhodacyclobutane 22, which carbometallates the alkene. The resulting rhodacycle 23 




undergoes -hydride elimination from the exocyclic position followed by C-H reductive elimination to 
afford pyrrolidine 21. This was advanced to (-)--kainic acid in four steps. More recently, Evans and 
co-workers demonstrated that rhodacycles related to 23, containing -sulfide moieties, undergo 
competitive -sulfide elimination to provide allylsulfur-substituted five-membered rings.41 
 
Scheme 6: Rh(I)-catalysed (3+2) cycloaddition of ACP 20 in the total synthesis of (-)--kainic acid. 
 Evans and co-workers have also shown that carbon monoxide can serve as a single-carbon 
component in Rh(I)-catalysed (3+1+2) cycloadditions of ACPs 24 to form 5,6-heterocycles (e.g. 25a 
and 25b) (Scheme 7A).42 Computational studies suggest that the initially formed rhodacyclobutane 26 
isomerises via trimethelenemethane complex 27 to form Rh(III)-allyl species 28. Note that Ni-
analogues of trimethelenemethane complex 27 have been ruled out as intermediates in related 
transformations.43-44 Rh(III)-allyl species 28 undergoes carbonylation and reductive elimination to 
afford the observed products. In the presence of a chiral P,N-ligand, good levels of enantioselectivity 
Scheme 5: Rh(I)-catalysed (3+2+2) cycloaddition of ACPs wtith external alkynes 




(e.g. 89% e.e. for 29) were achieved (Scheme 7B). Kim and Chung disclosed a related procedure in 
which tethered alkynes are used to make phenols.45 Further investigations into the mechanism of 
(3+1+2) cycloadditions of ACPs resulted in the isolation of a neutral Rh(III)-complex, related to 
trimethelenemethane 27, which proved to be catalytically competent.46 Ultimately this led to the 
development of (3+2+2) cycloadditions of ACPs 30 with external allenes to form 5,7-bicycles 
containing tri- and tetrasubstituted alkenes (e.g. 31a and 31b) (Scheme 7C).47 Additionally, by 
increasing the alkyne tether length, 6,7-heterocycles could be accessed using this methodology.  
 
Scheme 7 
It has been known since the 1970s that Ni(0)-catalysts tend to undergo oxidative addition to the 
proximal C-C bonds of ACPs, which is in contrast to the Rh(I)- and Pd(0)-catalysed reactions discussed 
so far.43-44 Consequently, ACP-based substrates can afford different product scaffolds depending on the 
catalytic system employed. Mascareñas and co-workers demonstrated this effect in a Ni(0)-catalysed 
(3+2+2) cycloaddition of ACPs 32 with external alkenes to form 6,7-bicycles 33a/b (Scheme 8A).48 
Computational studies indicate that Ni(0)-addition to the proximal C-C bond of ACPs 32 is directed by 
the tethered alkyne. The resulting nickelacycle 34 undergoes consecutive alkyne and alkene 




carbometallation to provide intermediate 35a. Reductive elimination from 35 affords 6,7-bicyclic 
products. Subsequent reports have expanded on the synthetic utility of nickelacycles related to 35a.49 
Included in these reports is an example by Zhang and co-workers whereby reductive elimination from 
nickelacycle 35b provides aryl-fused products 37 (Scheme 8B).50   
 
Scheme 8 
 Subtle changes to the catalytic system have been found to influence the regioselectivity of 
Ni(0)-addition to ACPs. For example, Kambe, Terao and co-workers reported that a phosphine-ligated 
Ni(0)-catalyst inserts into the proximal C-C bond of simple ACPs 38a, which, in the presence of aryl 
Grignard reagents, leads to the formation of -substituted styrenes (e.g. 39a and 39b) (Scheme 9A). In 
contrast, NiCl2-based conditions (i.e. in the absence of a phosphine ligand) initiate by Ni(0)-addition to 
the distal C-C bond of simple ACPs 38b resulting in the formation of 1,4-dienes (e.g. 40a and 40b)  
when coupled with vinyl Grignard reagents (Scheme 9B). Both transformations involve Ni-Mg 
transmetallation of the corresponding nickelacyclobutane (41 or 43) to form bimetallic intermediates 
(42 or 44). Reductive elimination from the Ni(II)-moiety affords a Grignard reagent, which is quenched 
by the addition of an electrophile. More recently, intermolecular hydroamidation of ACPs has been 
reported51 in which a Pd(0)-catalyst inserts into the distal C-C bond.52  







 Saturated cyclopropanes are less strained than the cyclopropenes or alkylidenecyclopropanes 
discussed so far, and are therefore less reactive towards oxidative addition by transition metals.21 
However, adjacent unsaturation, as is present in vinylcyclopropanes (VCPs), serves to activate the 
cyclopropane to C-C oxidative addition. Seminal studies by Wender and co-workers introduced VCPs 
as five-carbon components in Rh(I)-catalysed (5+2) cycloadditions, and this strategy has resulted in the 
development of a suite of synthetic methods.53-55 A general mechanism for the reaction between VCPs 
and Rh(I)-catalysts is depicted in Scheme 10A. Initially, Rh(I)-coordination to the -bond of the VCP 
triggers oxidative addition to the cyclopropane, forming Rh(III)-allyl intermediates 46. These 
intermediates can act as either a five-carbon component (i.e. via species 45) or a three-carbon 
component (i.e. via species 47) in subsequent processes.  
 Wender and co-workers introduced alkoxy-substituted VCP 48 as a five-carbon component in 
(5+2) cycloadditions (Scheme 10B). Upon cyclisation, the alkoxy-substituent of VCP 48 is incorporated 
as an enol ether moiety, which can then be hydrolysed to unveil a ketone.56-59 For example, under Rh(I)-
catalysis, VCP 48 can undergo a (5+2) cycloaddition with electron-deficient alkynes to form seven-
membered divinylketones (e.g. 51) upon hydrolysis of the initially formed enol ether (not shown).60 
Divinylketones of this type are primed for Lewis-acid promoted Nazarov cyclisations to form 5,7-




carbocycles (e.g. 52a and 52b). The mechanism of the (5+2) cycloaddition of VCP 48 and external 
alkynes 49 is proposed to begin with the formation of Rh(III)-allyl species 50. This carbometallates the 
external alkyne, and subsequent reductive elimination forms the seven-membered ring. The mechanism 
has since been studied by computational methods,61 and a Rh(III)-allyl complex analogous to 50 has 
been isolated and characterised by X-ray crystallography.62 
 
Scheme 10 
 A key breakthrough in the application of VCPs in C-C activation methodologies was the 
discovery of superior cationic Rh(I)-catalysts, which allowed related transformations to proceed at 




room temperature.63-64 This ultimately led to the development of cationic Rh(I)-catalyst 53, which is a 
highly efficient catalyst for a variety of VCP-based protocols including the (5+2) cycloaddition of VCP 
48 with non-polarised alkynes (Scheme 10C).65-66 Further contributions from Wender and co-workers 
include the application of propargylsilanes as two-carbon components in (5+2) cycloadditions. Here, 
cyclic allylsilanes are formed and these can undergo further complexity generating transformations.67 
For example, (5+2) cycloaddition of VCP 48 with propargylsilane 54 (bearing an additional propargylic 
alcohol) provided allylsilane 55 (Scheme 10D).68 This then underwent an acid-mediated vinylogous-
Petersen elimination to afford dienes 56, which took part in a (Rh-catalysed or thermal) Diels-Alder 
cycloaddition with an added dienophile providing cycloadducts (e.g. 57a and 57b).  
Yu and co-workers have utilised VCPs as three-carbon components in cycloaddition reactions. 
For example, Rh(I)-catalysed (3+2) cycloaddition of VCPs 58, bearing tethered alkenes, afforded 5,6- 
and 5,7-heterocycles (e.g. 59a and 59b) (Scheme 11A).69 Here, Rh(I)-addition to VCP 58 forms Rh(III)-
allyl intermediate 60 in an identical manner to the previous methodologies. However, subsequent 
intramolecular carbometallation proceeds such that only the cyclopropane carbons are incorporated into 
the newly formed cyclopentane ring. Potential (5+2) cycloaddition products were not observed. 1,1-
Disubstituted VCPs 61 undergo a similar enantioselective (3+2) cycloaddition when treated with a 
cationic (R)-H8-BINAP-ligated Rh(I)-catalyst thus affording 5,5-heterobicycles 62a/b (Scheme 11B).70 
Computational studies suggest that rhodacycle 63 is formed reversibly prior to the enantiodetermining 
alkyne carbometallation step. Similar non-enantioselective processes employing tethered alkenes and 
allenes have been reported.71 
 
Scheme 11 




The Yu group have also reported Rh(I)-catalysed carbonylative (3+1+2) cycloadditions of 
VCPs 64 to form 5,6- and 6,6-heterobicycles (e.g. 65a and 65b), where CO presumably inserts into a 
Rh(III)-allyl species (see 63 above) prior to carbometallation of the -unsaturate (Scheme 12A).71 
Interestingly, subtle variation of the reaction solvent (i.e. 1,2-DCE instead of PhMe) and CO partial 
pressure resulted in a second equivalent of CO being incorporated into fused-tricycles 66a/b (Scheme 
12B).72 Here, it is proposed that the vinyl moiety and CO inserts into rhodacycle 67 (instead of reductive 
elimination directly from 67) to form rhodacycle 68 from which reductive elimination provides the 
observed tricyclic products. Yu and co-workers have also published protocols whereby the VCP serves 
as a five-carbon component,73 which culminated in a carbonylative (5+2+1) cycloaddition applied to 
the total synthesis of hirsutic acid.74 
 
Scheme 12 
 Tang and co-workers have shown that allenylcyclopropanes (formed in-situ from 
propargylcyclopropanes 69) can take part in C-C activation-based processes to form cyclohexenones 
70a/b (Scheme 13).75 The transformation is initiated by the Rh(I)-mediated rearrangement of 
propargylcyclopropanes 69 to allenylcyclopropane 71. Rh(I)-addition gives rhodacycle 72 from which 
carbonylation and reductive elimination give the observed products. Notably, the scope of this 
methodology extends to both cis- and trans-1,2-disubstituted cyclopropanes both of which proceed by 
cleavage of the less-substituted C-C bond of the cyclopropane. Another carbonylative cyclisation of 
allenylcyclopropanes has been applied to the formal synthesis of (-)-galanthamine.76  





Scheme 13: Rh(I)-catalysed carbonylative (5+1) cyclisation of in-situ generated allenylcyclopropanes. 
Recently, Wang and co-workers reported that Rh(I)-carbenes add to the distal C-C bond of 
siloxy-VCPs, which serves as a novel mode of C-C activation for this class of cyclopropane. As a result, 
highly substituted skipped dienes (e.g. 74a and 74b) could be accessed by the reaction of siloxy-VCPs 
73 with Rh(I)-carbenes (Scheme 14). The transformation is proposed to begin with the formation of a 
Rh(I)-carbene which was shown to undergo oxidative addition to the distal C-C bond of VCPs 73 
resulting in Rh(III)-intermediate 75. 1,2-Migration into rhodacycle 75 is followed by -hydride 
elimination and C-H reductive elimination in the formation of the observed products. The mechanism 
of the transformation was corroborated by stoichiometric and computational experiments.77 
 
Scheme 14: C-C oxidative addition of a Rh(I)-carbene to siloxy-VCPs. 
 Donor-acceptor vinylcyclopropanes, where the cyclopropane is substituted by electron-
withdrawing moieties, undergo SN2-like oxidative addition by transition-metals (Scheme 15A). This 
forms acyclic intermediates 76, which possess both an electrophilic metal-allyl moiety and a 
nucleophilic stabilised carbanion. The allyl-moiety of intermediates 76 can undergo reaction with 
nucleophiles (e.g. Grignard reagents), or polarised -unsaturates (e.g. ketones, imines). Various Pd-, 
Fe- and Ni-catalysed examples of this process have been reported.78-84 Matsubara and co-workers 
described a Ni(0)-catalysed (3+2) cycloaddition of donor-acceptor VCPs 77 with imines to form 




pyrrolidines, which proceeded by a slightly different mechanism (Scheme 15B).85 In this case, Ni(0)-
addition is proposed to form Ni(II)-allyl complex 78 (instead of analogous acyclic intermediates 76), 
which engaged imines to form pyrrolidines. 
 Krische and co-workers reported that, under Ir(I)-catalysed transfer hydrogenation conditions, 
donor-acceptor VCPs form nucleophilic -allyl complexes 80 (Scheme 15C).86 This polarity inversion 
of VCPs was demonstrated by the coupling of VCPs 79 with added or in-situ generated aldehydes to 
form homoallylic alcohols with high levels of diastereo- and enantiocontrol (91–98% e.e.). The 
reductant in this process is provided by the Ir(I)-mediated dehydrogenation of an alcohol, which 
generates a suitable aldehyde coupling partner in the transfer hydrogenation process. This strategy has 









1.2.1.4 Cyclopropyl ketone and imines 
 C-C oxidative addition to cyclopropanes with adjacent polarised unsaturation (e.g. cyclopropyl 
ketones and imines) is less well developed than for VCPs because electron-deficient cyclopropanes are 
less activated to metal addition. Nevertheless, several examples of C-C activation processes involving 
cyclopropyl ketones (or imines) are known, and these typically proceed by a similar mechanism to 
vinylcyclopropanes (see Scheme 10, A). This class of substrate is appealing in the context of C-C 
activation because substituted-analogues are often synthetically accessible in enantioenriched form. 
Liu, Montgomery and co-workers;89-90 and Ogoshi and co-workers91-93 have shown that under 
Ni(0)-catalysis, cyclopropyl ketones or imines can incorporate alkenes to provide functionalised 
cyclopentanes. For example, Ni(0)-activation of cyclopropylketones 81 provides nickelacycle 82 which 
reacts with polarised alkenes to form the observed cyclopentanes (Scheme 16A). In order to expand the 
methodology to include external alkynes, Ogoshi and co-workers employed the Lewis acid, Me2AlCl, 
which facilitated the synthesis of cyclopentenes (Scheme 16B).93 The mechanism of the Lewis acid-
mediated coupling is proposed to begin with the formation of four-membered nickelacycle 83. 
Stoichiometric experiments indicate that four-membered nickelacycle 83 is stabilised by a Ni-Cl 
interaction thus preventing isomerisation to a six-membered nickelacycle (cf. 82). Migratory insertion 
of the external alkyne into nickelacyclobutane 83, and reductive elimination affords cyclopentenes.  
 
Scheme 16 
A Pd(0)-catalysed hydrosilylation of cyclopropyl ketones was developed by Oshima and co-
workers, which provided access to (Z)-silyl enol ethers 84a/b (Scheme 18A).94 The mechanism of the 
transformation begins with the formation of six-membered palladacycle 85, which isomerised to five-
membered palladacycle 86 via consecutive -hydride elimination and hydrometallation steps as 




evidenced by deuterium labelling studies. Palladacycle 86 undergoes transmetallation with a tertiary 
silane and reductive elimination to give the observed products. In a related Ni(0)-catalysed reaction, 
cyclopropyl ketones react to form six-membered nickelacycles 87 which are trapped by B2Pin2 to form 
boryl enol ethers 88b. Upon C-B reductive elimination and hydrolysis of the resulting boryl enol ethers, 
alkylboronic esters (e.g. 89a and 89b) are formed (Scheme 18B).95 Ye and co-workers  have since 
reported a related dual Ni/Al-catalysed enantioselective coupling of cyclopropylamides and alkynes.96 
 
Scheme 18 
 Zhang and co-workers have also shown that propargylic cyclopropyl ketones 90 can be 
activated by a simple neutral Rh(I)-catalyst, under carbonylative conditions, to form furan-fused 
cyclopentanones (e.g. 91a and 91b) (Scheme 19).97 The transformation is proposed to initiate by C-C 
oxidative addition to cyclopropylketone 90. The resulting rhodacyclobutane 92 undergoes 
Scheme 19: Rh(I)-catalysed carbonylative rearrangement of alkynyl cyclopropyl ketones. 




cycloisomerisation to rhodacycle 93. This is followed by CO insertion and reductive elimination to give 
the furan-fused products. 
1.2.1.5 Directed metal-addition to unactivated cyclopropanes 
 C-C activation of non-activated cyclopropanes is well-established but traditionally restricted to 
simple reduction and isomerisation processes.16, 98 Application of this substrate class to complexity 
generating reactions is challenging because of the often low regioselectivity observed for metal addition 
to minimally differentiated C-C bonds and the poor stability of the resulting organometallic 
intermediates. Directed C-C oxidative addition processes can alleviate these issues. A directing-group 
strategy has been adopted at Bristol to facilitate the carbonylative formation of rhodacyclopentanones 
95 from non-activated cyclopropane derivatives 94 (Scheme 20).99-100 Rhodacyclopentanones generated 
in this way have been trapped by tethered -unsaturates and nucleophiles providing access to 
structurally complex heterocyclic scaffolds.99, 101-106 The development of this approach has been 
discussed and the resulting methodologies have been reviewed.100, 107 An in-depth discussion of the 
carbonyl-directed carbonylative ring expansion strategy, developed at Bristol, will be presented in 
Section 1.3, and methodologies based around this process will be introduced at appropriate points 
throughout this thesis. 
 
Scheme 20: Rh(I)-catalysed carbonylative ring expansion of aminocyclopropanes. 
 Recently, other examples of processes involving directed C-C addition processes of non-
activated cyclopropanes have emerged. In 2017, Takai, Murai and co-workers published a pyridine-
directed, Ir(I)-catalysed hydrosilylation of cyclopropanes 96 to form linear silanes (e.g. 97a and 97b) 
(Scheme 21A).108 Control experiments provided evidence for the proposed mechanism. This begins 
with the formation of a Ir(I)-silane species, which is directed by the pyridine moiety to the proximal C-
C bond of the cyclopropane to form iridacyclobutane 98. Subsequent regioselective C-Si reductive 
elimination takes place to form six-membered Ir(I)-chelate 99 such that the pyridine-Ir bonding 
interaction is maintained. Reaction of Ir(I)-species 99 with a second equivalent of silane gives the 
product and regenerates the Ir(I)-silane catalyst. 
 In 2018, Asako, Takai and co-workers demonstrated the pyridine-directed Mo(0)-catalysed 
retrocyclopropanation of cyclopropylarenes 100 to form pyrido[2,1-a]isoindoles (e.g. 101a and 101b) 
(Scheme 21B).109 The retrocyclopropanation reaction is proposed to initiate by pyridine-directed 




Mo(0)-addition to the proximal C-C bond of the cyclopropane. The resulting four-membered Mo(II)-
intermediate 102 undergoes a retro-(2+2)-cycloaddition to generate ethene and Mo-carbene species 103, 
which is intercepted by the pyridyl group to form the observed products. Ethene generated in this 
process was observed by NMR studies, and computational studies support the proposed mechanism.  
 
Scheme 21 
1.2.2 Cyclobutane-based processes 
 Cyclobutane-based rings possess significant ring strain, albeit typically less than cyclopropane-
based rings, and the C-C bonds are less bent than in cyclopropanes (see Section 1.2).18 As a result, C-C 
oxidative addition to cyclobutanes by transition metals is currently limited to highly strained analogues 
containing sp2-centres, such as biphenylenes, and (benzo)cyclobutanones. Other cyclobutane-based 
rings undergo C-C cleavage via -carbon elimination, but these examples are outside the scope of the 
current discussion.15  Biphenylenes are among the most strained cyclobutane rings, and, as a result, have 
a rich history of transition metal-mediated C-C activation processes. However, the organometallic 
intermediates (and resulting products) formed in biphenylene-based processes are largely composed of 
sp2-centres, so will not be discussed here in detail; several reviews are available which cover this 
topic.15, 110 





 Seminal studies by Murakami and co-workers on Rh(I)-catalysed C-C oxidative addition to 
cyclobutanones showed that the catalyst added to the weaker acyl-C bond, which provided an 
alternative entry to rhodacyclopentanones (Scheme 22A).111-112 Rhodacyclopentanones generated in this 
way have since been incorporated into several methodologies which have provided access to diverse 
heterocyclic compounds. The chemistry of rhodacyclopentanones has been recently reviewed.113 
Building upon earlier work by Murakami and co-workers,114 Cramer and co-workers achieved 
the enantioselective synthesis of benzo-fused bridged compounds (e.g. 105a and 105b) from 
cyclobutanones 104 using an (R)-DTBM-SEGPHOS-ligated Rh(I)-catalyst (Scheme 22B).115-116 The 
transformation is proposed to begin with enantioselective Rh(I)-addition to the acyl-C bond of 
cyclobutanones 104 to form rhodacyclopentanones 106. Alkene carbometallation is followed by 
reductive elimination to provide the observed products. Further developments allowed the insertion of 
ketones and aldehydes into analogous rhodacyclopentanones (not shown) allowing the enantioselective 
synthesis of bridged lactones (e.g. 107a and 107b) (Scheme 22C).117 The successful application of an 
aldehyde in this process is notable because these are prone to C-H oxidative addition by Rh(I)-catalysts.  
 
Scheme 22 




Decarbonylation of rhodacyclopentanones is an often-encountered side-reaction of these 
processes. To avoid this, Ko and Dong118 adapted the pyridyl-directed C-C activation strategy of Jun 
and Lee119 to cyclobutanone-based processes. Here, cyclobutanones 108 are treated with a 
stoichiometric quantity of 2-amino-3-methylpyridine, which results in the in-situ formation of imine 
110 (Scheme 23A). The imine-based directing group then directs Rh(I)-addition to provide 
Rh(III)-species 111, from which CO extrusion cannot occur. Instead, Rh(III)-intermediate 111 is 
Scheme 23 




intercepted by the tethered alkene to form bridged heterocyclic imines which are hydrolysed upon work-
up to provide the ketone products (e.g. 109a and 109b). 
A closely related process employed tethered allenes to intercept rhodacyclopentanones in the 
enantioselective synthesis of [4.2.1] bridged compounds without the use of an imine-directing group 
(Scheme 23B).120 C-C oxidative addition of a TADDOL-phosphoramidite-ligated Rh(I)-catalyst into 
cyclobutanone 112 and allene-insertion formed Rh(III)-allyl intermediate 114. β-Hydride elimination 
from C2, hydrometallation and reductive elimination took place to provide [4.2.1] bridged compounds 
(e.g. 113a and 113b) in preference to [3.3.1] products 115 (via C-C1 reductive elimination from 114). 
Recently, rhodacyclopentanones generated from unsymmetrical cyclobutanones 116 were trapped by 
tethered alkynes to generate 5,6-enones (Scheme 23C).121 The regioselectivity of the initial Rh(I)-
addition step was investigated by 13C-labelling studies, which indicated a preference for addition to the 
less-substituted acyl-C bond. The resulting rhodacyclopentanone 118 isomerises via a 
retrocarbonylation/carbonylation sequence to access the productive regioisomer 119. Alkyne 
carbometallation and reductive elimination provided the observed products.   
 A significant restriction of most C-C oxidative addition methodologies is the requirement of 
high reaction temperatures (typically 90–150 °C). In what was a significant development in this respect, 
Murakami and co-workers presented the P,N,P-ligand-bound Rh(I)-catalyst 120 which catalysed the 
room temperature decarbonylation of cyclobutanone 121 to form cyclopropane 122 (Scheme 24A).122 
This advance suggests that the design of an optimised catalyst system for C-C oxidative addition to 
cyclobutanones might significantly improve these processes.  
 Whereas the majority of cyclobutane-based C-C activation processes are catalysed by 
Rh(I)-species, Murakami and co-workers reported a Pd(0)-catalysed transformation of cyclobutanones 
123 into acylsilanes 124 (Scheme 24B).123 Mechanistic studies imply that the transformation is initiated 
by Pd(0)-addition to the Si-Si bond of cyclobutanone 123 to form electron-rich Pd(II)-intermediate 125. 
Then, intramolecular Pd(II)-addition to the cyclobutanone results in the formation of 
Pd(IV)-intermediate 126, which undergoes consecutive C-Si/acyl-Si reductive eliminations to form 
acylsilanes 124.  







 Benzocyclobutanones are another class of cyclobutanone that have been incorporated into C-C 
activation methodologies. The acyl-C(sp3) and acyl-C(sp2) bonds of the cyclobutanone ring are 
differentiated, which raises the possibility of forming one of two regioisomeric intermediates upon C-C 
oxidative addition. In 1992, Liebeskind showed that Wilkinson’s catalyst preferentially inserted into 
the less-hindered C-C bond of benzocyclobutanone 127 to form rhodacyclopentanone 128, which, upon 
heating, isomerised to the more stable regioisomer 129 (Scheme 25A).124 Computational studies have 
since shown that isomerisation likely occurs by a retrocarbonylation/carbonylation sequence.125 The 
Dong laboratory have exploited the rearrangement of benzocyclobutanone-derived 
rhodacyclopentanones for the development of several intramolecular cycloadditions. In early work, the 
C-C addition preference of a Rh(I)-catalyst was demonstrated in the isomerisation of simple 
benzocyclobutanones 130 to benzocyclopentanones (e.g. 131a and 131b) (Scheme 25B).126 Here, 
Rh(I)-addition to the less substituted acyl-C(sp3) bond of benzocyclobutanone 130 forms 
rhodacyclopentanone 132 from which -hydride elimination and hydrometallation forms six-membered 
rhodacycle 133. Reductive elimination then forms the observed indanones. Further evidence for this 
mechanism was later provided using computational methods.127  
 At higher reaction temperatures (>130 °C vs 90 °C), the initially formed rhodacyclopentanone 
(e.g. 128) isomerises to the thermodynamically preferred regioisomer (e.g. 129), which can then take 
part in further intramolecular transformations. This allowed benzocyclobutanones 134, bearing tethered 




alkenes, to undergo intramolecular cycloaddition to form tricyclic benzene derivatives (e.g. 135a and 
135b) (Scheme 25C).128-129 Since this early example, several groups have published related 
transformations in which various phenol, or aniline tethered -unsaturates (including alkynes,130 
acrylamides,131 ketones132 and oximes133) are inserted into rhodacyclopentanones to form tricyclic 
compounds, often with enantiocontrol. Additionally, a Co(0)-catalysed process has been reported.134 
 
 Scheme 25 
 Intramolecular trapping of benzocyclobutanone-derived rhodacyclopentanones by alkenes has 
been showcased in the total synthesis of several natural products, which is a testament to the maturity 
of these processes. For example, Dong and co-workers have recently disclosed the asymmetric total 
synthesis of (-)-cycloclavine and (-)-5-epi-cycloclavine, which is enabled by an asymmetric Rh(I)-
catalysed cycloaddition of benzocyclobutanone 136 (Scheme 25D).135 Benzocyclobutanone 136 was 
prepared in three steps and underwent a highly efficient and enantioselective Rh(I)-catalysed 




intramolecular cycloaddition to form tricyclic compound 137 in 95% yield (98% e.e.). This compound 
was progressed in a diastereoselective manner to (-)-cycloclavine in a further six steps. The scope of 
the optimised Rh(I)-catalysed cycloaddition conditions was demonstrated to be broad. 
The Dong group have also demonstrated the feasibility of related decarbonylative processes. 
When benzocyclobutanones 138, bearing tethered alkynes were treated with a DTBM-Segphos-ligated 
Rh(I)-catalyst, indanones (e.g. 139a and 139b) were formed (Scheme 26A).130 Decarbonylation may 
take place from rhodacyclopentanone 140, or from the intermediate resulting from migratory insertion 
of the alkyne. An alternative order of steps is also possible as was demonstrated by the decarbonylative 
synthesis of spiro-compounds (e.g. 142a and 142b) from benzocyclobutanones 141 containing tethered 
alkenes (Scheme 26B).136 Here, incorporation of the alkene into rhodacyclopentanone 143 and 




 The majority of C-C activation processes involving benzocyclobutanones are catalysed by 
Rh(I)-complexes. However, Murakami and co-workers have recently described a Pd(0)-catalysed 
intermolecular cross metathesis of benzocyclobutanones 144 with silacyclobutanes to form benzofused 
eight-membered rings (e.g. 145a and 145b) (Scheme 27).137 Optimisation studies identified 
t-octylisocyanide as a key additive; this led to the isolation of palladacyclopentanone 146, which was 
then shown to be catalytically active. The proposed mechanism involves oxidative addition of 




palladacycle 144 to a silacyclobutane, providing Pd(IV)-complex 147 from which Si-C reductive 
elimination gives Pd(II)-intermediate 148. Acyl-C reductive elimination then provides the observed 
products. Later, the order of the catalytic steps was corroborated by computational methods.138  
 
Scheme 27: Pd(0)-catalysed intermolecular cross-metathesis of benzocyclobutanones with silacyclobutanes. 
 The processes outlined in this introduction illustrate the diverse sp3-rich structures that have 
been accessed using methodologies that employ oxidative addition of transition metal catalysts to C-C 
bonds of strained carbocycles. A particularly appealing application of these methodologies is their use 
for the synthesis of medium-sized ring systems. Indeed, the research contained within this thesis 
concerns the synthesis of various seven and eight-membered heterocycles via rhodacyclopentanones, 
which are generated from cyclopropanes by a strategy developed at Bristol. Key aspects of this strategy 
will now be presented as an introduction to the research contained in the following sections.  
1.3 A directing group strategy for the generation of rhodacyclopentanones   
 In 2013, former PhD student Dr Megan Shaw developed a strategy for the regioselective 
generation of rhodacyclopentanones from aminocyclopropanes.99-100 The strategy employs a 
carbonyl-based directing group to promote regioselective oxidative addition of a Rh(I)-catalyst to the 
proximal C-C bond “p” of aminocyclopropanes 149 (Scheme 28). Migratory insertion of carbon 
monoxide into the resulting rhodacyclobutane 150 affords rhodacyclopentanones 151, in which the 
Rh-O interaction is preserved. In this manner, a single rhodacyclopentanone can be generated out of 
three possible regioisomers (see the dashed box). Importantly, the steps leading up to 
rhodacyclopentanone formation (C-C oxidative addition and CO migratory insertion) have been shown 
to be reversible. Shaw and former PhD student, Dr Niall McCreanor, demonstrated the synthetic utility 
of these rhodacyclopentanones in the synthesis of complex N-heterocycles.  





Scheme 28: Directing-group strategy for the generation of rhodacyclopentanones. 
1.3.1 The importance of the directing group 
 Key to the success of this strategy is the use of an appropriate combination of directing group 
and Rh(I)-catalyst. Initially, the role of the directing group was confirmed by carrying out an insertion 
experiment on cyclopropanes in the absence and presence of a directing group. An insertion experiment 
involves the reaction of a cyclopropane with a Rh(I)-catalyst under a non-carbonylative atmosphere 
(Scheme 29). Rhodacyclobutanes formed in this way are unstable and degrade via -hydride elimination 
and C-H reductive elimination to form alkene products. The regiochemistry observed in the alkene 
products is an indication of the regiochemical preference of the Rh(I)-addition step: branched alkenes 
indicate addition to distal bond “d”, whereas linear alkenes indicate addition to proximal bond “p”. 
 
Scheme 29: Insertion experiment to determine the site of metal addition to cyclopropanes. 
 Shaw carried out insertion experiments with a cationic Rh(I)-catalyst on cyclopropane 152 
(lacking a directing group) and aminocyclopropane 155 (bearing a carbamate directing group). Under 
these conditions, cyclopropane 152 reacted to form branched alkenes 153a and 153b exclusively, thus 
indicating Rh(I)-addition to the distal C-C bond “d” (Scheme 30A). In contrast, aminocyclopropane 
155 reacted to form linear alkene 157 in quantitative yield via directed Rh(I)-addition to the proximal 
C-C bond “p” (Scheme 30B). Conversely, when aminocyclopropane 155 was treated with a neutral 
Rh(I)-catalyst, branched alkene 156 was the sole product. It was reasoned that the neutral Rh(I)-catalyst 




is not sufficiently Lewis-acidic to be directed under non-carbonylative conditions. Shaw further 
demonstrated that other N-based directing groups are capable of directing Rh(I)-addition, including 
amides and sulfonamides. 
 
Scheme 30 
 The insertion studies discussed above indicate the regioselectivity of Rh(I)-addition to 
cyclopropanes in the absence of carbon monoxide, but it was postulated that this preference might 
change under carbonylative conditions because the electron-withdrawing CO ligands would make the 
Rh(I)-catalyst more “cationic” in character. In order to probe this, a range of stable 
rhodacyclopentanones were synthesised by the reaction of [Rh(CO)2Cl]2 with aminocyclopropane-
derivatives and characterised by NMR, IR and X-ray crystallography. For example, 
cyclopropylcarbamate 158 was reacted with a stoichiometric quantity of [Rh(CO)2Cl]2 to form 
rhodacyclopentanone 159 in 75% isolated yield (Scheme 31). The X-ray structure of complex 159 
reveals the rhodacyclopentanone regioisomer resulting from directed Rh(I)-addition to the proximal 
cyclopropyl C-C bond. In addition, the Rh-O directing group interaction is maintained. Further 
complexes bearing different directing groups were synthesised and their CO stretching frequencies 
measured in order to determine the relative strength of carbonyl-based directing groups. The CO 
stretching frequencies indicate that directing group strength is proportional to the Lewis basicity of the 
carbonyl (i.e. directing group strength increases in the order amide (2046 cm-1) < carbamate (2044 cm-
1) < urea (2023 cm-1)).  





Scheme 31: X-ray crystal structure of a rhodacyclopentanone. 
1.3.2 Rh(I)-catalysed (3+1+2) cycloadditions of cyclopropane derivatives 
 Next, Shaw demonstrated that rhodacyclopentanones generated by the directing group strategy 
could be incorporated into cycloaddition reactions. It was discovered that treatment of cyclopropylureas 
160 with a neutral Rh(I)-catalyst under a carbonylative atmosphere resulted in a (3+1+2) cycloaddition 
to form heterobicyclic enones 161 (Scheme 32A). The proposed mechanism begins with the formation 
of rhodacyclopentanone 162 via urea-directed Rh(I)-addition to cyclopropylureas 160. Directing group 
dissociation and alkyne coordination is followed by alkyne migratory insertion and reductive 
Scheme 32 




elimination to provide the observed products. Optimisation of the reaction parameters revealed that a 
strongly coordinating urea directing group is required to outcompete the alkyne for coordination of the 
Rh(I)-catalyst. In this way, both the directed C-C addition and subsequent alkyne coordination steps are 
facilitated. The original “neutral” catalytic conditions require long reaction times (>72 h), which is 
proposed to be the result of inefficient coordination between the neutral Rh(I)-catalyst and the directing 
group. This problem was solved by employing a combination of a cationic Rh(I)-catalyst and the 
coordinating solvent, benzonitrile. The new “cationic” conditions afforded universally decreased 
reaction times (<48 h) and an improvement in the substrate scope, as exemplified by the improved yield 
for thiophene derivative 161b (see Scheme 32, A). 
 In 2015, Shaw and McCreanor published a second protocol employing the directed formation 
of rhodacyclopentanones.102 In this example, a cationic Rh(I)-catalyst mediates the (3+1+2) 
cycloaddition of cyclopropylcarbamates 163 with tethered alkenes to form bicyclic ketones 164 
(Scheme 32B). Notably, the efficiency of the (3+1+2) cycloaddition was improved by the addition of 
dimethyl fumarate and iso-butyramide additives. The role of these additives is not clear, but it was 
proposed that dimethyl fumarate may act as an electron-deficient ligand. Importantly, high 
diastereoselectivity was achieved in this process under cationic conditions for substrates bearing 
substitution on the alkene tether (i.e. at R1 or R2). This selectivity arises from reversible Rh(I)-addition 
to the diastereotopic proximal C-C bonds of cyclopropylcarbamate 163 (i.e. “m” or “n”) to form 
diastereomeric rhodacyclopentanones 162b or 162c, which undergo alkene insertion at different rates.  
1.3.3 Directed Rh(I)-addition to 1,2-disubstituted cyclopropanes 
Application of 1,2-disubstituted cyclopropanes to C-C oxidative addition-based processes is 
desirable because they provide access to more highly substituted cycloadducts (Scheme 33A). 
Additionally, substituted cyclopropanes are often available in an enantioenriched form, potentially 
giving access to enantioenriched cycloadducts.139-141 However, additional substitution on the 
cyclopropane ring introduces complications regarding the regioselectivity of C-C oxidative addition. 
For example, 1,2-disubstituted cyclopropanes can exist as either trans- or cis-diastereomers (see trans-
165 and cis-165) where each of the four proximal C-C bonds (i.e. “a” vs “b” vs “c” vs “d”) are sterically 
and electronically differentiated (Scheme 33B). Consequently, directed C-C oxidative addition by a 
Rh(I)-catalyst to these cyclopropanes could give rise to four isomeric rhodacyclopentanones 166a-d, 
and therefore four diastereomeric cycloadducts. The product formed by reaction of a 1,2-disubstituted 
cyclopropane therefore depends on the stereochemistry of the cyclopropane starting material (trans- or 
cis-), and the regioselectivity of the Rh(I)-addition step. 






Shaw and McCreanor investigated 1,2-disubstituted cyclopropanes in (3+1+2) cycloadditions 
in order to investigate the regioselectivity of the Rh(I)-addition step. When trans-substituted 
cyclopropane trans-167 was subjected to the “cationic” conditions, enone 168 was formed (45% yield, 
8:1 r.r.) as a result of Rh(I)-addition to the less sterically hindered C-C bond “b” (Scheme 34A). Notably 
(3+1+2) cycloaddition of trans-167 proceeded with complete retention of the cyclopropane 
stereocentres, providing enone 168 as a single diastereomer. Similarly, trans-cyclopropylcarbamate 
trans-170 reacted via Rh(I)-addition to the less-hindered bond “b” giving ketone 171 (65% yield) with 
complete stereoretention and regiocontrol (Scheme 34B). Conversely, cis-substituted cyclopropane cis-
172 provided cycloadduct 173 (42% yield, 4.5:1 d.r., >15:1 r.r.) via Rh(I)-addition to the more 
substituted C-C bond “a”. It was proposed that the contrasteric regioselectivity observed for cis-
substituted cyclopropane 172 was a result of the more electron-rich C-C bond “a” outcompeting bond 
“b” for initial coordination to the Rh(I)-catalyst, and therefore undergoing preferential oxidative 
addition. A similar effect has been observed whereby cis-alkenes coordinated more strongly to Rh(I)-
organometallics than trans-alkenes.142 The same regioselectivity for Rh(I)-addition to the more 
hindered bond “a” of cis-substituted cyclopropanes was observed in the formation of 
rhodacyclopentanone 175 from the stoichiometric reaction of cis-substituted cyclopropane cis-174b 
(Scheme 34C). The structure of rhodacyclopentanone 175 was determined by detailed NMR studies. 
These studies on the regioselectivity of Rh(I)-addition to substituted cyclopropanes demonstrate that 




both product regioisomers can be accessed selectively by utilising either the trans- or cis-diastereomer 
of the substrate. 
 
Scheme 34 
1.4 Nucleophilic addition to rhodacyclopentanones 
1.4.1 Intermolecular nucleophilic addition to rhodacyclopentanones  
 During investigations into the (3+1+2) cycloaddition of cyclopropylcarbamate 176, McCreanor 
isolated carbonylation product 177 resulting from nucleophilic addition of iso-butyramide to 
rhodacyclopentanone 178 (Scheme 35A). Nucleophilic addition to a rhodacyclopentanone can 
foreseeably have occurred by one of three mechanisms: i) nucleophilic addition to the 
rhodacyclopentanone carbonyl, ii) nucleophilic addition to the Rh(III)-centre or iii) -bond metathesis 
(Scheme 35B). Murakami and co-workers had previously reported that rhodacyclopentanones can 




undergo intramolecular nucleophilic addition of phenolic oxygen nucleophiles.143 Nevertheless, the 
formation of adduct 177 serves as the first example of intermolecular nucleophilic addition to a 
rhodacyclopentanone. The novelty of this process prompted McCreanor to investigate the 
intermolecular process further.   
 
Scheme 35 
 Initial investigations involved nucleophilic addition to the rhodacyclopentanone generated from 
cyclopropylcarbamate 179 under cationic conditions (Scheme 36A). It was discovered that phenol and 
benzyl alcohol are effective nucleophiles, which lead to the formation of -amino acid ester derivatives 
180a and 180b in moderate yields. -Amino acids are important biologically active chemical motifs 
however these can be synthesised readily.144-145 Recently, Wang and co-workers published a related 
protocol involving intermolecular nucleophilic addition of -hydroxy ketones to rhodacyclopentanones 
to form -amino acid esters (e.g. 191a and 191b) (Scheme 36B).146 Here, rhodacyclopentanone 192 is 
formed by directed Rh(I)-addition to cyclopropylureas 190. Then, a chelating nucleophile is required 
to aid coordination to the rhodacyclopentanone 192 resulting in the formation of intermediate 193 from 
which reductive elimination and protodemetallation provides the observed products. Due to the limited 
synthetic value of an intermolecular protocol for nucleophilic addition to rhodacyclopentanones, 
McCreanor’s focus shifted to the development of an intramolecular cyclisation because it was 
recognised that this might be well suited to the synthesis of valuable medium-sized rings. 






Medium-sized rings (8–11 membered rings) are typically more difficult to synthesise than five 
or six-membered rings because of additional kinetic and thermodynamic barriers to cyclisation. For 
example, it is kinetically unfavourable to bring two ends of a linear cyclisation precursor together in 
order to react, and this becomes less favourable as the length of the cyclisation precursor increases 
(Scheme 37).147 Additionally, medium-sized rings are more strained than five or six-membered rings, 
thus resulting in a greater thermodynamic barrier to cyclisation.148 The proposed strategy for the 
synthesis of medium-sized rings via intramolecular nucleophilic addition to rhodacyclopentanones 
would mitigate both of these barriers to cyclisation. The kinetic barrier to cyclisation would be reduced 
through the formation of a kinetically accessible 5,5-bicyclic intermediate 194 by intramolecular 
nucleophilic addition to a rhodacyclopentanone. Additionally, the thermodynamic penalty for forming 
a strained medium-sized ring is offset by the cleavage of a highly strained cyclopropane-based substrate.  
 





Scheme 37: Strategy for the synthesis of medium-sized rings via kinetically accessible intermediates. 
1.4.2 Intramolecular nucleophilic addition to rhodacyclopentanones: (6+1) 
carbonylative cyclisation of cyclopropylureas 
In order to investigate the strategy outlined in Scheme 37, McCreanor synthesised a selection 
of aminocyclopropanes bearing directing groups and tethered O- or N-nucleophiles, and subjected them 
to Rh(I)-catalysis under a CO atmosphere (more details are provided in Section 2.2.1). It was discovered 
that cyclopropylurea 195a underwent Rh(I)-catalysed carbonylative (6+1) carbonylative cyclisation to 
form seven membered diazepanes 196a and 197a (57%, 3.8:1 196a:197a) which differ by the oxidation 
level of the C4-C5 position (Scheme 38A). 1,3-Diazepanes are important heterocycles, which are found 
in biologically active compounds including the potent HIV-integrase inhibitor, DMP 450,149 the -
lactamase inhibitor, MK-7655,150 and the natural mast cell inhibitor, (+)-monanchorin151 (Scheme 38B).  
 
Scheme 38 
 The mechanism of the (6+1) carbonylative cyclisation is proposed to proceed by urea-directed 
formation of rhodacyclopentanone 198 (Scheme 39). Ligand exchange of the carbonyl for the N-
nucleophile and deprotonation provides intermediate 199. C-N Reductive elimination then forms 




diazepane 200, which can either undergo protodemetallation to form saturated diazepanes, or -hydride 
elimination to form unsaturated diazepanes. -Hydride elimination from diazepane 200 forms a Rh(I)-
hydride 201, from which the active catalyst is regenerated by oxidative protonation and reductive 
elimination of dihydrogen (see the dashed box). Rh(III)-dihydrides have previously been reported to 
reductively eliminate dihydrogen.143, 152  
 
Scheme 39: Proposed mechanism for the (6+1) carbonylative cyclisation and regeneration of the Rh(I)-catalyst. 
1.4.2.1 Optimisation of the (6+1) carbonylative cyclisation of cyclopropylureas 
Optimisation studies were directed at improving the yield and selectivity of the reaction, and 
selected results are shown in Table 1. The discovery conditions formed unsaturated diazepane 196a in 
57% yield with poor selectivity (3.8:1, 196a:197a) over the saturated diazepane 197a (Entry 1). 
Initially, it was confirmed that cationic Rh(I)-catalysts are superior to neutral Rh(I)-catalysts. A 
significant improvement was achieved by employing PPh3 as the ligand, which provided unsaturated 
diazepane 196a in 90% yield but with only moderate selectivity (9:1, 196a:197a) over the saturated 
product (Entry 2). The oxidation level selectivity could be greatly improved (85%, 25:1, 196a:197a) by 
lowering the reaction temperature (Entry 3). The non-coordinating solvent 1,2-DCB was found to be 
the optimal solvent, with coordinating solvents such as benzonitrile affording the desired cycloadduct 
in diminished yield (Entry 4). 
At this point, the optimal conditions for the (6+1) carbonylative cyclisation afforded excellent 
selectivity for unsaturated diazepane 196a. An attempt was made to develop complimentary conditions 
for the formation of saturated diazepane 197a to allow oxidation level divergent access to either 
diazepane. Several protic and hydridic additives were tested in order to promote protodemetallation 
from intermediate 200 (see Scheme 39), but selectivity in favour of the unsaturated diazepane 196a 
remained (Entries 5-7). However, during these studies it was discovered that a substoichiometric 
quantity of benzoic acid (10 mol%) improved the yield of the unsaturated diazepane (Entry 8). 
Interestingly, by lowering the partial pressure of CO and employing the electron-deficient ligand 




P(3,4,5-(F)3C6H2)3, the selectivity of the process could be reversed (37%, 1:2, 196a:197a) in favour of 
the saturated diazepane 197a, albeit with a significant decrease in overall yield (Entries 9 and 10). 
McCreanor’s optimised conditions for the formation of unsaturated diazepane 196a were used to 
investigate the scope of the reaction. 
 
Table 1: Selected results from McCreanor’s optimisation of the (6+1) carbonylative cyclisation of trisubstituted 
cyclopropylurea 195a. 
1.4.2.2 Scope of the (6+1) carbonylative cyclisation of cyclopropylureas 
McCreanor synthesised a variety of cyclopropylureas (details in Section 2.1.2.1) to investigate 
the scope of the (6+1) carbonylative cyclisation, and the results are displayed in Table 2. Primary alkyl 
and aryl substitution was tolerated at R1 as demonstrated by the formation of diazepanes 196b and 196c 
in 78% and 48% yield, respectively. Interestingly, reaction of N,N’-disubstituted urea 202a (R1 = H) 
formed the saturated diazepane 204a selectively (1:6, 203a:204a) in a combined yield of 63%; the 
implications of this result will be discussed further in Section 2.1.2.3. Substitution of the nucleophilic 
nitrogen (R2) was less well tolerated except for simple alkyl substituted cyclopropylurea 195d, which 
formed diazepane 196d in 94% yield. Aryl and secondary alkyl substituents at R2 performed poorly 
generating the corresponding diazepanes 196e-g in low yield (14–39% yield). Finally, N,N-disubstituted 
urea 195h (R2 = H) formed the corresponding diazepane 196h in only 22% yield. 





Table 2: Scope of McCreanor’s conditions for the (6+1) carbonylative cyclisation of cyclopropylureas. 
McCreanor demonstrated the reactivity of the enelactam moiety of unsaturated diazepanes by 
carrying out a Pictet-Spengler-like cyclisation (Scheme 40). Ureas 195i and 195j, which possess 
tethered electron rich aromatics, underwent high yielding (6+1) carbonylative cyclisations to form the 
corresponding diazepanes (not shown) 196i (77%) and 196j (92%), respectively. Upon treatment with 
TFA, the enelactam functionality was protonated, allowing Pictet-Spengler-like cyclisation to form 
tricyclic compounds 205i and 205j in 91% and 76% yield, respectively.  
 
Scheme 40: Pictet-Spengler cyclisation of unsaturated diazepanes to give tricyclic products. Regents and 
conditions: i) [Rh(cod)2]OTf (2.5 mol%), PPh3 (5 mol%), CO (1 atm), PhCO2H, 1,2-DCB (0.2 M), 100 °C; ii) 
TFA (1000 mol%), CH2Cl2 (0.1 M), 60 °C. 
 McCreanor began to investigate the scope of the reaction with respect to both cis- and trans-
1,2-disubstituted cyclopropanes. Based on previous work in Bristol (see Section 1.3.3), trans-
cyclopropane trans-206a was expected to form C4-substituted diazepane 207a by Rh(I)-addition to the 
less hindered C-C bond “b” (Scheme 41). Unexpectedly, trans-206a reacted via C-C bond “a” to form 
C3-substituted diazepane 208a in 45% yield and as a single regioisomer with complete selectivity over 




the saturated product. Also unexpectedly, cis-substituted cyclopropane cis-206a reacted via less 
hindered C-C bond “b” resulting in the selective formation of C4-substituted diazepane 207a (8:1 r.r.) 
with complete selectivity for the unsaturated compound. Thus, the regiochemical outcome of the (6+1) 
carbonylative cyclisation of substituted cyclopropane-based substrates is the opposite to what was 
expected based on previous studies. Mechanistic studies directed at understanding this phenomenon are 
presented in Section 2.1.4.2. McCreanor also synthesised and tested several other classes of substituted 
cyclopropane-based substrate in the (6+1) carbonylative cyclisation, and the results are presented in the 
proceeding sections. 
 
Scheme 41: Regioselectivity of the (6+1) carbonylative cyclisation of trans- and cis-1,2-disubstituted 
cyclopropylureas. 
1.4.3 Summary of McCreanor’s investigations into the (6+1) carbonylative cyclisation 
 McCreanor’s discovery of the (6+1) carbonylative cyclisation of cyclopropylureas via 
intramolecular nucleophilic addition to rhodacyclopentanones serves as a realisation of the general 
strategy outlined in Scheme 37. The optimised conditions tolerated simple primary alkyl substitution at 
the R1 and R2 positions but proved unsatisfactory in more challenging cases. 1,2-Disubstituted 
cyclopropanes were briefly investigated, which revealed a reversal in regioselectivity when compared 
to previous work carried out in Bristol. The switch in C4-C5 oxidation level selectivity observed in the 
reaction of N,N’-disubstituted cyclopropylurea 202a (Table 2) raised the possibility of developing an 
oxidation level divergent synthesis of diazepanes.  
  




1.5 Project aims 
In the previous section, Shaw and McCreanor’s development of a directing group strategy for 
the formation of rhodacyclopentanones and application to the synthesis of sp3-rich heterobicyclic 
molecules at Bristol was described. McCreanor then made the discovery that rhodacyclopentanones 
could be trapped by nucleophiles, which resulted in the identification of the (6+1) carbonylative 
cyclisation of cyclopropylureas to form diazepanes. Nucleophilic addition to rhodacyclopentanones is 
an under-explored mode of reactivity, which holds great promise for the synthesis of valuable medium-
sized rings.  
The research described in this thesis is split into two Chapters. Chapter 2 details a project 
investigating nucleophilic addition to rhodacyclopentanones. The initial goal of this project was to 
develop improved reaction conditions for the (6+1) carbonylative cyclisation of cyclopropylureas and 
reinvestigate the scope of the transformation. Mechanistic studies were then to be carried out in order 
to understand the factors affecting C4-C5 oxidation level selectivity in the product diazepanes and the 
unexpected regioselectivity of Rh(I)-addition to substituted cyclopropanes. A second aim of this project 
was to test the generality of the intramolecular nucleophilic addition to rhodacyclopentanones in the 
hope that this strategy could be expanded to allow access to further heterocyclic structures. 
The aim of Chapter 3 was to apply a rhodacyclopentanone-based methodology, developed at 
Bristol, to the total synthesis of a natural product. Here, Shaw’s (7+1) carbonylative cyclisation of 
cyclopropylacrylamides was to be investigated as an asymmetric entry to the azocane ring system of 
the pyrrolizidine alkaloid, (R)-otonecine. A secondary aim of this project was to develop a short 
synthesis of the dicarboxylic necic acids, which, together with (R)-otonecine, form the other otonecine-
type pyrrolizidine alkaloids. The successful synthesis of (R)-otonecine would constitute the first 
asymmetric total synthesis of this natural product, whereas none of the other otonecine-type PAs have 
been synthesised before. 




Chapter 2 – Intramolecular nucleophilic addition to rhodacyclopentanones 
Section 1.4.2 outlined McCreanor’s discovery of the (6+1) carbonylative cyclisation of 
cyclopropylureas to form diazepanes by intramolecular nucleophilic addition to rhodacyclopentanones. 
The reaction conditions developed by McCreanor allowed the efficient cyclisation of simple substrates, 
but the scope of the cyclisation was narrow. Investigations described in this thesis began with the 
development of optimised conditions for the (6+1) carbonylative cyclisation. 
2.1 Further development of the (6+1) carbonylative cyclisation of cyclopropylureas 
Aspects of this chapter have been adapted from a communication. 
(McCreanor, N. G.†; Stanton, S.†; Bower, J. F. J. Am. Chem. Soc. 2016, 138, 11465. †N. G. 
McCreanor and S. Stanton contributed equally) 
2.1.1 Optimisation of the (6+1) carbonylative cyclisation of cyclopropylureas  
  The conditions developed by McCreanor allowed the (6+1) carbonylative cyclisation of parent 
trisubstituted cyclopropylurea 195a in 96% yield and with high selectivity (15:1, 196a:197a) over the 
saturated diazepane (Table 1). Cyclohexylurea 195g was chosen as a substrate for further optimisation 
because it cyclised under McCreanor’s conditions to form diazepane 196g in only 39% yield with 35% 
of the starting material remaining (Entry 1, Table 3). This was presumably due to the large cyclohexyl 
R2-substituent. Initially, several solvents (benzonitrile, anisole, PhMe, 1,4-dioxane) and 
triarylphosphine ligands were tested, but these did not improve the yield of diazepane 196g. The Rh(I)-
counterion was found to influence the reaction as illustrated by the improved yield of 44% of diazepane 
196g when 3.5 mol% of [Rh(cod)2]BARF was employed (Entry 2). Further improvements were 
Table 3: Selected results from the optimisation of the (6+1) carbonylative cyclisation of cyclopropylurea 195g. 




obtained by increasing the catalyst loading (53% yield at 7.5 mol%, Entry 3) and the duration of the 
reaction (68% yield over 48 h, Entry 4). An acceptable isolated yield of 69% of diazepane 196g was 
achieved by employing 7.5 mol% of [Rh(cod)2]BARF and 15 mol% benzoic acid over 72 h (Entry 5). 
In all these studies, the unsaturated diazepane 196g was formed with high selectivity (>15:1 196g: 197g) 
over the saturated diazepane 196g.  
2.1.2 Scope of the (6+1) carbonylative cyclisation of cyclopropylureas 
Having optimised the conditions for the (6+1) carbonylative cyclisation of “challenging” 
cyclohexylurea 195g, the scope of the cyclisation was reinvestigated. In addition to trisubstituted 
cyclopropylureas, a range of N,N’-disubstituted cyclopropylureas were synthesised because it was 
observed that cyclisation of benzyl cyclopropylurea 202a formed the C4-C5 saturated diazepane 204a 
selectively (see Table 2).  
2.1.2.1 Synthesis of cyclopropylureas 
McCreanor employed a two step sequence to synthesise several trisubstituted cyclopropylureas 
with various substituents at the R1 and R2 positions (Scheme 42A). The sequence began with the 
preparation of secondary amines by reductive amination of cyclopropylamine and the corresponding 
aldehyde, or by Buchwald-Hartwig cross-coupling in the case of naphthyl cyclopropylurea 195b. The 
secondary amines were then coupled with either an isocyanate to form trisubstituted cyclopropylureas, 
or with in-situ generated isocyanic acid as in the case of N,N-disubstituted cyclopropylurea 195h. Two 
additional trisubstituted cyclopropylureas 195l and 195m were synthesised by a streamlined procedure, 
which avoided the need to isolate the intermediate secondary amines (Scheme 42B). Aminoester 
derivative 195l was synthesised in 49% yield by a one-pot procedure involving alkylation of 
cyclopropylamine with t-butyl bromoacetate followed by urea formation with benzyl isocyanate. 
Similarly, bis-cyclopropylurea 195m was formed in 45% yield by alkylation of cyclopropylamine with 
(bromomethyl)cyclopropane and subsequent urea formation. 
 N,N-Disubstituted cyclopropylureas 202a-h were prepared by reaction of cyclopropylamine 
with the corresponding isocyanate in generally excellent yield (42–96% yield) and in less than one hour 
from commercially available reagents (Scheme 43). Monosubstituted cyclopropylurea 202i was 
prepared in 4% yield by reaction of cyclopropylamine with in-situ generated isocyanic acid. 





Scheme 42: A) Reagents and conditions: i) corresponding aldehyde, NaHCO3, MeOH, reflux, 16 h then NaBH4, 
0 °C to r.t., 16 h; ii) 2-Bromonaphthalene, Pd2(dba)3, BINAP, NaOt-Bu, PhMe, 80 °C, 16 h; iii) corresponding 
isocyanate, NEt3, CH2Cl2, 0 °C to r.t., 1 h; iv) KOCN, aq. 5 M HCl, r.t., 36 h. B) Reagents and conditions: i) t-
butyl bromoacetate, NEt3, CH2Cl2, r.t., 7 h then benzyl isocyanate, r.t., 17 h, 49%; ii) (bromomethyl)cyclopropane, 
DMSO, r.t., 20 h then benzyl isocyanate, CH2Cl2, 0 °C to r.t., 16 h, 45%. aSynthesised by McCreanor. 
 
Scheme 43: Synthesis of N,N’-disubstituted cyclopropylureas. Reagents and conditions: i) corresponding 
isocyanate, NEt3, CH2Cl2, 0 °C to r.t., 1 h; Compound 202i  KOCN, aq. 5 M HCl. aSynthesised by McCreanor 
2.1.2.2 (6+1) carbonylative cyclisation of trisubstituted cyclopropylureas 
 The newly optimised conditions for the (6+1) carbonylative cyclisation were used to 
reinvestigate the scope of the (6+1) carbonylative cyclisation (Table 4). The majority of trisubstituted 




cyclopropylureas cyclised with high efficiency to afford diazepanes in greater than 60% yield and with 
essentially complete selectivity for the unsaturated product (typically >15:1, 196:197). Alkyl and aryl 
R1-substituents were well tolerated as shown by the formation of diazepanes 196a-c,l,m in excellent 
yields (60–87% yield). It is noteworthy that the potentially labile tert-butyl ester of substrate 195l 
remained intact to provide diazepane 196l in 65% yield. Also, preferential Rh(I)-addition to the 
aminocyclopropane moiety of substrate 195m to form diazepane 196m (87% yield) in the presence of 
a second cyclopropane unit illustrates the exquisite C-C bond selectivity afforded by the directing 
group. Likewise, primary and secondary alkyl R2-substituents were well tolerated as indicated by the 
formation of diazepanes 196d and 196g in 85% and 69% yield, respectively. Finally, N,N-disubstituted 
cyclopropylurea 195h cyclised efficiently to form diazepane 196h in 54% yield and with 8:1 selectivity 
over 197h. It was discovered that trisubstituted cyclopropylureas containing aryl substituents at R2 are 
a limitation of the methodology. For example, phenyl cyclopropylurea 195e formed diazepane 196e in 
only 28% yield. Similarly, electron-rich aryl cyclopropylurea 195k cyclised to form diazepane 196k in 
a similarly poor 28% yield, which suggests that the poor reactivity is not due to N-aryl nucleophiles 
being less nucleophilic.  
 
Table 4: Scope of the (6+1) carbonylative cyclisation of trisubstituted cyclopropylureas. 
2.1.2.3 (6+1) carbonylative cyclisation of N,N’-disubstituted cyclopropylureas 
 The scope of the (6+1) carbonylative cyclisation with respect to N,N’-disubstituted 
cyclopropylureas was also investigated, and the results are shown in Table 5. Importantly, all the N,N’-




disubstituted cyclopropylureas favoured the formation of the saturated diazepane over the unsaturated 
variant. Thus, the C4-C5 oxidation level can be controlled by the choice of R1-substituent: when R1 = 
alkyl or aryl the unsaturated diazepane forms preferentially, but when R1 = H the saturated diazepane 
forms preferentially. In general, the magnitude of the oxidation level selectivity of N,N’-disubstituted 
cyclopropylureas (>1:12, 203:204) was less than for trisubstituted cyclopropylureas (typically >15:1, 
196:197). Mechanistic investigations into the factors governing oxidation level selectivity are presented 
in Section 2.1.4.1. 
N,N’-Disubstituted cyclopropylureas bearing alkyl R2-substituents were well tolerated in the 
cyclisation (see 204a-e) including sterically demanding variants such as tert-butylurea 202d (53% yield, 
1:4 203d:204d). The successful cyclisation of tert-butylurea 202d is significant as it suggests that Rh(I)-
addition to the cyclopropyl C-C bond is O-directed and not N-directed. Oxidation level selectivity was 
insensitive to the size of the R2-group (compare 204b, 204c, 204d), but was affected by the electronics 
of the nucleophile. For example, less nucleophilic aminoester 202e formed saturated product 204e in a 
1:1 ratio with its unsaturated analogue 203e.  
 
Table 5: Scope of the (6+1) carbonylative cyclisation of N,N’-disubstituted cyclopropylureas. 
 Interestingly, N-aryl nucleophiles performed well in the (6+1) carbonylative cyclisation of 
N,N’-disubstituted cyclopropylureas, which contrasts trisubstituted cyclopropylureas where N-aryl 
nucleophiles are a limitation (see 196e/k, Table 4). Phenylcyclopropylurea 202g reacted to form 
cyclisation product 204g in 67% yield and with good selectivity for the saturated product (1:12, 
203g:204g). The nucleophilicity of the N-aryl nucleophile was varied by incorporation of different 
para-substituents (see 202f (R = CF3) and 202h (R = OMe)) on the aryl ring. Both aryl ureas 202f and 
202h cyclised in high yield (71% and 63%, respectively), but electron-deficient aryl urea 202f was less 
selective for the saturated diazepane 204f (1:3 203f:204f vs. 1:12 203h:204h). Finally, monosubstituted 




cyclopropylurea 202i cyclised to form the unsaturated diazepane 203i in 54% isolated yield. The 
reported selectivity of the cyclisation of cyclopropylurea 202i reflects the fact that it was purified by 
filtration due to the low solubility of this compound.  
2.1.3 Scope of the (6+1) carbonylative cyclisation of substituted cyclopropanes 
 The optimised conditions for the (6+1) carbonylative cyclisation allowed the cyclisation of a 
diverse selection of trisubstituted and N,N’-disubstituted cyclopropylureas in generally high yields and 
with control over the oxidation level of the C4-C5 position. Next, the scope of the optimised conditions 
with respect to substrates composed of 1,2-disubstituted cyclopropanes and fused cyclopropanes was 
reinvestigated. In particular, further information was required in order to explain the unexpected 
regioselectivity of Rh(I)-addition to trans- and cis-1,2-disubstituted cyclopropanes (see Section 
1.4.2.2). Several representative 1,2-disubstituted cyclopropane-based substrates were prepared with 
simple alkyl R3-substituents (R3 = Me, n-Bu and c-Hex) of varying size. Additionally, fused 
cyclopropanes were investigated in the (6+1) carbonylative cyclisation. 
2.1.3.1 Synthesis of cyclopropylureas containing 1,2-disubstituted cyclopropanes 
In addition to the substrates containing 1,2-disubstituted cyclopropanes synthesised by 
McCreanor (indicated in Scheme 44), several others examples were prepared following a previously 
reported route (Scheme 44A).102 Initially, cyclohexylepoxide 210c was obtained by epoxidation of 
vinylcyclohexane 209c in 75% yield. Epoxides 210b (commercially available) and 210c underwent 
trans-selective Wadsworth-Emmons cyclopropanation with triethylphosphonoacetate (TEPA) to 
furnish cyclopropyl esters 211b and 211c in 94% and 79% yield, respectively.153 Hydrolysis then 
provided carboxylic acids 212b and 212c. Carboxylic acids 212a-c (212a was commercially available 
in a 5:1 d.r.) underwent Curtius rearrangement with diphenylphosphoryl azide (DPPA) in t-BuOH to 
provide Boc-protected amines trans-213a-c. Boc-deprotection using trifluoroacetic acid, and reductive 
amination with benzaldehyde provided benzyl amines trans-214a-c. At this point, diastereomers trans-
214a and cis-214b were separated by column chromatography, which provided access to both 
diastereomers of the (7+1) substrate. Benzyl amines 214a-c were treated with benzyl isocyanate to form 
the trisubstituted trans-cyclopropylureas trans-206a-c and cis-206a in 82–89% yield. Additionally, 
N,N’-disubstituted trans-cyclopropylureas trans-215b and trans-215c were formed in excellent yields 
from Boc-protected cyclopropylamines trans-213b and trans-213c by Boc-deprotection and urea 
formation. Enantioenriched trans-methyl cyclopropylcarboxylic acid (S,S)-208a was prepared from 
commercially available (R)-propylene oxide by a reported procedure154 and was advanced to 
enantiopure cyclopropylurea (S,S)-206a (99% e.e., not shown) by the same route. 





Scheme 44: A) Compounds trans-206a and cis-206a were prepared by McCreanor. Reagents and conditions: i) 
m-CPBA, CH2Cl2, 0 °C to r.t., 18 h, 75%; ii) triethylphosphonoacetate, n-BuLi, 1,2-DME, 130 °C, 18 h; iii) 4 M 
aq. NaOH, MeOH, r.t., 18 h; iv) DPPA, NEt3, t-BuOH, 80 °C, 17 h; v) TFA, CH2Cl2, r.t., 30 min then 
benzaldehyde, NaHCO3, MeOH, reflux, 18 h then NaBH4, 0 °C to r.t., 18 h; vi) benzyl isocyanate, CH2Cl2, r.t., 1 
h; vii) TFA, CH2Cl2, 0 °C to r.t., 30 min then benzyl isocyanate, CH2Cl2, r.t., 1 h. aCommercially available. b 
Commercially available in 5:1 (trans:cis) d.r.. cTrans- and cis-diastereomers were separated by chromatography. 
dSynthesised by McCreanor. B) Reagents and conditions: i) ethyl diazoacetate, Rh2(OAc)4, CH2Cl2, r.t., 16 h; ii) 
Lindlar’s catalyst, H2 (1 atm), EtOAc, r.t., 3 h; iii) NaOH, MeOH, r.t., 16 h; iv) DPPA, NEt3, t-BuOH, reflux, 48 
h; v) TFA, CH2Cl2, r.t., 16 h; vi) benzaldehyde, NaHCO3, MeOH, reflux, 16 h then NaBH4, 0 °C to r.t., 16 h; vii) 
benzyl isocyanate, NEt3, CH2Cl2, 0 °C to r.t., 1 h. 
 




 The synthesis of cis-cyclopropylurea cis-206b was carried out by McCreanor (Scheme 44B). 
1-Hexyne underwent Rh2(OAc)4-catalysed cyclopropenation with ethyl diazoacetate to form 
cyclopropene 217 in 69% yield. The cis-stereochemistry of the cyclopropane substituents was installed 
by heterogeneous hydrogenation of cyclopropene 217 using Lindlar’s catalyst to provide cis-
cyclopropane cis-211b in 76% yield as a single diastereomer. The remaining steps to form cis-
substituted cyclopropylureas cis-206b and cis-215b were analogous to that described for trans-
cyclopropylureas. 
2.1.3.2 (6+1) carbonylative cyclisation of trans-1,2-disubstituted cyclopropylureas 
 The substituted cyclopropylureas were subjected to the optimised (6+1) carbonylative 
cyclisation conditions. Previously, McCreanor observed that trans-cyclopropylurea trans-206a reacted 
via Rh(I)-addition to the more hindered cyclopropyl C-C bond “a” as opposed to bond “b” to provide 
C3-substituted diazepanes, which contrasted previous studies at Bristol (see Section 1.3.3). Under the 
optimised (6+1) carbonylative cyclisation conditions, trisubstituted cyclopropylureas containing  trans-
1,2-disubstituted cyclopropanes trans-206a and trans-206b also reacted via more hindered bond “a” to 
form C3-substituted diazepanes 208a and 208b in 70% and 59% yield, respectively (Table 1). By 
increasing the size of the cyclopropane R3-substituent the yield decreased as shown by trans-
cyclopropylurea trans-206c, which formed cyclohexyl-substituted diazepane 208c in 29% yield after 
73 h. Importantly, cyclisation of enantiopure trans-cyclopropylurea (S,S)-206a proceeded to form 
enantiopure diazepane (S)-208a with complete retention of the R3-substituted stereocentre (99% e.e.). 
This result confirms that the rhodacyclopentanone is configurationally stable under the reaction 
conditions. In each of these studies, the unsaturated products were formed as the sole product; the 
saturated diazepanes were not observed. 
 
Table 6: Scope of the (6+1) carbonylative cyclisation of trisubstituted cyclopropylureas containing trans-1,2-
disubstituted cyclopropanes. 




 N,N’-Disubstituted cyclopropylureas containing trans-1,2-disubstituted cyclopropanes were 
poor substrates for (6+1) carbonylative cyclisation because they formed complex mixtures of 
diazepanes (Table 7). For example, cyclisation of cyclopropylurea trans-215b proceeded with both low 
oxidation level selectivity (1:3, unsat:sat) and low regioselectivity (~1:1 r.r.) resulting in the formation 
of a complex mixture of four diazepanes (62% combined yield, ~1:4:1:2 218b:219b:220b:221b). The 
low regioselectivity observed for N,N’-disubstituted cyclopropylureas is in contrast to the trisubstituted 
cyclopropylureas presented in Table 6. Cyclohexyl-substituted cyclopropane trans-215c provided a 
similar product distribution and yield (57% combined yield, ~1:7:1:2, 218c:219c:220c:221c). 
 
Table 7: Scope of the (6+1) carbonylative cyclisation of disubstituted cyclopropylureas containing trans-1,2-
disubstituted cyclopropanes. 
2.1.3.3 (6+1) carbonylative cyclisation of cis-1,2-disubstituted cyclopropylureas 
 Previously, McCreanor observed that cis-cyclopropylurea cis-206a reacted via Rh(I)-addition 
to the less hindered cyclopropyl C-C bond “b” as opposed to bond “a” to provide predominantly C4-
substituted diazepanes, which contrasted previous studies at Bristol (see Section 1.3.3). Under the 
optimised cyclisation conditions, cis-cyclopropylureas cis-206a,b and cis-215b reacted in accordance 
with McCreanor’s findings. For example, trisubstituted cyclopropylureas cis-206a and cis-206b 
cyclised to form the C4-substituted diazepanes 207a and 207b with moderate regioselectivity (5:1 r.r. 
for 207a and 6:1 r.r. for 207b), but with complete selectivity for the unsaturated diazepane (Table 8). 
N,N’-Disubstituted cyclopropylurea cis-215b also cyclised via Rh(I)-addition to cyclopropyl C-C bond 
“b”, but with the characteristic reversal in oxidation level selectivity observed for N,N’-disubstituted 
cyclopropylureas (see Section 2.1.2.3), to form saturated diazepane 221b (58%, 5:1 r.r.). 





Table 8: Scope of the (6+1) carbonylative cyclisation of cyclopropylureas containing cis-1,2-disubstituted 
cyclopropanes. 
2.1.3.4 Fused cyclopropylureas 
Cyclopropylureas containing fused cyclopropanes are valuable substrates for the (6+1) 
carbonylative cyclisation because they provide access to bicyclic diazepanes. Also note that the 
proximal C-C bonds of fused cyclopropanes (see bonds “p”, Scheme 45) are chemically identical, which 
eliminates the issue of regioselectivity in the Rh(I)-addition step. Previously, McCreanor discovered 
that cyclopropylurea trans-222, which contains a trans-fused cyclopropane, failed to undergo (6+1) 
carbonylative cyclisation (Scheme 45). It was proposed that the failure to cyclise was a result of a 
developing steric clash between the [Rh]-centre and fused-cyclohexane ring during C-N reductive 
elimination from rhodacyclopentanone 223. Additionally, the [Rh]-centre of resulting diazepane 224 
does not possess a syn--hydrogen for -hydride elimination. It was proposed that the cis-fused 
diastereomer cis-222, would be a suitable substrate for cyclisation because C-N reductive elimination 
from the corresponding rhodacyclopentanone, 225, would be accompanied by a minimal developing 
Scheme 45: Mechanistic rationale for the failed cyclisation of trans-fused cyclopropylurea trans-222. 




steric clash. Furthermore, the [Rh]-centre of intermediate 226 possesses a syn--hydrogen in order to 
form product 227. To test this hypothesis, cis-fused cyclopropane cis-222 was synthesised and subjected 
to the cyclisation conditions. 
The synthesis of cis-fused cyclopropane cis-222 was achieved using a cis-diastereoselective 
carbamatoorganozinc carbenoid-mediated aminocyclopropanation of alkenes, reported by Motherwell 
(Scheme 46A).155 The proposed mechanism of Motherwell’s reaction proceeds by Lewis acid-mediated 
condensation of methyl carbamate with triethyl orthoformate to form iminium species 228. Iminium 
228 is reduced by a zinc/copper amalgam to form zinc(II)-species 229, which serves as a carbene 
equivalent in the cyclopropanation of alkenes. Motherwell suggests that the cis-diastereoselectivity 
arises as a result of preferential approach of the alkene to zinc(II)-species 229, such that the R-
substituent is directed away from the bulky zinc centre (i.e. TS1 is favoured over TS2). 
 
Scheme 46: B) Reagents and conditions: i) methyl carbamate, Cu powder, Zn powder, ZnCl2, TMSCl, (EtO)3CH, 
Et2O, r.t., 18 h; ii) TMSI, CH2Cl2, reflux, 1 h then MeOH, reflux, 30 min; iii) benzaldehyde, NaHCO3, MeOH, 
reflux, 16 h then NaBH4, 0 °C to r.t., 12 h; iv) benzyl isocyanate, NEt3, CH2Cl2, 0 °C to r.t., 1 h. 
 
 




Under Motherwell’s conditions, cyclohexene underwent aminocyclopropanation to form cis-
fused aminocyclopropane cis-230 in 90% yield and 3:1 d.r. (Scheme 46B). The carbamate of 
aminocyclopropane cis-230 was removed in 87% yield using iodotrimethylsilane, and the resulting 
amine hydroiodide salt cis-231 underwent efficient reductive amination with benzaldehyde to form 
benzyl amine cis-232 in 71% yield. At this point the trans- and cis-diastereomers were partially 
separated by chromatography. Urea formation with benzyl isocyanate (93%) provided cis-fused 
substrate cis-222 as a single diastereomer. Additionally, N,N’-disubstituted cyclopropylurea cis-233 
was prepared by urea formation directly from amine hydroiodide salt cis-231 in 77% yield and 4:1 d.r. 
(inseparable mixture). Under the optimised (6+1) carbonylative cyclisation conditions, cis-fused 
substrate cis-222 formed bicyclic diazepane 227 in 54% yield (Scheme 47) thereby confirming the 
hypothesis proposed in Scheme 45. Additionally, N,N’-disubstituted substrate cis-233 (4:1 d.r.) cyclised 
to form a mixture of bicyclic diazepanes 234 (C3-C4 unsaturated) and 235 (C3-C4 saturated), where 
the alkene migrated into the presumably more stable tetrasubstituted position. 
 
Scheme 47: (6+1) carbonylative cyclisation of cis-fused cyclopropylureas. 
In conclusion, the optimised conditions for the (6+1) carbonylative cyclisation allow the 
efficient cyclisation of a diverse selection of trisubstituted and N,N’-disubstituted cyclopropylureas 
including multiple examples bearing substituted cyclopropanes. At this point, efforts were directed to 
gaining a better understanding of the mechanism of the (6+1) carbonylative cyclisation. In particular, 
an understanding of the factors which govern the oxidation level of the C4-C5 positions of the 
diazepanes and the regioselectivity of reactions involving 1,2-disubstituted cyclopropanes was desired. 
2.1.4 Mechanistic Studies into the (6+1) carbonylative cyclisation 
 Mechanistic studies were conducted to gain a better understanding of the factors that govern 
the oxidation level selectivity of the C4-C5 position of diazepanes (Section 2.1.2.2 and 2.1.2.3) and the 
unexpected regioselectivity of C-C oxidation addition to 1,2-disubstituted cyclopropanes (Section 




2.1.3). Information obtained in these studies is of general interest to the broader project because it might 
aid the control of selectivity in related processes. 
2.1.4.1 C4-C5 oxidation level selectivity 
 Previously it had been observed that the oxidation level of the C4-C5 position of diazepanes 
could be controlled by the choice of R1-substituent; specifically when R1 = alkyl or aryl the unsaturated 
diazepane forms preferentially, but when R1 = H the saturated diazepane forms preferentially. Efforts 
to override the substrate dependent selectivity by altering the cyclisation conditions failed, further 
highlighting the importance of the R1-substituent (Section 1.4.2.1). Notably, varying the amount of 
benzoic acid additive did not influence the oxidation level selectivity, which indicates that 
protodemetallation from intermediate 200 (see Scheme 48) might not be promoted by the addition of 
more acid.   
 It was originally proposed that the importance of the R1-substituent in determining the oxidation 
level of diazepanes was due to a steric interaction between the Rh(I)-moiety and R1-substituent of 
intermediate 200 (Scheme 48). When R1 is large (i.e. alkyl or aryl), the Rh(I)-moiety is pushed towards 
the C4-syn--hydrogen thereby promoting -hydride elimination.  In contrast, when R1 is small (i.e. R1 
= H) the steric repulsion is minimised, increasing the lifetime of intermediate 200 and resulting in a 
higher degree of protodemetallation. This mechanistic proposal was investigated by performing a 
deuterium incorporation experiment with deuterated N,N’-disubstituted cyclopropylurea d-202a 
(Scheme 49). In this way, the site of protodemetallation would be indicated by the presence of deuterium 
in the product diazepane 204a.  
 
Scheme 48: Initial rationale for C4-C5 oxidation level selectivity afforded by the R1-substituent. 
 Initially, deuterated N,N’-disubstituted cyclopropylureas d-202a (>95% deuterium 
incorporation at the indicated positions) was prepared by dissolving cyclopropylurea 202a in d4-
methanol and concentrating in vacuo three times (Scheme 49). Upon cyclisation, cyclopropylurea d-
202a provided diazepanes d-204a and 203a in 65% yield (2.5:1 d-204a:203a). Analysis of the product 
mixture by 1H and 2D-NMR revealed that saturated diazepane d-204a had significant deuterium 
incorporation at positions C3 (0.40 D), C4 (0.16 D) and C5 (0.56 D). No deuterium was observed on 
unsaturated diazepane 203a. Incomplete deuterium incorporation in saturated product d-204a is likely 
due to the presence of protic impurities, such as water, in the reaction solvent. 




 The result of the deuterium incorporation experiment on d-202a cannot be fully explained by 
the mechanism proposed in Scheme 48. Deuterium incorporation at C5 of saturated diazepane d-204a 
was expected, and presumably results from deuterodemetallation from intermediate 236 (Scheme 49). 
Deuterium incorporation at C4 and C3 was not expected, but might be explained by a reversible 
sequence of -hydride elimination and hydrometallation steps from intermediate 236, which would 
provide access to regioisomers 237 and 238. Deuterodemetallation from intermediates 237 and 238 
would explain the observed deuterium incorporation at C4 and C3 of saturated diazepane d-204a. At 
the time being it is not understood why no deuterium is incorporated into unsaturated diazepane 203a. 
 
Scheme 49: Deuterium incorporation experiment using d-202a and proposed reversible -hydride elimination. 
 To provide further evidence for the reversible -hydride elimination step implicated in Scheme 
49, a second deuterium incorporation experiment was performed on cis-1,2-disubstituted 
cyclopropylurea d-cis-215b (Scheme 50). It was postulated that the presence of a C4-n-butyl substituent 
would hinder the reversible -hydride elimination step resulting in less deuterium being incorporated 
at C4 and C3 of diazepane d-221b. Deuterated substrate d-cis-215b was prepared in an identical manner 
to d-202a. Under the (6+1) carbonylative cyclisation conditions, C4-substituted diazepane d-221b was 
isolated in 47% yield, but the C3-regioisomer 219b was not isolated. 1H and 2D-NMR analysis of C4-
substituted diazepane d-221b showed deuterium incorporation at both diastereotopic C5-positions, Dtrans 
(0.23 D)  and Dcis (0.19 D), and a trace amount at C4 (<0.05 D). No deuterium incorporation was 
measured at C3, which reduces the possibility of a deprotonation/deuteration sequence being 
responsible for deuteration of the C3-position of d-204a in the experiment above (Scheme 49). 
 Once again, the result of the deuterium incorporation experiment on d-cis-215b cannot be fully 
explained by the mechanism proposed in Scheme 49. Deuterium incorporation at Dtrans and C4 was 
expected, and is presumably a result of deuterodemetallation from intermediates 239 and 240, 
respectively. The lower magnitude of deuterium incorporation at C4 (<0.05%) of d-221b was also 
predicted as a result of an unfavourable equilibrium between C5-metallated intermediate 239 and C4-




metallated intermediate 240. However, deuteration of the C5-diastereotopic position, Dcis, is not 
explained by reversible -hydride elimination because -hydride elimination and hydrometallation are 
syn-specific processes. Therefore, deuteration of Dcis is proposed to proceed via intermediate imine 241 
from which deuterometallation could occur from either diastereotopic face of the imine. Imine 241 
could arise by two routes; tautomerisation of unsaturated diazepane 220b under the acidic conditions 
of the (6+1) carbonylative cyclisation, or by metallation of the N-H bond of saturated diazepane d-221b 
followed by C5--hydride elimination. The second mechanistic proposal, involving N-H metallation 
and -hydride elimination, is proposed because of an observation made by McCreanor regarding the 
successful cyclisation of trans-fused-cyclopropane trans-233.  
 
Scheme 50 
 McCreanor found that N,N’-disubstituted cyclopropylurea trans-233, which is composed of a 
trans-fused cyclopropane, underwent successful cyclisation to form bicyclic diazepanes 234 and 235 in 
a 1:1 ratio and in 76% combined yield (Scheme 51). The formation of saturated 235 was expected (i.e. 
by protodemetallation from intermediate 242), but it was not clear how unsaturated diazepane 234 was 
formed because -hydride elimination from intermediate 242 cannot take place due to the absence of a 
syn--hydrogen to the [Rh]-centre. It was proposed that N-H metallation of saturated product 235 by a 
Rh(I)-species gives Rh(I)-amine complex 243 from which -hydride elimination forms imine 244. 




Rh(I)-mediated dehydrogenation of secondary amines is a known process.156-157 Tautomerisation of the 
unsaturation of imine 244, to the presumably more stable tetrasubstituted position, provides diazepane 
234. Alternatively, -hydride elimination from intermediate 242 would give direct access to imine 244, 
however this was deemed unlikely because electron-withdrawing -substituents are known to retard -
hydride elimination.158 It would be informative to resubject pure saturated 235 to the cyclisation 
conditions to prove if this is indeed an intermediate in the formation of unsaturated 234, but this 
experiment was not carried out. 
 
Scheme 51: Mechanistic rationale for the (6+1) carbonylative cyclisation of N,N’-disubstituted trans-fused 
cyclopropylurea trans-233. 
The deuterium incorporation studies detailed in this section demonstrate that reversible -
hydride elimination from intermediates 200 is operative when R1 is small (i.e. R1 = H), which, in turn, 
promotes the formation of saturated diazepanes (Scheme 52). However, preliminary evidence obtained 
from the reaction of cis-1,2-disubstituted cyclopropane cis-206b suggests that unsaturated diazepanes 
may also be formed by the Rh(I)-mediated dehydrogenation of saturated diazepanes. Further evidence 
to this effect may be gained by resubjecting saturated diazepanes to the reaction conditions. 
 
Scheme 52: Current mechanistic understanding of the factors affecting C4-C5 oxidation level selectivity. 




2.1.4.2 Regioselectivity of the (6+1) carbonylative cyclisation of 1,2-disubstituted 
cyclopropanes 
 McCreanor’s studies and those presented in Section 2.1.3, involving the (6+1) carbonylative 
cyclisation of trans- and cis-1,2-disubstituted cyclopropylureas, demonstrate product regioselectivities 
which are opposite to that expected based on prior work carried out at Bristol (see Section 1.3.3). Trans-
1,2-disubstituted cyclopropanes were expected to react via Rh(I)-addition to the least sterically hindered 
C-C bond “b”, but were observed to react via the more hindered C-C bond “a” (Scheme 53). 
Furthermore, cis-1,2-disubstituted cyclopropanes were expected to react via the more sterically 
hindered bond “a”, but were observed to react via the less hindered bond “b”. Mechanistic studies were 
carried out to investigate the reasons for the unexpected regioselectivity.  
 
Scheme 53: Unexpected regioselectivity of the (6+1) carbonylative cyclisation of 1,2-disubstituted 
cyclopropylureas. 
 Previously, Shaw investigated the regioselectivity of Rh(I)-addition to 1,2-disubstituted 
cyclopropanes in the presence of CO by generating stable rhodacyclopentanones.101-102 Trans-
cyclopropylcarbamate trans-174a formed complex 246 by Rh(I)-addition to the less hindered C-C bond 
“b” whereas cis-cyclopropylcarbamate cis-174b formed complex 175 by Rh(I)-addition to the more-
hindered bond “a” (Scheme 54A). Then, insertion experiments (in the absence of CO) were carried out 
on the same cyclopropylcarbamates to confirm that the presence of CO did not influence the 
regioselectivity of Rh(I)-addition (Scheme 54B). In the event, trans-cyclopropylcarbamate trans-174a 
formed branched alkene 248a in 64% yield via insertion into expected C-C bond “b”. Cis-
cyclopropylcarbamate cis-174b formed linear alkene 247b in 45% yield via insertion into expected C-
C bond “a” along with 4% of branched isomer 248b. These results confirm that CO does not influence 
the regioselectivity of the C-C insertion step.   






Next, insertion experiments were performed on trans- and cis-1,2-disubstituted 
cyclopropylureas, trans-206a and cis-206a, to determine whether the urea directing group influenced 
the regioselectivity of Rh(I)-addition (Scheme 54C). In the absence of CO, trans-cyclopropylurea trans-
206a provided branched alkene 250 in 86% yield via insertion into the expected bond “b”. When cis-
cyclopropane cis-206a was subjected to the same conditions, linear alkene 249 was formed in 37% 
yield along with 4% of the branched regioisomer. Both of these results are in accordance with the 
previously reports and are in contrast to the regioselectivity of the (6+1) carbonylative cyclisation of 
cyclopropylureas observed by McCreanor and in Section 2.1.3. Therefore, it was concluded that product 
regioselectivity in the (6+1) carbonylative cyclisation of 1,2-disubstituted cyclopropane substrates is 




not a result of the urea directing group, but might be a result of reversible rhodacyclopentanone 
formation, whereby the selectivity is determined by a process other than the initial C-C oxidative 
addition step. 
 A model for the observed regioselectivity of trans-cyclopropylureas is proposed in Scheme 
55A. Based on previous studies, trans-cyclopropylureas trans-206 favours formation of 
rhodacyclopentanone 251 via Rh(I)-addition to C-C bond “b”. However, C-N reductive elimination to 
form intermediate 252 is slow due to a developing steric clash between the [Rh]-centre and R3-
substituent. Rhodacyclopentanone 251 therefore reverts to trans-cyclopropylureas trans-206  by retro-
carbonylation and C-C reductive elimination. Under equilibrium the disfavoured rhodacyclopentanone 
253 forms via Rh(I)-addition to hindered C-C bond “a” of cyclopropane trans-206. C-N Reductive 
Scheme 55 




elimination from intermediate 253 is fast because of the less demanding 1,3-relationship between the 
[Rh]-centre and R3-substituent of diazepane 254. -Hydride elimination from diazepane 254 provides 
C3-substituted diazepane 208. In cases where R1 = H, low regioselectivity is observed (see Table 7). 
This might be explained by considering the formation of corresponding intermediate 252 where the 
developing steric clash between the [Rh]-centre and R3-substituent is alleviated by the presence of a 
small R1-substituent (R1 = H). 
 A related argument for the selective formation of C4-substituted diazepanes from cis-1,2-
disubstituted cyclopropylureas is illustrated in Scheme 55B. Rhodacyclopentanone 256a is formed by 
favourable Rh(I)-addition to the more electron-rich bond “a” of cis-cyclopropylurea cis-206 and ligand 
exchange forms 256b. However, C-N reductive elimination from 256b is accompanied by a developing 
steric clash between the R2- and R3-substituents (shown on 256b). As a result, reversible 
rhodacyclopentanone formation allows equilibration to disfavoured rhodacyclopentanone 255a from 
which ligand exchange and all proceeding steps are facile, resulting in the selective formation of C4-
substituted diazepanes. Thus, the observed regioselectivity of the (6+1) carbonylative cyclisation is 
determined by the ease of C-N reductive elimination and not by Rh(I)-addition to the cyclopropane.  
2.1.5 Conclusion 
 Building on McCreanor’s discovery, the (6+1) carbonylative cyclisation of cyclopropylureas 
to form 1,3-diazepanes in which the key step is the nucleophilic addition of a N-nucleophile to a 
rhodacyclopentanone, was developed. The optimised conditions allowed the efficient cyclisation of 
diverse trisubstituted and N,N’-disubstituted cyclopropylureas including multiple classes of substituted 
cyclopropane. Furthermore, the oxidation level of the C4-C5 position of the product diazepanes could 
be controlled by the choice of the R1-substituent. The regioselectivity observed when 1,2-disubstituted 
cyclopropanes were employed was controlled by the C-N reductive elimination step and not by the 
initial C-C insertion step as in previous methodologies from the group. This preliminary example serves 
as a proof-of-concept for a broader strategy for the formation of medium-sized rings by the 
intramolecular nucleophilic trapping of rhodacyclopentanones. 
  




2.2 Further investigations into intramolecular nucleophilic addition to 
rhodacyclopentanones 
  The (6+1) carbonylative cyclisation of cyclopropylureas, described in Section 2.1, served as a 
proof of concept for a strategy for the formation of seven-membered, or larger heterocycles by 
intramolecular nucleophilic addition to rhodacyclopentanones. Subsequently, the generality of this 
process was investigated with the aim of identifying a second intramolecular protocol and gaining 
further insight into the factors governing the success of the cyclisation. 
2.2.1 Prior studies carried out by McCreanor 
 Prior to the discovery of the (6+1) carbonylative cyclisation of cyclopropylureas, McCreanor 
investigated several intramolecular systems that failed to undergo the desired carbonylative cyclisation 
(Scheme 56A). Notably, all the substrates were aminocyclopropane derivatives equipped with an amide 
directing group. Amides had previously been measured (by the CO stretching frequency of model 
rhodacyclopentanones, Section 1.3.1) to be weaker directing groups than carbamates and ureas, and 
were less effective in previous carbonylative cyclisations (Section 1.3.2). Furthermore, McCreanor 
investigated a narrow selection of nucleophiles (alcohols, phenols and an amide) most of which had 
been successful in the intermolecular protocol (Section 1.4.1).  
 During his investigations, McCreanor identified several side-products, which provide 
information regarding the problematic steps in the proposed catalytic cycles (Scheme 56B). For 
example, under Rh(I)-catalysed carbonylative conditions, several of the substrates shown in Scheme 
56A formed linear alkenes 260, or linear alkene adducts 261 (formed by intramolecular nucleophilic 
addition to the corresponding alkene). Linear alkenes 260 are formed by Rh(I)-addition to the proximal 
cyclopropyl C-C bond of aminocyclopropanes 257 and degradation of the resulting rhodacyclobutanes 
258 (via a similar mechanism to the insertion experiments discussed in Section 1.3.1). It has previously 
been mentioned that rhodacyclobutanes 258 are rapidly and reversibly converted to 
rhodacyclopentanones 259 in the presence of CO. Therefore, the formation of linear alkenes 260 (or 
alkene adducts 261) is considered indirect proof that the desired rhodacyclopentanone was formed, and 
consequently that one of the proceeding catalytic steps (directing group dissociation, nucleophile 
association, deprotonation or C-Nu reductive elimination) had failed. McCreanor also observed the 
formation of decyclopropanated side-products 262, which are formed by either directed or undirected 
Rh(I)-addition to the cyclopropane and hydrolysis of the resulting alkene. Therefore, decyclopropanated 
side-products are not an indication that Rh(I)-addition was directed. 






2.2.2 Attempts to identify a second intramolecular protocol 
 In order to investigate the generality of the nucleophilic cyclisation strategy outlined in Scheme 
37, several cyclopropane-based substrates were designed and tested. In the course of these 
investigations, the three main components of a cyclisation substrate (the cyclopropane, directing group 
and nucleophile) were varied. Typically, each substrate was reacted under several carbonylation 
conditions, which included a cationic Rh(I)-catalyst ([Rh(cod)2]BARF, [Rh(cod)2]BF4, or 
[Rh(cod)2]OTf), triarylphosphine ligand (typically PPh3 or P(3,5-bis(CF3)C6H3)3) and solvent (typically 
1,2-DCB or benzonitrile), in accordance with previous studies. Each reaction was run under a balloon-
pressure of CO and heated between 100–150 °C (or higher if little reactivity is observed) for at least 16 
hours.  
2.2.2.1 Homologated-cyclopropylureas  
 The success of the (6+1) carbonylative cyclisation of cyclopropylureas prompted investigations 
into homologated system 263, which upon cyclisation would form 1,3-diazocanes 265 (Scheme 57A). 




Here, an “electron-neutral” cyclopropylmethyl moiety is employed instead of an “electron-rich” 
aminocyclopropane. In general, electron-rich cyclopropanes are more susceptible to Rh(I)-addition than 
electron-deficient analogues.106,159 Furthermore, the additional methylene unit between the 
cyclopropane and directing group requires a six-membered chelate between the rhodacyclopentanone 
and directing group (see intermediate 264), which might hinder directed C-C oxidative addition. In 
order to investigate this proposal, trisubstituted cyclopropylmethylureas 263a and N,N’-disubstituted 
ureas 263b-d were synthesised in excellent yields (75–92%) by reacting the corresponding 
cyclopropylmethylamine (266a or 266b) with the desired isocyanate  (Scheme 57B). 
 
Scheme 57: A) Reagents and conditions: i) NEt3, CH2Cl2, r.t., 2 h. 
 Initially, insertion experiments were conducted on trisubstituted urea 263a and N,N’-
disubstituted urea 263b to determine whether directed Rh(I)-addition to the homologated cyclopropane 
was feasible (Scheme 58A). In the absence of CO, trisubstituted urea 263a underwent directed Rh(I)-
addition to form linear alkenes 267 in 50% yield, and none of the branched alkene was observed. Under 
identical conditions, N,N’-disubstituted urea 263b reacted to form cyclic urea 268 in 36% yield. Cyclic 
urea 268 is proposed to have formed by initial formation of linear alkene 269 (not observed). Transfer 
of the alkenyl fragment from one equivalent of alkene 269 to another equivalent of 269 could form 
dialkenyl species 270, which could undergo an intramolecular Mannich-type cyclisation to form 268. 
The formation of linear alkenes 267 and cyclic urea 268 indicate that Rh(I)-addition to the homologated 
cyclopropane of substrates 263a and 263b is directed, which set the stage for subsequent investigations 
into the carbonylative cyclisation of homologated cyclopropylureas.  




 Next, homologated ureas 263a-d were reacted under carbonylative cyclisation conditions 
(Scheme 58B). Initially, trisubstituted urea 263a was treated with various combinations of cationic 
Rh(I)-catalysts and mono-/bidentate phosphine ligands in the non-coordinating solvent 1,2-DCB, which 
resulted in the formation of linear alkenes 267 (50%) and none of the desired product 265a. Similarly, 
when N,N’-disubstituted urea 263b was subjected to carbonylative conditions, the desired diazocane 
265b was not observed. The formation of linear alkenes 267 from the reaction of trisubstituted urea 
263a indicates that the rhodacyclopentanone was being formed, but that one of the following steps 
failed. Therefore, bulky disubstituted ureas 263c and 263d were reacted under identical conditions in 
the hope that the large R2-substituents (t-Bu and mesityl) would promote C-N reductive elimination 
from rhodacyclopentanones 271.158 In the event, both homologated cyclopropylureas failed to form the 
corresponding (7+1) carbonylative cyclisation products 265c or 265d. At this point, investigations into 
the homologated cyclopropylureas were paused in favour of alternative systems. 
 
Scheme 58 




2.2.2.2 Carbon nucleophiles 
 Up until this point, only a narrow range of O- and N-based functional groups had been 
investigated as nucleophiles for addition to rhodacyclopentanones, and so alternative nucleophilic 
functional groups were considered. This led to the identification of enolates as potential C-based 
nucleophiles because enolates are known to undergo transmetallation with various transition metals, 
including rhodium, to form transition metal enolates.160-161 In order to investigate the feasibility of 
enolate addition to rhodacyclopentanones, cyclopropylamides 272, which contain enolisable C4-
positions, were designed (Scheme 59A). The cyclisation of cyclopropylamides 272 was proposed to 
begin with amide-directed formation of rhodacyclopentanone 274. Deprotonation of the C4-position of 
rhodacyclopentanone 274 would be facilitated by coordination to the Rh(III)-species, resulting in the 
formation of O-bound Rh(III)-enolate 275. Tautomerisation to C-bound Rh(III)-enolate 276 and C-C 
reductive elimination would ultimately form azepanes 273.  
 
Scheme 59: B) Reagents and conditions: i) phenylacetyl chloride, NEt3, CH2Cl2, 0 °C, 4 h; ii) cyanoacetic acid, 
DCC, DMAP, CH2Cl2, 0 °C to r.t., 4 h; iii) ethyl benzoylacetate, DMAP, PhMe, reflux, 18 h. 
 To test the hypothesis in Scheme 59A, cyclopropylamides 272a-c were synthesised with 
different anion-stabilising R2-substituents, in order to test nucleophilic C4-positions with a range of 




pKas (Scheme 59B). Phenyl derivative 272a was prepared by coupling benzylcyclopropylamine with 
phenylacetyl chloride in 51% yield. Cyano-derivative 272b was accessed by DCC-coupling of 
benzylcyclopropylamine and cyanoacetic acid in 53% yield, and dicarbonyl substrate 272c was formed 
in 91% yield by reacting benzylcyclopropylamine with ethyl benzoylacetate in the presence of DMAP.  
 Cyclopropylamides 272a-c were then exposed to a range of carbonylative cyclisation 
conditions. Phenyl derivative 272a underwent Rh(I)-addition to form linear alkenes 277 in 41% yield, 
but did not provide the desired azepane 273a (Scheme 59C). The formation of linear alkene 277 
suggested that rhodacyclopentanone 274 was formed, but enolate addition did not take place. Therefore, 
several inorganic bases (NaHCO3, CsCO3, KH2PO4) were included in the reaction to promote 
deprotonation of the C4-position, but this hindered Rh(I)-addition to the cyclopropane such that 
substrate 272a remained unreacted. Additionally, substrates 272b and 272c, bearing more acidic C4-
positions, also failed to form the desired azepanes under carbonylative cyclisation conditions. The 
apparent difficulty in accessing intermediate Rh(III)-enolates 275/276 appeared to hinder carbonylative 
cyclisation. This difficulty could be circumvented by forming the Rh(III)-enolates via a different order 
of catalytic steps. For example, C-bound Rh(I)-enolate 276 might be accessed by transmetallation of a 
preformed metal enolate 278,160, 162-163 or by 1,4-addition of a Rh(I)-species to cyclopropylacrylamide 
279 (Scheme 60). Resulting C-bound Rh(I)-enolate 280 formed in each case might undergo 
intramolecular Rh(I)-addition to the proximal cyclopropane C-C bond and carbonylation to provide an 
alternative entry to rhodacyclopentanone 276. These proposals were not investigated at this stage. 
 
Scheme 60: Alternative entry to rhodacyclopentanone 276 via initial formation of a Rh(I)-enolate. 
2.2.2.3 Modular substrates for systematic investigations 
 In the two systems described so far (Scheme 58 and 59), linear alkenes were the only discernible 
side-products of the attempted carbonylative cyclisation, which indicated that one of the steps after 
rhodacyclopentanone formation failed. Aside from the evidence provided by linear alkenes, no 
information regarding the problematic catalytic step could be derived because the cyclisation systems 
were significantly different. Therefore, a modular substrate was designed to allow each of the basic 




substrate components (cyclopropane, directing group and nucleophile) to be independently varied, 
thereby allowing a systematic study of the factors affecting cyclisation to form eight-membered 
heterocycles 281 (Scheme 61A). Key to this proposal was the use of a modular substrate, which could 
be prepared from a pool of electronically diverse nucleophile and directing group precursors. Cyclic 
sulfamidates were identified as particularly useful nucleophile precursors because these allowed the 
electronic properties of the nucleophile to be tuned through the choice of protecting group (PG) (Scheme 
61B).164 Additionally, cyclic sulfamidates are readily prepared from aminoalcohols of which many 
chiral analogues are commercially available.  
 
Scheme 61: C) Reagents and conditions: i) NaH, DMF, 30 min, r.t. then 2 M HCl, r.t., 30 min; ii) TFA, CH2Cl2, 
r.t., 1 h; iii) TsCl, NEt3, CH2Cl2, 0 °C to r.t., 16 h. 
 Experiments began with the synthesis of cyclopropylcarbamates 284a-c bearing a carbamate 
directing group and electronically differentiated N-nucleophiles (Scheme 61C). Cyclopropylcarbamate 
282 was deprotonated with NaH in DMF and treated with Boc-protected sulfamidate 283, which 
provided substrate 284a in 86% yield upon hydrolysis of intermediate 285. Boc-deprotection with 
trifluoroacetic acid proceeded to form primary amine 284b in 96% yield, which was then reacted with 
p-toluenesulfonyl chloride to form sulfonamide 284c in 50% yield. Using cyclic sulfamidate 283, three 
potential cyclisation substrates (284a-c) were synthesised in only five steps. 




Cyclopropylcarbamates 284a-c were subjected to several carbonylative cyclisation conditions, 
but desired diazepanes 287a-c were not observed (Scheme 62A). When N-tosyl substrate 284c was 
reacted, imidazolidine 286b was formed in 37% yield by intramolecular cyclisation of linear alkene 
288c, again suggesting that the cyclisation failed to proceed past the formation of the 
rhodacyclopentanone. It was considered that the proposed equilibrium between five-membered chelate 
289 and eight-membered chelate 299 would significantly favour the smaller of the two, thereby 
restricting coordination of the nucleophile to the Rh(III)-centre (Scheme 62B). A solution to this 
problem was envisaged in which the nucleophile also acts as a directing group for Rh(I)-addition to the 
cyclopropane. If successful, rhodacyclopentanone 300 would be formed thus avoiding a ligand 
exchange step (Scheme 62C).  
 
Scheme 62 
In order to test the hypothesis in Scheme 62C, cyclopropylanilines 302a and 302b, and 
aminoalcohol 303 were prepared (Scheme 63A). Cyclopropylaniline 301 was prepared by a Buchwald-
Hartwig amination with cyclopropylamine before being deprotonated with n-BuLi and reacted with 
Boc-sulfamidate 283, which resulted in the smooth formation of Boc-amine 302a in 81% yield. Boc-
deprotection and tosylation then provided tosylamine 302b in 15% yield over two steps. Aminoalcohol 
303 was prepared in 84% yield by ZnCl2-mediated nucleophilic ring-opening of ethylene oxide.  





Scheme 63: A) Reagents and conditions: i) bromobenzene, Pd2dba3, BINAP, sodium pentoxide, PhMe, 130 °C, 
16 h; ii) 283, n-BuLi, THF, 30 min, r.t. then aq. 2 M HCl, 30 min; iii) TFA, CH2Cl2, 0 °C to r.t. then TsCl, NEt3, 
CH2Cl2, 0 °C to r.t., 16 h; iv) ethylene oxide, ZnCl2, THF, r.t., 19 h. 
The attempted cyclisation of cyclopropylanilines 302a and 302b did not form desired 
diazocanes 305a/b, but did provide imidazolidines 304a (52% from 302a) and 304b (37% from 302b) 
(Scheme 63B). The formation of imidazolidines (presumably via linear alkenes 306) is an indication 
that Rh(I)-addition was directed by the nucleophile. When aminoalcohol 303 was reacted under 
carbonylative cyclisation conditions, linear alkane 307 was formed as the sole discernible product in 
29% yield (Scheme 63C). Linear alkane 307 is likely the product of reduction of linear alkene 308 by 
a Rh(III)-mediated transfer hydrogenation mechanism. Here, an alcohol would serve as a reductant 
forming aldehyde side-products 309 although these were not observed. Similar Rh(III)-catalysed 
transfer hydrogenations are known.165 Nevertheless, the formation of imidazolidines 304a and 304b, 
and linear alkane 307 implies that the nucleophiles were successful in directing Rh(I)-addition to 
cyclopropanes, but that one of the following catalytic steps failed. Having failed to achieve a 
carbonylative cyclisation of various substrates based on the modular system described in Scheme 61A, 
studies were moved to another example. A more informative systematic evaluation of the components 




of a successful nucleophilic trapping of rhodacyclopentanones would require the initial identification 
of a viable cyclisation substrate.  
2.2.2.4 Substrates for the synthesis of larger ring systems 
Medium-sized (defined as eight- to eleven-membered rings) cycloalkanes possess significant ring strain 
(approximate strain energy values of 9.4 kcal/mol for cyclooctane to 11.1 kcal/mol for 
cycloundecane166), which drops off substantially for twelve-membered rings (approximate strain energy 
values of 4.0 kcal/mol for cyclododecane166). In terms of lactones, the drop off in ring strain occurs on 
going from simple nine-membered lactones (approximate strain energy value of 11.6 kcal/mol167) to 
ten-membered lactones (approximate strain energy value of 8.2 kcal/mol167). Analysis of these values 
led Galli and Mandolini to conclude that the ring strain of the cyclisation product was a factor in their 
formation from linear substrates.148 Therefore, reductive elimination from rhodacyclopentanones to 
form medium-sized rings must be sufficiently exergonic to incorporate the ring strain of the product 
heterocycle, and this might have been a factor in the failed carbonylative cyclisations discussed so far.  
 
Scheme 64: B) Reagents and conditions: i) 6-hydroxyhexanoic acid, EDCI, DMAP, CH2Cl2, 0 °C to r.t., 16 h; ii) 
6-bromohexan-1-ol, MeCN, 80 °C, 6 h then dimethylcarbamoyl chloride, NEt3, CH2Cl2, 0 °C, 3 h. 
With this in mind, investigations were directed towards the formation of less strained twelve-
membered ring systems by cyclisation of substrates 310 bearing long nucleophile tethers (Scheme 64A). 
The proposed mechanism of cyclisation involves initial formation of rhodacyclopentanone 311 
followed by ligand exchange between the directing group and nucleophile. Reductive elimination from 
rhodacycle 312 would form twelve-membered lactones 313. Presumably, the use of a long nucleophile 
tether disfavours equilibration from five-membered chelate 311 to 10-membered rhodacycle 312 
thereby inhibiting cyclisation. Nevertheless, substrates 314 and 315 were targeted (Scheme 64B). Ester 




substrate 314 was formed in 84% yield, by EDCI-coupling of cyclopropylamine with 6-
hydroxyhexanoic acid. Urea substrate 315 was formed in 32% yield by a one-pot procedure involving 
initial alkylation of cyclopropylamine with 6-bromohexan-1-ol, followed by urea formation with 
dimethylcarbamoyl chloride. Unfortunately, when cyclisation substrates 314 and 315 were subjected to 
carbonylative cyclisation, neither of the desired twelve-membered lactones 313a nor 313b were 
observed.  
2.2.2.5 Conformationally restricted nucleophiles 
 The investigatory systems discussed in the previous section employed nucleophiles with a high 
degree of conformational flexibility between the cyclopropane and nucleophile. Presumably, too much 
conformational flexibility may hinder carbonylative cyclisation by imposing a kinetic barrier to 
nucleophilic addition to the rhodacyclopentanone. Therefore, substrates with a high degree of 
preorganisation were designed wherein the nucleophile was attached to the cyclopropane portion via 
conformationally rigid tethers.  
Firstly, cyclopropylimine 316a was targeted in which the cyclopropane and phenol nucleophile 
are connected by a rigid framework of sp2-hybridised carbon atoms (Scheme 65A). Here, 
cyclopropylimine 316a would presumably exist in the E-configuration, so isomerisation to Z-imine 
316b must take place under the reaction conditions prior to Rh(I)-addition. Phenol-directed 
rhodacyclopentanone formation and C-O reductive elimination would then provide benzolactone 317. 
Initially, cyclopropylimine 316a was synthesised in 97% yield by mixing benzaldehyde 318 and 
cyclopropylamine (Scheme 65B) in ethanol. Unfortunately, when subjected to various Rh(I)-catalysed 
carbonylative cyclisation conditions, imine 316 did not react to give the desired benzolactone 317. 
 
Scheme 65: B) Reagents and conditions: i) cyclopropylamine, EtOH, r.t., 16 h. 
 Next, cyclopropylketones 319 was targeted as a second class of cyclisation substrate exhibiting 
a large degree of preorganisation (Scheme 66A). In this case, ketone-directed rhodacyclopentanone 




formation would provide rhodacyclopentanone 321. Nucleophilic addition of the N-aryl nucleophile to 
rhodacyclopentanone 321 and C-N reductive elimination would form benzolactams 320. This substrate 
class posed several issues. For example, cyclopropylketones are challenging substrates because ketones 
are weak directing groups and Rh(I)-addition to electron-deficient cyclopropanes is challenging.159 
Conversely, the weak four-membered chelate in intermediate 321 might favour coordination of the N-
nucleophile to the Rh(III)-centre (as in 322). Furthermore, the highly electron-deficient 
rhodacyclopentanone 322 (due to the electron-withdrawing effect of the ketone) might undergo facile 
C-N reductive elimination to form benzolactams 320.  
Investigations began with the synthesis of cyclopropylketones 319a and 319b, which contained 
different N-protecting groups (Scheme 66B). The synthesis began with nucleophilic addition of 
cyclopropylmagnesium bromide onto benzonitrile 323, which formed the unsubstituted aniline (not 
shown) in 28% yield upon imine hydrolysis during the work-up. Substrates 319a and 319b were 
prepared by reaction of the aniline functionality with AcCl (75% yield for 319a) and p-toluenesulfonyl 
chloride (50% yield for 319b), respectively. When subjected to various Rh(I)-catalysed carbonylative 
cyclisation conditions, both substrates proved extremely resistant to C-C oxidative insertion, even at 
elevated temperatures of 170 C. Subsequent work carried out at Bristol has identified an efficient 
catalyst system for Rh(I)-addition to electron-deficient cyclopropanes, which may be applicable in the 
current reaction.159 
 
Scheme 66: B) Reagents and conditions: i) cyclopropylmagnesium bromide, THF, 0 °C, 6 h then aq. 2 M HCl, 
r.t., 28%; ii) AcCl, NEt3, CH2Cl2, 0 °C, 3 h, 75%; iii) TsCl, NEt3, CH2Cl2, 0 °C to r.t., 16 h, 50%. 
2.2.2.6 Cyclopropylmethylamides 
 Following on from the studies involving electron-deficient cyclopropanes, discussed above and 
in Section 2.2.2.1, “electron-neutral” cyclopropanes were investigated in the carbonylative cyclisation. 
Cyclopropylmethylamides were designed as an analogue of the cyclopropylureas discussed in Section 




2.1, which are electronically differentiated through the use of a weaker amide directing group and less-
activated alkylcyclopropane (Scheme 67A). The proposed mechanism of cyclisation of 
cyclopropylmethylamides begins with amide-directed formation of rhodacyclopentanones 324 
followed by ligand exchange with the nucleophile and concomitant deprotonation. C-N Reductive 
elimination from intermediates 325 would form azepanes. Cyclopropylmethylamide 328a was initially 
targeted. Hydrolysis of cyclopropylacetonitrile 326 formed carboxylic acid 327 quantitatively, and then 
DCC-coupling with benzylamine provided cyclopropylmethylamide 328a in 46% yield (Scheme 67B). 
 
Scheme 67: A) Reagents and conditions: i) KOH, H2O, reflux, 5 h; ii) benzylamine, DCC, DMAP, CH2Cl2, 0 °C 
to r.t., 2 h. 
 When cyclopropylmethylamide 328a was treated with cationic [Rh(cod)2]BARF and PPh3 in 
1,4-dioxane under a carbonylative atmosphere linear alkenes 329 were formed in 71% yield, indicating 
that the amide directing group had directed C-C oxidative addition to the electron-neutral cyclopropane 
(Scheme 68A). Fortunately, when the reaction was run in 1,2-DCB under otherwise identical 
conditions, the desired C4-C5 saturated azepane 330a and C4-C5 unsaturated azepane 331a were 
formed in 9% and 21% yield, respectively (Scheme 68B). The significant solvent effect on the success 
of the reaction highlights the difficulty in identifying new reactions of this type. 
 
Scheme 68  




2.2.3 (6+1) Carbonylative cyclisation of cyclopropylmethylamides to form azepanes 
 The (6+1) carbonylative cyclisation of cyclopropylmethylamide 328a to form azepanes 330a 
and 331a serves as the second example of an intramolecular protocol for the nucleophilic trapping of 
rhodacyclopentanones discovered in Bristol. Azepanes are prominent heterocycles found in many 
natural products, which have been the focus of significant interest for both their biological profiles and 
their synthetically challenging structures.168 Representative examples of bioactive azepane-based 
molecules include, the insecticide, (-)-stemaphylline; the potent protein kinase C inhibitor, balanol; and 
the antibiotic, Mecillinam (Figure 2).169-171 
 
Figure 2: Representative biologically active azepanes. 
2.2.3.1 Optimisation of the (6+1) carbonylative cyclisation of cyclopropylmethylamides 
 In Chapter 2, it was shown that the oxidation level of the C4-C5 position of 1,3-diazepanes 
could be controlled by appropriate substitution of the R1-position of the cyclopropylurea substrates: 
when R1 = alkyl or aryl the unsaturated product is preferred, whereas when R1 = H the saturated product 
was preferred (Scheme 69A). A mechanistic explanation for this phenomenon was proposed in Section 
2.1.4.1. The subsequently discovered (6+1) carbonylative cyclisation of cyclopropylmethylamides also 
provided C4-C5 saturated and unsaturated products, control over which would be highly desirable 
(Scheme 69B). Therefore, optimisation studies were carried out with the aim of improving the overall 
yield and oxidation level selectivity (for saturated or unsaturated) of the process.  
 
Scheme 69 




 Selected results from the optimisation of the (6+1) carbonylative cyclisation of 
cyclopropylmethylamide 328a are shown in Table 9. Initially, an extensive ligand screen was carried 
out. An electronically diverse selection of triarylphosphines and triarylarsines was tested, which 
provided some interesting observations. For example, As(3,5-(CF3)2C6H3)3, provided a 50% combined 
yield of azepane products whilst improving the selectivity towards saturated azepane 330a (1:1.3 
330a:331a) (Entry 2). Interestingly, when the reaction was run in the absence of an additional ligand, 
saturated azepane 330a was formed preferentially, albeit with low selectivity (42%, 1.8:1, 330a:331a) 
(Entry 3). Subsequent attempts to improve the reaction in the absence of an additional ligand failed. 
Nevertheless, this result suggested that a weakly binding ligand may be suitable. Further screening 
identified sulfides as interesting ligands, especially di-n-propylsulfide which provided a 42% yield with 
improved selectivity for saturated azepane 330a (2.1:1, 330a:331a) (Entry 4). Ultimately, the highly 
electron-deficient triarylphosphine, P(C6F5)3, was identified as the optimal ligand, which provided a 
72% yield with slightly improved selectivity for the saturated product 330a (2.4:1, 330a:331a) 
compared to sulfide ligands (Entry 5).  
 
Table 9: Selected results from the optimisation of the (6+1) carbonylative cyclisation of 
cyclopropylmethylamide 328a. 
 Next, various additives were screened because these have previously been shown to improve 
the efficiency of related transformations (see Table 1).102-103 Carboxylic acids and amides did not 
provide an improvement, but the inclusion of 5 mol% of pyridine improved both the yield (84%) and 
selectivity (3.2:1, 330a:331a) of the process in favour of the saturated product 330a (Entry 6). This 
result is unexpected because basic additives were previously found to inhibit C-C oxidative addition 
(Section 2.2.2.2). Next, a range of electron-rich and electron-deficient pyridine derivatives (e.g. 
lutidine), and related heterocycles (e.g. N-methylimidazole, quinoline and bipyridine) were screened as 
additives, but pyridine proved to be optimal. Further optimisation of the reaction parameters provided 




the desired product 330a in an excellent 95% combined yield and 5.3:1 ratio with unsaturated azepane 
331a (Entry 7). Encouragingly, the selectivity for the more sp3-rich saturated product 330a increased 
with the overall efficiency of the process. This is ideal in terms of the overarching aims of this project, 
which is to develop methodologies for the synthesis of chiral, sp3-rich heterocycles. It is not clear what 
the role of pyridine is in this reaction, but pyridine-ligated rhodium-complexes are well known and are 
catalytically active in several different reactions.172  
 The optimised carbonylative cyclisation conditions were used to investigate the scope of the 
reaction with respect to the R1 and R2 substituents (see Scheme 69). Initially, cyclopropylmethylamides 
328b (R2 = Ph) and 328c (R2 = c-Hex) were synthesised because the analogous cyclopropylureas were 
challenging substrates in the (6+1) carbonylative cyclisation (see Table 4) (Scheme 70A). Both 
substrates could be formed by EDCI-coupling of carboxylic acid 327 with either aniline (80% yield for 
328b) or cyclohexylamine (46% yield for 328c), respectively. Under the optimised carbonylative 
cyclisation conditions, cyclopropylmethylamide 328b reacted to form desired azepane 330b in 22% 
combined yield with poor oxidation level selectivity (1.8:1, 330b:331b) (Scheme 70B). Similarly, 
cyclohexyl substrate 328c reacted to form the desired product 330c in 23% combined yield with 
essentially no oxidation level preference (1.1:1, 330c:331c). 
 
Scheme 70: A) Reagents and conditions: i) EDCI, DMAP, amine, CH2Cl2, 0 °C to r.t., 24 h. 
 R1-Substituted cyclopropylmethylamide 333a was also prepared to investigate the effect of 
including an R1 substituent on the cyclisation (Scheme 71A). Carboxylic acid 327 was doubly 
deprotonated by the addition of two equivalents of LDA before the addition of one equivalent of benzyl 
chloride, which formed benzyl carboxylic acid 332 in 82% yield. DCC-coupling of carboxylic acid 332 
and benzylamine provided R1-substituted substrate 333a in 26% yield. It is useful to note that the 
success of the (6+1) carbonylative cyclisation of cyclopropylmethylamides relies upon the ability to 
synthesise enantioenriched cyclopropylmethylamides, cyclisation of which would provide access to 
enantioenriched azepanes. Steps towards this goal might be partially achieved by diastereoselective 
alkylation of a substrate containing Evans’ auxiliary (see alkylation product 334). This strategy has 




been successfully implemented in the asymmetric synthesis of SPPL2a inhibitors.173 Several alternative 
methods for the enantioselective alkylation of esters or carboxylic acids exist.174 When R1-substituted 
substrate 333a was subjected to the carbonylative cyclisation conditions, the desired azepane 335a was 
formed in 45% yield with poor oxidation level selectivity (1.8:1, 335a:336a) (Scheme 71B). 
 
Scheme 71: A) Reagents and conditions: i) LDA, THF, 0 °C, 15 min then benzyl chloride, 35 °C, 3 h; ii) DCC, 
DMAP, benzylamine, CH2Cl2, 0 °C to r.t., 3 h. 
 Amide 338 was also investigated whereby the carbonyl of the amide directing group was placed 
on the other side of the nucleophile relative to the cyclopropane such that carbonylative cyclisation 
would form azepane 339 (Scheme 72A). The synthesis of 338 was achieved by reduction of nitrile 326 
to the amine with in-situ generated AlH3, which was isolated as TFA salt 337. This was then reacted 
Scheme 72: A) Reagents and conditions: i) LiAlH4, conc. H2SO4, 0 °C to r.t., 15 min then 326, THF, r.t. to 40 
°C, 2 h then aq. KOH, Et2O, r.t., 15 min then TFA; ii) benzoyl chloride, aq. NaOH, r.t., 10 min. 




with benzoyl chloride, under Schotten-Baumann conditions, to form substrate 338 in 72% yield over 
two steps. When amide 338 was reacted under carbonylative conditions, desired azepane 339 was not 
observed (Scheme 72B). The failure to cyclise may be due to the requirement of a seven-membered 
chelate between the directing group and cyclopropane in order to access rhodacyclopentanone 340.  
 The previously optimised conditions for parent cyclopropylmethylamide 328a provided 
azepane 330a in excellent yield and moderate selectivity, but the optimised conditions were not 
applicable to more challenging substrates (i.e. 328b/c and 333a). Therefore, a second round of 
optimisation was carried out on R1-substituted substrate 333a, the results of which are summarised in 
Table 10. Efforts began by reinvestigating the pyridine and ligand loadings, temperature, and duration 
of the reaction, but no improvement was afforded. Next, the effect of the Rh(I)-catalyst counter-anion 
was probed. This was achieved by employing neutral Rh(I)-precatalyst, [Rh(cod)Cl]2, and various 
silver(I) salts (e.g. AgOAc, AgTFA, AgPF6), which form a cationic Rh(I)-catalyst in-situ. 
Encouragingly, when [Rh(cod)Cl]2 and AgSbF6 were employed, azepane 335a was formed in 45% yield 
with a slightly decreased selectivity (1.3:1, 335a:336a) for the saturated product (Entry 2). The fact that 
a comparable yield was achieved by the addition of a silver salt prompted further studies. As a result, it 
was discovered that the addition of a substoichiometric quantity of AgOAc to a cationic 
[Rh(cod)2]BARF system improved the yield of saturated azepane 335a (51%, 1:1.8, 335a:336a) (Entry 
3). Ag(I)-additives have previously been utilised in Rh-catalysed C-H activation175 and C-C 
activation176 processes where the role of the silver salt is to either mediate a concerted-metallation-
deprotonation step177-179, or to generate a Ag(I)-nucleophile in a cross-coupling reaction. It is unclear 
what the role of the silver salt is in the current process. 
 
Table 10: Selected results from the optimisation of the (6+1) carbonylative cyclisation of R1-substituted substrates 
333. 
 Having thoroughly investigated each parameter of the catalytic system, the R2-substituent was 
optimised. Primary amide 333b was synthesised in 76% yield from carboxylic acid 332 via reaction of 




the corresponding acid chloride with aqueous ammonia (Scheme 73). Fortunately, primary amide 333b 
cyclised with good efficiency to form azepane 335b in 74% combined yield and a 1.7:1 ratio with 
unsaturated analogue 336b (Entry 4, Table 10). Further modification of the reaction parameters 
increased the yield to 79% over two days, but failed to improve C4-C5 oxidation level selectivity (2:1 
335b:336b) (Entry 5).  
 
Scheme 73: Synthesis of primary cyclopropylmethylamide 333b. A) Reagents and conditions: i) (COCl)2, cat. 
DMF, CH2Cl2, 0 °C, 30 min then aq. NH3, r.t., 30 min. 
2.2.3.2 Cyclopropylmethylamides containing 1,2-disubstituted cyclopropanes 
 Expansion of the scope of the (6+1) carbonylative cyclisation of cyclopropylmethylamides to 
include 1,2-disubstituted cyclopropanes (substitution at R3) would be a valuable addition to this 
methodology because it would allow access to many diversely functionalised (and enantioenriched) 
azepanes (Scheme 74). However, the diastereoselective and enantioselective synthesis of R1- and R3-
substituted cyclopropylmethylamide substrates appeared to be challenging. Furthermore, carbonylative 
cyclisation of R3-substituted cyclopropylmethylamides could give rise to four possible azepanes (C3 vs 
C4 substituted, saturated vs unsaturated) and R1,R3-disubstituted cyclopropylmethylamides could give 
rise to seven possible azepanes. Therefore, the (6+1) carbonylative cyclisation must be highly regio- 
and oxidation level selective in order to be synthetically useful.  
 
Scheme 74: Stereochemical considerations arising from the (6+1) carbonylative cyclisation of 
cyclopropylmethylamides containing 1,2-disubstituted cyclopropanes. 
 Preliminary studies into the application of 1,2-disubstituted cyclopropylmethylamides to the 
(6+1) carbonylative cyclisation began with the synthesis of trans-cyclopropanes 343a and 343b 
(Scheme 75A). The synthesis was achieved starting from commercially available ,-unsaturated ester 
341, which underwent a Simmons-Smith cyclopropanation and ester hydrolysis to form carboxylic acid 




342 in 78% yield, as a single diastereomer. Secondary amide 343a was formed in 38% yield from 
carboxylic acid 342 by EDCI-coupling with benzylamine. Primary amide 343b was formed in 69% 
yield by converting carboxylic acid 342 to the corresponding acid chloride and reacting it with aqueous 
ammonia. Under the optimised (6+1) carbonylative cyclisation conditions, secondary amide 343a 
provided an intractable mixture of products. However, when primary amide 343b was reacted under 
carbonylative cyclisation conditions, C3-substituted azepane 344b formed preferentially, but as a 
mixture consisting of both saturated and unsaturated variants of the C4-regioisomer (5:1:1, 
344b:345b:346b) in 43% combined yield (Scheme 75B). The disappointing selectivity observed in this 
reaction mimics that observed for trans-1,2-disubstituted cyclopropylureas (Section 2.1.3.2, Table 7).  
 
Scheme 75: A) Reagents and conditions: i) CH2I2, Et2Zn, CH2Cl2, -10 °C to r.t., 2 h then aq. NaOH, reflux, 1 h; 
ii) EDCI, DMAP, benzylamine, CH2Cl2, 0 °C to r.t., 24 h; iii) (COCl)2, cat. DMF, CH2Cl2, 0 °C, 30 min then aq. 
NH3, r.t., 30 min. 
2.3 Summary and conclusions from the studies in Chapter 2 
 Building on the discovery made by McCreanor, a protocol for (6+1) carbonylative cyclisation 
of cyclopropylureas to form 1,3-diazepanes by intramolecular nucleophilic addition of N-nucleophiles 
to rhodacyclopentanones has been developed (Scheme 76A). It was found that the oxidation level of 
the C4-C5 position of the diazepanes could be controlled by appropriate choice of the cyclopropylurea 
R1-substituent, specifically: when R1 = alkyl or aryl the unsaturated diazepane forms preferentially, but 
when R1 = H the saturated diazepane forms preferentially. Mechanistic studies suggest that this is due 
to reversible -hydride elimination. The scope of the (6+1) carbonylative cyclisation was found to 
include various alkyl and aryl group at R1 and R2, with the exception of R2-aryl trisubstituted 
cyclopropylureas. Additionally, cyclopropylureas containing 1,2-disubstituted cyclopropanes were 
investigated, which were found to react via Rh(I)-addition to the unexpected cyclopropyl C-C bond, 




based on previous studies carried out at Bristol. A rationale for this observation was proposed based on 
reversible rhodacyclopentanone formation.  
 
Scheme 76 
 The (6+1) carbonylative cyclisation of cyclopropylureas served as a proof of concept for a 
general strategy for the formation of medium-sized rings by intramolecular nucleophilic addition to 
rhodacyclopentanones. Investigations into the generality of this strategy were carried out, which led to 
the discovery of a second protocol for the (6+1) carbonylative cyclisation of cyclopropylmethylamides 
to give azepanes (Scheme 76B). Optimisation studies identified pyridine and Ag(I)-salts as beneficial 
additives in this process. At the present level of development, azepanes bearing R1- and R2-primary 
alkyl substituents are formed in high yield, but with poor selectivity over the oxidation level of the C4-
C5 position. Further optimisation of the oxidation level selectivity of the process is required.  
 Subsequent research carried out at Bristol has identified several other methodologies based on 
intramolecular nucleophilic addition to rhodacyclopentanones. For example, Wang and co-workers 
discovered that rhodacyclopentanones 347, generated from N-arylcyclopropanes, could promote C-H 
metallation of the adjacent aryl (or vinyl) group en route to benzazepanes (e.g. 348a and 348b) (Scheme 
77).105 Several other related processes are currently in development at Bristol. 





Scheme 77: Wang’s protocol for the synthesis of benzazepanes from N-arylcyclopropanes. 
 Future directions in this project should focus on identifying the role of the various additives 
(amides/carboxylic acids, pyridine, Ag(I)-salts), and gaining a better understanding of the factors 
governing successful nucleophilic addition to rhodacyclopentanones. Progress towards either of these 
goals might benefit the development and expansion of related processes.  




Chapter 3 – Studies towards the total synthesis of otonecine and related 
pyrrolizidine alkaloids 
3.1 Introduction 
 In Chapter 2, the discovery and development of methodologies that employ nucleophilic 
addition to rhodacyclopentanones as the key mechanistic step was presented. Chapter 3 describes the 
application of a rhodacyclopentanone-based methodology, developed at Bristol, to the total synthesis 
of the natural product otonecine and related pyrrolizidine alkaloids. Section 3.1 will introduce the 
pyrrolizidine alkaloids and the natural product otonecine. An emphasis will be placed on the unique 
structure of otonecine and a transannular interaction, which is characteristic of this ring system. 
Previous total syntheses of (rac)-otonecine, and related studies, will then be discussed before the goals 
of this project are set out. In Section 3.2, studies carried out at Bristol towards the total synthesis of 
otonecine are presented. The later portions of Chapter 3 regard studies towards the synthesis of the necic 
acids of the otonecine-type pyrrolizidine alkaloids. Section 3.3.1 introduces previous synthesise of the 
necic acids and Section 3.3.3 covers research carried out at Bristol towards the development of a short 
enantioselective synthesis of these components.  
3.1.1 The pyrrolizidine alkaloids 
 The pyrrolizidine alkaloids (PAs) are a large family of over 660 natural compounds found in 
approximately 6000 species of flowering plant, where they are produced as a defence against grazing 
animals.180-181 The widespread occurrence of toxic PAs is problematic for livestock and humans who 
might accidentally ingest PAs through the consumption of PA containing plants or contaminated animal 
produce.182-184 In extreme cases, PA poisoning has been known to kill both livestock and humans.  
3.1.1.1 Structure of the pyrrolizidine alkaloids 
 The pyrrolizidine alkaloids are defined by the presence of a functionalised pyrrolizidine ring 
(indicated in blue), known as a necic base, which is typically substituted with combinations of hydroxyl 
and hydroxymethyl groups (Figure 3A).185 Approximately half of the necic bases are unsaturated at the 
C1-C2 position, which is a necessary structural feature for the biological activity of this family of natural 
compounds.186 Additionally, most necic bases also occur as the N-oxide. Variations of these structural 
features gives rise to many diverse and stereochemically-rich necic bases as demonstrated in Figure 
3A.187 The five most common necic bases are structurally related to retronecine as they each contain 
C1-hydroxymethyl and C7-hydroxyl substituents (Figure 3B). For example, heliotridine is the C7-
epimer of retronecine and platynecine is the C1-C2 saturated version. Otonecine is unique among the 




necic bases because it is an eight-membered ring, which lacks the ring junction N-C8 bond of the 
pyrrolizidine ring system. The ring junction bond is replaced with a N-methyl substituent and C8-
ketone.  
Typically, the necic bases are attached via ester linkages to one or more necic acids.185, 187 The 
structures shown in Figure 3C are representative of the types of ester linkages formed between necic 
acids and bases. Monoesters, such as lycopsamine, contain a single ester linkage, and diesters, such as 
7,9-diangeloylplatynecine, contain two necic acids joined by two ester linkages. The most common type 
of ester linkage, and most important in terms of the research contained in this chapter, is that which 
form macrocyclic diesters, such as senecionine. Here, the necic base is bound to a single dicarboxylic 




 The pyrrolizidine alkaloids are categorised by the type of ester linkages, and the largest category 
is the senecionine-type PAs, which are macrocyclic diesters composed of the necic bases shown in 
Figure 3B and a C10 dicarboxylic necic acid.188 A generic structure of a senecionine-type PA is shown 
in Figure 4A. Here, the necic base is bound via ester linkages at the C7 and C9-positions to the C16 and 
C11-position of the necic acid, respectively, resulting in a 12-membered macrocycle. Integerrinecic 
acid is representative of the most basic and common C10 dicarboxylic acids, important structural features 
of which are the C12,C13-vicinal stereocentres and the C15-exocyclic alkene (Figure 4B). All four 
diastereomers resulting from epimerisation of the C12-stereocentre and isomerisation of the C15-




exocyclic alkene are known, and each of these has been isolated as part of an otonecine-type 
macrocyclic diester (Figure 4C). In addition, many otonecine-type macrocyclic diesters are known that 




 Otonecine was first isolated in 1941 by Zhdanovich and Menshikov189, but it took a further 26 
years before Koretskaya and co-workers determined its exact structure.190-191 The first two crystal 
structures of otonecine-type PAs revealed a unique structural feature of the otonecine ring system. The 
first, disclosed by Wunderlich in 1967, was a CSA salt of retusamine in which the C8-ketone existed 
as a hemiaminal because of a transannular covalent bond between the tertiary amine and C8-position of 
the necic base (Figure 5A).191 The second crystal structure, published by Birnbaum in 1972, was of a 
free base of clivorine (Figure 5B).192 This also revealed a significant transannular interaction between 
the tertiary nitrogen and C8-carbon centre (N-C8 distance 1.99 Å), although this was weaker due to the 
absence of CSA. It is noteworthy that the transannular interaction causes the otonecine ring system to 
adopt a boat-boat conformation, which is similar to the pyrrolizidine ring of related PAs, and is vital for 
the biological mode of action of these compounds. Further evidence for the transannular interaction was 
measured by Furuya and Asada, who reported the ketone stretching frequency of ligularidine (see 




Figure 4, C) to be 1610 cm-1,193 which is significantly weaker than is expected for linear ketones (1725–
1705 cm-1)194 or ,-unsaturated ketones (1685–1665 cm-1).194 
 
Figure 5 
 The defining structural characteristic of otonecine is the transannular interaction between the 
tertiary amine lone pair and the *-orbital of the C8-ketone. This interaction defines the conformation, 
reactivity and biology of the free necic base and that of the otonecine-type macrocyclic diesters, and so 
has been researched extensively. The transannular interaction bestows otonecine-type PAs with unusual 
properties, which distinguish them from other PAs. Perhaps most significant is a dual-solubility in both 
non-polar and polar solvents, including water.195-196 This property was investigated by Lin and co-
workers, who compared the 1H and 13C NMR spectra of the otonecine-type PA, clivorine, when 
dissolved in d-chloroform and deuterium oxide (Table 11).197 The investigation revealed that otonecine 
exists in its neutral form when dissolved in d-chloroform (non-polar solvent) as determined by the 13C-
chemical shift of C8 (C 192.2 ppm). However, when characterised in deuterium oxide (polar solvent), 
the chemical shift of the C8-position underwent a significant upfield shift (C 145.1 ppm) indicating 
that the azocane adopts an ionised form where the transannular interaction was maximised (i.e. a N-C8 
covalent bond was present). Additionally, significant downfield shifts were measured for C3 and C5, 
and an HMBC correlation between the N-methyl protons and C8 was present in deuterium oxide. Such 
dual-solubility makes otonecine-type PAs highly bioavailable. 





Table 11: Selected 1H and 13C chemical shifts of the otonecine-ring system of clivorine in non-ionised and ionised 
forms. 
 Another consequence of the strong transannular interaction is the otonecine ring system can 
adopt two “diastereomeric” conformations where the N-centre and C8-centre might be considered 
stereocentres.198 This effect is illustrated by the trans-diastereomer and cis-diastereomer, shown in 
Scheme 78A, where the N-methyl and C8-oxygen substituents are positioned either trans or cis to the 
C7-alcohol. Evidence gained through NMR and crystallographic studies showed that otonecine-type 
macrocyclic diesters exist solely as the trans-diastereomer, which is believed to be a result of the 
rigidifying influence of the macrocycle.199 However, Röder and Liu reported that a macrocyclic diester 
of dihydrootonecine (see the dashed box) existed as an equilibrating mixture of the trans- and cis-
diastereomers, which implies that the C1 alkene of otonecine is also a stabilising feature.200  
 
Scheme 78 
 In the absence of a rigidifying macrocycle, otonecine can interconvert between both 
diastereomeric forms. Röder carried out an in-depth NMR analysis of otonecine hydrochloride, which 




was found to exist as an equilibrium mixture of diastereomeric bicyclic salts trans-349 and cis-349 
(C(8) 119.0 ppm and 120.1 ppm, respectively) (Scheme 78B). No detailed NMR analysis of the free 
base of otonecine has been carried out, but empirical observations indicate that the transannular 
interaction is reasonably weak and that the ring is conformationally flexible. For example, otonecine 
can form an oxime, which indicates that C8 is ketonic in reactivity.198 Additionally, otonecine has 
proved recalcitrant to crystallisation, and its NMR spectra are broad at room temperature.201  
 Interestingly, study of the various crystal structures of otonecine-type PAs allowed Bürgi and 
Dunitz to deduce the ideal angle of attack of a nucleophile onto a carbonyl.202 The authors measured N-
C8 bond distances of the crystal structures of several otonecine-type PAs and methadone (which 
exhibits a similar Nn-C(O)* interaction), and found that they ranged from 1.5 Å (i.e. a covalent bond) 
to 3 Å (i.e. a dipole-dipole interaction). The authors treated each crystal structure as a single reaction 
coordinate for the addition of a nucleophile to a carbonyl. They reported that as the N-C8 bond distance 
becomes shorter, the C8-carbonyl becomes less planar and more tetrahedral, suggesting a transition 
from sp2 to sp3 hybridisation. Furthermore, it was found that the nitrogen nucleophile approached the 
carbonyl in a straight line at a constant angle of 107°, which the authors concluded to be the strongly 
preferred orientation for nucleophilic attack onto a sp2-centre. Further evidence for this conclusion was 
later provided by theoretical calculations.203 
3.1.1.3 Biological aspects 
 Many pyrrolizidine alkaloids are hepatotoxic, carcinogenic, genotoxic, teratogenic and 
occasionally pneumotoxic to humans and animals.185 Human exposure to PAs typically occurs through 
the ingestion of contaminated grains, vegetables, salads or animal products such as honey and milk.204 
Developing countries are typically the worst affected by PA poisonings, however, developed countries 
are becoming increasingly at risk due to increasing consumption of teas and herbal remedies.205 One 
particularly catastrophic outbreak of PA poisoning took place in Afghanistan in 1974 to 1975 where 
contaminated bread was responsible for 7200 cases of liver disease and 1600 deaths.206-207 As a result 
of the threat to public health, the European Medicines Agency recommended a maximum daily intake 
of 0.35 g PAs/day.208  
The pyrrolizidine alkaloids themselves are non-toxic, but become metabolically activated in the liver.209-
211 Metabolic activation of bicyclic pyrrolizidines, such as retronecine, is initiated by cytochrome P450-
mediated oxidation of the C3-position (Scheme 79). The resulting hydroxy-PA rapidly aromatises upon 
elimination of the C3-hydroxide to form a pyrrole intermediate. The benzylic C7 and C9 esters of the 
pyrrole intermediates are activated towards nucleophilic substitution, and can react with nucleophilic 
amino acid residues, DNA/RNA bases and other nucleophiles, thereby exerting a toxic effect. 
Additionally, macrocyclic diesters can cross-link DNA giving them a greater toxic potential than 
monoester PAs.187 As was mentioned earlier, C1-C2-saturated PAs are considered non-toxic because 




they are unable to form pyrrole intermediates.210 Otonecine possesses identical biological activities to 
retronecine because it converges on the same reactive pyrrole intermediates upon metabolic activation. 
In this case, cytochrome P450 mediated oxidation of the N-methyl substituent forms hemiaminal 350.212 
Elimination of formaldehyde forms a secondary amine, which undergoes a spontaneous transannular 
condensation onto the ketone forming pyrrole intermediates. As a result of metabolic activation of PAs 
taking place in the liver, it is here where most of the damage is caused.213  
 
Scheme 79: Formation of a toxic pyrrole intermediate upon metabolic activation of retronecine-type and 
otonecine-type PAs. 
PAs can also be “metabolically deactivated”.187 For example, ester hydrolysis of PAs reduces 
the alkylating ability of the corresponding pyrrole intermediates. For this reason, free necic bases (such 
as otonecine) are not as toxic as their esters, but can still be activated under acidic conditions. 
Additionally, the free necic bases are more water soluble than the esters, which aids their excretion, or 
transport to other locations in the body.214-215  
 PAs have been investigated as treatments for numerous diseases. Several PAs have shown anti-
bacterial activity including the retronecine-type PA, usaramine, which can inhibit the formation of 
protective biofilms by certain bacteria, although the mechanism for this remains unclear.216 Another 
retronecine-type PA, indicine-N-oxide, was used to treat children with acute lymphoblastic leukaemia, 
which provided positive results.217 Unfortunately, this required very high doses of the active compound 




(2000 mg/m2/day), which resulted in mild hepatotoxicity. PAs have been investigated for several other 
therapeutic effects including the treatment of inflammation, HIV and Alzheimer’s.185 
3.1.2 Previous total synthesis of otonecine 
 This section concerns previous efforts towards the total synthesis of (rac)-otonecine 
and related studies. Previous synthesises of the necic acid portions of otonecine-type PAs and 
methods for forming macrocyclic diesters are summarised later in Section 3.3.1. 
The diverse and complex structures of the pyrrolizidine alkaloids in combination with their 
potent biological activities makes them an appealing target for synthesis. In particular, the small size 
and high stereochemical density of the necic bases has resulted in them becoming a proving ground for 
new methodologies. In contrast, otonecine has only been synthesised twice before, both times as a 
racemate. Consequently, none of the otonecine-type macrocyclic diesters have been synthesised. The 
lack of synthetic efforts towards the otonecine-type PAs perhaps reflects both the difficulty in 
synthesising medium-sized rings and the innately challenging otonecine ring system. The many 
synthetic routes to the Pyrrolizidine Alkaloids have been covered in a series of reviews.218-236 
 The first total synthesis of (rac)-otonecine was published by Yamada and co-workers in 
1983.237-238 Described over two papers is a divergent synthesis of both (rac)-retronecine and (rac)-
otonecine via common intermediate 354 (Scheme 80A).239 The synthesis of common intermediate 354 
began with Dieckmann cyclisation of diester 351 to form azocane 352. Benzyl deprotection of azocane 
352 caused the resulting secondary amine to undergo a spontaneous transannular condensation onto the 
ketone to form pyrrolizidine 353. -Oxidation of the -unsaturated ester provided common 
intermediate 354. The synthesis of (rac)-retronecine was completed by alkene reduction of intermediate 
354, which allowed the isolation of the correct C7,C8-diastereomer as lactone 355. From here, the C1-
C2 alkene was installed by via selenide 356 to provide (rac)-retronecine in 8 steps overall.  
 Yamada’s divergent synthesis of (rac)-otonecine from common intermediate 354 began with a 
sulfur-Michael addition/oxidation sequence to form lactone 357 (Scheme 80B). N-Methylation and 
treatment with NaH and PhSeCl simultaneously cleaved the ring junction N-C8-bond to reveal the 
azocane ring and install the selenium functionality of 359. Yamada then took advantage of the N-C8 
transannular interaction to carry out a chemoselective reduction of the lactone, in the presence of 
reducible ketone and phenylselenide functionalities. The lactone reduction was achieved by treating 
lactone 359 with diethylaluminium chloride, which promoted the formation of aminal 360 where the 
ketone is masked. Lactone reduction using DIBAL-H, and acetylation of the resulting diol formed 
diacetate 361 in 17% yield upon unmasking of the ketone during work-up. The synthesis of (rac)-
otonecine was completed in 11 total steps by elimination of the phenylselenide moiety of diacetate 361 




and deacetylation of the alcohols. Yamada’s seminal report remains the shortest total synthesis of (rac)-
otonecine to date.   
 
Scheme 80: A) Reagents and conditions (some details were not provided by the authors): i) KOt-Bu, xylene, 
reflux, 56 h, yield not provided; ii) Pd/C, H2, EtOH, 40 min, 96%; iii) LDA, THF, -78 °C, 100 min then 
MoO5·py·HMPA, -78 °C, 20 min, 52%; iv) PtO2, H2, MeOH, r.t., 3 h, 44%; v) LDA, Ph2Se2, HMPA, THF, -50 
°C, 90 min, 21%; vi) LiAlH4, THF, -10 °C, 2 h, 95%; vii) 30% H2O2/AcOH, r.t., 1.5 h, 53%. B) Reagents and 
conditions: i) LiSPh, PhSH/THF, r.t., 2 h, 70%; ii) Hg(OAc)2, AcOH/H2O, r.t. to 90 °C, 1 h, 76%; iii) MeI, 
acetone, reflux, 1 h, 95%; iv) NaH, PhSeCl, THF, r.t., 40 min, 74%; v) DIBAL, AlClEt2, PhMe, 45 °C, 1 h then 
Ac2O, pyridine, r.t., 5 h, 17%; vi) 30% H2O2, AcOH, r.t., 2 h; vii) NaOMe, MeOH, r.t., 30 min, 90% from 361. 
 The second total synthesis of (rac)-otonecine, published by Vedejs and co-workers in 1998, 
utilised a thioketone cycloaddition to form the azocane ring (Scheme 81).201,240 After significant 
investigation, thioether 362 (available in 5 steps) was identified as a viable substrate for the key 
cycloaddition. Upon irradiation with visible light in a highly purified solution of benzene, the thioether 
moiety of thioether 362 underwent a Norrish type-2 fragmentation to form thioketone 364, which 
underwent further cycloaddition with the Danishefsky diene 363. Resulting adduct 365 was treated with 
trifluoroacetic acid to reveal both the secondary amine and -unsaturated ketone, which underwent a 




spontaneous Michael addition forming bicyclic thioaminal 366 in 77% yield. The protected C7-alcohol 
of otonecine was installed by reduction of the ketone of thioaminal 366 and benzyl protection. 
 
Scheme 81: Vedejs’ total synthesis of (rac)-otonecine. Reagents and conditions: i) hν, PhH, r.t., 12 h then 
trifluoroacetic acid, CH2Cl2, r.t., 5 h, 77%; ii) L-Selectride, THF, r.t., 3 h, 97%; iii) NaH, imidazole, BnBr, 
THF/DMF, 0 °C to r.t., 11 h, 88%; iv) NaBH3CN, AcOH, TFE, r.t., 48 h; v) MeI, DBU, PhH, r.t., 14 h, 89% from 
367; vi) CbzCl, THF, r.t., 16 h, 95%; vii) tetrabutylammonium oxone, CH2Cl2, 0 °C, 1.5 h, 89%; viii) LiAlH4, 
THF, 0 °C to r.t., 8 h, 96%; ix) OsO4, TMEDA, THF, -70 °C, 42 h, 81%; x) OsO4, K3Fe(CN)6, CaO, t-BuOH/H2O, 
r.t., 55 min, 53%; xi) Burgess reagent, C6D6, r.t. to 36 °C to reflux, 36 h, 57%; xii) TMSOTf, thioanisole, CD3CN, 
0 °C, 30 min, 73%. 
 At this point, the azocane ring was revealed and efforts were directed to installing the C8-ketone 
and C1-C2 alkene of otonecine. Thioaminal 367 was reduced and S-methylated provided azocane 368, 
which was transformed into diol 369 over four steps. Oxidation of the secondary alcohol of diol 369 
was complicated by transannular nucleophilic attack by the tertiary amine, but was eventually achieved 
using osmium tetroxide-mediated conditions to form ketone 370. Ketone 370, containing both the 
tertiary amine and ketone of otonecine, existed as a mixture of non-ionised and ionised forms resulting 
in highly temperature- and pH-dependent NMR spectra. Interestingly, treatment of alcohol 370 with 




one equivalent of Burgess reagent formed charged species 371 where the ketonic oxygen had undergone 
preferential reaction in the presence of the tertiary alcohol. Addition of a further equivalent of Burgess 
reagent with heating formed bis-adduct 372, which underwent the desired elimination to provide 
dibenzylotonecine 373 after work-up. Lewis acid catalysed debenzylation completed the total synthesis 
of (rac)-otonecine in 20 steps overall. Vedejs commented that all the transformations in the presence of 
the tertiary amine and ketone were dominated by the transannular interaction, which complicated the 
use of electrophilic reagents in this “deceptively simple ring system”.  
 In 1983, Ban and co-workers published an informative synthesis of the otonecine-type PA 
degradation product, (rac)-dihydrodeoxyotonecine.241 The synthesis demonstrates how a N-C8 
transannular interaction can dramatically influence the reactivity of the ring system. The synthesis 
began with the preparation of azocane 375 in six steps by annulation of diketone 374 (Scheme 
82A).241,242 Direct C7-oxidation of ketone 375 failed, partly due to the propensity of the lactam to ring 
open under strongly basic or acidic conditions. On the other hand, bromination of the C7-position of 
ketone 375 formed bromide 376 quantitatively, but subsequent SN2-substitution of the bromide by 
NEt4OAc failed due to competing E1cB elimination of the bromide (i.e. 377 was formed). To 
circumvent this, the lactam of 375 was first reduced by a three step sequence, including ketone 
protection as the dimethyl acetal and deprotection, to form amine 378. However, subsequent C7-
oxidation of amine 378 failed because of the N-C8 transannular interaction, which reduced the ketonic 
properties of the ketone. 
 In order to install the C7-alcohol of dihydrodeoxyotonecine in the absence of a transannular 
interaction, and without competing elimination reactions, the authors carried out a three step synthesis 
of carbamate 379 (Scheme 82B). The ketone of carbamate 379 reacted efficiently with bromine, and 
the following SN2 reaction of 375 with sodium acetate proceeded in high yield to afford C7-acetate 390. 
The synthesis of dihydrodeoxyotonecine was completed after a five step sequence of 
protection/deprotection and reduction/oxidation steps. Ban’s studies highlight the difficulties in 
carrying out transformations on a functionally dense medium-sized ring and in the presence of the 
transannular interaction.  





Scheme 82: A) Reagents and conditions (some details were not provided by the authors): i) aq. K2CO3, MeOH, 
50 °C to 60 °C, 81%; ii) Br2, MeOH, quantitative; iii) Et4NOAc, acetone, reflux, 90%; iv) CH(OMe)3, H2SO4, 
MeOH, 63%; v) LiAlH4, THF, reflux; vi) 50% aq. trifluoroacetic acid, 63% from 375. B) Reagents and conditions: 
i) CH(OMe)3, H2SO4, MeOH; ii) LiAlH4, THF, reflux; iii) CbzCl, CHCl3, reflux, 81% from 375; iv) Br2, MeOH; 
v) Et4NOAc, acetone, reflux, 83% from 379; vi) NH3, MeOH, r.t.; vii) 2,3-dihydropyran, CSA, CH2Cl2; viii) 
LiAlH4, THF, reflux; ix) PCC, CH2Cl2, NaOAc; x) HCl, MeOH, r.t., 30% from 390. 
3.1.3 Rh(I)-catalysed (7+1) carbonylative cycloaddition approach to the total synthesis 
of otonecine 
 Note: Due to the well-documented importance of the 3-dimensional structure of medium-sized 
rings on their reactivity and the selectivity of their transformations, azocane rings contained in the 
remainder of this thesis will be depicted in 3-D. Therefore, C2-unsaturated azocanes will be depicted 
in the boat-chair conformation (see azocane, Scheme 83) and C1-unsaturated azocanes will be depicted 
in a boat-boat conformation like that of otonecine (see Scheme 83). Further evidence for the 
predominance of these conformations is provided by computational studies described in Chapter 
3.2.3.2.  




 As part of the ongoing project at Bristol developing rhodacyclopentanone-based methodologies 
for the synthesis of sp3-rich heterocycles, Dr Megan Shaw published the Rh(I)-catalysed (7+1) 
carbonylative cyclisation of cyclopropylacrylamides to form azocanes.101 The azocanes produced in this 
reaction bear several structural similarities to otonecine, which suggests that they might serve as 
intermediates in its total synthesis (Scheme 83). For example, the ketone of these azocanes is in the 
correct position relative to the amine, the azocanes are unsaturated in the C2-C3 position, which is one 
position away from the C1-C2 alkene in otonecine, and alkyl C1-substituents can be incorporated 
(perhaps enantioselectively) when 1,2-disubstituted cyclopropyl substrates are employed.  
 
Scheme 83: Structural similarities between azocanes produced in the (7+1) carbonylative cyclisation and 
otonecine.  
 The proposed mechanism of the (7+1) carbonylative cyclisation begins in an identical manner 
to the methodologies presented in Section 1.3 and Chapter 2. A cationic Rh(I)-catalyst undergoes 
carbonyl-directed oxidative addition to the proximal cyclopropyl C-C bond of cyclopropylacrylamides 
391 to form rhodacyclobutane 392 (Scheme 84). CO migratory insertion then forms 
rhodacyclopentanone 393. Upon coordination to the rhodacyclopentanone, the alkene undergoes 
migratory insertion into the Rh(III)-acyl bond of 394 to give bridged intermediate 395. -Hydride 
elimination takes place exclusively from the C2 position (versus C7), and C-H reductive elimination 
forms the azocane with regeneration of the Rh(I)-catalyst.  





Scheme 84: Mechanism of the Rh(I)-catalysed (7+1) carbonylative cyclisation of cyclopropylacrylamides. 
 In the processes discussed in Section 1.3 and Chapter 2, cyclopropane-based substrates 
containing 1,2-disubstituted cyclopropanes reacted in a regiodivergent manner depending on whether 
the trans- or cis-diastereomer of the substrate was employed.99, 102 However, in the (7+1) carbonylative 
cyclisation, cyclopropylacrylamides containing trans- or cis-1,2-disubstituted cyclopropanes both 
reacted via Rh(I)-addition to the more substituted C-C bond “a” resulting in the sole formation of C1-
substituted azocanes 396a (Scheme 85A). This is fortunate because it might allow the C1-
hydroxymethyl substituent of otonecine to be incorporated during the (7+1) carbonylative cyclisation 
of either trans- or cis-1,2-disubstituted cyclopropylacrylamides. The regioselectivity of the (7+1) 
carbonylative cyclisation of trans-1,2-disubstituted cyclopropylacrylamides was reasoned by 
considering alkene migratory insertion into the two possible rhodacyclopentanone intermediates 397a 
and 397b (Scheme 85B). Based on previously described studies, Rh(I)-addition is selective for the less-
substituted C-C bond “b” of trans-1,2-disubstituted cyclopropanes (Section 1.3.3). However, alkene 
migratory insertion into the resulting rhodacyclopentanone 397a is accompanied by a developing steric 
repulsion between the Rh(III)-centre and R2-substitutent (see intermediate 398a). Furthermore, 
resulting [Rh]-azocane 398a does not possess a syn--hydride to the Rh(III)-moiety for -hydride 
elimination. As has previously been discussed, rhodacyclopentanone formation is completely 
reversible, therefore, 397a can revert to the starting material, and Rh(I)-addition to the disfavoured C-
C bond “a” can take place resulting in the formation of rhodacyclopentanone 397b. Now, alkene 
migratory insertion into 397b is favourable because of the absence of a developing steric interaction, 
so bridged intermediate 398b, and consequently C1-substituted azocane 396, are formed. The 
regioselectivity observed for cis-1,2-disubstituted cyclopropanes in the (7+1) carbonylative cyclisation 
(i.e. via more substituted C-C bond “a”) is expected based on previous studies.102  






 Shaw also showed that the (7+1) carbonylative cyclisation of trans-1,2-disubstituted 
cyclopropanes is stereoretentive whereby the relative stereochemistry of 1,2-disubstituted 
cyclopropanes is retained in the product azocanes. This was confirmed by cyclisation of deuterated 
substrate 399, which formed 400 as a single diastereomer (Scheme 85C). Stereoretention in 
rhodacyclopentanone-based methodologies, developed at Bristol, has been demonstrated in related 
methodologies (Section 2.1.3.2).103 The ability to access azocanes in high enantiopurity by this method 
is important for the planned total synthesis of (R)-otonecine.  
 Studies towards the total synthesis of otonecine were undertaken at Bristol for several reasons. 
The otonecine-type PAs possess potent biological activities and interesting physical chemical properties 
because of the N-C8 transannular interaction, and so synthetic access to these compounds might aid 
investigations into their therapeutic potential. Also, the unique azocane ring structure and presence of 
the transannular interaction make otonecine a synthetically challenging target, which is highlighted by 
the fact that none of the otonecine-type PAs have previously been synthesised. Finally, lessons learned 
by applying a rhodacyclopentanone-based methodology developed at Bristol to a total synthesis might 
benefit the development of related methodologies. 




At the outset, it was planned that the otonecine-type macrocyclic diesters would be formed by 
the union of an otonecine and necic acid building block by a sequence of esterification and 
macrolactonisation reactions (Scheme 86A). Literature precedent for this 
esterification/macrolactonisation strategy will be presented in Section 3.3.1 along with previous 
synthesis of necic acids. 
A simple retrosynthetic analysis of (R)-otonecine is presented in Scheme 86B. The planned 
synthesis hinges on gaining access to a suitably functionalised, enantioenriched azocane by (7+1) 
carbonylative cyclisation of an enantioenriched cyclopropylacrylamide. The exact identity of the 
cyclopropylacrylamide was not certain because it was not clear if substrates bearing N-methyl or 
hydroxymethyl-substituted cyclopropanes would be tolerated in the (7+1) carbonylative cyclisation. 
Nevertheless, it was proposed that the cyclopropylacrylamide could be accessed from a protected allyl 
alcohol via asymmetric cyclopropanation and Curtius rearrangement. Depending on the optimal 
azocane, the final steps in the total synthesis of (R)-otonecine would require a diastereoselective -
ketone oxidation, lactam reduction and isomerisation of the alkene from C2 to C1.  
 
Scheme 86  




3.2 Studies towards the total synthesis of otonecine  
3.2.1 Studies into the (7+1) carbonylative cycloaddition 
3.2.1.1 Identification of a suitable (7+1) substrate 
 Synthetic studies towards the total synthesis of otonecine began with the identification of a 
suitable (7+1) carbonylative cycloaddition substrate. This required reinvestigation of the scope of the 
cycloaddition because certain substrate functionalities, which were deemed vital to the success of the 
project, were not considered in the original publication. Firstly, it was not known whether N-methyl 
cyclopropylacrylamides (indicated in blue) would be tolerated (Scheme 87). This addition to the scope 
was vital to the success of the project because it would avoid the need to carry out wasteful N-
functionalisations at a late-stage in the synthesis. Secondly, cyclisation of 1,2-disubstituted 
hydroxymethylcyclopropanes (indicated in green) would dramatically increase the efficiency of the 
proposed synthesis by incorporating the C1-hydroxymethyl moiety of otonecine during the (7+1) 
carbonylative cycloaddition. This class of 1,2-disubstituted cyclopropane had not been investigated in 
any of the rhodacyclopentanone-based methodologies developed at Bristol, so it was not clear if this 
would be successful. Finally, investigations would be carried out into cycloaddition substrates 
containing a vinylogous carbamate (indicated in red) because these might give access to C7-hydroxy 
azocanes, thus removing the need for an -ketone oxidation step. As described below, these issues 
regarding the scope of the (7+1) carbonylative cycloaddition were addressed by synthesising model 
acrylamide substrates and subjecting them to the (7+1) carbonylative cycloaddition conditions. 
 
Scheme 87: Desirable additions to the scope of the (7+1) carbonylative cycloaddition. 
 Acrylamide 402 was initially targeted in order to investigate whether N-methyl substitution was 
tolerated under the (7+1) carbonylative cycloaddition conditions (Scheme 88A). Following a route 
previously published by the Bower group, commercially available carboxylic acid trans-212a (8:1 d.r.) 
underwent Curtius rearrangement with diphenylphosphoryl azide in t-BuOH to form Boc-protected 
amine trans-213a (88%, 8:1 d.r.).102 N-Methylation using sodium hydride and iodomethane was 
straightforward generating carbonate 401 in 69% yield. The Boc-protecting group was removed on 
treatment with trifluoroacetic acid, and the resulting amine-TFA salt was reacted with acryloyl chloride 
to form acrylamide 402 (90%, 8:1 d.r.). This one-pot deprotection/acrylamide formation of Boc-
protected amines avoids the need to isolate the potentially volatile amine free base. Note that 




enantioenriched carboxylic acid (S,S)-212a (both enantiomers are accessible) can be prepared in one 
step by a Horner-Wadsworth-Emmons cyclopropanation using enantiomerically pure propylene 
oxide.154 
 Having prepared N-methyl substituted cyclopropylacrylamide, it was subjected to the (7+1) 
carbonylative cycloaddition conditions. When reacted with a [Rh(cod)2]BARF/P(p-CNC6H4)3 catalyst 
system in benzonitrile under a CO atmosphere, cyclopropylacrylamide 402 formed azocane 403a in 
37% yield, as a single regioisomer (Scheme 88B). Azocane 403a was considered a viable intermediate 
in the synthesis of (R)-otonecine because it contains the complete carbon skeleton of the natural product 
and is potentially available in an enantioenriched form. Therefore, this result served as validation of the 
retrosynthesis in Scheme 86B.  
 
Scheme 88: A) Reagents and conditions: i) Literature conditions: TEPA, HexLi, MeTHF, 150 °C, 18 h; ii) 
diphenylphosphoryl azide, NEt3, t-BuOH, 80 °C, 72 h, 88%, 8:1 d.r.; iii) NaH, MeI, THF, r.t., 16 h, 69%, 8:1 d.r.; 
iv) trifluoroacetic acid, CH2Cl2, r.t., 30 min then acryloyl chloride, K2CO3, acetone-water, 0 °C to r.t., 16 h, 90%, 
8:1 d.r.. 
 Next, acrylamide 409a, containing a benzyl-protected 1,2-disubstituted 
hydroxymethylcyclopropane, was synthesised to investigate whether substrates of this type would allow 
installation of the C1-hydroxymethyl group of otonecine during the (7+1) carbonylative cycloaddition 
step (Scheme 89A). Ally benzyl ether underwent high yielding epoxidation to provide epoxide 404 in 
94% yield, which was subjected to Horner-Wadsworth-Emmons cyclopropanation using TEPA, to form 
ester 405a as a single diastereomer in 52% yield. Ester hydrolysis provided carboxylic acid 406a (97%), 
which was advanced to cyclopropylacrylamide 409a by N-methylation (67%) and a one-pot Boc-




deprotection/acrylamide formation sequence (75%). When subjected to the (7+1) carbonylative 
cycloaddition conditions, C1-alkoxymethyl azocane 410a was formed, but was observed to degrade 
over time under the reaction conditions (Scheme 89B). As a result of its instability, azocane 410a could 
only be formed in 12% yield. Evidence for the mechanism of degradation of C1-alkoxymethyl azocane 
410a was provided by the tentative identification of alkene 411 in the crude reaction mixture. Alkene 
411 is likely formed by thermal elimination of the alkoxy-substituent of azocane 410a. Brief efforts to 
avoid deleterious elimination from azocane 410a failed to improve the yield of the (7+1) carbonylative 
cycloaddition, so studies involving acrylamide 409a were abandoned.  
 
Scheme 89: A) Reagents and conditions: i) m-CPBA, CH2Cl2, r.t., 16 h; ii) triethyl phosphonoacetate, NaH, 1,2-
DME, 0 °C to reflux, 24 h; iii) aq. 4 M NaOH, MeOH, r.t., 16 h; iv) diphenylphosphoryl azide, NEt3, t-BuOH, 80 
°C, 22 h; v) NaH, MeI, THF, r.t., 1 h; vi) trifluoroacetic acid, CH2Cl2, r.t., 30 min then acryloyl chloride, K2CO3, 
acetone-water, 0 °C to r.t., 16 h. 
 In order to improve the stability of C1-alkoxymethyl azocanes, it was proposed that a more 
electron donating O-protecting group might disfavour O-elimination by destabilising the resulting 
alkoxide. Therefore, acrylamide 409b was synthesised and tested in the (7+1) carbonylative 
cycloaddition (Scheme 90A). The synthesis began with commercially available diester 412, which 
underwent mono-hydrolysis when treated with one equivalent of base to generate carboxylic acid 413 
in 94% yield. Chemoselective borane reduction and TBS-protection of the resulting alcohol provided 
ester 405b in 86% yield over the two steps. Hydrolysis of the ester proceeded smoothly, but resulting 
silyl ether 406b was sensitive to desilylation upon acidification during the work-up, so an alternative 
step order was investigated to form acrylamide 409b. 




The synthetic sequence was reordered such that carboxylic acid 413 underwent Curtius 
rearrangement to give Boc-protected amine 414 in 57% yield, the ester of which was reduced using 
DIBAL-H to form alcohol 415 in 82% yield. The alcohol was TBS-protected in 59% yield, and N-
methylation formed carbamate 408b in 63% yield. The following Boc-deprotection step was carried out 
using ZnBr2 because of the observed sensitivity of TBS-protected alcohol 406b to Brønsted acids.243 
However, treatment of carbamate 408b with ZnBr2 provided both Boc-deprotected amine 416 and TBS-
deprotected alcohol 417 in 15% and 19% yields, respectively. Despite the disappointing yield of the 
Boc-deprotection step, amine 416 was treated with acryloyl chloride to yield the target acrylamide 409b 
in 63% yield. Under the (7+1) carbonylative cycloaddition, acrylamide 409b underwent non-specific 
degradation and target azocane 410b was not observed (Scheme 90B). Further studies into the (7+1) 
carbonylative cyclisation of substrates containing 1,2-disubstituted hydroxymethylcyclopropanes were 
abandoned due to the instability of the resulting azocanes. Instead, attempts would be made to install 
the C1-hydroxymethyl substituent of otonecine by late-stage C-H oxidation of the C1-methyl group. 
These studies are presented in Section 3.2.4.   
 
Scheme 90: A) Reagents and conditions: i) aq. 4 M NaOH, EtOH, r.t., 4 h; ii) BH3.THF, THF, 0 °C to r.t., 16 h 
then TBSCl, imidazole, DMF, r.t., 3 h; iii) aq. 4 M NaOH, MeOH, r.t., 16 h; iv) diphenylphosphoryl azide, NEt3, 
t-BuOH, 80 °C, 24 h; v) DIBAL, PhMe, -78 °C, 3 h; vi) TBSCl, imidazole, DMF, r.t.; vii) NaH, MeI, THF, r.t., 
16 h; viii) ZnBr2, CH2Cl2, r.t., 16 h; ix) acryloyl chloride, K2CO3, acetone-water, 0 °C to r.t., 16 h. 




 In the original investigations into the scope of the (7+1) carbonylative cycloaddition, Shaw 
observed that -methylacrylamide 418 cyclised to form C7-methyl azocane 419 in 10% yield (Scheme 
91A).101 Despite this, cyclopropylacrylamide Z-421, containing a vinylogous carbamate, was 
synthesised in order to access C7-hydroxyazocane 422 (Scheme 91B). The synthesis was achieved by 
coupling benzylcyclopropylamine and propiolic acid with DCC to form amide 420 in quantitative yield. 
Then Z-selective 1,4-addition of benzyl alcohol was achieved with catalytic silver(I) triflate to form 
desired Z-acrylamide Z-421in 65% yield.244 Treatment of acrylamide Z-421 under the (7+1) 
carbonylative cycloaddition conditions did not form azocane 422, but caused the isomerisation of the 
alkene to form E-acrylamide E-421 (Scheme 91C). The failure to form azocane 422 also suggested that 
E-acrylamides were not suitable (7+1) carbonylative cycloaddition substrates, so investigations into this 
class of substrate were halted. 
 
Scheme 91: B) Reagents and conditions: i) propiolic acid, DCC, DMAP, CH2Cl2, 0 °C to r.t., 2 h; ii) AgOTf, 
BnOH, 70 °C, 3 h. 
The studies into the model substrates above identified N-methyl cyclopropylacrylamide 402 
and azocane 403a as viable intermediates for the total synthesis of otonecine. Efforts were then directed 
towards optimising the (7+1) carbonylative cycloaddition of cyclopropylacrylamide 402 such that the 
reaction could be carried out efficiently on a larger scale. This would allow the remaining 
transformations in the synthesis to be investigated.  
3.2.1.2 Optimisation of the (7+1) carbonylative cycloaddition  
 Based on the results of the previous section, acrylamide 402 was chosen as a substrate for 
further optimisation, and selected results are shown in Table 12. The conditions developed by Shaw 
formed azocane 403a in a moderate 35% yield on 0.15 mmol scale with 10 mol% of [Rh(cod)2]BARF 




and 20 mol% of P(p-CNC6H4)3 (Table 12, Entry 1). Optimisation studies were undertaken with the goal 
of increasing the yield of azocane 403a, whilst reducing the catalyst and ligand loadings. The scale of 
the reaction would also need to be increased to facilitate studies on the remaining transformations.  
 Initially, a screen of commercially available mono- and bidentate phosphines, triarylarsines, 
phosphites, sulfur-based ligands, and N-heterocyclic carbenes was carried out in combination with a 
cationic Rh(I)-catalyst, but this failed to identify a ligand superior to P(p-CNC6H4)3. The first significant 
increase in yield of azocane 403a was achieved by including benzamide as an additive, which provided 
azocane 403a in 43% yield (Entry 2). Amide and carboxylic acid additives have provided a beneficial 
effect in related Rh(I)-catalysed carbonylative cycloadditions developed at Bristol.102-103, 105 
Subsequently, a screen of Lewis-basic additives identified sulfonamides and carboxylic acids as 
beneficial additives. For example, p-toluenesulfonamide and pivalic acid provided azocane 403a in 
40% and 49% yield, respectively (Entries 3 and 4). Interestingly, the tertiary amide, dimethylacetamide, 
also provided a substantial improvement when compared to benzamide, which suggests that an acidic 
proton is not vital for the beneficial effect of the additive (Entry 6). This finding apparently conflicts 
with the observation that trifluoroacetamide (48% yield, Entry 5) was also more effective than 
benzamide. Ultimately, the secondary amide, N-methyltrifluoroacetamide, was identified as a suitable 
additive, which provided azocane 403a in 51% yield (Entry 7). The role of amide/carboxylic acid 
additives in these reactions is unknown. It was observed empirically that Lewis-basic additives caused 
the reaction mixture to remain as a homogeneous solution and postponed the precipitation of Rh-black. 
This might indicate that Lewis-basic additives play a role in stabilising Rh-species in solution. The 
observation that dimethylacetamide (Entry 6) provided a beneficial effect suggest that the amide might 
be acting as a Lewis base, and not as a source of protons or as a hydrogen bond donor. 
 Having identified improved reaction conditions that provided azocane 403a in 51% yield on a 
0.15 mmol scale, investigations were directed towards increasing the scale of the reaction. When the 
reaction was carried out on a 0.50 mmol scale, the yield of azocane 403a fell to 41% under otherwise 
identical conditions (Entry 8). Analysis of the 1H NMR spectrum of the crude reaction mixture indicated 
that the phosphine ligand, P(p-CNC6H4)3, was no longer present. It was discovered that the phosphine 
ligand had been oxidised to the corresponding phosphine oxide, presumably by reaction with oxygen 
during the (7+1) carbonylative cycloaddition. Similar oxidation processes are catalysed by various 
transition metals.245-246 This reactivity is likely to have caused the reaction to lose efficiency, resulting 
in the reduced yield. It was proposed that the use of balloons to apply a CO atmosphere might also allow 
the introduction of oxygen into the reaction over time by diffusion through the rubber wall. Therefore, 
in order to minimise the amount of oxygen in the reaction, a more rigorous method of applying a CO 
atmosphere was investigated. This was achieved by performing the reaction in a sealed Schlenk tube 
under a CO atmosphere, which was set up via a three-way cylinder head attached to a Schlenk-line and 
CO cylinder (Further details are available in the Experimental section). When this new set up was 




employed, azocane 403a was formed in 51% yield on a 0.50 mmol scale (Entry 9). Furthermore, the 
new reaction set up increased the lifetime of the active catalytic species, which in turn allowed a 
reduction in both the Rh(I)-catalyst and ligand loadings whilst also providing a modest increase to the 
yield of azocane 403a (54% yield, Entry 10).  
 
Table 12: Selected results from the optimisation of the (7+1) carbonylative cycloaddition of 
cyclopropylacrylamide 402. 
 The newly optimised conditions for the Rh(I)-catalysed (7+1) carbonylative cycloaddition of 
acrylamide 402 enable the reaction to be run routinely on a multi-mmol scale. This allowed the focus 
of the investigations to shift towards the remaining transformations in the total synthesis of otonecine. 
Further optimisation of the (7+1) carbonylative cycloaddition of cyclopropylacrylamide 402 should be 
directed towards identifying the optimum additive for this transformation. Elucidating the exact role of 
these additives may allow the rational design of an improved catalyst system applicable to related 
reactions. 
3.2.2 The post-cycloaddition transformations 
 The optimised conditions for the (7+1) carbonylative cycloaddition of cyclopropylacrylamide 
402 provided suitable quantities of viable intermediate azocane 403a, which facilitated further 
investigations into the post-cycloaddition transformations towards the total synthesis of otonecine. The 
four post-cycloaddition transformations included (Scheme 92): 1) oxidation of the C7-position by a 




diastereoselective -ketone oxidation; 2) lactam reduction; 3) alkene isomerisation from the C2 to the 
C1-position; 4) C-H oxidation of the C9-position. At the outset of the project, it was unclear in what 
order the post-cycloaddition transformations should be carried out, however, three assumptions were 
made: 
• The C7-alcohol of otonecine should be installed by diastereoselective -ketone oxidation 
before alkene isomerisation to the C1-position, in order to transfer the C1-stereochemistry. 
• The lactam reduction should be carried out towards the end of the synthesis to limit potential 
complications due to the transannular interaction.  
• The C9-alcohol of otonecine might be installed by an allylic oxidation, so should be carried out 
after alkene isomerisation to the C1-position. 
The following studies aimed to identify suitable means of carrying out the remaining transformations 
and to provide further information regarding a suitable order of steps. 
 
Scheme 92: Post-cycloaddition transformations required in the synthesis of otonecine. 
3.2.2.1 -Ketone oxidation 
 The first post-cycloaddition transformation to be attempted was the diastereoselective -ketone 
oxidation because it was likely to be the first post-cycloaddition transformation in the total synthesis of 
otonecine. Previously, Still and Galynker reported that eight-membered cyclic ketone 423 underwent 
highly regio- and diastereoselective alkylation under kinetic conditions, which favoured the formation 
of trans dialkylketone 424 (Scheme 93A).247 It was hoped that the C7-oxidation of azocane 403a, under 
similar conditions, might also proceed with high levels of regio- and diastereoselectivity. Therefore, 
initial attempts were made to oxidise the C7-position of azocane 403a in a single step by oxidation of 
the metal enolate. Azocane 403a was deprotonated with LiHMDS under cryogenic conditions, and the 
resulting lithium enolate was reacted directly with molecular oxygen and P(OEt)3, or Davis oxaziridine, 
but no C7-oxidised products were formed (Scheme 93B).  






 An alternative one-pot method for carrying out the C7-oxidation was briefly investigated. 
Tomkinson and co-workers have reported several acyl-oxime reagents that can react with ketones to 
form -acyl ketones via House rearrangement of the intermediate enamines (Scheme 94).248-252 
However, acyl-oxime 426 could not be condensed onto the ketone of azocane 403a, even in the presence 
of strong Brønsted and Lewis acids, so this method was abandoned.  
 
Scheme 94: Failed C7-acetylation of azocane 403a by a House rearrangement. 
 Having failed to install the C7-alcohol onto azocane 403a by direct oxidation of a metal enolate, 
a two step Rubottom oxidation sequence was attempted, which required highly regioselective 
conditions for the formation of TBS-silyl enol ether 427a. The TBS-group was chosen so that it might 
act as a protecting group for the C7-alcohol in subsequent transformations. To begin, azocane 403a was 
added to an excess of LiHMDS, and the resulting lithium enolate was quenched with TBSCl to provide 
silyl enol ether 427a in 59% yield, but as a mixture of regioisomers (5:2 427a:427b) (Table 13, Entry 
1). When freshly prepared LDA was employed, an improved product ratio was afforded (41%, 25:1 
427a:427b), but this result was irreproducible (Entry 2). Deprotonation of azocane 403a at -78 °C was 
observed to be immediate (accompanied with the formation of a yellow colour) but subsequent reaction 
with TBSCl was slow at room temperature, which presumably allowed the lithium enolate to isomerise. 
Therefore, attempts were made to increase the rate of silylation by using TIPSOTf, as a more 




electrophilic silylating reagent,253 but this failed to form 427a (Entry 3). Next, additives were trialled in 
an attempt to improve the regioselectivity of silyl enol ether formation by dissuading the formation of 
lithium aggregates.254-255 When LiCl was added, degradation was observed (Entry 4), but the addition 
of DMPU was found to significantly increase the rate of silylation at room temperature, providing 427a 
in 70% yield and 8:1 r.r in favour of the desired silyl enol ether (Entry 5). 
 
Table 13: Selected results from the optimisation of the synthesis of silyl enol ether 427a. 
Having gained reliable access to silyl enol ether 427a, the Rubottom oxidation was attempted. 
Under basic-buffered conditions, m-CPBA reacted with silyl enol ether 427a to form desired C7-siloxy 
ketone 429 as a single diastereomer, but as an inseparable mixture with acetal 430 (39% combined 
yield, 4:1 429:430) (Scheme 95A). Acetal 430 is likely formed by addition of m-chlorobenzoate to 
oxonium species 431 (Scheme 95B). Acetal 430 could not be separated from C7-silyloxide 429 by 
column chromatography or by aqueous work-up, but could be removed after treatment with DBU, 
which formed C7-benzoate 432 in 77% yield by acetyl migration and elimination of the C8-silyloxy 
group (Scheme 95C). It should be noted that the relative stereochemistry of the C1- and C7-positions 
of 429 (not determined at this point) is inconsequential because the C1-stereocentre will be removed 
later in the synthesis upon isomerisation of the alkene. Therefore, the Rubottom oxidation was identified 
as a promising method for the diastereoselective C7-oxidation. 






3.2.2.2 Enelactam reduction 
 Investigations turned to the lactam reduction, primarily to gain an appreciation for the reactivity 
of the enelactam functionality of azocanes, but also to test whether a chemoselective lactam reduction 
in the presence of the ketone was feasible. Additionally, a successful reduction at this stage might 
provide valuable experience in the handling and purification of azocanes that contain a N-C8 
transannular interaction. Chemoselective reduction of lactams (or amides) in the presence of ketones is 
challenging, but several protocols have been reported,256 and a few of these have been employed in the 
synthesis of natural products.257-259 Among these methodologies, those that employ Lewis-acidic 
transition-metal hydrides that can selectively coordinate to Lewis-basic amide carbonyl have proved to 
particularly powerful (see 433, Scheme 96, A). However, under these conditions the C2-alkene of 
azocane 403a might restrict transition-metal hydride reduction of the lactam, by reducing the Lewis-
basicity of the lactam carbonyl. In the event, azocane 403a did not react when subjected to 
Mo(CO)6/TMDSO260 or IrCl(CO)(PPh3)2/TMDSO261 (Scheme 96A). 
Instead, the ketone of azocane 403a was protected as the 1,3-dioxolane in high yield (92% yield 
of 434) to investigate lactam reduction by stronger reducing agents (Scheme 96B). When treated with 
triflic anhydride, the lactam of protected azocane 434 underwent a clean reaction to form triflimide 435 
(as determined by 1H NMR analysis), but subsequent addition of Hantzsch ester262 or sodium 
cyanoborohydride263 resulted in degradation. Finally, silyl enol ether 427a was treated with lithium 
aluminium hydride, which resulted in the formation of the unexpected ring contraction product 438 in 
32% yield (Scheme 96C). This highly substituted cyclohexane derivative is proposed to form by partial 




lactam reduction of silyl enol ether 427a to form [Al]-intermediate 436. During work-up 436 likely 
undergoes ring opening to form acyclic intermediate 437, the aldehyde and enamide functionalities of 
which recombine to give cyclohexane 438. The failure to reduce species 436 might have been due to 
poor N-lone pair overlap with the *-orbital of the C-O[Al] bond as a result of the conformation of the 
azocane ring.  
 
Scheme 96: B) Reagents and conditions: i) ethylene glycol, BF3·Et2O, CH2Cl2, 0 °C to r.t. 
Efforts to reduce the lactam of azocanes containing the enelactam functional group failed under 
mild chemoselective reducing conditions as well as more forcing conditions. This was believed to be a 
result of the presence of the C2-alkene, which reduces the nucleophilicity of the lactam carbonyl and 
promotes ring opening of partially reduced intermediates. As a result of these considerations it was 
concluded that the lactam reduction should be carried out after alkene isomerisation.  
3.2.3 Alkene isomerisation 
3.2.3.1 Attempted alkene isomerisation under equilibrating conditions 
 The next post-cycloaddition transformation to be studied was the alkene isomerisation from the 
C2-position of azocane formed during the (7+1) carbonylative cycloaddition, to the C1-position as in 
otonecine. Studies began by subjecting azocane 403a to various equilibrating conditions in the hope 
that the C1-alkene isomer was thermodynamically more favourable than the C2-isomer. Azocane 403a 
was treated with a range of bases (NEt3, DBU, MTBD and KOt-Bu) but enone 439a was not observed 
(Scheme 97A). Similarly, attempts to isomerise the alkene using Schwartz’s reagent264 failed to produce 




any of the desired isomer 439a. Finally, an attempt to protonate the C3-position of enolate 440 (formed 
by deprotonation of the C1-position of -siloxyketone 429) with BHT, a sterically bulky acid, also 
failed (Scheme 97B). These results indicate that the unwanted C2-alkene isomers (as in azocane 403a) 
are thermodynamically more stable than the desired C1-alkene isomers (as in enone 439a), and so non-
equilibrating alkene isomerisation conditions might be required.  
  
Scheme 97 
3.2.3.2 Computational studies into the relative stability of alkene isomers 
3.2.3.2.1 Conformations of eight membered rings 
 Prior to the calculations presented in the following section, it is pertinent to introduce the 
common conformations adopted by eight membered rings because conformation has a dramatic 
influence on the stability and reactivity of cyclic molecules.247 The simplest eight-membered ring, 
cyclooctane, has been shown to exist predominantly in a boat-chair conformation (Scheme 98).247 The 
boat-chair conformation possesses two unfavourable eclipsed ethane linkages (highlighted in red) and 
no significant transannular repulsions. By comparison, the slightly less stable chair-chair (or crown) 
conformation contains four eclipsed ethane linkages. Less stable still, the boat-boat conformation 
exhibits four eclipsed ethane linkages as well as a significant transannular repulsion. It is difficult to 
predict the conformation of more functionalised eight-membered ring because the addition of 
functionality might alleviate or introduce unfavourable interactions.265 Previously, Shaw disclosed a 
crystal structure of simple azocane 441.101 This shows that it adopts a boat-chair conformation in the 
solid state, which is in accordance with the conformation adopted by cyclooctanone.266 In contrast, 
crystal structures of the otonecine-type PAs (including clivorine) show the azocane ring system 
adopting a boat-boat conformation because of the stabilising N-C8 transannular interaction.199, 267  





Scheme 98: Common conformations of eight-membered rings and comparison with the conformations adopted 
by azocane 441 and otonecine. 
3.2.3.2.2 Computational studies 
 The failure to observe the desired C1-alkene isomer 439a under various equilibrating conditions 
suggested that there was a large thermodynamic preference for the C2-isomer in azocane 403a. Further 
evidence for this proposition was obtained by calculating the relative stability of C2- and C1-alkene 
isomers using computational methods (further details are provided in the experimental Section 4.6). 
Computational chemistry has proved to be successful in predicting and rationalising the outcomes of 
reactions, and is therefore increasingly being employed as a predictive tool in the synthesis of natural 
products.268-270 Of particular relevance to the proceeding discussion, computational chemistry has been 
used to predict the outcome of reactions involving thermodynamic equilibria.271 Therefore, with 
guidance from Dr. Natalie Fey, low energy conformations of each alkene isomer were identified by 
carrying out a conformer distribution calculation using the Spartan software. The resulting low energy 
conformations were optimised by performing energy optimisation calculations using hybrid density 
functional theory (B3LYP)272-276 and the 6-31G(d)277-279 basis set using the Gaussian software.280 The 
lowest energy conformation of each alkene isomer, found in this way, were compared to provide an 
energy difference, which indicated the more thermodynamically stable alkene isomers. 
To begin, C2-alkene isomer 403a and the corresponding C1-alkene isomer 439a, were 
compared (Figure 6). The lowest energy conformation of C2-alkene 403a was identified as boat-chair 
conformer BC-403a where the C1-methyl group is in the equatorial position, which closely resembles 
the crystal structure of simple azocane 441, obtained by Shaw (Scheme 98). The second most stable 
conformation calculated for C2-alkene 403a was boat-boat conformer BB-403a, which was calculated 
to be 12.7 kJ/mol less stable than BC-403a. In contrast, the lowest energy conformation of C1-alkene 
isomer 439a was calculated to be boat-boat conformer BB-439a, which was slightly preferable to chair-
chair conformer CC-439a (+0.4 kJ/mol). Notably, the nitrogen lone pair of boat-boat conformer BB-




439a is directed towards the *-orbital of the C8-ketone, invoking a weak transannular interaction (N-
C8 distance of 2.89 Å). Finally, comparison of the most stable conformations of the two alkene isomers 
(C2-alkene conformer BC-403a vs. C1-alkene conformer BB-439a) suggests that the C2-alkene isomer 
is 19.9 kJ/mol more stable than the C1-alkene isomer, which is in line with the findings in Scheme 97. 
This raised the question: at which point in the proposed total synthesis of otonecine from azocane 403a 
will the C1-alkene isomer become more thermodynamically favoured than the C2-isomer? To 
investigate this question, calculations were carried out to compare C2- and C1-alkene isomers of several 
possible intermediates towards otonecine. 
 
Figure 6 
 Firstly, lactam reduction products, 442 and 443, were compared (Figure 7). It was predicted 
that in the absence of the C5-carbonyl, a N-C8 transannular interaction would be formed, which might 
increase the stability of the C1-alkene isomer 443 relative to the unwanted C2-isomer. Indeed, C2-
isomer 442 was calculated to prefer boat-boat conformation BB-442 over twisted boat-chair conformer 
BC-442 by 3.4 kJ/mol, presumably as a result of a N-C8 transannular interaction (indicated). C1-alkene 
isomer 443 was predicted to adopt boat-boat conformation CC-443, also containing a transannular 
interaction. Comparison of the favourable conformations of the two alkene isomers, BB-442 and CC-
443, revealed a thermodynamic preference for the C2 enamine by +10.5 kJ/mol. Therefore, these results 
suggest that by reducing the lactam the C1-alkene isomer 443 becomes less disfavoured, but not 
preferred. 






 Next, the electronic impact of the C9-alcohol was investigated by comparing alkene isomers, 
444 and 445 (Figure 8). C2-alkene 444 was calculated to adopt boat-chair conformer BC-444 in 
preference over boat-boat conformer BB-444 (+9.7 kJ/mol). A hydrogen bonding interaction between 
the C9-alcohol and C8-ketone (indicated by a dashed line) appears to stabilise the boat-chair 
conformation. C1-alkene isomer 445 is predicted to adopt boat-boat conformer BB-445. Comparison 
of the favoured conformations of C2- and C1-alkene isomers (BC-444 vs BB-445) showed a strong 
preference for the undesired C2-alkene isomer (+16.9 kJ/mol), perhaps indicating that the C9-alcohol 
stabilises the unwanted C2 isomer. 
 
Figure 8 




 The unexpected thermodynamic preference for the C2-alkene isomer in each of the hypothetical 
intermediates above prompted comparison of the natural product otonecine with both diastereomers of 
its C2-alkene isomer, trans-446 and cis-446 (Figure 9). The two lowest energy conformations of trans-
446, chair-chair conformer CC-trans-446 and boat-boat conformer BB-trans-446 were found to be 
essentially identical in energy (+0.1 kJ/mol). Both conformations contain a C9-alcohol to C8-ketone 
hydrogen bond while chair-chair conformation CC-trans-446 also contains a transannular C7-OH-N 
hydrogen bond. The most stable conformation calculated for cis-C2-alkene cis-446 was boat-chair 
conformer BC-cis-446, which also contained hydrogen bonds between the C8-ketone and each alcohol. 
Finally, stable conformers of otonecine were calculated, which provided boat-boat conformation BB-
otonecine as the most stable conformation. Notably, this contains the N-C8 transannular interaction 
characteristic of the natural product. 
  
Figure 9 
 Surprisingly, comparison of the most stable conformations of otonecine and unnatural C2-
alkene isomer 446 indicated that the C2-alkene isomer conformation BC-cis-446 was preferred to the 
otonecine conformer BB-otonecine by +5.0 kJ/mol. This is a small energy difference, which suggests 
that both alkene isomers might be present in an equilibrating system, although there is no indication in 
the literature that this is the case. It should also be considered that the results of these calculations might 
not be accurate. However, the results of the calculations described in this section suggested that the 
alkene isomerisation step, en route to the total synthesis of otonecine, cannot be achieved under 
equilibrating condition, so an alternative method was investigated.  
 
 




3.2.3.3 The development of a kinetic alkene isomerisation 
 The apparent sustained thermodynamic preference for C2-alkene isomers over the desired C1-
alkene isomers necessitated the development of a kinetic alkene isomerisation. It was recognised that 
this might be achieved by appropriate functionalisation of the enelactam functional group of azocane 
403a. For example, the nucleophilic enelactam moiety might be leveraged to place a leaving group at 
C2, which might then be elimination by E1cB elimination to reinstall the alkene in the C1-position as 
in 439a (Scheme 99). Depending on the conditions used, an additional C3-reduction step might be 
required in order to render the net-alkene isomerisation, redox neutral.  
 
Scheme 99: Proposed strategy for the kinetic alkene isomerisation. 
3.2.3.3.1 Studies in the presence of a protected ketone 
 Investigations into the kinetic alkene isomerisation began by subjecting protected azocane 434 
to known conditions for the functionalisation of enelactam moieties such that a leaving group is placed 
at C2. Protected azocane 434 was utilised in the first instance to simplify the system and allow the C3-
reduction step to be attempted without the possibility of reducing the ketone. Initially, protected azocane 
434 was found to be unreactive in the presence of PhI(OAc)2281 or m-CPBA,282 precluding the formation 
of diacetate 447 or epoxide 448 (Scheme 100A). However, on treatment with NBS in methanol,283 
protected azocane 434 reacted to form C3-methoxide 449 in high yield (85%) as an inconsequential 
mixture of diastereomers (6:1 d.r., relative stereochemistry not determined) (Scheme 100B). 
Subsequent attempts to reduce the C3-position of C3-methoxide 449 by treatment with 
BF3·Et2O/Et3SiH failed to form bromide 450.284 Additionally, an attempt to perform a one pot 
electrophilic bromination/C3-reduction by the combination of NBS with various reducing agents also 
failed to provide bromide 450.  
  





Scheme 100: B) Reagents and conditions: i) NBS, MeOH, THF, -78 °C to 0 °C to r.t., 1 h; ii) Failed aminal 
reduction conditions: BF3·Et2O/Et3SiH; iii) Failed conditions: NBS/Et3SiH, NBS/NaBH3CN.  
 It was envisaged that the problematic C3-reduction step could be avoided by performing an 
anti-Markovnikov hydrofunctionalisation of protected azocane 434 such that a hydride is introduced at 
C3. An appealing method of achieving such a transformation is by a hydroboration/oxidation sequence, 
although this would necessitate the use of a ketone protecting group to avoid overreduction.285 
Accordingly, protected azocane 434 was treated sequentially with BH3·THF and then NaOH/hydrogen 
peroxide, which provided the lactam reduction product, aminoalcohol 451, as the sole product in 40% 
yield (1:1 d.r.) (Scheme 101A). This serendipitous discovery was potentially useful because lactam 
reduction is one of the post-cycloaddition transformations required in the synthesis of otonecine. 
Unfortunately, attempts to improve the yield of aminoalcohol 451, including the use of alternative 
oxidants (perborate, trimethylamine N-oxide286), solvents (dichloromethane, toluene) and boranes 
(BH3·DMS, thexyl borane), failed.  
 Nevertheless, focus turned to removing the acetal protecting group and eliminating the C2-
alcohol of aminoalcohol 451. Ideally, both transformations would take place in one pot via intermediate 
enol ether 452, which might eliminate the C2-alcohol under acidic conditions (Scheme 101B). 
However, several acidic conditions for the deprotection of acetals resulted in the loss of aminoalcohol 
451, but failed to provide deprotected product 453. Similarly, C2-acetate 454 could not be deprotected 
under a variety of Brønsted and Lewis-acidic conditions. Finally, attempts were made to eliminate the 
C2-alcohol prior to removal of the protecting group by treating aminoalcohol 451 with Burgess reagent 
or methanesulfonyl chloride (Scheme 101C). In the latter case, it was proposed that the mesylate group 
of 455 would be eliminated by intramolecular SN2-substitution by the tertiary amine to form aziridinium 
456, which might undergo ring opening to form alkene 457. However, both conditions failed to provide 
alkene 457. 





Scheme 101: B) Reagents and conditions: i) Failed conditions: aq. HCl or HCl, MeOH or pTSA, acetone ii) 
Ac2O, DMAP, NEt3, CH2Cl2, r.t., 1 h; iii) Failed conditions: trifluoroacetic acid, CH2Cl2 or aq. HCl or In(OTf)3, 
acetone or PdCl2(MeCN)2, acetone. C) Reagents and conditions: i) Burgess reagent, PhMe; ii) Conditions 
attempted: MsCl, NEt3, CH2Cl2. 
 Up to this point, difficulties in removing the 1,3-dioxolane protecting group had restricted the 
use of aminoalcohol 451 in the synthesis of otonecine, and so an alternative C8-ketone protecting group 
was investigated. To this end, diethylacetal 459 was targeted because acyclic acetal protecting groups 
are more labile than cyclic acetals (Scheme 102A).287 When azocane 403a was treated with 
triethylorthoformate in the presence of catalytic p-TSA, diethylacetal 459 was formed as the minor 
product along with enol ether 458 in 51% combined yield (2:1, 458:459), which was deemed 
unsatisfactory for the purpose. Finally, attempts to carry out the hydroboration/oxidation sequence on 
unprotected azocane 403a and silyl enol ether 427a, in the hope that the ketone would not be reduced, 
provided complex mixtures of products (Scheme 102B and 102C). Despite the potential advantage of 
the hydroboration/oxidation sequence in terms of step economy, this strategy was abandoned due to 




poor yields and the difficulties encountered removing acetal protecting groups. However, the use of 
BH3·THF to generate aminoalcohol 451 was the first time that the lactam had been completely reduced, 
which might benefit future studies. 
 
Scheme 102: Reagents and conditions: i) (EtO)3CH, pTSA, EtOH, r.t., 16 h; ii) BH3·THF, THF, -78 °C to r.t., 
1.5 h then 30% aq. H2O2, 2 M aq. NaOH, 30 min. 
3.2.3.3.2 Studies in the presence of the ketone 
 Note: Benzyl-substituted azocane 441 was employed as a model substrate in the following 
investigations. It was concluded from the studies in the previous section, that ketal protecting groups 
should be avoided, so subsequent attempts to functionalise the enelactam moiety employed the 
unprotected azocanes 403a and 441. Recently, Nicewicz and co-workers published a methodology for 
the anti-Markovnikov hydroacetoxylation of electron-rich alkenes using mild photoredox-catalysed 
conditions.288-289 This transformation was promising because it might install an acetate leaving group at 
the C2-position (see 460) whilst avoiding the need for an additional C3-reduction step. Unfortunately, 
azocane 403a did not react under the hydroacetoxylation conditions, perhaps because the enelactam 
was too electron-deficient to undergo SET oxidation by the photoredox catalyst (Scheme 103A). 
Similarly, azocane 403a did not react to give C3-methoxide 461 when treated with NBS in methanol 
(Scheme 103B); conditions that were successful in the presence of the 1,3-dioxolane protecting group 
(see Scheme 100, B). Furthermore, a range of halo-succinimide reagents failed to react with azocane 
403a, including a NBS/DBU combination that provides a highly electrophilic source of bromine.290 
Additionally, attempted epoxidation of azocane 441 to form epoxide 463 with m-CPBA failed in place 
of a high yielding Baeyer-Villiger oxidation providing nine-membered lactone 462 (Scheme 103C). It 
became apparent from the studies above that azocane 403a was less reactive towards electrophiles than 
protected azocane 434.  






 The enelactam of azocane 441 was eventually found to react with bromine in methanol,291 
which provided C2-methoxide 464a and bridging acetal 465 as an inseparable mixture (3.3:1 464a:465) 
in quantitative combined yield (Scheme 104A). Bridging acetal 465 is proposed to have formed by 
addition of methanol to the C8-position of iminium 466, which allows for transannular addition of the 
C8-oxygen to the C3-iminium. The mixture of C3-methoxide 464a and hemiaminal 465 was reacted 
with DBU, which resulted in a rapid and clean E1cB elimination from 464a to form the C1-alkene 467 
as a mixture with acetal 465 (84%, 2:1, 467:465) (Scheme 104B). This result was the first time that the 
C2-alkene isomer had been isomerised to the desired C1-position. 
 
Scheme 104 




 To complete the net-alkene isomerisation, the C3-position of enone 467 had to be reduced. 
Previous attempts to reduce the C3-position of related azocanes failed under acid-promoted conditions 
(Scheme 100B). Similarly, under both trifluoroacetic acid and BF3·Et2O promoted conditions in the 
presence of Et3SiH reductant, the C3-position of enone 467 was not reduced, but instead spirocycle 468 
was isolated (Scheme 105A). Spirocycle 468 is formed as a result of a redox-neutral rearrangement of 
enone 467. This rearrangement is proposed to begin with the acid promoted ring-opening of enone 467 
by cleavage of the N-C3 bond. The resulting acyclic intermediate 469 then cyclises via the C8-ketone. 
The observed ring-opening of enone 467, as opposed to elimination of the C3-methoxide, might be 
promoted by the release of ring-strain and unfavourable orbital overlap between the nitrogen lone pair 
and C3-O anti-bonding orbitals. 
 
Scheme 105 
 It was anticipated that the desired C3-reduction of enone 467 might be achieved by replacing 
the C3-methoxide with a better leaving group. Therefore, azocane 441 was treated with bromine in the 
presence of a range of alternative nucleophiles, but none of the corresponding adducts 464 were stable 
enough to be isolated (Scheme 105, B). However, during these studies it was serendipitously discovered 
that dibromide 470 was stable in a dichloromethane solution and could be cleanly converted to C3-




methoxide 464a upon addition of methanol, indicating that the C3-bromide of 470 is labile (Scheme 
105C). This intriguing observation raised the possibility that the C3-position of dibromide 470 could 
be reduced by the addition of a suitable reducing agent. 
3.2.3.3.3 Identification of a hydrobromination/E1cB sequence  
 The proposed reduction of the C3-position of dibromide 470 needed to take place in a single 
pot because 470 degraded during isolation. Therefore, in order to avoid mixing potentially incompatible 
oxidants (bromine) and reductants (Et3SiH or NaBH3CN), bromine would be quenched prior to the 
introduction of the reducing agent. In the event, a solution of azocane 441 and sodium bicarbonate in 
dichloromethane was treated with bromine until consumption of 441 as determined by a persistent 
brown colouration (Scheme 106). Next, the alkene, 2,3-dimethylbut-2-ene (as a solution in 
tetrahydrofuran), was added as a bromine scavenger until the characteristic brown colour of bromine 
had disappeared. Finally, sodium cyanoborohydride was added to the solution of dibromide 470, which 
successfully reduced the C3-position to form bromide 471 in 46% yield along with C8-alcohol 472 in 
36% yield. Exploration of the reaction parameters of the newly developed hydrobromination revealed 
that the incidental addition of tetrahydrofuran during the bromine quench was vital to the success of the 
reaction because sodium cyanoborohydride is poorly soluble in neat dichloromethane. Additionally, it 
was discovered that the initial bromination of azocane 441 must be carried out in neat dichloromethane 
because this failed in the presence of tetrahydrofuran. Furthermore, the mild reducing agent, 
triethylsilane, failed to reduce the C3-position. 
 
Scheme 106: One-pot hydrobromination of enelactam 441. 
 Encouraged by the successful development of the hydrobromination conditions, -
bromoketone 471 was subjected to the standard E1cB elimination conditions (DBU in 
dichloromethane), which proceeded rapidly and cleanly, but formed exclusively the undesired C2-
alkene isomer 441 in 67% yield (Scheme 107A). Fortunately, use of a weaker base (NEt3) allowed a 
controlled E1cB elimination to give desired C1-alkene isomer 473 in 81% yield. Notably, when C1-
alkene isomer 473 was resubjected to basic conditions, the alkene fully isomerised back to the 
thermodynamically more stable position providing C2-alkene isomer 441 in quantitative yield. 






 The yield for the two step kinetic alkene isomerisation of model compound 441 (46% then 81% 
yield) was unsatisfactory due to overreduction of the ketone of bromide 471 during the 
hydrobromination step. Fortunately, it was discovered that the yield of the hydrobromination improved 
in the presence of the C1-methyl group of azocane 403a, providing bromide 474a in a reproducible 
65% yield (Scheme 107B). E1cB elimination from bromide 474a was slower in the presence of the C1-
methyl group, which meant that enone 439a began to isomerise to form 403a before bromide 474a was 
consumed. Therefore, it was necessary to monitor the E1cB elimination closely by TLC to achieve 
optimum yields. Future studies should focus on identifying conditions, which avoid this deleterious 
alkene isomerisation during the E1cB elimination step. The successful development of a kinetic alkene 
isomerisation was an important milestone in this project, which paved the way for investigations into 
the remaining post-cycloaddition transformations. 
3.2.4 Incorporation of the C9-alcohol 
 Having developed reliable conditions for the alkene isomerisation step, attention turned to 
installing the C9-alcohol. It was previously found that 1,2-disubstituted hydroxymethylcyclopropanes 
were unsuitable substrates for (7+1) carbonylative cycloaddition due to the propensity of the C9-
alkoxide of the product azocanes to eliminate under the reaction conditions (Section 3.2.1.1). Therefore, 
the plan was to install the C9-alcohol by a “late-stage” oxidation after the (7+1) carbonylative 
cycloaddition. Initially, attempts were made to do so by an allylic oxidation. 
 
 




3.2.4.1 Allylic C-H oxidation 
 Unactivated primary C-H bonds are typically the least activated C-H bonds towards oxidation 
in a given organic molecule, and are therefore very challenging to functionalise.292-293 By comparison, 
allylic C-H bonds are more readily oxidised because they are activated by hyperconjugation ((alkene)-
*(C-H)) with the adjacent -system. This consideration prompted attempts to install the C9-alcohol 
of otonecine by allylic oxidation of enone 439a (Scheme 108A). One issue with this proposal is the 
presence of a second allylic position at C3, which may receive additional activation from the lactam 
nitrogen lone pair. However, competitive oxidation of C3 may be restricted by the increase in ring strain 
associated with rehybridisation from sp3 to sp2 upon homolytic C-H cleavage. Regardless of these 
concerns, enone 439a was subjected to two common sets of allylic oxidation conditions, which proceed 
by differing mechanisms - radical (NBS, AIBN) and pericyclic (SeO2). Unfortunately, neither sets of 
conditions provided the desired reactivity when applied to enone 439a. 
 
Scheme 108 
 The difficulty in achieving a selective oxidation of the C9-position in the presence of the 
competing C3-position is partly explained in Baran and co-workers total synthesis of (-)-taxuyunnanine 
D.294 Their synthesis required a regioselective allylic oxidation of the C10 position of taxane 476 in the 
presence of a second allylic position at C18 (Scheme 108B). The authors carried out DFT calculations 
to determine the relative stability of intermediate radicals at C10 and C18 in order to predict the 
preferred site of C-H oxidation. The results suggested that the ,-unsaturated ketone of taxane 476 
directs oxidation to the C10-position instead of the C18-position because the resulting radical at C10 is 
conjugated. This directing effect could be overcome by carrying out the allylic C-H oxidation on acetate 
477 where the C10-position is deactivated. The results presented in Scheme 108A, in combination with 




Baran’s report, suggest that incorporation of the C9-alcohol by an allylic oxidation is unlikely, so 
alternative C-H oxidation methods were investigated. 
3.2.4.2 Directed C-H oxidation 
 The use of directing groups to achieve C-H functionalisations can overcome existing electronic 
preferences in complex molecules.295 Among these directing group strategies, the -functionalisation 
of ketone-derivatives has proved to be very successful. For example, Schönecker and co-workers 
reported a methodology, which is appealing in the current context, for the copper-catalysed -
oxygenation of imines 478 (Scheme 109A).296-297 On completion of the -oxygenation, the imine 
directing group was removed on work-up to provide -hydroxy ketones, such as 479. This methodology 
was later improved upon by Baran and co-workers.298-299 Unfortunately, application of this methodology 
to the -oxygenation of azocane 403a failed because imine 480 was highly unstable to hydrolysis, which 
restricted its isolation and use in the proceeding oxidation (Scheme 109B).  
 
Scheme 109 
 A similar strategy, originally developed by Baldwin and co-workers,300 and later Sanford and 
co-workers, employs ketone-derived oximes as directing groups for -oxygenation of unactivated C-H 
bonds (Scheme 110A). In Sanford’s catalytic protocol, O-alkyl oximes are proposed to coordinate 
Pd(OAc)2 and direct C-H metallation to the -C-H bond by a concerted metallation-deprotonation 
mechanism (Scheme 110B).301 A stoichiometric oxidant, PhI(OAc)2, oxidises the Pd(II)-centre of 
intermediate 481 to Pd(IV)-intermediate 482, which undergoes C-O reductive elimination to provide -
acetyl oximes. These are converted to -acetoxy ketones upon removal of the oxime. This methodology 
has been applied in several total syntheses.302  






 Efforts to apply this methodology to the total synthesis of otonecine began with the synthesis 
of O-methyl oxime 483a. This was formed by condensation of methoxyamine hydrochloride onto 
ketone 403b, which proceeded in quantitative yield (Scheme 111A). The resulting O-methyl oxime 
483a existed as a mixture of diastereomers about the oxime C-N double bond, which interconvert under 
the acidic reaction conditions. Treatment of O-methyl oxime 483a with Pd(OAc)2 and PhI(OAc)2 in a 
1:1 mixture of acetic acid and acetic anhydride formed desired C9-acetate 484a, albeit in only 29% 
yield. Next, O-methyl oxime 485 was prepared from enone 439b in quantitative yield to see whether 
allylic activation of the C9-position would increase the yield of the oxygenation (Scheme 111B). 
Surprisingly, under oxygenation conditions, allylic C9-acetate 486 was not formed. Fortunately, a 
modest improvement in yield was achieved when the oxidation was performed on hydrobromination 
product 487a (formed in 71% yield from bromide 474b), which formed acetate 488a in 40% yield 
(Scheme 111C).  





Scheme 111: A + B + C) Reagents and conditions: i) HONH2·HCl, NaOAc, EtOH, r.t., 1 h; ii) Pd(OAc)2, 
PhI(OAc)2, AcOH/Ac2O, 100 °C, 6 h.  
 A drawback of using oxime directing groups is they are typically challenging to remove, often 
requiring harsh acidic conditions. Indeed, all attempts to hydrolyse oximes 484a and 488a, under acidic 
conditions, failed to provide the corresponding ketones, instead resulting in non-specific degradation 
under more forcing conditions (Scheme 112A and 112B). To circumvent this drawback, Sanford and 
co-workers reported the use of O-acetyl oximes (formed in-situ from hydroxy oximes) as removable 
directing groups for -oxygenation reactions, which could be removed under comparatively mild 
conditions when compared to O-alkyl oximes (Scheme 112C).303 However, the electron-withdrawing 
effect of the acetate group reduces the directing group ability of O-acetyl oximes, often resulting in a 
lower yielding oxygenation when compared to O-alkyl oximes. Indeed, when hydroxy oxime 483b, 
formed by condensation of hydroxylamine hydrochloride onto azocane 403b in 96% yield (3:1 d.r.), 
was subjected to the catalysis conditions, desired oxygenated product 484c was formed in only 10% 
yield along with 46% yield of unreacted O-acetyl oxime 483c (Scheme 112D).  





Scheme 112: A + B) Reagents and conditions: i) HClO4, acetone, r.t., 5 h. D) Reagents and conditions: i) 
HONH2·HCl, NaOAc, EtOH, r.t., 1 h; ii) Pd(OAc)2, PhI(OAc)2, AcOH/Ac2O, 100 °C, 6 h. 
 Undeterred by the difficulties encountered in removing the oxime directing group, further 
transformations were attempted on C9-oxidised products. Firstly, enelactam 484a was treated with the 
recently developed hydrobromination conditions, but bromide 488a did not form, presumably due to 
the presence of the electron-rich oxime (Scheme 113A). Nevertheless, E1cB elimination from bromide 
488a, synthesised as in Scheme 111B, resulted in a highly chemoselective elimination of the bromide 
to form C1-alkene 486 with no trace of C9-acetate elimination side products. The Pd(II)-catalysed C9-
oxygenation was also attempted on azocanes bearing a C7-alcohol substituent. Here, the steric bulk of 
the C7-substituent was expected to have a detrimental effect on the C9-oxygenation by forcing the O-
alkyl oxime to adopt the unproductive cis-geometry (see Scheme 110B). O-Alkyl oxime 489, bearing a 
C7-TBS-protected alcohol, was formed from azocane 429 under alternative conditions using pyridine 
as a solvent in excellent yield (96%) and as a single C-N double bond diastereomer (Scheme 113B). As 
predicted, Pd(II)-catalysed C9-oxygenation of O-methyl oxime 489 failed. Therefore, the TBS-
protecting group of 489 was removed using TBAF (89% yield) and resulting alcohol 490 was reacted 
under the catalytic conditions, but no oxidation took place, with C7-acetate 491 being the only product 
formed. It is clear from these results that the Rubottom oxidation would need to be carried out after the 
C9-oxygenation and removal of the oxime directing group if this strategy was to employed in the total 
synthesis of otonecine. 





Scheme 113: A) Reagents and conditions: i) Br2, NaHCO3, CH2Cl2 then 2,3-dimethylbut-2-ene then NaBH3CN, 
THF, 0 °C to r.t., 30 min; ii) DBU, CH2Cl2, r.t., 15 min. B) Reagents and conditions: i) MeONH2·HCl, pyridine, 
r.t., 16 h; ii) Pd(OAc)2, PhI(OAc)2, AcOH/Ac2O, 100 °C, 6 h; iii) TBAF, THF, r.t., 30 min. 
3.2.4.3 Studies towards improved conditions for oxime-directed C-H acetoxylation 
 The studies described in the previous section identified several limitations of the oxygenation 
methodology developed by Sanford and co-workers.301, 303 For example, O-alkyl oxime directing groups 
exhibited moderate reactivity in the C9-oxygenation of azocanes and these proved problematic to 
remove. Additionally, the oxygenation is carried out in a 1:1 mixture of acetic acid and acetic anhydride, 
which drastically limits the functional group tolerance of the process. However, it was recognised that 
despite its limitations, the -hydroxylation of oximes achieved a challenging and valuable 
transformation, which showed promise in the current context. Therefore, attempts were made to 
improve the methodology. 
3.2.4.3.1 Bidentate oxime-based directing groups 
Note: The work in this section was carried out in collaboration with Rachael Ambler, as part of her 
final year MSci research project at Bristol.304 
 It was proposed that the low yields obtained in the oxygenation of azocanes in Scheme 111 
might be a result of the relatively weak directing ability of mono-dentate oximes, and that this might be 
overcome by employing a bidentate oxime directing group. Bidentate oxime directing groups have 
shown large potential in the -functionalisation of ketone derivatives. For example, the Yu lab have 




shown that carboxylic acid oxime directing groups are effective in directing the Pd(II)-catalysed -
arylation and -iodination of unactivated C-H bonds (Scheme 114A).305-306 Here, the carboxylic acid 
oxime acts as L,X-type (L = dative ligand, X = covalent ligand) bidentate directing group for the Pd(II) 
catalyst, thus promoting C-H metallation and further stabilising the resulting intermediates. Despite the 
well documented success of bidentate oximes of this type, these have not been reported in Pd(II)-
catalysed C-H acetoxylations.  
 
Scheme 114: B + C) Reagents and conditions: i) 493, NaOAc, EtOH, reflux, 1 h; ii) Pd(OAc)2, PhI(OAc)2, 
AcOH/Ac2O, 80 °C, 6 h; 
Note that from here on, the carboxylic acid oxime directing group shown in azocane 492 will 
be referred to as L,X-DG, where “L,X” refers to the mixed dative/covalent binding mode of the 
directing group to the Pd(II)-catalyst. This will help to distinguish the directing groups in the following 
discussion. To test whether a bidentate directing group could increase the yield of the -oxygenation of 
azocane derivatives, L,X-DG azocane 492 was prepared in quantitative yield by condensation of 
alkoxyamine hydrochloride 493 onto azocane 403a (Scheme 114B). Directing group L,X-DG, bearing 
geminal dimethyl substituents, was chosen to aid studies into the removal of this directing group, which 
will be discussed in Section 3.2.4.3.3. Under identical Pd(II)-catalysed oxygenation conditions, L,X-
DG azocane 492 degraded, presumably by acid-mediated hydrolysis of the enelactam functionality. 
Therefore, alkoxyamine hydrochloride 493 was condensed onto bromide 474a to provide L,X-DG 
bromide 494 in 93% yield (Scheme 114C). When subjected to the oxygenation conditions, L,X-DG 




bromide 494 underwent a highly efficient oxygenation, providing C9-acetate 495 in 92% yield. This 
result demonstrates the beneficial effect of the L,X-type bidentate directing group. 
 The discovery that L,X-type bidentate directing groups provided a large improvement in the 
efficiency of the -oxygenation of azocanes, encouraged further efforts to improve the reaction 
conditions of the -oxygenation and oxime removal. Specifically, the following aims were set out:  
• Identify an optimal bidentate directing group for the -oxygenation of C-H bonds. 
• Identify an alternative, non-acidic solvent to acetic acid. 
• Develop mild conditions for the removal of the new bidentate oxime directing group. 
 It was recognised that any improvements to the conditions introduced by Sanford and co-
workers, would be of interest to the broader synthetic community. Therefore, these studies were carried 
out using commercially available -methyl ketones with a view to applying the resulting conditions to 
the synthesis of otonecine at a later point. 
Studies began by confirming that the L,X-type bidentate directing group, identified in the 
previous section, was indeed superior to monodentate O-alkyl oximes. This was achieved by carrying 
out a direct comparison with an example taken from Sanford’s original publication (i.e. O-methyl oxime 
496a). Therefore, camphor derivatives, O-methyl oxime 496a and carboxylic acid oxime 496b, 
synthesised according to literature procedures, were reacted under the exact -oxygenations conditions, 
reported by Sanford (90 °C, 9 hours). Under these conditions, C9-acetate 497a (R = Me) was formed 
in 60% yield and C9-acetate 497b (R = CH2CO2H) was formed in 75% yield (Scheme 115). However, 
when the temperature and duration of the -oxygenation were decreased (80 °C, 3 hours), the L,X-type 
bidentate directing group outperformed the monodentate directing group by providing C9-acetate 497b 
in 75% yield compared to C9-acetate 497a in less than 10% yield. It was concluded that the L,X-type 
bidentate directing group was a superior directing group for the -oxygenation of C-H bonds.  
 
Scheme 115: Comparison of the C-H oxygenating ability of mono- and bidentate oxime directing groups. 
 Having confirmed that bidentate directing groups were superior, Ambler investigated 
alternative bidentate directing groups in the -oxygenation reaction.304 A drawback of L,X-type 
bidentate directing groups was the work-up and purification of compounds containing this directing 
group was complicated by the carboxylic acid. Therefore, alternative L,L-type bidentate directing group 




L,L-DG was designed, where the carboxylic acid was replaced by a datively bonding (L-type) pyridyl 
group. The studies in this section employed 2-methylcyclohexanone as a simple, commercially 
available -oxygenation substrate. 
 
Scheme 116: A) Reagents and conditions: i) 2-chloromethylpyridine, NEt3, MeCN, 80 °C, 2.5 h; ii) conc. HCl, 
H2O, 90 °C, 5 h; iii) 2-methylcyclohexanone, NaOAc, EtOH, 80 °C, 16 h. 
 Alkoxyamine dihydrochloride 499 was synthesised by Ambler in two steps (Scheme 116A). N-
Hydroxyphthalimide was alkylated with 2-chloromethylpyridine to provide N-alkoxyphthalimide 498 
in 30% yield, which was subsequently hydrolysed to give the alkoxyamine dihydrochloride 499 in 84% 
yield. This was condensed onto 2-methylcyclohexanone to give L,L-DG substrate 500 in 93% yield. 
Under the -oxygenation conditions, L,L-DG substrate 500 provided desired acetate 501 in 11% yield 
along with 65% yield of diacetate 502 (Scheme 116B). A control experiment, carried out in the absence 
of Pd(OAc)2 under otherwise identical conditions, resulted in the formation of diacetate 502 in nearly 
identical yield (64% yield), which indicated that PhI(OAc)2 was the oxidant in this process. Based on 
this evidence, it was proposed that diacetate 502 was formed by PhI(OAc)2-mediated oxidation of the 
activated benzylic position of L,L-DG substrate 500, to give conjugated species 503, which is cleaved 




by two equivalents of acetic acid (Scheme 116C). This mechanism suggests that O-acetyl oxime 504 
should be formed as a side-product, although this was not observed.  
 This unanticipated oxidative degradation of L,L-DG substrate 500 raised an interesting 
possibility in terms of directing group removal (Scheme 116D). It was proposed that by deactivating 
the benzylic position of the L,L-type directing group towards oxidation, -oxygenation might become 
the faster process. This might allow the development of a one-pot -oxygenation/oxidative degradation 
process to provide -acetyl oximes 505, which can be converted to the corresponding ketones under 
relatively mild conditions. This intriguing proposal has not been investigated further at this point. 
3.2.4.3.2 Solvent screen 
 Sanford’s reported conditions for the -oxygenation of oximes uses acetic acid as a solvent, 
which drastically limits the scope of the reaction.301 A milder alternative would be beneficial both for 
the total synthesis of otonecine and for the wider synthetic community. It was hoped that the improved 
activity of L,X-DG would allow an alternative solvent to be employed. A potential disadvantage of 
moving away from acetic acid as a solvent, was that this might restrict isomerisation of the oxime C-N 
double bond, which would limit the yield of the -oxygenation.  
 The results of a solvent screen are shown in Table 14. Cyclohexanone-derivative 506, bearing 
L,X-DG (prepared in one step from 2-methylcyclohexanone), was subjected to Pd(II)-catalysis with 
PhI(OAc)2 in a 1:1 mixture of acetic acid, which formed acetate 507 was formed in 76% yield (Entry 
1). Neat acetic anhydride provided a clean reaction and high yield of acetate 507 (71%, Entry 2), but 
acetic anhydride contains acetic acid, so was avoided. The non-polar and polar-aprotic solvents 
indicated in Entry 3, resulted in significant degradation and poor yields of acetate 507 (10–31% yield, 
Entry 3). Interestingly, methanol provided methyl ether 508a (Ralkyl = Me) in 75% yield with less than 
5% of acetate 507 formed (Entry 4). Using a very similar Pd(OAc)2/PhI(OAc)2/MeOH system, Chen 
and co-workers developed a protocol for the directed synthesis of alkyl ethers by C-H 
functionalisation.307-308 They proposed that the formation of occurs via reductive elimination from an 
intermediate analogous to Pd(IV)-alkoxide intermediate 509.308 Despite the excellent yield of the -
methoxylation in methanol, these products were not appealing in the context of the total synthesis of 
otonecine because methyl ethers require harsh conditions to be converted to the corresponding alcohols. 
Therefore, the -oxygenation was carried out in sterically demanding alcohol solvents in order to 
dissuade C-Oalkyl reductive elimination and favour formation of acetate 507. Trimethylsilanol and 
isopropanol failed to provide acetate 507, but t-butanol formed 507 in 29% yield along with 10% of 
corresponding tert-butyl ether 508b (Ralkyl = t-Bu) (Entry 5). Finally, addition of toluene as a co-solvent 
with t-butanol (1:1 ratio) provided a modest improvement in the yield of acetate 507 (34%, Entry 6). 





Table 14: Selected results from a solvent screen for the -oxygenation of bidentate oxime 506. 
 During the studies detailed above, it was noticed that a significant number of side-products 
were being formed by acetate exchange with the PhI(OAc)2 oxidant (Scheme 117). This resulted in the 
formation of complex mixtures of iodine(III)-adducts, which impeded the desired oxygenation reaction 
and complicated analysis of the reaction mixtures. Presumably by carrying out the reaction in acetic 
acid, the formation of such iodine species is statistically disfavoured. After some experimentation it was 
found that the unwanted iodine(III)-adducts could be broken up at the end of the reaction by stirring the 
crude mixture with potassium carbonate in methanol. This unanticipated reactivity might be avoided by 
choosing an alternative oxidant, such as oxone, which has been shown to be able to oxidise Pd(II) to 
Pd(IV) in related transformations.309 Despite the efforts above, a suitable replacement for acetic acid 
was not identified. With the exception of methanol (Entry 4), all of the solvents tested resulted in the 
formation of multiple unidentifiable side-products, which resulted in poor yields of acetate 507 and 
hard to purify crude mixtures. 
 
Scheme 117: Iodine(III)-adducts formed between carboxylic acid directing groups and PhI(OAc)2. 
 




3.2.4.3.3 Removal of the bidentate oxime directing group 
 It was previously discussed that oximes are difficult to remove and often require very harsh 
acidic conditions to do so, which restricts their use as directing groups (Scheme 112).303 Therefore, the 
success of -oxygenation methodology in the synthesis of otonecine hinged on identifying a suitable 
means of removing the L,X-type oxime directing group. The gem-dimethyl substituted directing group 
L,X-DG was chosen because it has been shown to undergo fragmentation by single electron transfer 
(SET).310 For example, Leonori and co-workers have shown that identical L,X-DG oximes can undergo 
a SET initiated fragmentation when subjected to photoredox catalysis, resulting in the formation of 
iminyl radicals (Scheme 118A).311 The iminyl radicals proceeded to undergo further fragmentation, or 
intramolecular hydrogen abstraction to generate various valuable products. It was proposed that SET 
degradation of L,X-DG might be leveraged as a method of removing the directing group. For example, 
photoredox-initiated SET degradation of L,X-DG acetate 495 would form iminyl radical 510, which 
might be trapped by intermolecular hydrogen abstraction and imine hydrolysis to form ketone 511 
(Scheme 118B). One concern with this proposal was iminyl radical 510 might alternatively undergo 
further fragmentation and elimination of the -bromine atom to form linear nitrile 512. Yu and co-
workers have reported that related L,X-DG directing groups can be removed by Mn(OAc)2-initiated 
SET fragmentation, although this requires expensive hexafluoroisopropanol as a solvent.312 
 Preliminary studies were carried out on L,X-DG azocane 492 because of the ease of preparation 
of this molecule and because it wasn’t expected to undergo ring-opening fragmentation (Scheme 118C). 
Based on Leonori’s research and prior experience with Nicewicz conditions for the hydroacetylation of 
alkenes, highly oxidising acridinium photocatalyst Acr-BF4 (*E1/2 = 2.2 V vs SCE)288 was employed 
along with lutidine as a base, and thiophenol as a hydrogen-donor, in 1,2-dichloroethane. Under these 
conditions, L,X-DG azocane 492 was irradiated with blue LED’s (Further details are available in 
Experimental Section 4.4), which resulted in a remarkably clean reaction achieving 50% conversion (as 
determined by 1H NMR analysis of the crude reaction mixture) to the desired azocane 403a over 16 
hours. However, when L,X-DG bromide 494 was subjected to identical conditions, no reaction was 
observed. Similarly, L,X-DG bromide 494 did not react under Yu’s conditions for the removal of 
oximes (Mn(OAc)2/hexafluoroisopropanol). Clearly, the photoredox-initiated SET cleavage of L,X-DG 
shows great promise for achieving a mild method of removing the directing group, but further 
optimisation of the reaction conditions is required. 






 The oxime-directed C-H oxygenation methodology developed by Sanford showed promise as 
a method to install the C9-alcohol of otonecine. However, in order to realise this potential, several 
improvements to the original conditions are required. In collaboration with Ambler, a superior bidentate 
oxime directing group, L,X-DG, was identified, which provided a significant yield increase under less 
forcing conditions. Unfortunately, an alternative reaction solvent to acetic acid was not identified. 
Finally, preliminary studies indicate that photoredox-initiated SET cleavage could serve as a mild 
method for the removal of L,X-DG. Further optimisation may ultimately provide a valuable 
methodology both for the synthesis of otonecine, but also for the wider synthetic community.   




3.2.4.4 Tamao-Fleming strategy for the installation of the C9-alcohol 
 During the studies into directed C-H oxygenations, interest arose in the Ir(I)-catalysed -C-H 
oxygenation of silanols, developed by Hartwig and co-workers.313 The mechanism of this 
transformation is proposed to begin with the formation of Ir(I)-intermediate 513 by Ir(I)-metallation of 
the Si-H bond of dialkylsilylethers (Scheme 119A). Intramolecular metallation of the -C-H bond of 
Ir(I)-intermediate 513 is followed by C-Si reductive elimination to form cyclic silanols. Therefore, the 
dialkylsilylether moiety acts as a covalent directing group for Ir(I)-catalysed C-H silylation of the -C-
H bond. Tamao-Fleming oxidation of cyclic silanols affords 1,3-diols as a product of net--C-H 
oxygenation of dialkylsilylethers. This methodology has been applied in a complex natural product 
setting.314 In what would be a novel application of the methodology, it was proposed that a silyl enol 
ether such as 514 might be a suitable substrate for Ir(I)-catalysed -C-H silylation, forming silacycle 
515 (Scheme 119B). Dual Tamao-Fleming/Rubottom oxidation of which might install both the C9 and 
C7 alcohols in a single pot. Brief attempts to form silyl enol ether 514 were met with difficulty due to 
silyl enol ether hydrolysis, which precluded investigations into the C-H silylation step. Future attempts 
should focus on a more stable silyl enol ether, bearing larger alkyl groups.  
 
Scheme 119: A) Reagents and conditions: i) LDA, ClSiMe2H, DMPU, THF, -78 °C, 30 min; ii) [Ir(OMe)(cod)]2, 
3,4,7,8-tetramethyl-1,10-phenanthroline, norbornadiene, THF, 120 °C. 
 The investigations above inspired a potential solution to the challenge of introducing the C9-
alcohol of otonecine. This involved the use of a C9-silane as a masked alcohol, which could be 
incorporated at an early point in the synthesis and unmasked by Tamao-Fleming oxidation at a later 
time. Silanes have been used extensively as masked alcohols in complex settings.315-317 Of the various 
silanes that have been shown to undergo Tamao-Fleming oxidation, dimethylphenylsilanes have 
received the most attention because they are particularly stable to a broad variety of commonly 
encountered conditions. However, the highly acidic conditions required to activate 
dimethylphenylsilanes for Tamao-Fleming oxidation (e.g. HBF4·Et2O), were undesirable in the current 
synthesis because several azocane intermediates have been found to be unstable under acidic conditions. 




Therefore, investigations into the Tamao-Fleming approach employed the benzyldimethylsilane 
(BDMS) group, which can be activated by reaction with TBAF.318 To implement this strategy, the 
BDMS group was incorporated at the beginning of the synthesis via allyl silane 516 (Scheme 120). 
Allyl silane 516 would be advanced to 1,2-disubstituted silylmethylcyclopropane substrate 517, which 
would provide azocane 518 upon (7+1) carbonylative cycloaddition. Silylmethylcyclopropanes had not 
been investigated in rhodacyclopentanone based methodologies, developed at Bristol, so it was unclear 
if 517 would be a suitable substrate for (7+1) carbonylative cycloaddition. At the outset, it was unclear 
at which point the Tamao-Fleming oxidation would take place in the synthetic sequence, so this would 
be determined at a later stage. 
 
Scheme 120: Proposed Tamao-Fleming strategy for the introduction of the C9-alcohol. 
3.2.4.5.1 Synthesis of silylmethyl-substituted cyclopropanes 
 Investigations into the Tamao-Fleming approach for the installation of the C9-alcohol of 
otonecine began with the synthesis of 1,2-disubstituted silylmethylcyclopropane 517 (Scheme 121A). 
The synthesis began with allylbenzyldimethylsilane 516, which was commercially available, but was 
also synthesised by reaction of benzylmagnesium chloride with allyl(chloro)dimethylsilane in 75% 
yield on a 100 mmol scale. Rh(II)-catalysed cyclopropanation with ethyl diazoacetate proceeded to give 
ester 519 in 59% yield and 5:2 d.r.. Ester hydrolysis (99% yield, 5:2 d.r.) and Curtius rearrangement 
proceeded in excellent yields, and the resulting diastereomeric cyclopropylamines, trans-521 (67% 
yield) and cis-521 (29% yield), were separated by column chromatography. Both diastereomers of 
cyclopropylacrylamide 517 are likely productive in the (7+1) carbonylative cycloaddition, so both 
diastereomers of protected amine 521 were carried through the N-methylation and acrylate formation 
steps in excellent yield. This robust synthesis produced multi-mmol quantities of 
cyclopropylacrylamide 517, which enabled investigations into the (7+1) carbonylative cycloaddition 
and post-cycloaddition steps.  





Scheme 121: A) Reagents and conditions: i) BnCl, Mg, Et2O, reflux, 16 h; ii) Rh2(OAc)4, ethyl diazoacetate, 
CH2Cl2, r.t., 16 h; iii) 4 M aq. NaOH, MeOH, 50 °C, 2 h; iv) diphenylphosphoryl azide, NEt3, t-BuOH, 80 °C, 72 
h; v) NaH, MeI, THF, 50 °C, 5 h; vi) trifluoroacetic acid, CH2Cl2, r.t., 30 min then acryloyl chloride, K2CO3, 
acetone-water, 0 °C to r.t., 16 h. 
 In the future, it might be necessary to synthesise cyclopropylacrylamide 517 in an 
enantioenriched form for the asymmetric synthesis of (R)-otonecine. This might be achieved by a 
methodology published by Mendoza and co-workers for the Ru(II)-catalysed asymmetric 
cyclopropanation of alkenes (including allylsilanes) to give trans-1,2-disubstituted cyclopropyl esters 
524 (Scheme 121B).319 The synthetic versatility of the resulting phthalimide cyclopropyl esters 524 was 
demonstrated through various transformation including a Curtius rearrangement. Inspired by 
Mendoza’s methodology and a report by Zhang and Qian,320 it was envisaged that 
cyclopropylacrylamide trans-517 could be accessed in short order by difunctionalisation of isocyanate 
525. The proposed key step involves Curtius rearrangement of 524, as in Mendoza’s report, to form 
isocyanate 525. This could be reacted with a nucleophilic vinyl reagent (such as vinyl lithium) and then 
with an electrophilic methylating reagent such as iodomethane to give cyclopropylacrylamide trans-
517. Successful execution of this proposal would provide cyclopropylacrylamide trans-517 in three 
steps from commercially available silane 516. 
3.2.4.5.2 (7+1) carbonylative cycloaddition of silylmethyl-substituted 
cyclopropylacrylamides 
 Both diastereomers of cyclopropylacrylamide 517 were tested in the (7+1) carbonylative 
cycloaddition using a sealed reaction vessel in accordance with the studies in Section 3.2.1.2. Under the 




previously optimised (7+1) carbonylative cycloaddition conditions, cyclopropylacrylamide trans-517 
formed desired azocane 518 in 7% yield (Entry 1), although the product was stable under the reaction 
conditions, suggesting that the reaction could be optimised. Initially, it was discovered that by lowering 
the reaction temperature (130 °C from 150 °C) and running it for four days, azocane 518 was formed 
in 24% yield with 32% of the starting material remaining (Entry 2). A ligand screen of various 
triarylphosphines and triarylarsines gave interesting results. Notably, the use of electron-rich ligands, 
such as triphenylphosphine, provided low yields of azocane 518 (16%), but very high recovery of the 
starting material (82%) (Entry 3). In this case the ligand is presumably stabilising a catalytic 
intermediate, thereby preventing non-specific degradation. Unfortunately, further attempts to optimise 
the use of electron-rich ligands were not fruitful. Triphenylarsine provided azocane 518 in 22% yield 
with 24% of cyclopropylacrylamide trans-517 remaining, and was therefore chosen for further 
optimisation (Entry 4).  
 
Table 15: Selected results from the optimisation of the Rh(I)-catalysed (7+1) carbonylative cycloaddition of 
trans-517. 
 Next, alternative additives (to N-methyltrifluoroacetamide) were screened because additives 
were previously shown to have a dramatic effect on the yield of (7+1) carbonylative cycloadditions 
(Section 3.2.1.2). During these studies, benzoic acid (32% yield, Entry 5), benzamide (31% yield, Entry 
6) and fumaric acid (35% yield, Entry 7) were found to provide a greater yield of azocane 518. The 
conditions shown in Entry 7 were carried out on multi-mmol scale with no significant decrease in yield, 
so were chosen in order to investigate the following steps. Additionally, cis-1,2-disubstituted 
cyclopropylacrylamide cis-517 reacted under the newly optimised conditions to give azocane 518 in 
30% yield. Further optimisation of the (7+1) carbonylative cycloaddition of cyclopropylacrylamides 




517 is clearly required and should focus on a further in-depth survey of ligands and additives. It is worth 
noting the significant electronic effect that the silylmethyl-substituent had on the reactivity the 
cyclopropylacrylamide as illustrated by the substantially different conditions (temperature, ligand and 
additive) necessary for an efficient (7+1) carbonylative cycloaddition when compared to alkyl-
substituted cyclopropylacrylamide 402 (Section 3.2.1.2). 
3.2.4.5.3 Validation of the Tamao-Fleming approach  
 The optimised conditions for the (7+1) carbonylative cycloaddition of cyclopropylacrylamides 
517 provided sufficient quantities of azocane 518 to attempt the Tamao-Fleming oxidation with the aim 
of identifying the ideal point in the synthesis to carry out the transformation. To begin, azocane 518 
was treated under the standard conditions for Tamao-Fleming oxidation (TBAF then H2O2/NaOH) 
(Scheme 122). Encouragingly, this provided C9-alcohol 526 in 50% yield, which served as the first 
time that the C9-alcohol has been installed in the presence of the ketone during these studies. Next, the 
C2-alkene of azocane was isomerised to the C1-position, by the previously developed two step 
hydrobromination/E1cB elimination sequence, providing enone 528 in 35% yield over the two steps. 
Under the standard conditions (TBAF/hydrogen peroxide) for Tamao-Fleming oxidation, enone 528 
gave a mixture of alkenes 530, likely by protodesilylation of the C9-position of proposed intermediate 
529, instead of the benzylic position. Trost and co-workers have developed anhydrous conditions 
(TBAF/urea hydrogen peroxide) for the Tamao-Fleming oxidation of benzylsilanes, specifically to 
avoid protodesilylation.318 However, under the anhydrous conditions, enone 528 also reacted to form 
alkenes 530. Nevertheless, the synthesis of C9-alcohol 526, by Tamao-Fleming oxidation of azocane 
518 marks a significant milestone towards the total synthesis of otonecine, whereby conditions for three 
out of the four post-cycloaddition transformations had been identified.  
 
Scheme 122: Validation of the Tamao-Fleming strategy by the synthesis of C9-alcohol 526.  




3.2.5 Studies towards the total synthesis of (rac)-otonecine  
 At this stage in the project, efforts were directed towards completing the total synthesis of (rac)-
otonecine. The step order shown in Scheme 123 was deduced based on the findings detailed in the 
previous sections. Firstly, azocane 518 would undergo a two step Rubottom oxidation then Tamao-
Fleming oxidation to install the C7- and C9-alcohols of azocane 531. These would both be protected as 
TBS-ethers in order to reduce the polarity of the molecule and provide steric shielding of the C8-ketone 
in preparation for the two remaining steps, which uses reducing agents. Next, alkene isomerisation by 
the hydrobromination/E1cB elimination sequence would provide enone 532 and set the stage for the 
final lactam reduction and deprotection steps to access (rac)-otonecine. 
 
Scheme 123: Proposed order of the post-cycloaddition transformations of azocane 518. 
3.2.5.1 Synthesis of an advanced lactam intermediate 
 The previously developed conditions for the generation of kinetic silyl enol ethers from 
azocanes (Section 3.2.2.1) provided poor results when applied to azocane 518 (Scheme 124). Lithium 
enolate 533, formed by deprotonation of azocane 518 with LDA/DMPU, was observed to be unstable 
in solution at -78 °C, and the subsequent reaction with TBSCl was very slow, providing an impure 
mixture of silyl enol ether 534a regioisomers. Additionally, Rubottom oxidation of crude silyl enol 
ether 534a was poor yielding due to the formation of significant quantities of C7-benzoate 536 (via a 
acetal intermediate, see 430, Scheme 95) (41% combined yield, 2:1, 535a:536). Improvements to the 
two step procedure were made by reversing the order of addition of reagents in order to limit the lifetime 
of lithium enolate 533, and by employing TMSCl as a more reactive electrophile. Therefore, LDA was 
added to a mixture of azocane 518 and TMSCl at -78 °C, which immediately formed silyl enol ether 
534b as a single regioisomer. Importantly, the addition of LDA was monitored closely by TLC to avoid 
formation of a new non-polar compound, likely by further reaction of silyl enol ether 534b. The 
structure of the new side-product was not confirmed, but was proposed to be bis-silyl enol ether 537. 




This new method routinely provided silyl enol ether 534b in >80% yield as a single regioisomer, which 
was carried through to the Rubottom oxidation without column chromatography. 
 
Scheme 124: Development of a reliable two step Rubottom oxidation sequence for the installation of the C7-
alcohol onto azocane 528. 
 The low yields obtained in the Rubottom oxidation of TBS-silyl enol ether 534a was partly due 
to the competitive formation of C8-hemiacetal 536. A report by Wang and co-workers suggests that 
hemiacetal formation is promoted by the presence of base in the Rubottom oxidation, which extends 
the lifetime of oxonium intermediate 431 (see Scheme 95B, Section 3.2.2.1).321 Therefore, Rubottom 
oxidation of silyl enol ether 534b was carried out in the absence of sodium bicarbonate, which 
successfully reduced the formation of a hemiacetal analogue. Finally, the crude reaction mixture was 
hydrolysed under acidic conditions to provide C7-alcohol 535b in 60% yield over the two steps, as a 
1:1 mixture of diastereomers (separable by chromatography). The diastereoselectivity of the Rubottom 
oxidation (1:1 d.r.) will need to be addressed for the asymmetric synthesis of otonecine, however it was 
inconsequential for the synthesis of (rac)-otonecine, so a mixture of both diastereomers was carried 
through to the next step. 
 Tamao-Fleming oxidation of C7-hydroxyazocane 535b proved to be challenging (Scheme 
125). Under standard aqueous conditions (TBAF/hydrogen peroxide), C7-hydroxyazocane 535b 
reacted rapidly to form diol 538, which was visible by TLC. However, diol 538 is very polar and highly 
water soluble, which complicated its isolation. Attempts to isolate diol 538 from the aqueous phase 
during the work-up required repeated extraction of the aqueous phase, which contaminated diol 538 
with copious amounts of tetrabutyl ammonium salts. Furthermore, concentration of the resulting 




organic extracts caused the degradation of diol 538, presumably due to the presence of residual 
peroxide.  
 
Scheme 125: Synthesis of enone 532a from azocane 535b. 
 Focus turned to the anhydrous Tamao-Fleming conditions (TBAF/urea hydrogen peroxide) 
developed by Trost.318 Under these conditions, C9-alcohol 535b was converted to diol 538 in three 
hours, which was isolated as a mixture with tetrabutylammonium salts upon reduction of residual 
peroxide and extensive extraction of the aqueous phase. Attempts to remove the tetrabutylammonium 
salts by precipitation, or column chromatography failed due to the high polarity of the diol. Therefore, 
crude diol 538 was silylated to afford bis-TBS ether 539 in 29% yield from C9-alcohol 535b, which 
was isolated after a standard aqueous work-up and column chromatography. Hydrobromination of bis-
TBS ether 539 proceeded smoothly to provide C2-bromide 540 as an inconsequential mixture of 
diastereomers (not characterised). E1cB elimination from bis-TBS ether 540 was slow due to the 
sterically congested nature of the C1-position, which resulted in the unwanted isomerisation of the 
alkene back to the C2-position becoming competitive. This was avoided by stopping the reaction early 
at the expense of low yields of enone 532a (32% yield). Nevertheless, sufficient quantities of enone 
532a were obtained through this route to attempt the penultimate lactam reduction. 
3.2.5.2 Attempts to reduce the lactam of an advanced intermediate 
 Up until this point, the lactam reduction step had received only sporadic attention, but this 
revealed several valuable and unexpected observations. As was described in Section 3.2.2.2, lactam 
reduction in the presence of the C2-alkene (as in 427a, Scheme 96C) often resulted in partial reduction 
and ring-opening of the strained azocane ring. However, some success was realised on treatment of 
protected azocane 434 with BH3·THF, which provided aminoalcohol 451 (Section 3.2.3.3.1). Later in 
the project, BH3·THF successfully reduced the lactam of oxime 485, providing amine·BH3 adduct 541 




in 59% yield (Scheme 126). Borane-amine adducts have found use as amine protecting groups in the 
synthesis of complex molecules and might be useful in the current context by masking the N-C8 
transannular interaction.322 
 
Scheme 126: Borane reduction of the lactam of oxime 485 to form amine-borane adduct 541. 
 With this information in hand, the penultimate lactam reduction of bis-TBS ether 532a was 
attempted using BH3·THF. In the event, the lactam of 532a underwent a rapid reaction with BH3·THF, 
but failed to provide protected otonecine 543. Instead, a structurally related compound was isolated, the 
structure of which is yet to be fully assigned. Preliminary data (1H, 13C, COSY, HSQC, HMBC, HRMS, 
see experimental) suggests that the unknown product contains the structural motif shown in 542 where 
the lactam has been fully reduced and the C1-alkene has migrated to form an extended enol structure. 
 
Scheme 127 
 To avoid consuming valuable bis-TBS ether 532a, model enone 439a was employed in order 
to further investigate the lactam reduction step. Lactam reduction of model enone 439a with BH3·THF 
proceeded in a similar fashion to above, forming a compound bearing the structural motif of 544 
(Scheme 127B). Enol 544 was then subjected to a range of conditions in an attempt to promote 
formation of desired enone 443. Enol 544 was found to be stable to protic solvents (methanol), basic 




conditions (DBU) and aq. NH4Cl, but rapidly degraded when treated with trifluoroacetic acid (standard 
extraction methods for otonecine involves the use of strongly acidic conditions, including refluxing aq. 
10% HCl323). Having failed to form bis-TBS otonecine 543 using BH3·THF, several alternative 
chemoselective lactam reduction conditions (including Ir(CO)Cl(PPh3)2/TMDSO,261 Lawesson’s 
reagent/Raney nickel and Zn(OAc)2/(EtO)3SiH324) were screened using model compound 439a, but 
none of these provided enone 443. 
 The remaining quantity of bis-TBS ether 532a was reacted with alane (AlH3), which exhibits 
similar reactivity to borane and is known to reduce challenging lactams in the presence of other 
reducible functionality (Scheme 128).325 In the event, bis-TBS ether 532a was consumed rapidly, 
forming the previously observed enol 542 as well as a C8-reduction product 545. An attempt to 
reoxidise the C8-alcohol of alcohol 545 failed to form bis-TBS otonecine 543. 
 
Scheme 128: Formation of alcohol 545 by the reduction of enone 532a using alane. 
 At this point, studies towards the total synthesis of (rac)-otonecine were paused due to time 
constraints. The penultimate lactam reduction step proved to be challenging, often resulting in the 
formation of an unidentified side-product tentatively containing the structural motif 542. Complete 
structural elucidation of this side-product might aid in the identification of a suitable method for the 
reduction of the lactam moiety of bis-TBS ether 532a.  
  




3.3 Studies towards the total synthesis of the C10 dicarboxylic necic acids 
 The research described so far in Chapter 3 demonstrates significant progress towards the total 
synthesis of otonecine. Therefore, parallel studies were initiated to investigate the synthesis of the C10 
dicarboxylic necic acids, with the goal of achieving the first total synthesis of an otonecine-type 
macrocyclic diester. This section begins with a review of previous synthetic efforts towards the C10 
necic acids. Then, in Section 3.3.3, research carried out at Bristol towards the asymmetric synthesis of 
some of these compounds will be presented.  
3.3.1 Previous syntheses of C10 dicarboxylic necic acids 
The C10 dicarboxylic necic acids have received less synthetic attention than the necic bases with 
most studies targeting integerrinecic acid and its diastereomers (Figure 4). Nevertheless, several distinct 
strategies have emerged for the preparation of racemic and enantiomerically enriched dicarboxylic necic 
acids, and these strategies are discussed herein. Additionally, most of these reports were carried out as 
part of a synthesis of a retronecine-type macrocyclic diester, lessons from which may prove valuable 
for the current project. Therefore, the strategies employed to form PA macrocyclic diesters are included. 
3.3.1.1 Isomerisation of senecic acid 
 During early studies towards determining the structure of the C10 dicarboxylic necic acids, 
Richardson and Warren observed that senecic acid (isolated from a natural source) underwent 
lactonisation and concomitant alkene isomerisation when treated with dilute hydrochloric acid to form 
integerrinecic acid lactone (Scheme 129).326 This finding was confirmed by hydrolysis of the resulting 
lactone, which provided integerrinecic acid. The authors concluded that the E-alkene geometry is more 
stable than the Z-alkene geometry in this class of molecules. Integerrinecic acid lactone, and it’s 
diastereomers, has since become a popular intermediate in the synthesis of C10 dicarboxylic acids.327 
 
Scheme 129: Acid-mediated conversion of senecic acid to integerrinecic acid. Reagents and conditions (some 
details were not provided by the authors): i) dilute HCl; ii) aq. NaOH, reflux. 
3.3.1.2 Michael addition strategy for the synthesis of integerrinecic acid and senecic acid
  
 Culvenor and Geissman completed the first formal total synthesis of (+)-integerrinecic acid and 
(rac)-senecic acid, in 1961 (Scheme 130A).328 The synthesis of (+)-integerrinecic acid began with 
propargylic acetate 546, which was subjected to an unselective Ni(CO)4-mediated hydrocarboxylation, 




providing branched -unsaturated ester 547a in 21% yield, after esterification. Michael addition of 
ethyl methylacetoacetate to -unsaturated ester 547a formed diester 548, which was immediately 
advanced to ketoacid 549 by hydrolysis. Hydrocyanation of ketoacid 549 and hydrolysis of the resulting 
nitrile formed a complex mixture of three species from which desired lactone (rac)-550 could be 
separated in 24% yield. Racemic lactone (rac)-550 was resolved by crystallisation with brucine thus 
completing a formal seven step total synthesis of (+)-integerrinecic acid. Culvenor also demonstrated 
that the Z-alkene of integerrinecic acid lactone could be isomerised to the E-alkene by irradiation with 
ultraviolet light to form the senecic acid lactone (Scheme 130B). Hydrolysis of senecic acid lactone 
formed (rac)-senecic acid in eight steps overall. 
 
Scheme 130: A) Reagents and conditions (some details were not provided by the authors): i) Ni(CO)4, 
EtOH/AcOH/H2O, reflux, 1 h, 25%; ii) CH2N2, Et2O, 0 °C, 84%; iii) ethyl methylacetoacetate, NaOEt, EtOH, r.t., 
1.5 h then 1 M aq. NaOH, r.t., 5 h; iv) NaCN, H2O then conc. HCl, 100 °C, 3 h, 24% of (rac)-550; v) Resolution 
achieved by crystallisation with brucine. B) Reagents and conditions (some details were not provided by the 
authors): h, EtOH, 10 h, 33%; ii) 1 M aq. NaOH, 1 h. 
In 1982, Drewes and Emslie published a short and efficient six step synthesis of (rac)-
integerrinecic acid, adopting a similar strategy to Culvenor (Scheme 131).329 Acrylate 547b was formed 
in 87% yield by an improved method involving Baylis-Hillman reaction between ethyl acrylate and 
acetaldehyde, and acetylation. Acrylate 547b underwent a Michael addition /elimination sequence with 




silyl enol ether 552 to form ketoacid 549, which was reacted with sodium cyanide and then concentrated 
hydrochloric acid to form (rac)-integerrinecic acid.  
 
Scheme 131: Drewes and Emslie’s synthesis of (rac)-integerrinecic acid. Reagents and conditions (some details 
were not provided by the authors): i) acetaldehyde, DABCO, r.t., 7 d, 94%; ii) Ac2O, conc. H2SO4, 0 °C, 30 min, 
93%; iii) 552, TiCl4, CH2Cl2, -78 °C, 3 h, 63%; iv) 1 M aq. KOH, r.t., 12 h, 69%; v) NaCN, 0.01 M aq. H2SO4, 
H2O, 0 °C, 78%; vi) conc. HCl, 5 °C, 12 h, 63%. 
3.3.1.3 Baeyer-Villiger oxidation for the formation of lactones 
 In 1982, Narasaka and Uchimaru published an alternative method for the synthesis of 
integerrinecic acid lactone, employing a Baeyer-Villiger oxidation to access functionalised lactone 554a 
(Scheme 132A).330-332 The synthesis began with a one-pot conjugate addition/carboxylation and 
methylation of 2-methyl-2-cyclopentenone, which provided cyclopentanone 553a in 80% yield over the 
two steps. Regioselective Baeyer-Villiger oxidation of 553a formed lactone 554a in 76% yield. The 
exocyclic alkene unit was installed by a two step aldol condensation to form integerrinecic acid lactone 
555 (60% yield from 554a), thus completing a seven step formal synthesis of (rac)-integerrinecic acid. 
Lactone 554a and the two step aldol condensation have been employed in several syntheses of necic 
acids. 
 Narasaka and co-workers simultaneously published the first total synthesis of the retronecine-
type macrocyclic diester, (rac)-integerrimine (Scheme 132B).331-332 The synthesis required 
integerrinecic acid lactone (rac)-555 to undergo nine further manipulations to reach protected anhydride 
(rac)-556, which was coupled with protected retronecine (rac)-567 to give monoester 568. 
Macrolactonisation was achieved by TBS-deprotection of the C9-alcohol of monoester 568 and 
oxidation of the methyl thiomethylester, which served to activate the C11-ester to cyclisation. Final 
deprotection steps formed (rac)-integerrimine, which was separated from its unnatural diastereomer.  





Scheme 132: A) Reagents and conditions (some details were not provided by the authors): i) Me2Culi, Et2O, -
20 °C, 3 h then dry ice, 1.5 h, 80%; ii) CH2N2, Et2O; iii) m-CPBA, Li2CO3, CH2Cl2, reflux, 13.5 h; iv) LDA, THF, 
-78 °C, 15 min then acetaldehyde, -40 °C, 1 h; v) 2-fluoro-1-methylpyridinium p-toluenesulfonate, CH2Cl2, NEt3, 
0 °C, overnight. B) Reagents and conditions (some details were not provided by the authors): i) 2-chloro-1-
methylpyridinium iodide, CH2Cl2, 2-(trimethylsilyl)ethanol, NEt3, r.t., overnight, 98%; ii) LiOH, 28% aq. H2O2, 
THF/H2O, r.t., 3 h, 71%; iii) chloromethyl methyl sulfide, NaI, (i-Pr)2NEt, 1,2-dimethoxyethane, r.t., overnight 
then reflux, 1 h, 92%; iv) chloromethyl methyl ether, NaI, (i-Pr)2NEt, 1,2-dimethoxyethane, reflux, 12 h, 88%; v) 
TBAF, THF, r.t., 3.5 h, 93%; vi) 28% aq. H2O2, 0.1 M aq. (NH4)6Mo7O24, acetone/H2O, r.t., 3 h, 89%; vii) 
chloromethyl methyl sulfide, NaI, (i-Pr)2NEt, 1,2-dimethoxyethane, r.t., 6 h, 86%; viii) 1 M aq. NaOH, 1,2-
dimethoxyethane, r.t., 5 h, 100%; ix) 2-chloro-1-methylpyridinium iodide, NEt3, CH2Cl2, r.t., 24 h, 91%; x) n-
BuLi, DMAP, THF, 0 °C to r.t., 4.5 h; xi) NH4F, MeOH/H2O, 60 °C, 6 h, 82%; xii) 28% aq. H2O2, 0.1 M aq. 
(NH4)6Mo7O24, EtOH/H2O, r.t., 1.5 h, 73%; xiii) Ph3CLi, THF, -78 °C, 2 h, 41%; xiv) 1 M aq. H2SO4, Zn, 1,2-
dimethoxyethane, r.t., 1 h, 59%; xv) 1 M aq. H2SO4, 1,2-dimethoxyethane, 40 °C, 2.5 h, 86%. 
3.3.1.4 Niwa’s enantioselective synthesis of (+)-integerrinecic acid and (-)-integerrimine
  
 Niwa, Yamada and co-workers reported the first enantioselective synthesis of (+)-integerrinecic 
acid and (-)-integerrimine in 1986 (Scheme 133A).333-335 Initially, carboxylic acid 569 was reduced in 
preparation for Sharpless asymmetric epoxidation (71% yield, 96% e.e.). Nucleophilic ring opening of 
the resulting epoxide with Me3Al provided alcohol 570. Oxidative cleavage of the terminal alkene 
caused a spontaneous lactonisation forming lactone 554a, which was advanced to integerrinecic acid 
lactone 555 by a two step aldol condensation resulting in a formal twelve step synthesis of (+)-
integerrinecic acid. 





Scheme 133: A) Reagents and conditions (some details were not provided by the authors): i) LiAlH4, THF, r.t., 
12 h, 69%; ii) Ti(i-OPr)4, diethyl (+)-tartrate, t-BuOOH, CH2Cl2, -25 °C, 3 h, 71%, 96% e.e.; iii) Me3Al, hexane, 
0 °C, 2 h, 72%, iv) 3,5-dinitrobenzoyl chloride, pyridine, 0 °C to r.t., 3 h, 88%; v) RuCl3.3H2O, NaIO4, pH 7 
phosphate buffer, CCl4/MeCN, r.t., 1 h then p-TSA, PhH, reflux, 1 h, 99%; vi) NaOMe, MeOH, r.t., 30 min then 
p-TSA, PhH, reflux, 1 h, 76%; vii) RuCl3.3H2O, NaIO4, pH 7 phosphate buffer, CCl4/MeCN, 0 °C to r.t., 2.5 h 
then CH2N2, Et2O, 79%; viii) LDA, THF, -78 °C, 1 h then acetaldehyde, -30 °C, 2 h; ix) MsCl, pyridine, r.t., 2 h; 
x) DBU, PhH, reflux, 2 h, 34% over three steps. A) Reagents and conditions (some details were not provided by 
the authors): i) NaOMe, MeOH, r.t., 2.5 h; ii) Ac2O, DMSO, 40 °C, 24 h, 61% over two steps; iii) KOH, MeOH, 
H2O, reflux, 1 h, 88%; iv) DCC, CH2Cl2, r.t., 2 h; v) (+)-retronecine, Bu2SnO, 4Å MS, PhH, reflux, 19 h then 571, 
r.t., 3 h, 98% over two steps from 572; vi) 2,4,6-trichlorobenzoyl chloride, NEt3, THF, r.t., 2 h then DMAP, PhMe, 
reflux, 3.5 h, 75%; vii) Ph3C·BF4, CH2Cl2, r.t., 1.5 h, 81%. 
 Niwa, Yamada and co-workers employed a novel route to the synthesis of (-)-integerrimine 
(Scheme 133B).334-335 Integerrinecic acid lactone 555 was transformed into cyclic anhydride 571 over 
four steps, and this was coupled regioselectively with a tin derivative of retronecine, 572, providing 
monoester 573 in 53% yield. Yamaguchi macrolactonisation and MTM-deprotection formed (-)-
integerrimine. The retronecine-type macrocyclic diester, senecionine, was later synthesised by an 
analogous route via UV-light induced isomerisation of the alkene of lactone 555 (see Scheme 130, B).336 
 White and Jayasinghe reported an alternative asymmetric synthesis of integerrinecic acid 
lactone 555 in 1988, which employed the natural product, (R)-pulegone. Initially, (R)-pulegone was 
advanced to citronellal 574 by a known three step sequence (Scheme 134A).337-338 Citronellal 574 then 
underwent methylenation and Luche reduction to give allylic alcohol 575, which was transformed into 
epoxide 576 by a diastereoselective Sharpless epoxidation. Acid-promoted lactonisation and iodination 
of epoxide 576 provided lactone 577. Finally, radical reduction of the iodide and oxidation of the 
primary alcohol formed lactone 577, thereby completing a formal 18 step total synthesis of (+)-
integerrinecic acid. 




 White and co-workers also published a synthesis of (-)-integerrimine from protected 
integerrinecic acid 579 and TBS-protected retronecine 567 (Scheme 134B).338 Initial esterification to 
form monoester 580 was achieved by activation of the carboxylic acid of necic acid 579 with diethyl 
chlorophosphite, which was coupled with deprotonated retronecine derivative 567. In this case, 
macrolactonisation was achieved by chemoselective deprotection of the TMSE-ester moiety, activation 
of the C9-alcohol as the mesylate and intramolecular SN2-substitution. TBS-deprotection formed (-)-
integerrimine in four steps from the necic acid and base components. 
 
Scheme 134: A) Reagents and conditions (some details were not provided by the authors): i) HCl (g), -10 °C to 
r.t., 11 h then aq. NaOH, r.t., overnight, 53%; ii) LiAlH4, Et2O, 0 °C, 1 h, 97%; iii) PCC, NaOAc, CH2Cl2, r.t., 2 
h, 70%; iv) LDA, THF, -78 °C then Eschenmoser’s salt, -78 °C to r.t., 5 h then MeI, MeOH, 0 °C to r.t., overnight 
then 5% aq. NaHCO3, r.t., 16 h, 78%; v) CeCl3·6H2O, NaBH4, MeOH, 0 °C, 10 min, 95%; vi) Ti(i-OPr)4, 
diisopropyl (+)-tartrate, cumene hydroperoxide, 3Å MS, CH2Cl2, -5 °C, 8 h, 81%; vii) TBDPSCl, imidazole, 
DMAP, DMF, r.t., 5 h, 90%; viii) O3, CH2Cl2, -78 °C, 45 min then CrO3, -10 °C, 45 min then CH2N2, Et2O, 45%; 
ix) trifluoroacetic acid, CHCl3, -10 °C to 0 °C, 1 h, 50%; x) PPh3, imidazole, I2, PhH, reflux, 1.5 h, 90%; xi) n-
Bu3SnH, AIBN; xii) TBAF, THF; xiii) RuCl3.3H2O, NaIO4, pH 7 phosphate buffer, CCl4/MeCN/H2O, r.t., 3 h, 
73%. B) Reagents and conditions (some details were not provided by the authors): i) (EtO)2POCl, NEt3, THF, 0 
°C to r.t., 3 h then 567, DMAP, n-BuLi, 0 °C to r.t., 5 h, 51%; ii) NH4F, MeOH/H2O, 60 °C, 4 h, 67%; iii), MsCl, 
CH2Cl2, 0 °C, 30 min then TBAF, MeCN, r.t., 30 min, 75%; iv) 48% aq. HF, MeCN, r.t., 12 h, 67%. 
White and co-workers also reported a synthesis of (+)-usaramine, the necic acid portion of 
which contains an additional C12-hydroxymethyl group (Scheme 135A).338 This functionalised necic 
acid is also found as part of the otonecine-type macrocyclic diester, hydroxysenkirkine (Figure 4D). 
Epoxide 581 was initially prepared in six steps via by Sharpless epoxidation of allylic alcohol 575. 




Lewis acid mediated ring opening of the epoxide with pivalic acid and ketal protection provided ketal 
582. Several redox transformations were required to advance ketal 582 to carboxylic acid 583, which 
then underwent ketal deprotection and lactonisation to form six-membered lactone 584. Lactone 584 
was advanced to suitable coupling partner 586 in five steps, including aldol addition/elimination and 
ring opening of the lactam. Therefore, protected necic acid coupling partner 586 was synthesised in 22 
steps from (R)-pulegone. White’s synthesis of (+)-usaramine employed N-protected retronecine 587 in 
order to avoid oxidative aromatisation of the necic base during the esterification step (Scheme 135B). 
The remainder of the macrolactonisation sequence proceeded as in White’s synthesis of (-)-
integerrimine (Scheme 134B). 
 
Scheme 135: A) Reagents and conditions (some details were not provided by the authors): i) pivalic acid, Ti(Oi-
Pr)4, PhH, r.t., 20 min, 51%; ii) 2,2-dimethoxypropane, CSA, CH2Cl2, r.t., 5 h, 98%; iii) LiAlH4, Et2O, reflux, 1 
h, 90%, iv) PCC, DMF, r.t., 30 h, 67%; v) CH2N2, Et2O, r.t., 99%; vi) 2-(trimethylsilyl)ethanol, Ti(OEt)4, 100 °C, 
50 h, 93%; vii) O3, CH2Cl2, -78 °C, 45 min then DMS, r.t., 7 h, 98%; viii) RuCl3·3H2O, NaIO4, CCl4/MeCN, pH 
7 phosphate buffer, r.t., 20 min, 67%; ix) AcOH/H2O, 75 °C, 8 h, 96%; x) 2-chloro-1-methylppyridinium iodide, 
DMAP, MeCN, 0 °C to r.t., 13 h, 74%; xi) MOMCl, (i-Pr)2NEt, THF, 50 °C, 15 h, 91%; xii) lithium N-
isopropylcyclohexylamide, acetaldehyde, THF, -60 °C to -20 °C, 1.5 h, 85%; xiii) Ac2O, NEt3, DMAP, CH2Cl2, 
0 °C, 6 h; xiv) DBU, CH2Cl2, 4 °C, 15 h, 75% over two steps; xv) 3M aw. HCl, THF, r.t., 1 h, 90%; xvi) LiOH, 
H2O2. B) Reagents and conditions (some details were not provided by the authors): i) (EtO)2POCl, NEt3, THF, 0 
°C to r.t., 3 h then 587, DMAP, n-BuLi, 0 °C to r.t., 8 h, 55%; ii) NH4F, MeOH/H2O, 60 °C, 6 h, 65%; iii), MsCl, 
NEt3, CH2Cl2, r.t., 2 h then TBAF, MeCN, r.t., 2 h, 75%; iv) EtOH, reflux, 1.5 h then 1 M aq. HCl, THF, 40°C, 1 
h, 67%. 




In 1996, Niwa, Yamada and co-workers published a synthesis of necic acid lactone 554b en 
route to the retronecine-type macrocyclic diester, (+)-yamataimine (Scheme 136).339 The relative 
stereochemistry of the necic acid of (+)-yamataimine (C12S, C13R) is diastereomeric to integerrinecic 
acid and senecic acid. Cyclopentanone 589 was readily prepared from (R)-pulegone in 49% yield over 
two steps. Methylation of cyclopentanone 589 was poorly diastereoselective (3:1 d.r.) providing 
cyclopentanone 553b in 59% yield. The following Baeyer-Villager oxidation showed no 
regioselectivity resulting in the formation of a 1:1 ratio of lactones 554b and 554a (each in 40% yield). 
The C15-ethyl group of protected necic acid 590 was installed by the standard three step aldol 
condensation, employed in Niwa’s previous synthesis of integerrinecic acid (Scheme 133A), followed 
by highly diastereoselective hydrogenation of the resulting exocyclic alkene. Methanolysis 
(K2CO3/methanol) of the resulting lactone (not shown) caused partial isomerisation of the C15-position, 
which, after further hydrolysis, provided protected necic acid 590 as a 2:1 mixture of C15-diastereomers 
(68% yield from 554b). The remainder of the synthesis of (+)-yamataimine was accomplished using 
the strategy employed by Niwa, Yamada and co-workers in the synthesis of (-)-integerrimine (Scheme 
133B). 
 
Scheme 136: Niwa and Yamada’s enantioselective synthesis of (+)-yamataimine. Reagents and conditions (some 
details were not provided by the authors): i) Br2, NaHCO3, Et2O, r.t., 40 °C then NaOMe, MeOH, reflux, 
2.5 h, 77%; ii) O3, DMS, MeOH, -78 °C, 63%; iii) MeI, K2CO3, acetone, r.t., 11 h, 59% of 553b; iv) m-
CPBA, Li2CO3, CH2Cl2, reflux, 4 d, 40% of 554b; v) LDA, THF, -78 °C, 1 h then acetaldehyde, -30 °C, 2 
h; vi) MsCl, pyridine, r.t., 2 h; vii) DBU, PhH, reflux, 2 h, 77% from 554b; viii) 10% Pd/C, H2, EtOAc, r.t., 16 h, 
98%, single C15-diastereomer; ix) K2CO3, MeOH, r.t., 13 h then Ac2O, DMSO, 40 °C, 24 h, 99%, 2:1 d.r.; x) 5 
M aq. LiOH, THF/H2O, r.t., 2 d, 91%; xi) DCC, CH2Cl2, r.t., 2 h; xii) (+)-retronecine, Bu2SnO, Dean-Stark 
apparatus, PhH, reflux, 24 h then 590, PhMe, r.t., 16 h, 81% over two steps; xiii) DCC, DMAP, CSA, CHCl3, r.t., 
5 d, 16%; xiv) Ph3C·BF4, CH2Cl2, r.t., 16 h, 64%. 
 




3.3.1.5 Niwa’s model studies into the formation of otonecine-type macrocyclic diesters 
 The macrolactonisation strategies discussed up until this point have focussed on the synthesis 
of retronecine-type macrocyclic diesters, so it is unclear whether these methods will be applicable to 
the synthesis of otonecine-type macrocyclic diesters. In 1994, Niwa and co-workers published the only 
existing model studies into the macrolactonisation of (rac)-otonecine with a simple necic acid surrogate 
591 (Scheme 137). The authors differentiated the two carboxylic acids of 591 by forming cyclic 
anhydride 592, which was regioselectively opened by reaction with trifluoroethanol to give C11-
monoester 593. Unexpectedly, the secondary C7-alcohol of (rac)-otonecine underwent selective 
esterification in the presence of the primary C9-alcohol to form monoester 594. The authors suggest 
that the secondary C7-alcohol was more reactive than the primary C9-alcohol due to a hydrogen bond 
with the highly polarised ketone (due to the N-C8 transannular interaction). Macrolactonisation of 
monoester 594 was achieved by transesterification in the presence of DMAP to form the model 
otonecine-type macrocyclic diester 595. 
 
Scheme 137: Yamada’s synthesis of model otonecine-type pyrrolizidine alkaloid 595. Reagents and conditions 
(some details were not provided by the authors): i) DCC, CH2Cl2; ii) TFE, pyridine, 72% from 591; iii) (rac)-
otonecine, DCC, CSA, DMAP, CHCl3, r.t., 1.5 h, ; iv) Bu3SnOMe, DMAP, PhMe, reflux, 22 h, 46%. 
3.3.2 Summary of the existing methods for the synthesis of C10 dicarboxylic necic acids 
and macrocyclic diesters 
To summarise, several strategies for the synthesis of C10 dicarboxylic necic acids were 
disclosed in the period 1967 to 1996, but since then no new examples have been published. Most of 
these strategies suffer from either long step counts, inefficient or unselective transformations, or are not 
asymmetric, which renders them unsuitable in the current context. For example, the shortest route to 
any of the C10 dicarboxylic acids, Drewes and Emslie’s five step synthesis of integerrinecic acid 
(Scheme 131), provides the necic acid as its racemate and requires the use of toxic sodium cyanide. By 




comparison, the existing asymmetric syntheses require longer step counts (10 to 22 steps), which is 
perhaps a reflection of them being limited by the number of asymmetric methodologies available at the 
time. The shortest of these asymmetric syntheses, Niwa and Yamada’s ten step synthesis of protected 
necic acid 590 from (R)-pulegone, contains poorly selective methylation and Baeyer-Villiger oxidation 
steps, which severely reduced the overall efficiency of the route. Additionally, the strategies described 
above are unsuitable for the divergent synthesis of diastereomeric C10 dicarboxylic necic acids.  
The existing macrocyclisation strategies require significant modifications and protection of the 
necic acid and necic base portions to facilitate coupling. This is illustrated in Narasaka’s early synthesis 
of (rac)-integerrimine, where the necic acid coupling partner (rac)-556 is prepared in nine steps from 
integerrinecic acid lactone (rac)-555 and requires a further six steps to access the natural product 
(Scheme 132). Promisingly however, the only model studies towards the formation of an otonecine-
type macrocyclic diester, Yamada’s synthesis of model macrocyclic diester 595 (Scheme 137), 
proceeded in only four steps.  
3.3.3 Development of an enantioselective synthesis of the C10 dicarboxylic necic acids 
The considerations outlined in the previous section prompted attempts to develop a short and 
selective synthesis of the C10 dicarboxylic acids. The ideal synthesis would provide a highly selective 
entry to all the diastereomers shown in Figure 4 and be adaptable to the synthesis of some of the higher 
functionalised necic acids (see Figure 4).   
3.3.3.1 First-generation retrosynthesis of (rac)-integerrinecic acid 
 Retrosynthetic analysis of integerrinecic acid identified primary alcohol 597 as a potential key 
intermediate, which could be advanced to the target molecule by olefination of phosphonoacetate 596 
(Scheme 138A). This strategy was appealing because both C15 alkene isomers (E or Z) could potentially 
be accessed stereoselectively by appropriate choice of olefination conditions (e.g. Horner-Wadsworth-
Emmons340 or Still-Gennari341). The C12,C13-vicinal stereocentres of primary alcohol 597 might be 
formed by nucleophilic ring opening of epoxide 598, which in turn is accessed via E-,-unsaturated 
ester E-599. The asymmetric synthesis would require an enantioselective epoxidation of ,-
unsaturated ester E-599, which might be achieved by several protocols.342-344 Finally, synthesis of the 
C12-diastereomers of integerrinecic acid and senecic acid would be achieved from Z-,-unsaturated 
ester Z-599 by an otherwise identical route (Scheme 138B).  






 Initial synthetic studies were directed towards the synthesis of (rac)-integerrinecic acid. 
Following a literature procedure, diol 601 was protected as the bis-THP acetal in quantitative yield, 
before undergoing ozonolysis to give aldehyde 600a, which was immediately subjected to Wittig 
olefination to afford E-,-unsaturated ester E-599a in 64% yield (Scheme 139A).345 At this point, 
epoxidation of ,-unsaturated ester E-599a was carried out in a non-enantioselective manner, by 
treatment with m-CPBA, which gave epoxide 602 in 67% yield after THP-deprotection. Alcohol-
directed nucleophilic ring opening of epoxide 602 with MeMgBr and copper(I) iodide proceeded 
rapidly to form diol 597a in 70% yield. This robust sequence provided substantial quantities of the key 
intermediate, primary alcohol 597a, for investigations into the olefination step.  
 In order to install the phosphonoacetate moiety, diol 597a was reacted with methanesulfonyl 
chloride and the resulting mesylate was treated with deprotonated triethyl phosphonoacetate (TEPA). 
Unfortunately, the reaction did not form diester 596a, but resulted in intramolecular nucleophilic 
substitution of the mesylate by the tertiary alcohol, forming oxirane 604 30% yield. To avoid this 
intramolecular etherification, the tertiary alcohol of mesylate 603 was acetylated, but subsequent 
reaction with TEPA also failed (Scheme 139B). Therefore, alkyliodide 606a was targeted in the hope 
that the iodide would undergo successful intermolecular substitution. Whereas reaction of mesylate 605 
with sodium iodide caused degradation, alkyliodide 607a could be accessed by an alternative route 
involving iodination (30% yield) and acetylation (90% yield) of diol 597a. Unfortunately, alkyliodide 
607a also failed to form diester 596a when reacted with deprotonated TEPA. At this point, the 
retrosynthetic analysis in Scheme 138 was re-evaluated because of the difficulties in synthesising 




diester 596a and because the current proposal was not significantly more step economical (>10 steps to 
access integerrinecic acid) than previous reports. 
 
Scheme 139: A) Reagents and conditions: i) 3,4-dihydropyran, p-TSA, CH2Cl2, r.t., 1.5 h, 98%; ii) O3, CH2Cl2, -
78 °C, 5 h then PPh3, r.t., 2 h; iii) t-butyl 2-(triphenylphosphoranylidene)propionate, CH2Cl2/PhMe, r.t., 16 h, 64% 
from 601; iv) m-CPBA, CH2Cl2, r.t., 48 h; v) p-TSA, MeOH, r.t., 4 h, 67% from E-599a; vi) MeMgBr, CuI, THF, 
-15 °C, 15 min, 70%; vii) MsCl, NEt3, CH2Cl2, 0 °C, 15 min then TEPA, NaH, THF, 0 °C – reflux, 3 h, 30%. B) 
Reagents and conditions: i) MsCl, NEt3, CH2Cl2, 0 °C, 15 min; ii) Ac2O, DMAP, pyridine, r.t., 16 h, 49%; iii) 
TEPA, NaH, THF, 50 °C; iv) NaI, acetone, 50 °C; v) PPh3, I2, imidazole, CH2Cl2, 0 °C to r.t., 16 h, 30%; vi) 
Ac2O, DMAP, pyridine, r.t., 6 h, 91%.  
3.3.3.2 Second-generation retrosynthesis of integerrinecic acid and its diastereomers 
 The second-generation retrosynthetic analysis of integerrinecic acid is shown in Scheme 140. 
The retrosynthesis relies on two key transformations, the asymmetric crotylation of a pyruvate ester to 
form the C12,C13-vicinal stereocentres, and a Negishi cross-coupling to attach the exocyclic alkene 
portion. The proposed strategy is highly modular, such that the four necic acid diastereomers 
(integerrinecic acid, senecic acid, C12-epi-integerrinecic acid and C12-epi-senecic acid) might be 




accessed in a divergent manner by appropriate choice of crotylboron reagent (i.e. E-608 or Z-608) and 
Negishi cross-coupling electrophile (i.e. E-611 or Z-611).  
 
Scheme 140: Asymmetric crotylation and Negishi cross-coupling towards the C10 dicarboxylic necic acids.  
 The proposed synthesis begins with the diastereoselective and enantioselective crotylation of a 
pyruvate ester to form alkenes 609a or 609b. Asymmetric allylation of aldehydes and ketones is a 
powerful method for the formation of chiral secondary and tertiary alcohols.346-347 Numerous allyl-metal 
reagents have been reported to undergo such a reaction, and, among these, allylboron reagents have 
been particularly successful. However, whereas the asymmetric allylation of aldehydes is highly 
developed, the asymmetric allylation of ketones remains challenging and is typically limited to activated 
ketones.348 Nevertheless, this strategy was appealing because both diastereomers of the crotylation 
product might be accessed depending on whether the E- or Z-crotylboron reagent is used. For example, 
E-crotylboron reagent E-608 would react with pyruvate ester via six-membered chair transition state 
TS1. Here the vinyl methyl moiety of boron reagent is positioned in a pseudo-equatorial position and 
the ester moiety of pyruvate ester is positioned in a pseudo-equatorial position such that (R,R)-alkene 
609a is formed (Scheme 141). Alternatively, by employing Z-crotylboronic ester Z-608, the methyl 
moiety of boron reagent is positioned in a pseudo-axial orientation in the corresponding transition state 
TS2, resulting in the formation of (R,S)-alkene 609b. Alkenes 609a and 609b, resulting from the 
crotylation reaction, might be advanced to alkyliodides 610a and 610b by standard functional group 
transformations (Scheme 140). Then, Negishi cross-coupling, between an alkyl zinc reagent derived 
from alkyliodides 610a and 610b, and electrophiles E-611 or Z-611s would rapidly form the desired 
necic acid in a protected form. 





Scheme 141: Asymmetric and diastereoselective crotylation of a pyruvate ester. 
 The viability of the second-generation strategy was investigated by targeting integerrinecic 
acid. Initially, a literature survey was conducted to identify suitable conditions for the asymmetric 
crotylation of pyruvate esters, but no examples existed at the time. However, a report by Schaus and 
co-workers described the highly enantioselective crotylation of phenylmethylketone to form either 
alkene 613a or 613b depending on the crotylboron reagent used (i.e. E-612 or Z-612) (Scheme 
142A).348-349 This methodology employs BINOL-derived catalyst (S)-614, which is proposed to undergo 
ligand exchange with an allylboronic ester to form active chiral boronate species 615 (Scheme 142B). 
Upon allylboration of an aryl ketone, BINOL-derived catalyst (S)-614 is regenerated from resulting 
species 616 by ligand exchange with t-BuOH.  
 
Scheme 142 
 Schaus’ conditions were chosen to investigate the crotylation of pyruvate ester 617 by E-
crotylboronic ester E-612 (Scheme 143). The TMSE-ester of 617 was chosen to provide an orthogonal 
mode of deprotection (i.e. TBAF) at a later stage in the synthesis where other ester functionalities might 
be present. E-Crotylboronic ester E-612 was prepared in 51% yield by a known procedure involving 




deprotonation of but-2-ene with Schlosser’s base and borylation of the resulting lithiated species.349 
Pyruvate ester 617 was prepared by EDCI coupling of pyruvic acid with 2-trimethylsilylethanol in 62% 
yield. Gratifyingly, under Schaus’ BINOL-catalysed conditions, pyruvate ester 617 underwent rapid 
crotylation with E-crotylboronic ester E-612 to provide alkene 618 in 80% yield, as a single 
diastereomer and in a promising 70% e.e.. The relative stereochemistry of alkene 618 was confirmed 
by comparison of the 13C chemical shifts with a literature compound (Further details are available in 
the Experimental Section 4.5). It is important to note that these results are entirely unoptimised. Further 
improvements to the enantioselectivity of the reaction might be achieved by lowering the reaction 
temperature to minimise background non-enantioselective crotylation reactions.  
 
Scheme 143: Application of Schaus’ conditions to the asymmetric crotylation of pyruvate ester 617. Reagents 
and conditions: i) KOt-Bu, n-BuLi, THF, -78 °C to -52 °C, 15 min then B(Oi-Pr)3, -78 °C, 3 h then 3 M aq. HCl 
then 1,3-propanediol, 4 Å MS, r.t., 16 h, 51%; ii) 2-(trimethylsilyl)ethanol, EDCI, DMAP, CH2Cl2, r.t., 16 h, 62%; 
iii) (S)-614, t-BuOH, PhMe, r.t., 3 h, 80%, >25:1 d.r., ~70% e.e.. 
Having identified promising conditions for the crotylation reaction, attention was turned to the 
proposed Negishi cross-coupling. Negishi cross-couplings are a mild method for the coupling of sp3 
and sp2-hybridised carbon-centres in the presence of various sensitive functional groups, which has 
resulted in it having been employed extensively in the total synthesis of complex molecules.350-351 The 
functional group tolerance of the Negishi cross-coupling is demonstrated by Donohoe and co-workers 
in the synthesis of dehydromicrosclerodermin B (Scheme 144A).352 Here, Negishi cross-coupling of 
alkylzinc species 620 (formed from the corresponding alkyliodide) with 2-bromoindole 619 was carried 
out in the presence of an acidic N-H bond and TMSE-ester, to form product 621 in 69% yield. A 
literature survey did not find any examples of -bromoacrylates being used as electrophiles in Negishi 
cross-couplings, so due to the structural similarities between the reagents in Scheme 144A and the 
proposed Negishi cross-coupling described in Scheme 140, investigations began with the conditions 
reported by Donohoe. 
Exploratory studies into the proposed Negishi cross-coupling were carried out with model 
alkyliodide 622 and -bromoacrylate E-611 (Scheme 144B). According to Donohoe’s conditions, 




alkylzinc reagent 623 was formed from alkyliodide 622 by reaction with activated zinc. Alkylzinc 
reagent 622 was then added to -bromoacrylate E-611 in the presence of catalytic Pd2dba3 and SPhos, 
which provided cross-coupling product 624 in 35% yield. Note, due to availability issues, the 
suboptimal ligand, SPhos, was used in this reaction instead of QPhos. Although further optimisation is 
required, the formation of cross-coupling product 624 suggests that the proposed coupling of complex 
alkyliodide 610 and -bromoacrylate E-611 might be achieved under these conditions. 
 
Scheme 144: A) Reagents and conditions: i) Zn dust, TMSCl, dibromoethane, DMF, r.t., 2 h; ii) Pd2(dba)3, SPhos, 
DMF, 40 °C, 16 h, 35%. 
 Next a suitable alkyl iodide species was targeted in order to investigate the Negishi cross-
coupling. Therefore, alcohol 618 was acetylated before undergoing reductive ozonolysis to form alcohol 
625 in 86% yield (Scheme 145). When subjected to standard iodination conditions, the acetate of 
alcohol 625 migrated to the primary alcohol resulting in the formation of primary acetate 626 and none 
of the desired iodide 607b. Therefore, an alternative order of transformations was investigated. 
Reductive ozonolysis of alkene 618 formed diol 597b albeit in a disappointing 27% yield. Iodination 
of diol 597b successfully formed iodide 606b but in only 47% yield. Despite the poor yields, iodide 
606b is a viable substrate for investigating the proposed Negishi coupling.    
 No further investigations were carried out towards the synthesis of integerrinecic acid due to 
time constraints. It is clear from the immediately high yielding and selective formation of alkene 618 
by crotylation of pyruvic ester 617, subsequent synthesis of iodide 606b and promising model studies 
into the sp2-sp3 Negishi cross-coupling that this novel strategy shows great promise in the synthesis of 
integerrinecic acid and its natural diastereomers.  





Scheme 145: Synthesis of alkyliodide 606b from alkene 618. Reagents and conditions: i) Ac2O, DMAP, pyridine, 
r.t., 6 h, 86%; ii) O3, CH2Cl2/MeOH, -78 °C then NaBH4, 0 °C, 30 min, 86%; iii) PPh3, I2, imidazole, CH2Cl2, 0 
°C to r.t., 16 h, 50%; iv) O3, CH2Cl2/MeOH, -78 °C then NaBH4, 0 °C, 3 h, 27%; v) PPh3, I2, imidazole, CH2Cl2, 
0 °C to r.t., 16 h, 42%.  
3.3 Summary and conclusions from the studies in Chapter 3 
 Significant progress has been made towards the total synthesis of otonecine using the (7+1) 
carbonylative cycloaddition of cyclopropylacrylamides developed at Bristol. Cyclopropylacrylamide 
trans-517 was identified as the optimal substrate for the (7+1) carbonylative cycloaddition, which was 
prepared by a robust five step sequence from allylsilane 516. The current synthesis of 
cyclopropylacrylamide trans-517 is not asymmetric, but strong literature precedent suggests that it may 
be prepared rapidly in an enantioenriched form. The existing conditions for the Rh(I)-catalysed (7+1) 
carbonylative cycloaddition were not suitable for the current application, so these were reoptimised. 
This led to the identification of beneficial additives and an alternative reaction set-up, which 
dramatically increased the efficiency of the (7+1) carbonylative cycloaddition and allowed access to 
suitable quantities of azocane 518 for further studies.  
 Extensive investigations into the four post-cycloaddition transformations provided suitable 
conditions for three of these and identified a viable sequence for these to be carried out. Firstly, azocane 
518 underwent a two step Rubottom oxidation to install the C7-alcohol of otonecine. This was achieved 
in good yield, but further development is required to improve the diastereoselectivity of this reaction. 
Perhaps the greatest challenge encountered in this project was the incorporation of the C9-alcohol. 
Several methods were investigated, but Tamao-Fleming oxidation of the C9-silane proved to be 
successful, albeit in low yield under the current conditions. The alkene isomerisation from the C2-
position (as in 539) to the C1-position (as in 532a) was another challenging transformation, which was 
achieved by a two step kinetic method employing a one-pot hydrobromination of the enelactam moiety. 
Unfortunately, the penultimate lactam reduction of lactam 532a failed to form bis-TBS protected 
otonecine, instead forming an unassigned side-product under a variety of chemoselective reduction 




conditions. Future efforts should aim to understand why this side-product is being formed, which might 
provide a solution to this final transformation.  
 
Scheme 146: Current progress towards the total synthesis of otonecine and the otonecine-type pyrrolizidine 
alkaloids. 
 In parallel studies towards the synthesis of the C10 dicarboxylic necic acids, a potentially short 
and divergent synthesis has been designed. The asymmetric crotylation of pyruvate ester 617 promises 
to provide a highly efficient and diastereodivergent entry to alkene 618, which contains the C12,C13-
vicinal stereocentres of the necic acids. Model studies have identified conditions for the Negishi 
coupling of a simple alkyl iodide with -bromoacrylate E-611, which might be applicable to the cross-
coupling shown in Scheme 146.  




 Completion of the asymmetric synthesis of (R)-otonecine and the C10 dicarboxylic necic acids 
would set the stage for the first total synthesis of an otonecine-type PA, such as neosenkirkine. Model 
studies reported by Niwa and co-workers suggest that the union of (R)-otonecine and a necic acid might 
be achieved with relative efficiency.  
 
 




Chapter 4 – Experimental 
General Experimental Details. Starting materials sourced from commercial suppliers were used as 
received unless otherwise stated. Dry solvents, where necessary, were obtained by distillation using 
standard procedures or by passage through a column of anhydrous alumina using equipment from 
Anhydrous Engineering based on the Grubb’s design.353 The removal of solvents in vacuo was achieved 
using both a Büchi rotary evaporator (bath temperatures up to 40 °C) at a pressure of either 15 mmHg 
(diaphragm pump) or 0.1 mmHg (oil pump), as appropriate, and a high vacuum line at room 
temperature. Reactions requiring anhydrous conditions were run under an atmosphere of dry nitrogen 
or argon; glassware was either flame dried immediately prior to use or placed in an oven (200 °C) for 
at least 2 h and allowed to cool either in a desiccator or under an atmosphere of nitrogen or argon; liquid 
reagents, solutions or solvents were added via syringe through rubber septa. Commercially available 
Merck Kieselgel 60F254 aluminium backed plates were used for TLC analysis. Visualisation was 
achieved by either UV fluorescence or basic KMnO4 solution and heat. Flash column chromatography 
(FCC) was performed using silica gel (Aldrich 40-63 μm, 230-400 mesh). The crude material was 
applied to the column as a solution in the corresponding solvent system, CH2Cl2, or by pre-adsorption 
onto silica, as appropriate. Melting points were determined using a Reichert melting point table and 
temperature controller and are uncorrected. Infra-red spectra were recorded in the range 4000-600 cm-
1 on a Perkin Elmer Spectrum either as neat films or solids compressed onto a diamond window. 
Abbreviations used are: w (weak), m (medium) or s (strong). NMR spectra were recorded using either 
a Varian 400 MHz or JOEL ECS 400 MHz spectrometer. Chemical shifts (δ) are quoted in parts per 
million (ppm), coupling constants (J) are given in Hz to the nearest 0.5 Hz. Other abbreviations used 
are s (singlet), d (doublet), t (triplet), m (multiplet) and br (broad). 1H and 13C NMR spectra were 
referenced to the appropriate residual solvent peak. Assignments of 1H NMR and 13C NMR signals were 
made, where possible, using COSY, DEPT135, HSQC, HMBC and NOE experiments. Where mixtures 
of products (e.g. diastereomers, regioisomers or 8 vs 9) have been isolated together, they have been 
characterised separately where possible. Numbering systems for NMR signal assignments are specified 
on the structure and are not related to those used for the compound names. Mass spectra were 
determined by the University of Bristol mass spectrometry service by either electron impact (EI+) or 
chemical ionisation (CI+) using a Fisons VG Analytical Autospec spectrometer, or by electrospray 
ionisation (ESI+) using a Brüker Daltonics Apex IV spectrometer. Chiral SFC was performed using the 
racemate as a standard on an Agilent 1290 Infinity system equipped with a quaternary pump, diode 
array detector and column thermostat under the conditions specified in each case.




4.1 General Procedures 
General procedure A for the formation of ureas from cyclopropylamines 
To a solution of amine (110 mol%) and NEt3 (200 mol%) in CH2Cl2 (0.3 M) at 0 °C was added the 
specified isocyanate (100 mol%). The reaction mixture was warmed to room temperature and stirred 
for 16 h. The solution was diluted with CH2Cl2 (3 mL/mmol) and washed with water (5 mL/mmol), 
1 M aq. HCl (5 mL/mmol), sat. aq. NaHCO3 (5 mL/mmol) and brine (5 mL/mmol). The organic layer 
was dried over Na2SO4 and concentrated in vacuo. The product was purified by FCC, under the 
conditions noted, to afford the title compound. 
General procedure B for the carbonylative cyclisation of cyclopropane-based substrates 
An oven dried reaction tube fitted with a magnetic stirrer was charged with benzoic acid (15 mol%), 
the specified Rh(I)-catalyst (3.5–10 mol%), PPh3 (twice the number of moles of Rh(I)-catalyst) and 
cyclopropylurea (100 mol%). The tube was fitted with a rubber septum and purged with argon. Argon 
sparged anhydrous 1,2-DCB (0.2 M) was added via syringe before the solution was aged the solution 
was aged for ca. 5 minutes. The reaction tube was purged with CO (balloon) for 20 minutes then the 
reaction mixture was sparged for 10 seconds. The reaction was heated at the specified temperature (90–
100 °C) under CO (balloon) until complete consumption of the starting material was observed by TLC 
(23–92 h). The reaction mixture was cooled to room temperature, concentrated in vacuo and purified 
by FCC, under the conditions noted, to afford the target heterocycle. 
General Procedure C for the hydrolysis of cyclopropyl esters to form cyclopropyl carboxylic acids 
To a stirring solution of the ester (100 mol%) in MeOH (0.5 M) was added 4 M aq. NaOH (500 mol%). 
The reaction was stirred at the specified temperature for the specified time. MeOH was removed in 
vacuo and the aqueous layer was diluted with water (5 mL/mmol) before being acidified to pH ~1 with 
conc. HCl. The aqueous layer was extracted with Et2O (3 × 5 mL/mmol), and the combined organics 
were dried over Na2SO4, filtered and concentrated in vacuo to provide the title compound. 
General Procedure D for the Curtius rearrangement of cyclopropylcarboxylic acids to form Boc-
protected cyclopropylamines 
To a stirring solution of carboxylic acid (100 mol%) in dry t-BuOH (1 M) was added NEt3 (110 mol%) 
then diphenylphosphoryl azide (110 mol%) after 10 minutes. The reaction was stirred at room 
temperature for 30 minutes, heated at 80 °C for the specified time and then concentrated in vacuo. The 
resulting residue was dissolved in sat. aq. NaHCO3 (5 mL/mmol) and extracted with Et2O (3 × 
5 mL/mmol). The combined organics were washed with brine (5 mL/mmol), dried over Na2SO4 and 
concentrated in vacuo. Purification by FCC, under the conditions noted, provided the title compound. 




General procedure E for the one-pot Boc-deprotection/reductive amination of Boc-protected 
cyclopropylamines 
To a solution of the specified Boc-protected cyclopropylamine (100 mol%) in CH2Cl2 (1 M) was added 
trifluoroacetic acid (1000 mol%), and the reaction was stirred at room temperature for 30 minutes before 
being concentrated in vacuo. The resulting amine·TFA salt was dissolved in water (5 mL/mmol), and 
the aqueous phase was washed with CH2Cl2 (5 mL/mmol). The aqueous phase was basified to pH ~12 
by the addition of 2 M aq. NaOH and extracted with CH2Cl2 (3 × 3 mL/mmol). The combined organics 
were dried over Na2SO4, concentrated in vacuo and the residue was dissolved in MeOH (0.5 M). 
NaHCO3 (400 mol%) and benzaldehyde (95 mol%) were added, and the solution was heated at reflux 
for 24 h. The reaction mixture was cooled to 0 °C and NaBH4 (125 mol%) was added portion-wise over 
10 minutes. The reaction was warmed to room temperature, stirred for 18 h and then concentrated in 
vacuo. Sat. aq. NaHCO3 (10 mL/mmol) and CH2Cl2 (5 mL/mmol) were added, the layers were 
separated, and the aqueous phase was further extracted with CH2Cl2 (2 × 5 mL/mmol). The combined 
organics were washed with brine (5 mL/mmol), dried over Na2SO4 and concentrated in vacuo. 
Purification by FCC, under the conditions noted, provided the title compound. 
General procedure F for the one-pot Boc-deprotection/urea formation of Boc-protected 
cyclopropylamines 
To a solution of Boc-protected cyclopropylamine (100 mol%) in CH2Cl2 (1 M) was added 
trifluoroacetic acid (1000 mol%), and the reaction was stirred at room temperature for 30 minutes before 
being concentrate in vacuo. The resulting trifluoroacetate salt and NEt3 (250 mol%) were dissolved in 
CH2Cl2 (0.3 M) before the addition of benzyl isocyanate (95 mol%). The reaction was stirred at room 
temperature for 2 h before being diluted with CH2Cl2 (5 mL/mmol). The solution was washed with 
water (5 mL/mmol), 1 M aq. HCl (5 mL/mmol), sat. aq. NaHCO3 (5 mL/mmol ) and brine (5 mL/mmol), 
dried over Na2SO4 and concentrated in vacuo. Purification by FCC, under the conditions noted, 
provided the target compound. 
General Procedure G for the N-methylation of Boc-protected amines 
To a stirring suspension of NaH (equivalents specified, 60% dispersion in mineral oil) in anhydrous 
THF (0.3 M) at 0 °C was added a solution of Boc-protected amine (100 mol%) in dry THF (2 M). The 
resulting suspension was stirred at 0 °C for 30 minutes before being warmed to room temperature. MeI 
(equivalents specified) was then added dropwise over 5 minutes and the reaction was stirred at the 
specified temperature for the specified time, or until complete by TLC. The completed reaction mixture 
was quenched with H2O (5 mL/mmol) and extracted with Et2O (3 × 5 mL/mmol). The combined 
organics were washed with brine (5 mL/mmol), dried over Na2SO4 and concentrated in vacuo. 
Purification by FCC, under the conditions noted, yielded the desired N-methyl carbamate. 




General Procedure H for the one pot Boc-deprotection/acrylamide formation 
To a stirring solution of Boc-protected amine (100 mol%), in CH2Cl2 (1 M), was added trifluoroacetic 
acid (1000 mol%). The reaction was stirred at room temperature until complete by TLC (typically 
15 minutes) before being concentrated in vacuo (residual trifluoroacetic acid was removed by 
redissolving the resulting residue in CH2Cl2 and concentrating in vacuo three times). The resulting 
trifluoroacetic acid salt was dissolved in acetone (0.4 M) and H2O (1.7 M), and K2CO3 (300 mol%) was 
added. The reaction mixture was cooled to 0 °C, and acryloyl chloride (200 mol%) was added dropwise 
by syringe over 5 minutes. The reaction mixture was stirred at room temperature for 16 h before being 
concentrated in vacuo, dissolved in H2O (5 mL/mmol), and extracted with CH2Cl2 (3 × 5 mL/mmol). 
The combined organics were washed with brine (5 mL/mmol), sat. aq. NaHCO3 (2 × 5 mL/mmol) and 
dried over Na2SO4 and concentrated in vacuo. Purification by FCC under the conditions noted yielded 
the desired acrylamide. Note: The resulting acrylamides have been observed to polymerise and were 
therefore stored in the freezer as a solution in Et2O. 
General Procedure I for the (7+1) carbonylative cycloaddition of cyclopropylacrylamides in a 
Schlenk tube 
To a flame-dried Schlenk tube equipped with a magnetic stirrer bar and Young’s tap adapter, was added 
the Rh(I)-catalyst (equivalents specified), ligand (equivalents specified) and additive (equivalents 
specified). The Schlenk tube was attached to a Schlenk line and CO cylinder via a three-way adapter. 
The flask was evacuated and refilled with nitrogen twice before being evacuated and refilled with CO 
(approximately 2 atm pressure). Whilst under a positive pressure of CO (approximately 2 atm), the 
Youngs tap was replaced with a rubber septum, which was pierced with a needle attached to a bubbler 
in order to monitor the pressure of CO. Meanwhile, acrylamide (100 mol%) was dissolved in argon 
sparged, anhydrous benzonitrile (0.1 M) in a flame-dried flask before being transferred to the Schlenk 
flask by syringe. The rubber septum was replaced with a Youngs tap and the Schlenk tube was sealed. 
The Schlenk tube was shaken to incorporate CO into the reaction mixture then heated at the specified 
temperature for the specified time. The Schlenk tube was then cooled to room temperature, and the 
reaction mixture was transferred to a separate flask before being concentrated in vacuo. The method of 
purification is specified.  
General Procedure J for the hydrobromination of enelactams 
Enelactam (100 mol%) in anhydrous CH2Cl2 (0.1 M) was transferred to a flame-dried flask containing 
NaHCO3 (300 mol%) under an atmosphere of argon. The resulting suspension was cooled to 0 °C. 
Bromine (~110 mol%) was added dropwise by syringe until a red/brown colour persists for longer than 
10 seconds. Immediately afterwards, excess bromine was consumed by the dropwise addition of 
2,3-dimethylbut-2-ene (1 M THF) until the solution became colourless. THF (0.2 M) was added, 
followed by NaBH3CN (150 mol%). The suspension was warmed to room temperature and stirred for 




30 minutes before being quenched with sat. aq. NH4Cl (5 mL/mmol). The aqueous layer was extracted 
with CH2Cl2 (3 × 5 mL/mmol) and the combined organics were dried over MgSO4, filtered and 
concentrated in vacuo. Purification by FCC, under the specified conditions, provided the title 
compound. 
General Procedure K for the E1cB elimination from -bromoketones 
The -bromoketone (100 mol%) was dissolved in CH2Cl2 (0.1 M) and base (specified equivalents) was 
added. The reaction was followed closely by TLC to minimise isomerisation of the desired 
,-unsaturated ketone. The reaction was quenched by the addition of sat. aq. NH4Cl (5 mL/mmol), 
and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL/mmol). The combined organics were dried 
over MgSO4, filtered and concentrated in vacuo. Purification by FCC provided the title compound. 
General Procedure L for the synthesis of oximes from ketones 
Oxime HCl salt (equivalents specified) and NaOAc (equivalents specified) were added to a stirring 
solution of ketone (100 mol%) in EtOH (0.1 M). The reaction was run for the specified time at the 
specified temperature before being concentrated in vacuo. The crude mixture was dissolved in sat. aq. 
NaHCO3 (5 mL/mmol) and extracted with Et2O (5 mL/mmol). The combined organics were dried over 
MgSO4, filtered and concentrated in vacuo to provide the title compound which was typically pure 
enough for the following step. 
General Procedure M for the synthesis of carboxylic acid containing oximes from ketones 
Oxime HCl salt (equivalents specified) and NaOAc (equivalents specified) were added to a stirring 
solution of ketone (100 mol%) in EtOH (0.1 M). The reaction was run for the specified time at the 
specified temperature before being concentrated in vacuo. The crude mixture was dissolved in Et2O 
(5 mL/mmol) and extracted with aq. 10 wt% K2CO3 (3 × 2 mL/mmol). The combined aqueous layer 
was acidified to pH ~1 with conc. HCl and extracted with Et2O (3 × 5 mL/mmol). The combined 
organics were dried over MgSO4, filtered and concentrated in vacuo to provide the title compound, 
which was typically pure enough for the following step. 
General Procedure N for the Pd(II)-catalysed -acetoxylation of oximes 
Oxime (100 mol%), Pd(OAc)2 (equivalents specified) and PhI(OAc)2 (equivalents specified) were 
dissolved in the specified solvent and heated at the specified temperature for the specified time. The 
completed reaction mixture was filtered through celite and concentrated in vacuo. The yield was 
determined by analysis of the 1H NMR spectrum against 1,4-DNB as an internal standard. Further 
purification will be specified. 
  




4.2 Experimental procedures for the studies in Section 2.1 
1,3-Dibenzyl-1-cyclopropylurea (195a) 
 
General procedure A: N-Benzylcyclopropanamine354 (1.77 g, 11.0 mmol) and benzyl isocyanate (1.24 
mL, 10.0 mmol) were employed. The crude mixture was purified by FCC (50% EtOAc/hexane) to yield 
the title compound 195a (2.26 g, 81%) as a colourless solid; m.p. 80–82 °C (CH2Cl2/hexane); νmax / 
cm-1: 3369 (s), 1635 (s), 1504 (s), 1285 (m), 1230 (m); 1H NMR (CDCl3, 400 MHz): δ 7.35–7.21 (10H, 
m, 2 × C6-H, 2 × C7-H, C8-H, 2 × C11-H, 2 × C12-H and C13-H), 5.61 (1H, t, J = 5.5 Hz, NH), 4.58 
(2H, s, C9-H2), 4.50 (2H, d, J = 5.5 Hz, C4-H2), 2.35 (1H, tt, J = 7.0, 4.0 Hz, C2-H), 0.78–0.74 (4H, m, 
C1-H2); 13C NMR (CDCl3, 100 MHz): δ 159.1 (C3), 139.8 (C5), 139.1 (C10), 128.7, 128.5, 128.0, 
127.5, 127.3, 127.0 (C6, C7, C8, C11, C12 and C13), 50.6 (C9), 44.9 (C4), 27.8 (C2), 8.8 (C1); HRMS: 
(ESI+) Calculated for C18H21N2O: 281.1648. Found [M + H]+: 281.1662. 
1,3-Dibenzyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (196a) and 1,3-Dibenzyl-1,3-diazepane-2,4-
dione (197a) 
 
General Procedure B: Urea 195a (53.2 mg, 0.150 mmol) and [Rh(cod)2]BARF (3.5 mol%) were 
employed, and the reaction was stirred for 24 h at 100 °C. The crude mixture was purified by FCC (25% 
EtOAc/hexane) to yield the title compound 196a (37.5 mg, 82%) as a yellow oil. Analysis of the crude 
reaction mixture by 1H NMR revealed a 20:1 (196a:197a) mixture of products. An analytical sample of 
197a was also isolated for characterisation. Data for major compound 196a: νmax / cm-1: 1699 (s), 
1647 (s), 1406 (s), 1395 (s), 1212 (s); 1H NMR (CDCl3, 400 MHz): δ 7.30–7.21 (8H, m, 2 × C9-H, 
C10-H, 2 × C13-H, 2 × C14-H, C15-H), 7.05–7.03 (2H, m, 2 × C8-H), 6.03 (1H, d, J = 7.0 Hz, C5-H), 
5.54 (1H, dt, J = 7.0, 7.0 Hz, C4-H), 5.05 (2H, s, C11-H2), 4.73 (2H, s, C6-H2), 3.08 (2H, d, J = 7.0 Hz, 
C3-H2); 13C NMR (CDCl3, 100 MHz): δ 170.0 (C2), 153.9 (C1), 137.6 (C12), 136.1 (C7), 130.3 (C5), 
128.7. 128.4, 128.1, 127.8, 127.6, 127.3 (C8, C9, C10, C13, C14, C15), 112.7 (C4), 53.0 (C6), 47.9 
(C11), 35.0 (C3); HRMS: (ESI+) Calculated for C19H18N2NaO2: 329.1260. Found [M + Na]+: 329.1249. 
The structure of this compound was confirmed by 2D NMR analysis. Key HMBC correlations are 
included on the compound structure above. Data for minor compound 197a: νmax / cm-1: 1694 (s), 




1656 (s), 1421 (s), 1214 (s), 1158 (s); 1H NMR (CDCl3, 400 MHz): δ 7.38–7.23 (8H, m, 2 × C9-H, 
C10-H, 2 × C13-H, 2 × C14-H, C15-H), 7.09–7.06 (2H, m, 2 × C8-H), 4.94 (2H, s, C11-H2), 4.60 (2H, 
s, C6-H2), 3.18 (2H, t, J = 7.0 Hz, C5-H2), 2.54 (2H, t, J = 7.0 Hz, C3-H2), 1.86 (2H, tt, J = 7.0, 7.0 Hz, 
C4-H2); 13C NMR (CDCl3, 100 MHz): δ 171.3 (C2), 157.6 (C1), 137.8 (C12), 136.7 (C7), 128.8, 128.7, 
128.5, 127.8, 127.5 (C8, C9, C10, C13, C14, C15), 51.8 (C6), 46.8 (C11), 45.6 (C5), 33.7 (C3), 25.7 
(C4); HRMS: (ESI+) Calculated for C19H20N2NaO2: 331.1417. Found [M + Na]+: 331.1416. The 
structure of this compound was confirmed by 2D NMR. Key HMBC correlations are included on the 
compound structure above. 
1-Benzyl-3-butyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (196b) and 3-Benzyl-1-butyl-1,3-
diazepane-2,4-dione (197b) 
 
General Procedure B: Urea 195b was synthesised by McCreanor103: Urea 195b (37.0 mg, 0.150 
mmol) and [Rh(cod)2]BARF (3.5 mol%) were employed, and the reaction was stirred for 25 h at 100 
°C. The crude mixture was purified by FCC (30% EtOAc/hexane) to yield the title compound 196b 
(33.3 mg, 82%) as a yellow oil. Analysis of the crude reaction mixture by 1H NMR revealed a 24:1 
(196b:197b) mixture of products. The minor product 197b was not isolated. Data for major compound 
196b: νmax / cm-1: 2958 (m), 1699 (s), 1647 (s), 1408 (s), 1212 (s); 1H NMR (CDCl3, 400 MHz): δ 7.29–
7.20 (5H, m, 2 × C12-H, 2 × C13-H, C14-H), 6.04 (1H, d, J = 7.0 Hz, C5-H), 5.56 (1H, dt, J = 7.0, 7.0 
Hz, C4-H), 5.00 (2H, s, C10-H2), 3.55 (2H, t, J = 7.0 Hz, C6-H2), 3.09 (2H, d, J = 7.0 Hz, C3-H2), 1.56–
1.48 (2H, m, C7-H2), 1.31–1.22 (2H, m, C8-H2), 0.90 (3H, t, J = 7.0 Hz, C9-H3); 13C NMR (CDCl3, 
100 MHz): δ 170.1 (C2), 153.6 (C1), 137.7 (C11), 130.7 (C5), 128.3, 127.8, 127.1 (C12, C13, C14), 
112.4 (C4), 49.9 (C6), 48.0 (C10), 34.9 (C3), 30.2 (C7), 19.9 (C8), 13.7 (C9); HRMS: (ESI+) Calculated 
for C16H20N2NaO2: 295.1417. Found [M + Na]+: 295.1419. Data for minor compound 197b: 
Characteristic signals only: 1H NMR (CDCl3, 400 MHz): δ 2.60 (2H, t, J = 7.0 Hz, C3-H2). 
1-Benzyl-3-(naphthalen-1-yl)-3,6-dihydro-1H-1,3-diazepine-2,7-dione (196c) and 3-Benzyl-1-
(naphthalen-1-yl)-1,3-diazepane-2,4-dione (197c) 
 




General Procedure B: Urea 195c was synthesised by McCreanor103: Urea 195c (47.5 mg, 0.150 mmol) 
and [Rh(cod)2]BARF (5.0 mol%) were employed, and the reaction was stirred for 72 h at 100 °C. The 
crude mixture was purified by FCC (30% EtOAc/hexane) to yield the title compound 196c (31.0 mg, 
60%) as a yellow oil. Analysis of the crude reaction mixture by 1H NMR revealed a 16:1 (196c:197c) 
mixture of products. The minor product 197c was not isolated. Data for major compound 196c: νmax 
/ cm-1: 2960 (s), 1701 (s), 1652 (s), 1394 (s), 1201 (s), 1141 (m); 1H NMR (CDCl3, 400 MHz): δ 7.88–
7.86 (2H, m, 2 × ArCH), 7.49–7.45 (2H, m, 2 × ArCH), 7.40–7.35 (5H, m, 2 × C9-H, 2 × C10-H, 
C11-H), 7.28–7.24 (2H, m, 2 × ArCH), 6.93 (1H, d, J = 8.5 Hz, 1 × ArCH), 6.11 (1H, dd, J = 7.0, 1.0 
Hz, C5-H), 5.65 (1H, dt, J = 7.0, 7.0 Hz, C4-H), 5.36 (1H, d, J = 14.5 Hz, 1 × C7-H), 4.90 (1H, d, J = 
14.5 Hz, 1 × C7-H), 3.50–3.40 (2H, m, C3-H2); 13C NMR (CDCl3, 100 MHz): δ 169.9 (C2), 153.6 (C1), 
137.4 (C8), 137.3 (C6), 134.6 (ArC), 131.6 (C5), 129.4 128.8, 128.7, 128.5, 128.5, 127.5 (C9, C10, 
C11, 3 × ArC), 127.3, 126.5, 126.0, 125.5, 121.8 (5 × ArCH), 111.1 (C4), 48.0 (C7), 35.0 (C3); HRMS: 
(ESI+) Calculated for C22H18N2NaO2: 365.1260. Found [M + Na]+: 365.1265. Data for minor 
compound 197c: Characteristic signals only: 1H NMR (CDCl3, 400 MHz): δ 3.26 (2H, t, J = 7.0 Hz, 
C5-H2). 
3-Benzyl-1-butyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (196d) and 1-Benzyl-3-butyl-1,3-
diazepane-2,4-dione (197d) 
 
General Procedure B: Urea 195d was synthesised by McCreanor103: Urea 195d (37.0 mg, 
0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were employed, and the reaction was stirred for 24 h at 
100 °C. The crude mixture was purified by FCC (20% EtOAc/hexane) to yield the title compound 196d 
(35.2 mg, 85%) as a yellow oil. Analysis of the crude reaction mixture by 1H NMR revealed a 20:1 
(196d:197d) mixture of products. The minor product 197d was not isolated. Data for major compound 
196d: νmax / cm-1: 2958 (m), 1698 (s), 1645 (s), 1407 (s), 1214 (s); 1H NMR (CDCl3, 400 MHz): δ 7.36–
7.26 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 6.10 (1H, d, J = 7.0 Hz, C5-H), 5.52 (1H, dt, J = 7.0, 7.0 
Hz, C4-H), 4.79 (2H, s, C6-H2), 3.80 (2H, t, J = 7.0 Hz, C11-H2), 2.99 (2H, d, J = 7.0 Hz, C3-H2), 1.55 
(2H, tt, J = 7.0, 7.0 Hz, C12-H2), 1.27 (2H, tq, J = 7.0, 7.0 Hz, C13-H2), 0.90 (3H, t, J = 7.0 Hz, C14-H3); 
13C NMR (CDCl3, 100 MHz): δ 170.1 (C2), 154.4 (C1), 136.6 (C7), 130.5 (C5), 128.8, 127.9, 127.8 
(C8, C9, C10), 113.0 (C4), 53.2 (C6), 45.4 (C11), 35.2 (C3), 30.4 (C12), 20.1 (C13), 13.8 (C14); 
HRMS: (ESI+) Calculated for C16H20N2NaO2: 295.1417. Found [M + Na]+: 295.1421. Data for minor 
compound 197d: Characteristic signals only:  1H NMR (CDCl3, 400 MHz): δ 4.66 (2H, s, C6-H2), 




3.75 (2H, t, J = 7.0 Hz, C11-H2), 3.36 (2H, t, J = 7.0 Hz, C5-H2), 2.50 (2H, t, J = 7.0 Hz, C3-H2); 
HRMS: (ESI+) Calculated for C16H22N2NaO2: 297.1573. Found [M + Na]+: 297.1575. 
3-Benzyl-1-phenyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (196e) and 1-Benzyl-3-phenyl-1,3-
diazepane-2,4-dione (197e) 
 
General Procedure B: Urea 195e was synthesised by McCreanor103: Urea 195e (40.0 mg, 0.150 mmol) 
and [Rh(cod)2]BARF (7.5 mol%) were employed, and the reaction was stirred for 70 h at 100 °C. The 
crude mixture was purified by FCC (15–25% EtOAc/hexane) to yield the title compound 196e 
(12.2 mg, 28%) as a yellow oil. Analysis of the crude reaction mixture by 1H NMR revealed a 5:1 
(196e:197e) mixture of products. The minor product 197e was not isolated. Data for major compound 
196e: νmax / cm-1: 2987 (s), 1705 (s), 1652 (s), 1403 (s), 1392 (s), 1226 (s); 1H NMR (CDCl3, 400 MHz): 
δ 7.45–7.19 (10H, m, 2 × C8-H, 2 × C9-H, C10-H, 2 × C12-H, 2 × C13-H, C14-H), 6.26 (1H, d, J = 
7.0 Hz, C5-H), 5.66 (1H, dt, J = 7.0, 7.0 Hz, C4-H), 4.81 (2H, s, C6-H2), 3.17 (2H, d, J = 7.0 Hz, 
C3-H2); 13C NMR (CDCl3, 100 MHz): δ 170.5 (C2), 153.7 (C1), 138.8 (C11), 136.4 (C7), 130.8 (C5), 
129.1, 128.8, 128.5, 128.3, 128.1, 128.0 (C8, C9, C10, C12, C13, C14), 113.3 (C4), 53.5 (C6), 35.2 
(C3); HRMS: (ESI+) Calculated for C18H16N2NaO2: 315.1104. Found [M + Na]+: 315.1092. Data for 
minor compound 197e: Characteristic signals only:  1H NMR (CDCl3, 400 MHz): δ 3.26 (2H, t, J = 
7.0 Hz, C5-H2). 
3-Benzyl-1-cyclohexyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (196g) and 1-Benzyl-3-cyclohexyl-
1,3-diazepane-2,4-dione (197g) 
 
General Procedure B: Urea 195g was synthesised by McCreanor103: Urea 195g (40.9 mg, 0.150 mmol) 
and [Rh(cod)2]BARF (7.5 mol%) were employed, and the reaction was stirred for 24 h at 100 °C. The 
crude mixture was purified by FCC (20% EtOAc/hexane) to yield the title compound 196g (31.0 mg, 
69%) as a yellow oil. Analysis of the crude reaction mixture by 1H NMR revealed a 23:1 (8d:9d) 
mixture of products. The minor product 197g was not isolated. Data for major compound 196d: νmax 
/ cm-1: 2928 (s), 1695 (s), 1648 (s), 1406 (s), 1394 (s), 1223 (s), 1049 (s); 1H NMR (CDCl3, 400 MHz): 
δ 7.36–7.24 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 6.09 (1H, d, J = 7.0 Hz, C5-H), 5.55 (1H, dt, J = 7.0, 




7.0 Hz, C4-H), 4.77 (2H, s, C6-H2), 4.14 (1H, tt, J = 12.0, 3.5 Hz, C11-H), 2.93 (2H, d, J = 7.0 Hz, 
C3-H2), 2.08–1.98 (2H, m, 2 × C12-H), 1.81–1.63 (5H, m, 2 × C12-H, 2 × C13-H, 1 × C14-H), 1.38–
1.11 (3H, m, 2 × C13-H, 1 × C14-H); 13C NMR (CDCl3, 100 MHz): δ 17.5 (C2), 153.9 (C1), 136.5 
(C7), 130.3 (C5), 128.8, 127.9, 127.8 (C8, C9, C10), 114.3 (C4), 57.5 (C11), 52.7 (C6), 35.4 (C3), 29.9 
(C12), 26.3 (C13), 25.4 (C14); HRMS: (ESI+) Calculated for C18H22N2NaO2: 321.1573. Found [M + 
Na]+: 321.1568. Data for minor compound 197g: Characteristic signals only: 1H NMR (CDCl3, 400 
MHz): δ 4.64 (2H, s, C6-H2). 
3-Benzyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (196h) and 1-Benzyl-1,3- diazepane-2,4-dione 
(196h) 
 
General Procedure B: Urea 195h was synthesised by McCreanor103: Urea 195h (28.5 mg, 
0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were employed, and the reaction was stirred for 72 h at 
100 °C. The crude mixture was purified by FCC (45% EtOAc/hexane) to yield the title compound 196h 
(17.5 mg, 54%) as a beige oil. Analysis of the crude reaction mixture by 1H NMR revealed an 8:1 
(196h:197h) mixture of products. The minor product 197h was not isolated. Data for major compound 
196h: νmax / cm-1: 3215 (m), 2987 (s), 1653 (s), 1412 (s), 1388 (s), 1260 (s), 1075 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.50 (1H, br. s, NH), 7.38–7.24 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 6.09 (1H, d, J = 
7.5 Hz, C5-H), 5.42 (1H, dt, J = 7.5, 7.0 Hz, C4-H), 4.78 (2H, s, C6-H2), 3.06 (2H, d, J = 7.0 Hz, 
C3-H2); 13C NMR (CDCl3, 100 MHz): δ 171.1 (C2), 151.2 (C1), 136.2 (C7), 130.8 (C5), 128.9, 128.0, 
127.9 (C8, C9, C10), 110.4 (C4), 52.6 (C6), 34.3 (C3); HRMS: (ESI+) Calculated for C12H12N2NaO2: 
239.0790. Found [M + Na]+: 239.0787. Data for minor compound 197h: Characteristic signals only: 
1H NMR (CDCl3, 400 MHz): δ 3.41 (2H, t, J = 7.0 Hz, C5-H2). 
1-Benzyl-1-cyclopropyl-3-(4-methoxyphenyl)urea (195k) 
 
General procedure A: Benzylcyclopropylamine (700 mg, 4.80 mmol) and 4-methoxyphenyl 
isocyanate (0.560 mL, 4.30 mmol) were employed to yield a crude mixture, which was purified by FCC 
(25% EtOAc/hexane) to yield the title compound (1.17 g, 91%) as a colourless solid; m.p. 88–90 °C 
(CH2Cl2/hexane) νmax / cm-1: 3352 (m), 1639 (s), 1510 (s), 1412 (m), 1225 (s), 1170 (m), 1035 (s); 1H 




NMR (500 MHz, CDCl3): δ 7.28–7.32 (5H, m, 2 × C11-H, 2 × C12-H, C13-H), 7.37 (2H, m, 2 × C6-H), 
7.21 (1H, br. s, NH), 6.86 (2H, m, 2 × C5-H), 4.62 (2H, s, C9-H2), 3.79 (3H, s, C8-H3), 2.50 (1H, m, 
C2-H), 0.94–0.86 (4H, m, 4 × C1-H2); 13C NMR (125 MHz, CDCl3): δ 156.6 (C3), 155.8 (C7), 138.8 
(C10), 132.2 (C4), 128.6, 128.1 (C11, C12), 127.2 (C13), 121.8 (C6), 114.3 (C5), 55.6 (C8), 50.5 (C9), 
28.2 (C2), 9.1 (C1); m/z (ESI+) HRMS: Calculated for C18H20N2NaO2: 319.1417. Found [M + Na]+: 
319.1422. 
3-Benzyl-1-phenyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (196k) and 1-Benzyl-3-(4-
methoxyphenyl)-1,3-diazepane-2,4-dione (197k) 
 
General Procedure B: Urea 195k (44.5 mg, 0.150 mmol) and Rh(cod)2BARF (7.5 mol%) were 
employed and the reaction was stirred for 90 h at 100 °C. The crude mixture was purified by FCC (40% 
EtOAc/hexane) to yield the title compound 196k (13.5 mg, 28%) as a colourless oil. Analysis of the 
crude reaction mixture by 1H NMR revealed a 5:1 (196k:197k) mixture of products. The minor product 
197k was not isolated. Data for major compound 196k:  νmax / cm-1: 2934 (m), 1705 (m), 1652 (s), 
1509 (s), 1391 (s), 1230 (s); 1H NMR (500 MHz, CDCl3): δ 7.37–7.29 (5H, m, 2 × C8-H, 2 × C9-H, 
C10-H), 7.12 (2H, m, 2 × C13-H), 6.94 (2H, m, 2 × C12-H), 6.25 (1H, d, J = 7.0 Hz, C5-H), 5.65 (1H, 
dd, J = 7.0, 7.0 Hz, C4-H), 4.80 (2H, s, C6-H2), 3.81 (3H, s, C15-H3), 3.16 (2H, d, J = 7.0 Hz, C3-H2); 
13C NMR (125 MHz, CDCl3): δ 170.9 (C2), 159.3 (C14), 154.1 (C1), 136.6 (C7), 131.6 (C11), 131.0 
(C10), 129.6 (C13), 129.0, 128.2 (C8, C9), 114.6 (C12), 113.5 (C4), 55.5 (C15), 53.6 (C6), 35.3 (C3); 
m/z (ESI+) HRMS: Calculated for C19H18N2NaO3: 345.1210. Found [M + Na]+: 345.1215. 
tert-Butyl N-(benzylcarbamoyl)-N-cyclopropylglycinate (195l) 
 
To a solution of cyclopropylamine (1.04 mL, 15.0 mmol) and NEt3 (2.79 mL, 20.0 mmol) in CH2Cl2 
(20 mL) was added t-butyl bromoacetate (1.48 mL, 10.0 mmol) at room temperature. The reaction 
mixture was stirred for 7 h before cooling to 0 °C. Benzyl isocyanate (1.84 mL, 20.0 mmol) was added 
and the reaction mixture was warmed to room temperature with stirring for a further 17 h. The resulting 
solution was diluted with CH2Cl2 (25 mL) and washed with water (30 mL), 1 M aq. HCl (30 mL), sat. 




aq. NaHCO3 (30 mL) and brine (30 mL) before being dried over Na2SO4 and concentrated in vacuo. 
The crude product was purified by FCC (40–50% EtOAc/hexane) to yield the title compound 195l (1.50 
g, 49%) as a colourless solid; m.p. 70–72 °C (CH2Cl2/hexane); νmax / cm-1: 3359 (s), 2973 (w), 1749 (s), 
1639 (s), 1526 (s), 1220 (s), 1151 (s); 1H NMR (CDCl3, 400 MHz): δ 7.36–7.31 (4H, m, 2 × C6-H, 2 × 
C7-H), 7.26 (1H, m, C8-H), 5.67 (1H, br. s, NH), 4.49 (2H, d, J = 5.5 Hz, C4-H2), 3.99 (2H, s, C9-H2), 
2.71 (1H, m, C2-H), 1.47 (9H, s, C12-H3), 0.80 (2H, m, 2 × C1-H), 0.73 (2H, m, 2 × C1-H); 13C NMR 
(CDCl3, 100 MHz): δ 170.1 (C10), 158.9 (C3), 139.7 (C5), 128.7 (C6), 127.6 (C7), 127.3 (C8), 81.5 
(C11), 50.1 (C9), 44.8 (C4), 28.7 (C2), 28.3 (C12), 8.8 (C1); HRMS: (ESI+) Calculated for 
C17H24N2NaO3: 327.1679. Found [M + H]+: 327.1684. 
tert-Butyl 2-(3-benzyl-2,4-dioxo-2,3,4,5-tetrahydro-1H-1,3-diazepin-1-yl)acetate (196l) and tert-
Butyl 2-(3-benzyl-2,4-dioxo-1,3-diazepan-1-yl)acetate (197l) 
 
General Procedure B: Urea 195l (45.7 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were 
employed, and the reaction was stirred for 48 h at 100 °C. The crude mixture was purified by FCC (20% 
EtOAc/hexane) to yield the title compound 196l (32.4 mg, 65%) as a colourless oil. Analysis of the 
crude reaction mixture by 1H NMR revealed a 23:1 (196l:197l) mixture of products. The minor product 
197l was not isolated. Data for major compound 196l: m.p. 113–116 °C (CH2Cl2/hexane); νmax / cm-1: 
2976 (w), 1747 (s), 1696 (s), 1647 (s), 1438 (s), 1219 (s), 1152 (s); 1H NMR (CDCl3, 400 MHz): δ 
7.30–7.19 (5H, m, 2 × C12-H, 2 × C13-H, C14-H), 6.02 (1H, d, J = 7.0 Hz, C5-H), 5.61 (1H, dt, J = 
7.0, 7.0 Hz, C4-H), 5.00 (2H, s, C10-H2), 4.14 (2H, s, C6-H2), 3.29 (2H, d, J = 7.0 Hz, C3-H2), 1.44 
(9H, s, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 170.5 (C2), 167.3 (C7), 154.3 (C1), 137.7 (C11), 130.9 
(C5), 128.5, 127.9, 127.3 (C12, C13, C14), 113.7 (C4), 82.7 (C8), 52.0 (C6), 48.2 (C10), 35.1 (C3), 
28.2 (C9); HRMS: (ESI+) Calculated for C18H22N2NaO4: 353.1472. Found [M + Na]+: 353.1476. Data 
for minor compound 197l: Characteristic signals only: 1H NMR (CDCl3, 400 MHz): δ 2.83 (2H, t, J 
= 7.0 Hz, C5-H2). 
3-Benzyl-1-cyclopropyl-1-(cyclopropylmethyl)urea (195m) 
 




(Bromomethyl)cyclopropane (0.970 mL, 10.0 mmol) was added to a stirring solution of 
cyclopropylamine (2.08 mL, 30.0 mmol) in DMSO (25 mL) at room temperature. The reaction was 
stirred for 20 h before being diluted with CH2Cl2 (200 mL) and washed with water (2 × 200 mL) and 
brine (200 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo (care was 
taken as the secondary amine was presumed to be volatile). The crude amine was dissolved in CH2Cl2 
(33 mL) and cooled to 0 °C before adding benzyl isocyanate (1.12 mL, 9.09 mmol). The reaction 
mixture was warmed to room temperature and stirred for 16 h. The reaction mixture was concentrated 
in vacuo to yield a crude mixture which was purified by FCC (25% EtOAc/hexane) to yield the title 
compound 195m (1.10 g, 45%) as a colourless solid; m.p. 74–75 °C (CH2Cl2/hexane); νmax / cm-1: 3375 
(s), 2922 (w), 1640 (s), 1628 (s), 1509 (s), 1274 (s); 1H NMR (CDCl3, 400 MHz): δ 7.30–7.18 (5H, m, 
2 × C6-H, 2 × C7-H, C8-H), 5.54 (1H, br. s, NH), 4.42 (2H, d, J = 6.0 Hz, C4-H2), 3.18 (2H, d, J = 
7.0 Hz, C9-H2), 2.54 (1H, m, C2-H), 1.00 (1H, m, C10-H), 0.76 (2H, m, C1-H2), 0.65 (2H, m, C1-H2), 
0.41 (2H, m, C11-H2), 0.20 (2H, m, C11-H2); 13C NMR (CDCl3, 100 MHz): δ 159.1 (C3), 140.0 (C5), 
128.7 (C7), 127.6 (C6), 127.2 (C8), 51.4 (C9), 44.8 (C4), 27.7 (C2), 10.1 (C10), 9.1 (C1), 3.5 (C11); 
HRMS: (ESI+) Calculated for C15H20N2NaO: 267.1468. Found [M + Na]+: 267.1470. 
1-Benzyl-3-(cyclopropylmethyl)-3,6-dihydro-1H-1,3-diazepine-2,7-dione (196m) and 3-Benzyl-1-
(cyclopropylmethyl)-1,3-diazepane-2,4-dione (197m) 
 
General Procedure B: Urea 195m (36.7 mg, 0.150 mmol) and [Rh(cod)2]BARF (3.5 mol%) were 
employed, and the reaction was stirred for 24 h at 100 °C. The crude mixture was purified by FCC (20% 
EtOAc/hexane) to yield the title compound 196m (35.0 mg, 86%) as a brown oil. Analysis of the crude 
reaction mixture by 1H NMR revealed a 20:1 (196m:197m) mixture of products. The minor product 
197m was not isolated. Data for major compound 196m: νmax / cm-1: 3003 (w), 1699 (s), 1648 (s), 
1409 (s), 1214 (s); 1H NMR (CDCl3, 400 MHz): δ 7.31–7.19 (5H, m, 2 × C11-H, 2 × C12-H, C13-H), 
6.13 (1H, d, J = 7.0 Hz, C5-H), 5.59 (1H, dt, J = 7.0, 7.0 Hz, C4-H), 5.01 (2H, s, C9-H2), 3.46 (2H, d, 
J = 7.0 Hz, C6-H2), 3.14 (2H, d, J = 7.0 Hz, C3-H2), 1.04 (1H, m, C7-H), 0.49 (2H, m, 2 × C8-H), 0.26 
(2H, m, C8-H); 13C NMR (CDCl3, 100 MHz): δ 170.4 (C2), 153.9 (C1), 137.9 (C10), 130.9 (C5), 128.4, 
127.9, 127.2 (C11, C12, C13), 112.7 (C4), 54.5 (C6), 48.1 (C9), 35.1 (C3), 10.2 (C7), 3.6 (C8); HRMS: 
(ESI+) Calculated for C16H18N2NaO2: 293.1260. Found [M + Na]+: 293.1270. Data for minor 
compound 9i: Characteristic signals only: 1H NMR (CDCl3, 400 MHz): δ 2.65 (2H, t, J = 7.5 Hz, 
C3-H2). 
 






General procedure A: Cyclopropylamine (0.762 mL, 11.0 mmol) and benzyl isocyanate (1.09 mL, 
10.0 mmol) were employed. The crude mixture was purified by recrystallisation (CH2Cl2/hexane) to 
yield the title compound 202a (1.58 g, 83%) as a colourless solid; m.p. 139–140 °C (CH2Cl2/hexane); 
νmax / cm-1: 3309 (s), 1623 (s), 1574 (s), 1453 (m), 1255 (s); 1H NMR (CDCl3, 400 MHz): δ 7.37–7.25 
(2 × C6-H, 2 × C7-H, C8-H), 5.31 (1H, br. s, NH), 4.79 (1H, br. s, NH), 4.47 (2H, d, J = 6.0 Hz, C4-H2), 
2.46 (1H, tt, J = 7.0, 3.5 Hz, C2-H), 0.76–0.71 (2H, m, 2 × C1-H), 0.60–0.57 (2H, m, 2 × C1-H); 13C 
NMR (CDCl3, 100 MHz): δ 158.9 (C3), 139.4 (C5), 128.6, 127.4, 127.3 (C6, C7, C8), 44.2 (C4), 22.4 
(C2), 7.6 (C1); HRMS: (ESI+) Calculated for C11H14N2NaO: 213.0998. Found [M + Na]+: 213.0997. 
The spectroscopic properties of this compound were consistent with the data available in the 
literature.355 
3-Benzyl-1,3-diazepane-2,4-dione (204a) and 1-Benzyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione 
(203a) 
 
General Procedure B: Urea 202a (28.5 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were 
employed, and the reaction was stirred for 23 h at 90 °C. The crude mixture was purified by FCC (30% 
EtOAc/hexane) to yield the title compound 204a (20.3 mg, 62%, 1:4, 203a:204a) as a yellow oil. 
Analysis of the crude reaction mixture by 1H NMR revealed a 1:4 (203a:204a) mixture of products. 
Data for the mixture of compounds: νmax / cm-1: 3300 (m), 2987 (s), 1705 (s), 1537 (s), 1381 (s), 1255 
(s). Data for major compound 204a: 1H NMR (CDCl3, 400 MHz): δ 8.79 (1H, br. s, NH), 7.35–7.21 
(5H, m, 2 × C8-H, 2 × C9-H, C10-H), 4.50 (2H, d, J = 6.0 Hz, C6-H2), 3.89 (2H, t, J = 7.0 Hz, C5-H2), 
2.61 (2H, t, J = 7.0 Hz, C3-H2), 2.04 (2H, tt, J = 7.0, 7.0 Hz, C4-H2); 13C NMR (CDCl3, 100 MHz): δ 
177.1 (C2), 153.0 (C1), 138.3 (C7), 128.6, 127.4, 127.3 (C8, C9, C10), 45.7 (C5), 43.8 (C6), 33.4 (C3), 
17.1 (C4); HRMS: (ESI+) Calculated for C12H14N2NaO2: 241.0947. Found [M + Na]+: 241.0963. The 
structure of this compound was confirmed by 2D NMR. Key HMBC correlations are included on the 
compound structure above. Data for minor compound 203a: 1H NMR (CDCl3, 400 MHz): δ 8.79 (1H, 
br. s, NH), 7.35–7.21 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 6.12 (1H, dd, J = 7.0, 4.0 Hz, C5-H), 5.44 
(1H, dt, J = 7.0, 7.0 Hz, C4-H), 5.01 (2H, s, C6-H2), 3.20 (2H, d, J = 7.0 Hz, C3-H2); 13C NMR (CDCl3, 




100 MHz): δ 169.0 (C2), 154.2 (C1), 137.5 (C7), 128.3, 127.9, 127.3 (C8, C9, C10), 126.0 (C5), 110.1 
(C4), 48.0 (C6), 35.2 (C3); HRMS: (ESI+) Calculated for C12H12N2O2: 216.0899. Found [M]+: 
216.0898. The structure of this compound was confirmed by 2D NMR. Key HMBC correlations are 
included on the compound structure above. 
1-Butyl-3-cyclopropylurea (202b) 
 
General procedure A: Cyclopropylamine (0.760 mL, 11.0 mmol) and n-butyl isocyanate (1.13 mL, 
10.0 mmol) were employed. The crude mixture was purified by FCC (75% EtOAc/hexane) to yield the 
title compound 202b (1.29 g, 83%) as a colourless solid; m.p. 73–74 °C (CH2Cl2/hexane); νmax / cm-1: 
3305 (m), 2931 (m), 1626 (s), 1564 (s), 1250 (m), 1224 (m); 1H NMR (CDCl3, 400 MHz): δ 5.00 (1H, 
br. s, NH), 4.86 (1H, br. s, NH), 3.22 (2H, m, C4-H2), 2.41 (1H, m, C2-H), 1.49 (2H, m, C5-H2), 1.35 
(2H, m, C6-H2), 0.92 (3H, t, J = 7.0 Hz, C7-H3), 0.73–0.52 (4H, m, C1-H2); 13C NMR (CDCl3, 
100 MHz): δ 159.3 (C3), 40.1 (C4), 32.5 (C5), 22.5 (C2), 20.2 (C6), 13.9 (C7), 7.6 (C1); HRMS: (ESI+) 
Calculated for C8H16N2NaO: 179.1155. Found [M + H]+: 179.1160. 
3-Butyl-1,3-diazepane-2,4-dione (204b) and 1-Butyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione 
(203b) 
 
General Procedure B: Urea 202b (23.4 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were 
employed, and the reaction was stirred for 47 h at 90 °C. The crude mixture was purified by FCC (40% 
EtOAc/hexane) to yield the title compound 204b (19.8 mg, 72%, 5:1, 204b:203b) as a yellow oil. 
Analysis of the crude reaction mixture by 1H NMR revealed a 4:1 (204b:203b) mixture of products. 
Data for the mixture of compounds: νmax / cm-1: 3307 (w), 2958 (w), 1708 (s), 1541 (s), 1381 (s), 
1255 (s). Data for the major product 204b: 1H NMR (CDCl3, 400 MHz): δ 8.38 (1H, br. s, NH), 3.85 
(2H, t, J = 7.0 Hz, C5-H2), 3.29 (2H, m, C6-H2), 2.59 (2H, t, J = 8.0 Hz, C3-H2), 2.02 (2H, m, C4-H2), 
1.52 (2H, m, C7-H2), 1.36 (2H, m, C8-H2), 0.92 (3H, t, J = 7.0 Hz, C9-H2); 13C NMR (CDCl3, 
100 MHz): δ 177.1 (C2), 153.1 (C1), 45.8 (C5), 39.7 (C6), 33.6 (C3), 30.5 (C7), 20.2 (C8), 17.2 (C4), 
13.9 (C9); HRMS: (ESI+) Calculated for C9H16N2NaO2: 207.1104. Found [M + Na]+: 207.1100. Data 
for the minor product 203b: Characteristic signals only:  1H NMR (CDCl3, 400 MHz): δ 7.49 (1H, 




br. s, NH), 6.15 (1H, dd, J = 7.0, 7.0 Hz, C5-H), 5.42 (1H, m, C4-H), 3.77 (2H, t, J = 7.5 Hz, C6-H2), 
3.14 (2H, d, J = 7.0 Hz, C3-H2); 13C NMR (CDCl3, 100 MHz): δ 169.3 (C2), 154.9 (C1), 126.1 (C5), 
110.4 (C4), 45.3 (C6), 35.5 (C3), 31.8 (C7), 20.2 (C8), 13.9 (C9). 
1-Cyclohexyl-3-cyclopropylurea (202c) 
 
General Procedure A: Cyclopropylamine (0.760 mL, 11.0 mmol) and cyclohexyl isocyanate (1.28 
mL, 10.0 mmol) were employed to yield the title compound 202c (1.67 g, 92%) as a colourless solid; 
m.p. 125–126 °C (CH2Cl2/hexane); νmax / cm-1: 3325 (s), 2926 (w), 1629 (s), 1568 (s), 1253 (w); 1H 
NMR (CDCl3, 400 MHz): δ 4.84 (1H, br. s, NH), 4.60 (1H, br. s, NH), 3.64 (1H, m, C4-H), 2.41 (1H, 
m, C2-H), 1.95 (2H, m, C5-H2), 1.74–1.66 (2H, m, C6-H2), 1.64–1.57 (2H, m, C7-H2), 1.43–1.33 (2H, 
m, C6-H2), 1.23–1.10 (2H, m, C5-H2), 0.73 (2H, m, 2 × C1-H), 0.56 (2H, m, 2 × C1-H); 13C NMR 
(CDCl3, 100 MHz): δ 158.5 (C3), 48.8 (C4), 34.0 (C5), 25.8 (C7), 25.1 (C6), 22.5 (C2), 7.7 (C1); 
HRMS: (ESI+) Calculated for C10H18N2NaO: 205.1317. Found [M + Na]+: 205.1311. 
3-Cyclohexyl-1,3-diazepane-2,4-dione (204c) and 1-Cyclohexyl-3,6-dihydro-1H-1,3-diazepine-
2,7-dione (203c) 
 
General Procedure B: Urea 202c (27.3 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were 
employed, and the reaction was stirred for 51 h at 90 °C. The crude mixture was purified by FCC (25% 
EtOAc/hexane) to yield the title compound 204c (21.2 mg, 67%) as a pale yellow oil. Analysis of the 
crude reaction mixture by 1H NMR revealed a 12:1 (204c:203c) mixture of products. The minor product 
203c was not isolated. Data for the major product 204c: νmax / cm-1: 3291 (br.), 2929 (br.), 2854 (br.), 
17.6 (s), 1534 (s), 1380 (m), 1243 (m), 1219 (m);  1H NMR (CDCl3, 400 MHz): δ 8.35 (1H, br. m, NH), 
3.84 (2H, t, J = 7.0 Hz, C5-H2), 3.71 (1H, m, C6-H), 2.58 (2H, t, J = 8.0 Hz, C3-H2), 2.00 (2H, tt, J = 
8.0, 7.0 Hz, C4-H2), 1.92–1.88 (2H, m, 2 × C7-H), 1.72–1.67 (2H, m, 2 × C8-H), 1.60–1.55 (1H, m, 1 
× C9-H), 1.41–1.31 (2H, m, 2 × C8-H), 1.29–1.15 (3H, m, 2 × C7-H, 1 × C9-H); 13C NMR (CDCl3, 
125 MHz): δ 177.1 (C2), 152.2 (C1), 48.7 (C6), 45.8 (C5), 33.7 (C3), 33.1 (C7), 25.7 (C9), 24.8 (C8), 
17.1 (C4); HRMS: (ESI+) Calculated for C11H18N2NaO2: 233.1260. Found [M + Na]+: 233.1256. Data 




for the minor product 203c: Characteristic signals only:  1H NMR (CDCl3, 400 MHz): δ 6.16 (1H, 
dt, J = 6.0, 2.0 Hz, C4-H). 
1-(tert-Butyl)-3-cyclopropylurea (202d) 
 
General Procedure A: Cyclopropylamine (0.380 mL, 5.50 mmol) and tert-butyl isocyanate (0.430 mL, 
5.00 mmol) were employed to yield the title compound 202d (461 mg, 59%) as a colourless solid; νmax 
/ cm-1: 3323 (br.), 2965 (m), 1635 (s), 1557 (s), 1453 (m), 1360 (m), 1276 (m), 1218 (s); 1H NMR 
(CDCl3, 400 MHz): δ 4.86 (1H, br. s, NH), 4.54 (1H, br. s, NH), 2.38 (1H, m, C2-H), 1.35 (9H, s, 
C5-H3), 0.70 (2H, m, 2 × C1-H), 0.53 (2H, m, 2 × C1-H); 13C NMR (CDCl3, 100 MHz): δ 158.4 (C3), 
50.5 (C4), 29.6 (C5), 22.7 (C2), 7.6 (C1); HRMS: (ESI+) Calculated for C8H16N2NaO: 179.1155. Found 
[M + Na]+: 179.1155. 
3-(tert-Butyl)-1,3-diazepane-2,4-dione (204d) and 1-(tert-Butyl)-3,6-dihydro-1H-1,3-diazepine-
2,7-dione (203d) 
 
General Procedure B: Urea 202d (23.4 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were 
employed, and the reaction was stirred for 48 h at 90 °C. The crude mixture was purified by FCC (50% 
EtOAc/hexane) to yield the title compound 204d (21.2 mg, 53%, 5:1, 204d:203d) as a pale yellow oil. 
Analysis of the crude reaction mixture by 1H NMR revealed a 4:1 (204d:203d) mixture of products. 
Data for the mixture of compounds: νmax / cm-1: 3288 (br.), 2966 (br.), 1710 (s), 1547 (s), 1383 (m), 
1364 (m), 1263 9m), 1201 (m). Data for the major product 204d: 1H NMR (CDCl3, 400 MHz): δ 
8.41 (1H, br. s, NH), 3.82 (2H, t, J = 7.0 Hz, C5-H2), 2.58 (2H, t, J = 8.0 Hz, C3-H2), 1.99 (2H, tt, J = 
8.0, 7.0 Hz, C4-H2), 1.37 (9H, s, C7-H3); 13C NMR (CDCl3, 100 MHz): δ 177.0 (C2), 151.6 (C1), 50.9 
(C6), 45.6 (C6), 33.8 (C3), 29.0 (C7), 17.0 (C4); HRMS: (ESI+) Calculated for C9H16N2NaO2: 207.1104. 
Found [M + Na]+: 207.1114. Data for the minor product 203d: Characteristic signals only:  1H NMR 
(CDCl3, 400 MHz): δ; 13C NMR (CDCl3, 100 MHz): δ; 8.34 (1H, br. s, NH), 6.18 (1H, dt, J = 6.0, 2.0 
Hz, C5-H), 4.42 (1H, t, J = 2.0 Hz, C4-H), 1.40 (9H, s, C7-H3); 13C NMR (CDCl3, 100 MHz): δ 146.1 
(C5), 51.0 (C3), 29.1 (C7). 
 




Ethyl (cyclopropylcarbamoyl)glycinate (202e) 
 
General procedure A: Cyclopropylamine (0.760 mL, 11.0 mmol) and ethyl isocyanatoacetate 
(1.12 mL, 10.0 mmol) were employed to yield the title compound 202e (777 g, 42%) as a white solid; 
m.p. 122–123 °C (CH2Cl2/hexane); νmax / cm-1: 3341 (m), 2983 (m), 1741 (s), 1627 (s), 1586 (s), 1410 
(m), 1183 (s), 1031 (s); 1H NMR (400 MHz, CDCl3): δ 5.56 (1H, br. s, NH), 4.98 (1H, br. s, NH), 4.21 
(2H, q, J = 7.0 Hz, C6-H2), 4.03 (2H, d, J = 5.5 Hz, C4-H2), 2.50 (1H, m, C2-H), 1.28 (3H, t, J = 7.0 Hz, 
C7-H3), 0.77 (2H, m, 2 × C1-H2), 0.62 (2H, m, 2 × C1-H2); 13C NMR (100 MHz, CDCl3): δ 171.1 (C5), 
159.0 (C3), 61.5 (C6), 42.3 (C4), 22.5 (C2), 14.3 (C7), 7.6 (C1); m/z (ESI+) HRMS: Calculated for 
C8H14N2NaO3: 209.0897. Found [M + Na]+: 209.0893. 
Ethyl 2-(2,7-dioxo-1,3-diazepan-1-yl)acetate and (204e) and Ethyl 2-(2,7-dioxo-2,3,6,7-
tetrahydro-1H-1,3-diazepin-1-yl)acetate (203e) 
 
General Procedure B: Urea 202e (27.9 mg, 0.150 mmol) and Rh(cod)2BARF (5.0 mol%) were 
employed, and the reaction was stirred for 49 h at 90 °C. The crude mixture was purified by FCC (50% 
EtOAc/hexane) to yield the title compound 204e (22.2 mg, 69%, 1:1 ratio 204e:203e) as a pale yellow 
solid. Compounds could not be separated by FCC. Data for the mixture of compounds: νmax / cm-1: 
3310 (m), 2982 (m), 1710 (s), 1656 (s), 1532 (m), 1379 (s), 1204 (s); Data for saturated compound 
204e: 1H NMR (400 MHz, CDCl3): δ 7.64 (1H, br. s, NH), 6.20 (1H, dd, J = 7.0, 4.0 Hz, C5-H), 5.43 
(1H, dt, J = 7.0, 7.0 Hz, C4-H), 4.19 (2H, q, J = 7.0 Hz, C8-H2), 3.24 (2H, d, J = 7.0 Hz, C3-H2), 1.26 
(3H, t, J = 7.0 Hz, C9-H3); 13C NMR (100 MHz, CDCl3): δ 169.7 (C2), 168.7 (C7), 154.3 (C1), 126.3 
(C5), 109.8 (C4), 61.5 (C8), 46.3 (C6), 34.9 (C3), 14.2 (C9); m/z (ESI+) HRMS: Calculated for 
C9H14N2NaO4: 237.0846. Found [M + Na]+: 237.0844. Data for unsaturated compound 203d: 1H 
NMR (400 MHz, CDCl3): δ 8.80 (1H, br. s, NH), 4.21 (2H, q, J = 7.0 Hz, C8-H2), 4.06 (2H, d, J = 
5.5 Hz, C6-H2), 3.86 (2H, t, J = 7.0 Hz, C5-H2), 2.61 (2H, t, J = 8.0 Hz, C3-H2), 2.04 (2H, tt, J = 8.0, 
7.0 Hz, C4-H2), 1.28 (3H, t, J = 7.0 Hz, C9-H3); 13C NMR (100 MHz, CDCl3): δ 177.2 (C2), 169.7 (C7), 
153.2 (C1), 61.5 (C8), 45.7 (C5), 41.8 (C6), 33.4 (C3), 17.2 (C4), 14.2 (C9); m/z (ESI+) HRMS: 
Calculated for C9H13N2O4: 213.0870. Found [M + H]+: 213.0873. 






General procedure A: Cyclopropylamine (0.380 mL, 5.50 mmol) and 4-(trifluoromethyl)phenyl 
isocyanate (0.710 mL, 5.00 mmol) were employed to yield the title compound 202f (1.00 g, 82%) as a 
colourless solid; m.p. 180–181 °C (CHCl3); νmax / cm-1: 3313 (br.), 1651 (s), 1603 (m), 1544 (s), 1326 
(s), 1161 (s), 1107 (s), 1062 (s); 1H NMR (MeOD-d4, 400 MHz): δ 7.58–7.51 (4H, m, 2 × C5-H, 2 × 
C6-H), 2.60 (1H, m, C2-H), 0.75 (2H, m, 2 × C1-H), 0.51 (2H, m, 2 × C1-H); 13C NMR (CDCl3, 
100 MHz): δ 158.9 (C3), 144.6 (C8), 127.0, 119.4 (C5, C6), 23.3 (C2), 7.3 (C1); HRMS: (ESI+) 
Calculated for C11H11F3N2NaO: 267.0716. Found [M + Na]+: 267.0714. 
3-(4-(Trifluoromethyl)phenyl)-1,3-diazepane-2,4-dione (204f) and 1-(4-(Trifluoromethyl) 
phenyl)-3,6-dihydro-1H-1,3-diazepine-2,7-dione (203f) 
 
General Procedure B: Urea 202f (36.6 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0  mol%) were 
employed, and the reaction was stirred for 42 h at 90 °C. The crude mixture was purified by FCC (30% 
EtOAc/hexane) to yield the title compound 204f (29.1 mg, 71%, 3:1 204f:203f) as a yellow solid. 
Analysis of the crude reaction mixture by 1H NMR revealed a 3:1 (204f:203f) mixture of products. 
Data for the mixture of compounds: νmax / cm-1: 3131 (br.), 3075 (br.), 1707 (s), 1692 (s), 1602 (m), 
1557 (m), 1325 (m), 1112 (s). Data for major compound 204f: 1H NMR (CDCl3, 400 MHz): δ 10.80 
(1H, br. s, NH), 7.72–7.54 (4H, m, 2 × C7-H, 2 × C8-H), 3.96 (2H, t, J = 7.0 Hz, C5-H2), 2.71 (2H, t, J 
= 8.0 Hz, C3-H2), 2.11 (2H, tt, J = 8.0, 7.0 Hz, C4-H2); 13C NMR (CDCl3, 125 MHz): δ 177.7 (C2), 
126.4, 119.7 (C7, C8), 45.8 (C5), 33.6 (C3), 16.9 (C4); HRMS: (ESI+) Calculated for C12H11F3N2NaO2: 
295.0665. Found [M + Na]+: 295.0659. Data for minor compound 203f: 1H NMR (CDCl3, 400 MHz): 
δ 10.70 (1H, br. s, NH), 7.72–7.54 (4H, m, 2 × C7-H, 2 × C8-H), 7.40 (1H, dt, J = 6.0, 2.0 Hz, C5-H), 
6.29 (1H, dt, J = 6.0, 2.0 Hz, C4-H), 4.56 (2H, dd, J = 2.0, 2.0 Hz, C3-H2); 13C NMR (CDCl3, 125 MHz): 
δ 172.0 (C2), 147.3 (C5), 127.2 (C4), 126.4, 119.7 (C7, C8), 51.4 (C3). 
 
 






General procedure A: Cyclopropylamine (0.760 mL, 11.0 mmol) and phenyl isocyanate (0.900 mL, 
10.0 mmol) were employed to yield the title compound 202g (1.30 g, 74%) as a colourless solid; m.p. 
160–161 °C (CH2Cl2/hexane); νmax / cm-1: 3341 (w), 1642 (s), 1594 (s), 1547 (s), 1242 (s), 741 (s); 1H 
NMR (CDCl3, 400 MHz): δ 7.38 (2H, m, 2 × C5-H), 7.29 (2H, m, 2 × C6-H), 7.07 (1H, br. s, NH), 7.05 
(1H, m, C7-H), 5.17 (1H, br. s, NH), 2.59 (1H, m, C2-H), 0.81 (2H, m, 2 × C1-H), 0.62 (2H, m, 2 × 
C1-H); 13C NMR (CDCl3, 100 MHz): δ 156.8 (C3), 138.7 (C4), 129.2 (C6), 123.5 (C7), 120.2 (C5), 
22.7 (C2), 7.6 (C1); HRMS: (ESI+) Calculated for C10H12N2NaO: 199.0842. Found [M + Na]+: 
199.0847. 
3-Phenyl-1,3-diazepane-2,4-dione (204g) and 1-Phenyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione 
(203g) 
 
General Procedure B: Urea 202g (26.4 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were 
employed with 1,4-dioxane as solvent, and the reaction was stirred for 49 h at 90 °C. The crude mixture 
was purified by FCC (25% EtOAc/hexane) to yield the title compound 204g (20.5 mg, 67%, 25:1, 
204g:203g) as a beige solid. Analysis of the crude reaction mixture by 1H NMR revealed a 12:1 
(204g:203g) mixture of products. The minor product 203g was not isolated. Data for the major 
product 204g: m.p. 89–92 °C (CH2Cl2/hexane); νmax / cm-1: 3088 (m), 1719 (s), 1599 (s), 1556 (s), 1379 
(s), 1210 (s); 1H NMR (CDCl3, 400 MHz): δ 10.54 (1H, br. s, NH), 7.53 (2H, m, 2 × C8-H), 7.33 (2H, 
m, 2 × C7-H), 7.10 (1H, t, C9-H), 3.95 (2H, t, J = 7.2 Hz, C5-H2), 2.69 (2H, t, J = 8.0 Hz, C3-H2), 2.09 
(2H, dt, J = 8.0, 7.0 Hz, C4-H2); 13C (CDCl3, 100 MHz): δ 177.3 (C2), 150.1 (C1), 137.4 (C7), 129.0 
(C8), 124.0 (C10), 120.0 (C9), 45.7, 33.5 (C3, C5), 16.8 (C4). HRMS: (ESI+) Calculated for 
C11H12N2NaO2: 227.0791. Found [M + Na]+: 227.0791. Data for the minor product 203g: 
Characteristic signals only:  1H NMR (CDCl3, 400 MHz): δ 6.25 (1H, dt, J = 6.0, 2.0 Hz, C4-H). 
 
 






General procedure A: Cyclopropylamine (0.760 mL, 11.0 mmol) and 1-isocyanato-4-
methoxybenzene (1.09 mL, 10.0 mmol) were employed to yield the title compound 202h (1.98 g, 96%) 
as a colourless solid; m.p. 146–149 °C (CH2Cl2); νmax / cm-1: 3289 (m), 1637 (s), 1561 (s), 1508 (s), 
1243 (s); 1H NMR (CDCl3, 400 MHz): δ 7.28 (2H, m, 2 × C6-H), 6.86 (2H, m, 2 × C5-H), 6.68 (1H, 
br. s, NH), 3.79 (3H, s, C8-H3), 2.58 (1H, m, C2-H), 0.81 (2H, m, 2 × C1-H), 0.63 (2H, m, 2 × C1-H); 
13C NMR (CDCl3, 100 MHz): δ 156.5 (C7), 131.3 (C4), 123.3 (C6), 114.5 (C5), 55.6 (C8), 22.8 (C2), 
7.78 (C1); HRMS: (ESI+) Calculated for C11H14N2NaO: 229.0953. Found [M + Na]+: 229.0947. 
3-(4-Methoxyphenyl)-1,3-diazepane-2,4-dione (204h) and 1-(4-Methoxyphenyl)-3,6-dihydro-1H-
1,3-diazepine-2,7-dione (203h) 
 
General Procedure B: Urea 202h (30.9 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were 
employed, and the reaction was stirred for 25 h at 90 °C. The crude mixture was purified by FCC (30% 
EtOAc/hexane) to yield the title compound 204h (22.0 mg, 63%) as a colourless solid. Analysis of the 
crude reaction mixture by 1H NMR revealed a 12:1 (204h:203h) mixture of products. The minor product 
203h was not isolated. Data for major compound 204h: m.p. 114–116 °C (CH2Cl2/hexane); νmax / 
cm-1: 2918 (m), 1702 (s), 1552 (s), 1511 (s), 1382 (s), 1212 (s); 1H NMR (CDCl3, 400 MHz): δ 10.4 
(1H, br. s, NH), 7.42 (2H, m, 2 × C8-H), 6.86 (2H, m, 2 × C7-H), 3.94 (2H, t, J = 7.0 Hz, C5-H2), 3.78 
(3H, s, C10-H3), 2.68 (2H, t, J = 8.0 Hz, C3-H2), 2.07 (2H, tt, J = 8.0, 7.0 Hz, C4-H2); 13C NMR (CDCl3, 
100 MHz): δ 177.3 (C2), 156.4 (C9), 150.5 (C1), 130.6 (C6), 121.9 (C8), 114.3 (C7), 55.6 (C10), 45.8 
(C5), 33.7 (C3), 16.9 (C4); HRMS: (ESI+) Calculated for C12H14N2NaO3: 257.0902. Found [M + Na]+: 
257.08967. Data for the minor product 203h: Characteristic signals only:  1H NMR (CDCl3, 
400 MHz): δ 6.25 (1H, d, J = 6.0 Hz, C4-H). 
 
 






Cyclopropylamine (4.85 mL, 70.0 mmol) was added to 5 M aq. HCl (14 mL), dropwise at 0 °C followed 
by potassium cyanate (5.65 g, 69.0 mmol). The reaction mixture was then heated at 70 °C for 20 h 
before being cooled to room temperature and concentrated in vacuo. The resulting colourless solid was 
dissolved in water (250 mL) and the pH was adjusted to neutral. The aqueous solution was then 
extracted with EtOAc (3 × 100 mL). The combined organics were washed with brine (100 mL), dried 
over Na2SO4 and concentrated in vacuo affording the title compound 202i (273 mg, 4%) as a colourless 
solid; m.p. 122–124 °C (MeOH); νmax / cm-1: 3421 (m), 3332 (m), 1652 (s), 1602 (s), 1551 (s), 1340 (s); 
1H NMR (400 MHz, MeOD-d4): δ 2.46 (1H, m, C2-H), 0.70 (2H, m, 2 × C1-H2), 0.47 (2H, m, 2 × 
C1-H2); 13C NMR (100 MHz, CDCl3): δ 163.5 (C3), 23.4 (C2), 7.3 (C1); m/z (ESI+) HRMS: Calculated 
for C4H8N2NaO: 123.0534. Found [M + Na]+: 123.0528. 
 3,6-Dihydro-1H-1,3-diazepine-2,7-dione (203i) 
 
General Procedure B: Urea 202i (15.0 mg, 0.150 mmol) and Rh(cod)2BARF (5.0 mol%) were 
employed, and the reaction was stirred for 72 h at 100 °C. The crude mixture was filtered, washing with 
Et2O, to yield the title compound 203i (10.4 mg, 55%) as a brown solid; m.p. 185–187 °C (MeOH); 
νmax / cm-1: 3220 (m), 3083 (m), 2960 (m), 1694 (s), 1659 (s), 1427 (m), 1384 (s), 1287 (s), 1121 (s); 
1H NMR (400 MHz, CDCl3): δ 6.16 (1H, d, J = 7.5 Hz, C5-H), 5.31 (1H, dd, J = 7.5, 7.0 Hz, C4-H), 
3.11 (2H, d, J = 7.0 Hz, C3-H2); 13C NMR (100 MHz, CDCl3): δ 175.2 (C2), 172.7 (C1), 127.7 (C5), 












General Procedure B: Urea trans-206a was synthesised by McCreanor103: Urea trans-206a (44.2 mg, 
0.150 mmol) and [Rh(cod)2]BARF (7.5 mol%) were employed, and the reaction was stirred for 73 h at 
100 °C. The crude mixture was purified by FCC (10% EtOAc/hexane) to yield the title compound 208a 
(33.5 mg, 70%) as a yellow oil. Analysis of the crude reaction mixture by 1H NMR revealed complete 
selectivity for 208a over the corresponding saturated product and C4-substituted regioisomer. νmax / 
cm-1: 2987 (m), 1699 (s), 1649 (s), 1402 (s), 1265 (s), 1183 (s), 1076 (s), 1046 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.31–7.22 (8H, m, 2 × C9-H, C10-H, 2 × C13-H, 2 × C14-H, C15-H), 7.07–7.02 (2H, m, 
2 × C8-H), 5.99 (1H, dd, J = 7.0 Hz, 2.0 Hz, C5-H), 5.27 (1H, d, J = 14.5 Hz, 1 × C11-H), 5.21 (1H, 
dd, J = 7.0, 6.0 Hz, C4-H), 4.90 (1H, d, J = 14.5 Hz, 1 × C11-H), 4.83 (1H, d, J = 15.0 Hz, 1 × C6-H), 
4.66 (1H, d, J = 15.0 Hz, 1 × C6-H), 3.06 (1H, qdd, J = 7.0, 6.0, 2.0 Hz, C3-H), 1.35 (3H, d, J = 7.0 Hz, 
C16-H3); 13C NMR (CDCl3, 100 MHz): δ 172.3 (C2), 154.0 (C1), 137.7 (C12), 136.1 (C7), 128.7, 128.5, 
128.4, 128.1, 127.7, 127.6, 127.2 (C5, C8, C9, C10, C13, C14, C15), 120.2 (C4), 52.9 (C6), 48.2 (C11), 




Enantiopure substrate (S,S)-206a (99% e.e.) was synthesised starting from the commercially available 
and (R)-propylene oxide according to the literature procedure.101, 154 
Data for enantioenriched (S,S)-206a: [α]
27
D
  +41.1 (c = 1.2, CHCl3). 




The enantiopurity of this compound was determined by chiral SFC (Chiralpak IB, isocratic CO2-MeOH 





 (S)-1,3-Dibenzyl-6-methyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione ((S)-208a) 
 




General Procedure B: Urea (S,S)-206a (44.2 mg, 0.150 mmol) and [Rh(cod)2]BARF (7.5 mol%) were 
employed, and the reaction was stirred for 74 h at 100 °C. The crude mixture was purified by FCC (10% 
EtOAc/hexane) to yield the title compound (S)-208a (21.1 mg, 65%, 99% e.e.) as a yellow oil. 
Data for enantioenriched (S)-206a: [α]
27
D
  +205.2 (c = 1.2, CHCl3). 
The enantiopurity of this compound was determined by chiral SFC (Chiralpak IB, isocratic CO2-MeOH 












Ethyl (1R*,2R*)-2-butylcyclopropane-1-carboxylate (211b) 
 
This procedure was carried out in 6 identical reaction tubes in parallel. To a flame-dried screw-top 
tube, fitted with a rubber septum under an atmosphere of nitrogen was added 1,2-dimethoxyethane 
(11 mL) and triethyl phosphonoacetate (1.11 mL, 5.60 mmol). The reaction tube was then placed in an 
ice bath before the dropwise addition of n-BuLi (3.68 mL, 1.6 M in hexanes, 5.88 mmol). 
2-Butyloxirane (0.337 mL, 2.80 mmol) was then added and the reaction tube was sealed and heated at 
130 °C for 18 h before cooling to room temperature. The 6 identical reactions were combined at this 
point. The reaction mixture was transferred to a separating funnel with Et2O (50 mL) and sat. aq. NH4Cl 
(120 mL). The layers were separated and the aqueous layer was further extracted with Et2O (3 × 50 mL). 
The combined organics were dried over Mg2SO4 and concentrated in vacuo. Purification by FCC (5% 
EtOAc/Hexane) provided the title compound (2.86 g, 94%) as a pale yellow oil; νmax / cm-1: 2925 (m), 
1725 (s), 1449 (m), 1337 (m), 1264 (m), 1203 (m), 1176 (s), 1038 (m); 1H NMR (400 MHz, CDCl3): δ 
4.11 (2H, q, J = 7.0 Hz, C9-H2), 1.43–1.22 (8H, m, C2-H2, C3-H2, C4-H2, C5-H, C7-H), 1.25 (3H, t, J 
= 7.0 Hz, C10-H3), 1.14 (1H, m, 1 × C6-H2), 0.89 (3H, t, J = 7.0 Hz, C1-H3), 0.68 (1H, m, 1 × C6-H2). 
The spectroscopic properties of this compound were consistent with that available in the literature.356 
(1R*,2R*)-2-Butylcyclopropane-1-carboxylic acid (trans-212b) 
 
General procedure C: Ester 211b (2.70 g, 15.9 mmol) was employed to provide the title compound 
trans-212b (832 mg, 37%) as a yellow oil; νmax / cm-1: 1687 (s), 1457 (m), 1431 (m), 1229 (s); 1H NMR 
(400 MHz, CDCl3): δ 1.47–1.19 (9H, m, 2 × C7-H2, 2 × C6-H2, 2 × C5-H2, C4-H, C2-H, 1 × C6-H2), 
0.89 (3H, t, J = 7.0 Hz, 3 × C8-H3), 0.77 (1H, ddd, J = 8.0, 6.5, 4.0 Hz, 1 × C6-H2). The spectroscopic 
properties of this compound were consistent with that available in the literature.357 
tert-Butyl ((1R*,2R*)-2-butylcyclopropyl)carbamate (trans-213b) 
 




General procedure D: Carboxylic acid trans-212b (1.34 g, 9.39 mmol) was employed and the reaction 
was stirred for 3.5 h. The crude mixture was purified by  FCC (5% EtOAc/hexane) to yield the title 
compound 66 (976 mg, 49%) as a colourless oil; νmax / cm-1: 3329 (m), 2924 (m), 1693 (s), 1517 (m), 
1390 (m), 1365 (s), 1250 (m), 1170 (s); 1H NMR (400 MHz, CDCl3): δ 4.65 (1H, br. s, NH), 2.23 (1H, 
m, C7-H), 1.44 (9H, s, 3 × C10-H3), 1.41–1.27 (5H, m, C2-H2, C3-H2, 1 × C4-H2), 1.13 (1H, m, 1 × 
C4-H2), 0.88 (3H, t, J = 7.1 Hz, C1-H3), 0.80 (1H, m, C5-H), 0.59 (1H, m, 1 × C6-H2), 0.48 (1H, m, 1 




General procedure E: Boc-protected amine trans-213b (549 mg, 2.57 mmol) was employed and the 
residue was purified by FCC (15% EtOAc/hexane) to provide the title product (511 mg, 98%) as an 
orange oil; νmax / cm-1: 3293 (br.), 2955 (m), 2921 (m), 1646 (m), 1547 (m), 1453 (s), 1025 (m); 1H 
NMR (400 MHz, CDCl3): δ 7.37–7.22 (5H, m, 2 × C10-H, 2 × C11-H, C12-H), 3.82 (2H, s, C8-H2), 
1.87 (1H, m, C7-H), 1.75 (1H, br. s, NH), 1.38–1.26 (4H, m, C2-H2, C3-H2), 1.21–1.11 (2H, m, C4-H2), 
0.88 (3H, t, J = 7.0 Hz, C1-H3), 0.74 (1H, m, C5-H), 0.54 (1H, m, 1 × C6-H2), 0.24 (1H, m, 1 × C6-H2). 
The spectroscopic properties of this compound were consistent with that available in the literature.102 
1,3-Dibenzyl-1-((1R*,2R*)-2-butylcyclopropyl)urea (trans-206b) 
 
General procedure A: Amine trans-214b (497 mg, 2.44 mmol) was employed and the residue was 
purified by FCC (20% EtOAc/hexane) to provide the title compound (677 mg, 82%) as a colourless oil; 
νmax / cm-1: 2956 (m), 2923 (m), 1644 (s), 1513 (s), 1453 (m), 1352 (m), 1267 (m); 1H NMR (CDCl3, 
400 MHz): δ 7.37–7.21 (10H, m, 2 × C11-H, 2 × C12-H, C13-H, 2 × C16-H, 2 × C17-H, C18-H), 5.52 
(1H, m, NH), 4.57 (2H, s, C14-H2), 4.50 (2H, t, J = 5.0 Hz, C9-H2), 2.08 (1H, m, C7-H), 1.26–1.17 
(5H, m, 2 × C2-H, 2 × C3-H, 1 × C4-H), 1.12–1.01 (2H, m, 1 × C4-H, 1 × C5-H), 0.87 (1H, m, 1 × 
C6-H), 0.81 (3H, m, C1-H3), 0.55 (1H, m, 1 × C6-H); 13C NMR (CDCl3, 100 MHz): δ 159.0 (C8), 139.8 
(C10), 139.2 (C15), 128.8, 128.5, 127.9, 127.7, 127.4, 127.0 (C11, C12, C13, C16, C17, C18), 50.5 




(C14), 45.0 (C9), 34.5 (C7), 32.1 (C4), 31.1, 22.6 (C2, C3), 22.4 (C5), 15.8 (C6), 14.0 (C1); HRMS: 
(ESI+) Calculated for C22H28N2NaO: 359.2094. Found [M + Na]+: 359.2094. The relative 
stereochemistry of this compound was corroborated by nOe experiments (as indicated on the compound 
structure). A strong nOe was observed between C7-H and C4-H2. No significant nOe was observed 
between C7-H and C5-H. 
1,3-Dibenzyl-6-butyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (208b) 
 
General Procedure B: Urea trans-206b (50.5 mg, 0.150 mmol) and [Rh(cod)2]BF4 (10 mol%) were 
employed, and the reaction was stirred for 45 h at 100 °C. The crude mixture was purified by FCC 
(7.5% EtOAc/hexane) to yield the title compound 208b (32.2 mg, 59%) as a yellow solid. Analysis of 
the crude reaction mixture by 1H NMR revealed complete selectivity for 208b over the corresponding 
saturated product and C4-substituted regioisomer; m.p. 88–89 °C (CH2Cl2/hexane); νmax / cm-1: 2954 
(m), 1688 (s), 1646 (s), 1446 (m), 1405 (s), 1332 (m), 1272 (m), 1181 (m);  1H NMR (CDCl3, 400 
MHz): δ 7.31–7.21 (8H, m, 2 × C9-H, C10-H, 2 × C13-H, 2 × C14-H, C15-H), 7.06–7.03 (2H, m, 2 × 
C8-H), 6.01 (1H, dd, J = 7.0, 2.0 Hz, C5-H), 5.26–5.23 (2H, m, C4-H, 1 × C11-H), 4.90 (1H, d, J = 
14.5 Hz, 1 × C11-H), 4.81 (1H, d, J = 15.0 Hz, 1 × C6-H), 4.68 (1H, d, J = 15.0 Hz, 1 × C6-H), 2.89 
(1H, m, C3-H), 1.96 (1H, m, 1 × C16-H), 1.64 (1H, m, 1 × C16-H), 1.33–1.25 (4H, m, 2 × C17-H, 2 × 
C18-H), 0.89 (3H, m, C19-H3); 13C NMR (CDCl3, 125 MHz): δ 171.8 (C2), 154.2 (C1), 137.9 (C12), 
136.3 (C7), 129.0, 128.8, 128.5, 128.2, 127.9, 127.7, 127.3 (C5, C8, C9, C10, C13, C14, C15), 119.7 
(C4), 22.9 (C6), 48.2 (C11), 43.7 (C3), 29.3 (C17), 27.9 (C16), 22.5 (C18), 14.1 (C9); HRMS: (ESI+) 
Calculated for C23H26N2NaO2: 385.1886. Found [M + Na]+: 385.1891.  
2-Cyclohexyloxirane (210c) 
 




m-CPBA (2.93 g, 17.0 mmol) was added to a stirring solution of vinylcyclohexane (1.37 mL, 
10.0 mmol) in CH2Cl2 (40 mL) at 0 °C. The reaction was warmed to room temperature and stirred for 
18 h during which time a white precipitate formed. The reaction mixture was transferred to a separating 
funnel with CH2Cl2 (40 mL) and sat. aq. Na2SO3 (50 mL). The phases were separated, and the organic 
layer was washed with sat. aq. NaHCO3 (2 × 50 mL) and brine (50 mL) then concentrated in vacuo to 
provide the title compound (947 mg, 75%) as a colourless oil; 1H NMR (400 MHz, CDCl3): δ 2.72–
2.68 (2H, m, 1 × C1-H2, C2-H), 2.52 (1H, m, 1 × C1-H2), 1.89–1.64 (5H, m, 5 × cyclohexyl CH), 1.29–
1.04 (6H, m, 6 × cyclohexyl CH); 13C NMR (100 MHz, CDCl3): δ 56.8 (C2), 46.1 (C1), 40.5 (C3), 29.9, 
29.0, 26.5, 25.8, 25.7 (5 × cyclohexyl CH2). The spectroscopic properties of this compound were 
consistent with that available in the literature.358 
Ethyl (1R*,2S*)-2-cyclohexylcyclopropane-1-carboxylate (211c) 
 
This procedure was carried out in 3 identical reaction tubes in parallel. To a flame-dried sealable tube, 
fitted with a rubber septum, under an atmosphere of nitrogen was added 1,2-dimethoxyethane (5.0 mL) 
and triethyl phosphonoacetate (0.990 mL, 5.00 mmol). The reaction tube was then placed in an ice bath 
before the dropwise addition of n-BuLi (3.27 mL, 1.6 M in hexanes, 5.25 mmol). 2-Cyclohexyloxirane 
210c (316 mg, 2.50 mmol) was then added and the reaction tube was sealed and heated at 130 °C for 
18 h before cooling to room temperature. The 3 identical reactions were combined at this point. The 
reaction mixture was transferred to a separating funnel with Et2O (20 mL) and sat. aq. NH4Cl (20 mL). 
The layers were separated, and the aqueous layer was further extracted with Et2O (3 × 20 mL). The 
combined organics were dried over Mg2SO4 and concentrated in vacuo. Purification by FCC (5% 
EtOAc/hexane) provided the title compound (1.16 g, 79%) as a pale yellow oil; 1H NMR (400 MHz, 
CDCl3): δ 4.11 (2H, qd, J = 7.1 Hz, 2.0 Hz, C6-H2), 1.78–1.59 (5H, m, 5 × cyclohexyl CH), 1.38 (1H, 
ddd, J = 8.2 Hz, 4.5 Hz, 4.1 Hz, C4-H), 1.27–1.03 (7H, m, 5 × cyclohexyl CH, C2-H, C3-H), 1.25 (3H, 
t, J = 7.1 Hz, C7-H3), 0.74–0.62 (2H, m, C1-H, C3-H); 13C NMR (100 MHz, CDCl3): δ 174.9 (C5), 
60.4 (C6), 41.8 (C1), 32.8, 32.6 (2 × cyclohexyl CH2), 29.5 (C2), 26.5, 26.3, 26.2 (3 × cyclohexyl CH2), 
19.1 (C4), 14.4, 14.3 (C3 and C7); The spectroscopic properties of this compound were consistent with 








(1R*,2S*)-2-Cyclohexylcyclopropane-1-carboxylic acid (trans-212c) 
 
General procedure C: Ester 211c (1.16 g, 5.89 mmol) was employed to provide the title compound 
(844 mg, 85%) as a colourless oil; 1H NMR (400 MHz, CDCl3): δ 1.78–1.62  (5H, m, 5 × cyclohexyl 
CH), 1.39 (1H, ddd, J = 8.5, 4.5, 4.5 Hz, C2-H), 1.30 (1H, m, C4-H), 1.20–1.03 (6H, m, 1 × C3-H2, 5 
× cyclohexyl CH), 0.81 (1H, m, 1 × C3-H), 0.70 (1H, m, C5-H); 13C NMR (100 MHz, CDCl3): δ 181.0 
(C1), 41.8 (C5), 32.7, 32.6 (2 × cyclohexyl CH), 30.6 (C4), 26.5, 26.2, 26.2 (3 × cyclohexyl CH), 18.9 
(C2), 15.2 (C3); The spectroscopic properties of this compound were consistent with that available in 
the literature.101 
tert-Butyl ((1R*,2S*)-2-cyclohexylcyclopropyl)carbamate (trans-213c) 
 
General procedure D: Carboxylic acid trans-212c (800 mg, 4.76 mmol) was employed and the 
reaction was stirred for 17 h. The crude mixture was purified by FCC (5% EtOAc/hexane) to yield the 
title compound (975 mg, 86%) as a colourless oil; 1H NMR (400 MHz, CDCl3): δ 4.62 (1H, br. s, NH), 
2.28 (1H, m, C4-H), 1.90 (1H, m, 1 × cyclohexyl CH), 1.69–1.61 (4H, m, 4 × cyclohexyl CH), 1.44 
(9H, s, 9 × C7-H3), 1.19–0.96 (5H, m, 5 × cyclohexyl CH), 0.69–0.49 (4H, m, C1-H, C2-H and C3-H2); 
The spectroscopic properties of this compound were consistent with that available in the literature.101 
(1R*,2S*)-N-Benzyl-2-cyclohexylcyclopropan-1-amine (trans-214c) 
 
General procedure E: Boc-protected amine trans-213c (450 mg, 1.88 mmol) was employed and the 
residue was purified by FCC (10% EtOAc/hexane) to provide the title compound (375 mg, 87%) as a 
colourless oil; 1H NMR (400 MHz, CDCl3): δ 7.34–7.22 (5H, m, 2 × C10-H, 2 × C11-H, C12-H), 3.81 
(2H, s, C8-H2), 1.93 (1H, ddd, J = 6.7, 3.2, 3.2 Hz, C7-H), 1.78–1.60 (5H, m, 5 × cyclohexyl CH), 1.22–
0.97 (5H, m, 5 × cyclohexyl CH), 0.64–0.46 (3H, m, C4-H, C5-H, 1 × C6-H2), 0.30 (1H, m, 1 × C6-H2); 




13C NMR (100 MHz, CDCl3): δ 140.8 (C9), 128.5, 128.3, 126.9 (C10, C11, C12), 53.9 (C8), 41.1 (C4), 
36.4 (C7), 33.2, 32.6 (2 × cyclohexyl CH2), 27.7 (C5), 26.7, 26.4 (3 × cyclohexyl CH2), 12.6 (C6); The 
spectroscopic properties of this compound were consistent with that available in the literature.101 
1,3-Dibenzyl-1-((1R*,2S*)-2-cyclohexylcyclopropyl)urea (trans-206c) 
 
General procedure A: Amine trans-214c (355 mg, 1.55 mmol) was employed and the residue was 
purified by FCC (15–20% EtOAc/hexane) to provide the title compound (500 mg, 89%) as a colourless 
solid; m.p. 73–74 °C (CH2Cl2/hexane); νmax / cm-1: 3346 (m), 2922 (m), 1630 (s), 1518 (s), 1349 (m), 
1221 (m), 696 (s);  1H NMR (CDCl3, 400 MHz): δ 7.37–7.21 (10H, m, 2 × C11-H, 2 × C12-H, C13-H, 
2 × C16-H, 2 × C17-H, C18-H,), 5.63 (1H, t, J = 5.0 Hz, NH), 4.64 (1H, d, J = 15.5 Hz, 1 × C14-H), 
4.51 (1H, d, J = 15.5 Hz, 1 × C14-H), 4.49 (2H, m, C9-H2), 2.20 (1H, m, C7-H), 1.68–1.50 (5H, m, 5 
× cyclohexyl CH), 1.13–0.88 (6H, m, C4-H, 5 × cyclohexyl CH), 0.82 (1H, m, 1 × C6-H), 0.64–0.47 
(2H, m, C5-H, 1 × C6-H); 13C NMR (CDCl3, 100 MHz): δ 159.0 (C8), 139.7 (C10), 139.4 (C15), 128.7, 
128.5, 127.9, 127.7, 127.4, 126.9 (C11, C12, C13, C16, C17, C18), 50.7 (C14), 45.1 (C9), 41.0 (C5), 
33.7 (C7), 32.7, 32.1 (2 × cyclohexyl CH2), 28.7 (C4), 26.3, 26.1, 26.1 (3 × cyclohexyl CH2), 14.7 (C6); 
HRMS: (ESI+) Calculated for C24H30N2NaO: 385.2256. Found [M + Na]+: 385.2342. 
1,3-Dibenzyl-6-cyclohexyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (208c) 
 
General Procedure B: Urea trans-206c (54.4 mg, 0.150 mmol) and [Rh(cod)2]BF4 (7.5 mol%) were 
employed, and the reaction was stirred for 73 h at 100 °C. The crude mixture was purified by FCC 
(7.5% EtOAc/hexane) to yield the title compound 208c (16.9 mg, 29%) as a yellow oil. Analysis of the 
crude reaction mixture by 1H NMR revealed complete selectivity for 208c over the corresponding 




saturated product and C4-substituted regioisomer. νmax / cm-1: 2923 (m), 2850 (m), 1698 (m), 1646 (s), 
1401 (s), 1178 (m);  1H NMR (CDCl3, 400 MHz): δ 7.30–7.21 (8H, m, 2 × C9-H, C10-H, 2 × C13-H, 
2 × C14-H, C15-H), 7.07–7.03 (2H, m, 2 × C8-H), 6.01 (1H, dd, J = 7.0, 1.5 Hz, C5-H), 5.38 (1H, dd, 
J = 7.0, 7.0 Hz,  C4-H), 5.18 (1H, d, J = 14.5 Hz, 1 × C11-H), 4.92 (1H, d, J = 14.5 Hz, 1 × C11-H), 
4.84 (1H, d, J = 15.0 Hz, 1 × C6-H), 4.63 (1H, d, J = 15.0 Hz, 1 × C6-H), 2.67 (1H, m, C3-H), 1.96–
1.86 (2H, m, C16-H, 1 × C17-H), 1.79 (1H, m, 1 × cyclohexyl CH), 1.70–1.63 (3H, m, 3 × cyclohexyl 
CH), 1.34–1.08 (3H, m, 3 × cyclohexyl CH), 0.91–0.79 (2H, m, 1 × C17-H, 1 × cyclohexyl CH); 13C 
NMR (CDCl3, 125 MHz): δ 170.7 (C2), 154.2 (C1), 137.9 (C12), 136.2 (C7), 129.1 (C5), 128.8, 128.5, 
128.2, 127.9, 127.8, 127.3 (C8, C9, C10, C13, C14, C15), 117.8 (C4), 52.9 (C6), 50.2 (C3), 48.3 (C11), 
35.7 (C16), 31.9 (C17), 30.3, 26.5, 26.1, 25.9 (C17, 2 × C18, C19); HRMS: (ESI+) Calculated for 
C25H28N2NaO2: 411.2043. Found [M + Na]+: 411.2050.  
1-Benzyl-3-((1R*,2R*)-2-butylcyclopropyl)urea (trans-215b) 
 
General procedure F: Boc-protected amine trans-213b (427 mg, 2.00 mmol) was employed and the 
residue was purified by FCC (40% EtOAc/hexane) to provide the title compound (463 mg, 94%) as a 
colourless solid; m.p. 80–83 °C (CH2Cl2/hexane); νmax / cm-1: 3318 (m), 2915 (m), 1625 (s), 1570 (s), 
1454 (m), 1242 (s), 1067 (m), 696 (s); 1H NMR (CDCl3, 400 MHz): δ 7.35–7.23 (5H, m, 2 × C11-H, 2 
× C12-H, C13-H), 5.23 (1H, br. m, NH), 4.74 (1H, br. s, NH), 4.43 (2H, m, C9-H2), 2.14 (1H, m, C7-H), 
1.35–1.16 (6H, m, 2 × C2-H, 2 × C3-H, 2 × C4-H), 0.94–0.82 (4H, m, C1-H3, C5-H), 0.69 (1H, m, 1 × 
C6-H), 0.51 (1H, m, 1 × C6-H); 13C NMR (CDCl3, 125 MHz): δ 159.0 (C8), 139.4 (C10), 128.8, 127.7, 
127.4 (C11, C12), 127.4 (C13), 44.4 (C9), 32.0 (C4), 31.3 (C3), 29.1 (C7), 22.5 (C2), 21.5 (C5), 14.9 
(C6), 14.1 (C1); HRMS: (ESI+) Calculated for C15H22N2NaO: 269.1624. Found [M + Na]+: 269.1618. 
The relative stereochemistry of this compound was corroborated by nOe experiments (as indicated on 
the compound structure). A strong nOe was observed between C7-H to C4-H2. No significant nOe was 










diazepane-2,4-dione (219b), 1-Benzyl-6-butyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (220b) and 
3-Benzyl-6-butyl-1,3-diazepane-2,4-dione (221b) 
 
General Procedure B: Urea trans-5v (36.9 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were 
employed, and the reaction was stirred for 38 h at 100 °C. The crude mixture was purified by FCC (20% 
EtOAc/hexane) to yield the title compounds (28.8 mg, 70%, ~1:4:1:2, 218b:219b:220b:221b) as a 
brown oil. Data for the mixture of compounds: νmax / cm-1: 3298 (m), 2928 (m), 1705 (s), 1541 (s), 
1361 (m), 1272 (m). Data for product 218b: Characteristic signals only: 1H NMR (CDCl3, 400 MHz): 
δ 7.36–7.22 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 6.10 (1H, m, C5-H), 5.14 (1H, dd, J = 6.5, 6.5 Hz, 
C4-H), 5.07 (1H, d, J = 14.5 Hz, 1 × C6-H), 4.97 (1H, d, J = 14.5 Hz, 1 × C6-H), 3.05 (1H, m, C3-H), 
2.00 (1H, m, 1 × C11-H), 0.96–0.89 (3H, m, C14-H3); 13C NMR (CDCl3, 100 MHz): δ 124.6 (C5), 
117.0 (C4), 48.3 (C6), 43.9 (C3), 28.4 (C11). Data for product 219b: Characteristic signals only: 1H 
NMR (CDCl3, 400 MHz): δ 8.81 (1H, br. s, NH), 7.33–7.24 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 4.50 
(2H, m, C6-H2), 3.93 (1H, m, 1 × C5-H), 3.66 (1H, m, 1 × C5-H), 2.60 (1H, m, C3-H), 2.20 (1H, m, 1 
× C4-H), 1.68 (1H, m, 1 × C4-H), 1.50–1.24 (6H, m, C11-H2, C12-H2,  C13-H2), 0.93–0.89 (3H, m, 
C14-H3); 13C NMR (CDCl3, 100 MHz): δ 179.2 (C2), 44.4 (C3), 43.9, 43.9 (C5, C6), 24.1 (C4), 14.1 
(C14); HRMS: (ESI+) Calculated for C16H22N2NaO2: 297.1573. Found [M + Na]+: 297.1583. Data for 
product 220b: Characteristic signals only: 1H NMR (CDCl3, 400 MHz): δ 8.79 (1H, br. s, NH), 7.36–
7.22 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 6.87 (1H, m, C5-H), 4.55 (2H, m, C6-H2), 4.34 (2H, m, 
C3-H2), 2.27 (2H, m, C11-H2), 1.53 (2H, m, C12-H2), 1.41–1.28 (2H, m, C13-H2), 0.93 (3H, m, 
C14-H3); 13C NMR (CDCl3, 125 MHz): δ 138.3 (C5), 49.2 (C3), 43.9 (C6), 25.2 (C11). Data for 










General procedure F: Boc-protected amine trans-213c (350 mg, 1.46 mmol) was employed and the 
residue was purified by FCC (40% EtOAc/hexane) to provide the title compound (345 mg, 87%) as a 
colourless solid; m.p. 80–83 °C (CH2Cl2/hexane); νmax / cm-1:3319 (br.), 2919 (m), 2847 (m), 1626 (s), 
1589 (s), 1577 (s), 1446 (m), 1255 (m), 1235 (m); 1H NMR (CDCl3, 400 MHz): δ 7.35–7.22 (5H, m, 2 
× C11-H, 2 × C12-H, C13-H), 5.27 (1H, br. m, NH), 4.68 (1H, br. m, NH), 4.42 (2H, m, C9-H2), 2.19 
(1H, m, C7-H), 1.73–1.60 (5H, m, 5 × cyclohexyl CH), 1.18–0.94 (5H, m, 5 × cyclohexyl CH), 0.75 
(1H, m, C4-H), 0.64 (1H, m, 1 × C6-H), 0.61–0.51 (2H, m, C5-H, 1 × C6-H); 13C NMR (CDCl3, 
125 MHz): δ 158.9 (C8), 139.3 (C10), 128.7, 127.8, 127.5 (C11, C12, C13), 44.5 (C9), 40.8 (C5), 32.9, 
32.3 (2 × cyclohexyl CH2), 28.2 (C4), 27.9 (C7), 26.4, 26.2, 26.1 (3 × cyclohexyl CH2), 13.7 (C6); 
HRMS: (ESI+) Calculated for C17H24N2NaO: 295.1786. Found [M + Na]+: 295.1775. 
1-Benzyl-5-cyclohexyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (218c), 3-Benzyl-6-cyclohexyl-1,3-
diazepane-2,4-dione (219c), 1-Benzyl-6-cyclohexyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione 
(220c) and 3-Benzyl-5-cyclohexyl-1,3-diazepane-2,4-dione (221c), 
 
General Procedure B: Compound trans-215c (40.8 mg, 0.150 mmol) and [Rh(cod)2]BARF 
(7.5 mol%) were employed, and the reaction was stirred for 72 h at 100 °C. The crude mixture was 
purified by FCC (25% EtOAc/hexane) to yield the title compounds (25.6 mg, 57%, 1:7.7:1:1.4, 
218c:219c:220c:221c) as a brown oil; The compounds could not be separated by FCC. The products 
were assigned by analogy to 218b, 219b, 220b, 221b. Data for the mixture of compounds: νmax / 
cm-1: 3305 (br.), 2923 (m), 2853 (m), 1707 (s), 1537 (s), 1449 (m), 1360 (m), 1259 (m). Data for 
product 218c: Characteristic signals only: 1H NMR (CDCl3, 400 MHz): δ 6.09 (1H, m, C5-H), 5.27 




(1H, t, J = 7.0 Hz, C4-H). Data for product 219c: Characteristic signals only: 1H NMR (CDCl3, 
400 MHz): δ 3.87 (1H, m, 1 × C5-H), 3.66 (1H, m, 1 × C5-H); HRMS: (ESI+) Calculated for 
C18H24N2NaO2: 323.1730. Found [M + Na]+: 323.1739. Data for product 220c: Characteristic signals 
only: 1H NMR (CDCl3, 400 MHz): δ 6.81 (1H, s, C5-H); 13C NMR (CDCl3, 125 MHz): δ 136.8 (C5). 
Data for product 221c: Characteristic signals only: 1H NMR (CDCl3, 400 MHz): δ 4.05 (1H, dd, J = 
11.0, 8.0 Hz, 1 × C5-H), 3.43 (1H, dd, J = 11.0, 9.0 Hz, 1 × C5-H), 2.62 (1H, m, 1 × C3-H), 2.35 (1H, 
m, 1 × C3-H); 13C NMR (CDCl3, 125 MHz): δ 49.8 (C5), 38.2 (C3).  
1,3-Dibenzyl-5-methyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (207a) and 1,3- Dibenzyl-6-
methyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (208a) 
 
General Procedure B: Urea cis-206a was synthesised by McCreanor103: Urea cis-206a (44.2 mg, 
0.150 mmol) and [Rh(cod)2]BARF (7.5 mol%) were employed, and the reaction was stirred for 72 h at 
100 °C. The crude mixture was purified by FCC (25% EtOAc/hexane) to yield title compound 207a 
(32.6 mg, 68%) as a pale yellow oil. Analysis of the crude reaction mixture by 1H NMR revealed a 5:1 
(207a:208a) mixture of products. Data for major regioisomer 207a: νmax / cm-1: 2971 (s), 1698 (s), 
1646 (s), 1408 (s), 1214 (s); 1H NMR (CDCl3, 400 MHz): δ 7.35–7.21 (8H, m, 2 × C9-H, C10-H, 2 × 
C13-H, 2 × C14-H, C15-H), 7.08–7.04 (2H, m, 2 × C8-H), 5.78 (1H, q, J = 1.5 Hz, C5-H), 5.04 (2H, s, 
C11-H2), 4.71 (2H, s, C6-H2), 3.04 (2H, s, C3-H2), 1.86 (3H, s, C16-H3); 13C NMR (CDCl3, 100 MHz): 
δ 169.2 (C2), 154.1 (C1), 137.6 (C12), 136.3 (C7), 128.7, 128.4, 128.1, 127.7, 127.6, 127.2 (C8, C9, 
C10, C13, C14, C15), 124.5 (C5), 124.0 (C4), 52.9 (C6), 47.6 (C11), 40.8 (C3), 19.6 (C16); HRMS: 
(ESI+) Calculated for C20H20N2NaO2: 343.1417. Found [M + Na]+: 343.1408.  
1,3-Dibenzyl-5-butyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione (207b) and 1,3- Dibenzyl-6-butyl-
3,6-dihydro-1H-1,3-diazepine-2,7-dione (208b) 
 
General Procedure B: Urea cis-206b was synthesised by McCreanor103: Urea cis-206b (50.5 mg, 
0.150 mmol) and [Rh(cod)2]OTf (7.5 mol%) were employed, and the reaction was stirred for 73 h at 
100 °C. The crude mixture was purified by FCC (50% EtOAc/hexane) to yield the title compound 207b 
(34.6 mg, 64%) as a yellow oil. Analysis of the crude reaction mixture by 1H NMR revealed a 6:1 




(207b:208b) mixture of products. Data for major compound 207b: νmax / cm-1: 1697 (m), 1647 (s), 
1412 (m), 1215 (s);  1H NMR (CDCl3, 400 MHz): δ 7.34–7.24 (8H, m, 2 × C9-H, C10-H, 2 × C13-H, 
2 × C14-H, C15-H), 7.08–7.06 (2H, m, 2 × C8-H), 5.75 (1H, t, J = 1.0 Hz, C5-H), 5.05 (2H, s, C11-H2), 
4.72 (2H, s, C6-H2), 3.04 (2H, s, C3-H2), 2.14 (2H, td, J = 7.0, 1.0 Hz, C16-H2), 1.45–1.39 (2H, m, 
C17-H2), 1.27–1.18 (2H, m, C18-H2), 0.87 (3H, t, J = 7.5 Hz, C19-H3); 13C NMR (CDCl3, 125 MHz): 
δ 169.7 (C2), 154.1 (C1), 137.7 (C12), 136.3 (C7), 128.7, 128.3, 128.1, 128.0, 127.7, 127.6, 127.2 (C4, 
C8, C9, C10, C13, C14, C15), 124.1 (C5), 53.0 (C6), 47.5 (C11), 39.4 (C3), 33.7 (C16), 29.0 (C17), 




General procedure A: cis-Cyclopropylamine I was synthesised by McCreanor103: Amine I (283 mg, 
2.50 mmol) and benzyl isocyanate (309 μL, 2.50 mmol) were employed. The crude mixture was purified 
by FCC (75% EtOAc/hexane) to yield the title compound (430 mg, 70%) as a colourless solid; m.p. 
66–68 °C (CH2Cl2/hexane); νmax / cm-1: 3319 (s), 2927 (s), 1625 (s), 1572 (s), 1267 (s), 1240 (s); 1H 
NMR (CDCl3, 500 MHz): δ 7.31–7.22 (5H, m, 2 × C11-H, 2 × C12-H, C13-H), 5.44 (1H, br. s, NH), 
4.92 (1H, br. s, NH), 4.40 (2H, d, J = 6.0 Hz, C9-H2), 2.45 (1H, m, C7-H), 1.45 (1H, m, 1 × C4-H), 
1.37–1.28 (4H, m, C2-H2, C3-H2), 1.19 (1H, m, 1 × C4-H), 0.89–0.84 (4H, m, C1-H3, 1 × C6-H), 0.13 
(1H, m, 1 × C6-H); 13C NMR (CDCl3, 125 MHz): δ 159.5 (C8), 139.5 (C10), 128.5, 127.4, 127.2 (C11, 
C12, C13), 44.2 (C9), 31.7 (C3), 27.0 (C4), 26.7 (C7), 22.6 (C2), 18.1 (C5), 14.0 (C1), 12.8 (C6); 
HRMS: (ESI+) Calculated for C15H23N2O: 247.1805. Found [M + H]+: 247.1804. The relative 
stereochemistry of this compound was corroborated by nOe experiments (as indicated on the compound 
structure). A strong nOe was observed between C7-H to C5-H. No significant nOe was observed 
between C7-H and C4-H2. 
3-Benzyl-6-butyl-1,3-diazepane-2,4-dione (221b) and 3-Benzyl-5-butyl-1,3-diazepane-2,4-dione 
(219b) 
 




General Procedure B: Urea cis-215b (37.0 mg, 0.150 mmol) and [Rh(cod)2]BARF (7.5 mol%) were 
employed, and the reaction was stirred for 38 h at 90 °C. The crude mixture was purified by FCC (20% 
EtOAc/hexane) to yield the title compound 221b and 219b (24.0 mg, 58%, 10:1, 221b:219b) as a yellow 
oil. Analysis of the crude reaction mixture by 1H NMR revealed a 5:1 (221b:219b) mixture of products. 
Data for product 221b: νmax / cm-1: 3304 (m), 2925 (m), 1709 (s), 1537 (s), 1260 (s); 1H NMR (CDCl3, 
400 MHz): δ 8.75 (1H, br. s, NH), 7.39–7.20 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 4.50 (2H, d, J = 
6.0 Hz, C6-H2), 4.04 (1H, dd, J = 11.0, 7.5 Hz, 1 × C5-H), 3.44 (1H, dd, J = 11.0, 7.0 Hz, 1 × C5-H), 
2.69 (1H, m, 1 × C3-H), 2.35–2.26 (2H, m, 1 × C3-H, C4-H), 1.52–1.26 (6H, m, C11-H2, C12-H2, C13-
H2), 0.91 (3H, t, J = 7.0 Hz, C14-H3); 13C NMR (CDCl3, 100 MHz): δ 176.7 (C2), 153.0 (C1), 138.3 
(C7), 128.6, 127.6, 127.3 (C8, C9, C10), 51.2 (C5), 43.8 (C6), 39.9 (C3), 33.8 (C11), 30.7 (C4), 29.5 
(C12), 22.6 (C13), 13.9 (C14); HRMS: (ESI+) Calculated for C16H22N2NaO2: 297.1573. Found [M + 
Na]+: 297.1572. Data for product 219b: Partial characterisation on S37. 
Methyl ((1R*,6S*,7S*)-bicyclo[4.1.0]heptan-7-yl)carbamate (cis-230) and Methyl 
((1R*,6S*,7R*)-bicyclo[4.1.0]heptan-7-yl) (tran-230) 
 
Adapted from a literature procedure155: Methyl carbamate (2.40 g, 32.0 mmol), copper powder 
(889 mg, 14.0 mmol), zinc powder (13.1 g, 200 mmol) and ZnCl2 (4.22 g, 31.0 mmol) were suspended 
in dry Et2O (50 mL) in a flame-dried flask under an atmosphere of nitrogen. Cyclohexene (1.01 mL, 
10.0 mmol) was added followed by the dropwise addition of freshly distilled (Hickman still) TMSCl 
(14.0 mL, 110 mmol) over 30 minutes at room temperature. Triethyl orthoformate (6.15 mL, 
37.0 mmol) was then added by syringe pump (1.1 mL/hr). The reaction mixture was stirred for 18 h at 
room temperature before the addition of sat. aq. NaHCO3 (150 mL). The resulting biphasic solution was 
filtered through a short pad of celite, separated and the aqueous solution was further extracted with Et2O 
(3 × 50 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo. The resulting 
oil was dissolved in MeOH (10 mL), and K2CO3 (2 g) was added before stirring for 1 hr. The reaction 
mixture was concentrated in vacuo, dissolved in water (100 mL) and extracted with CH2Cl2 (3 × 
100 mL). The combined organics were washed with brine (150 mL), dried over Na2SO4 and 
concentrated in vacuo. The crude product was purified by FCC (10% EtOAc/Hexane) to yield the title 
compounds (1.53 g, 90%, 3:1 d.r.) as a pale yellow oil. The product diastereomers were inseparable by 
FCC. Data for the mixture of compounds: νmax / cm-1: 3317 (br.), 2930 (m), 1702 (s), 1519 (m), 1449 
(m), 1240 (m), 1076 (m); Data for major diasteromer cis-230: 1H NMR (400 MHz, CDCl3): δ 4.57 
(1H, br. s, NH), 3.77–3.61 (3H, br. s, C6-H3), 2.52 (1H, br. m, C4-H), 1.95–1.82 (2H, m, 2 × C1/2-H2), 
1.39–1.00 (8H, m, 6 × C1/2-H2, 2 × C3-H); Data for minor compound trans-230: 1H NMR (400 MHz, 




CDCl3): δ 4.80 (1H, br. s, NH), 3.77–3.61 (3H, br. s, C6-H3), 2.24 (1H, br. m, C4-H), 1.75–1.66 (2H, 
m, 2 × C1/2-H2), 1.39–1.00 (6H, m, 4 × C1/2-H2, 2 × C3-H). The spectroscopic properties of this 
compound were consistent with that available in the literature.155 
(1R*,6S*,7S*)-Bicyclo[4.1.0]heptan-7-amine hydroiodide (cis-231) and (1R*,6S*,7R*)-
Bicyclo[4.1.0]heptan-7-amine hydroiodide (trans-231) 
 
Iodotrimethylsilane (2.45 mL, 17.2 mmol) was added To a stirring solution of carbamate cis-230 
(1.46 g, 8.61 mmol, 3:1 d.r.) in CH2Cl2 (86 mL) at room temperature. The reaction mixture was heated 
at reflux for 1 h before cooling to room temperature. MeOH (17 mL) was added and the reaction mixture 
was heated at reflux for 30 minutes before being cooled to room temperature and concentrated in vacuo. 
The resulting orange solid was suspended in Et2O (20 mL) and filtered, washing with Et2O, to yield the 
title compounds (1.79 g, 87%, 3:1 d.r.,) as a brown solid. The product diastereomers were not separable 
at this point. Data for the mixture of compounds: νmax / cm-1: 2922 (s), 1571 (m), 1352 (m), 1066 (s); 
HRMS: (ESI+) Calculated for C7H14N: 112.1121. Found [M+H]+: 112.1123. Data for major 
compound cis-231: 1H NMR (MeOD-d4, 400 MHz): δ 2.53 (1H, t, J = 8.0 Hz, C4-H), 2.13–2.03 (2H, 
m, 2 × C2-H2), 1.56–1.46 (2H, m, 2 × C2-H2), 1.46–1.36 (2H, m, 2 × C1-H2), 1.33–1.13 (4H, m, 2 × 
C1-H2, 2 × C3-H); 13C NMR (MeOD-d4, 100 MHz): δ 31.1 (C4), 22.0 (C1), 17.7 (C2), 11.4 (C3). Data 
for minor compound trans-231: 1H NMR (MeOD-d4, 400 MHz): δ 2.36 (1H, t, J = 8.0 Hz, C4-H), 
1.98–1.85 (2H, m, 2 × C2-H2), 1.76–1.67 (2H, m, 2 × C2-H2), 1.35–1.07 (6H, m, 4 × C1-H2, 2 × C3-H); 
13C NMR (MeOD-d4, 100 MHz): δ 34.1 (C4), 22.4 (C2), 21.8 (C1), 17.0 (C3). 
(1R*,6S*,7S*)-N-Benzylbicyclo[4.1.0]heptan-7-amine (cis-232) and (1R*,6S*,7R*)-N-
Benzylbicyclo[4.1.0]heptan-7-amine (trans-232) 
 
To a stirring solution of amine·hydroiodide salt cis-231 (1.50 g, 6.30 mmol, 3:1 d.r.) in MeOH (14 mL) 
was added NaHCO3 (2.11 g, 25.1 mmol) and benzaldehyde (0.58 mL, 5.65 mmol), and the reaction 
mixture was heated at reflux for 8 h. The reaction mixture was cooled to 0 °C before NaBH4 (285 mg, 




7.52 mmol) was added portion-wise. The reaction mixture was warmed to room temperature and stirred 
for 16 h. The reaction mixture was concentrated in vacuo before adding water (80 mL) and extracting 
with CH2Cl2 (3 × 30 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo. 
The residue was purified by FCC (30% EtOAc/hexane) to afford cis-232 (807 mg, 71%) as a pale yellow 
oil and trans-232 (267 mg, 23%) as a pale yellow oil. Data for product cis-232: νmax / cm-1: 3290 (br.), 
2927 (s), 1642 (s), 1542 (m), 1495 (m), 1452 (m); 1H NMR (CDCl3, 400 MHz): δ 7.40–7.21 (5H, m, 2 
× C7-H, 2 × C8-H, C9-H), 3.81 (2H, s, C5-H2), 2.03 (1H, t, J = 7.5 Hz, C4-H), 1.85–1.73 (2H, m, 2 × 
C2-H), 1.59–1.49 (2H, m, 2 × C2-H), 1.47–1.31 (2H, m, 2 × C1-H), 1.30–1.17 (2H, m, 2 × C1-H), 
0.86–0.83 (2H, m, 2 × C3-H); 13C NMR (CDCl3, 100 MHz): δ 141.4 (C6), 128.4, 128.3, 126.9 (C7, C8, 
C9), 54.0 (C5), 36.4 (C4), 22.8 (C1), 18.5 (C2), 12.3 (C3); HRMS: (ESI+) Calculated for C14H20N: 
202.1590. Found [M+H]+: 202.1596. The relative stereochemistry of this compound was corroborated 
by nOe experiments (as indicated on the compound structure). An nOe was observed between C5-H2 
and C2-H2. No significant nOe was observed between C5-H2 and C3-H. Data for product trans-232: 
νmax / cm-1: 2923 (s), 2850 (s), 1449 (s), 1295 (m); 1H NMR (CDCl3, 400 MHz): δ 7.35–7.23 (5H, m, 2 
× C7-H, 2 × C8-H, C9-H), 3.81 (2H, s, C5-H2), 1.89–1.80 (3H, m, 2 × C2-H, C4-H), 1.72 (1H, br. s, 
NH), 1.62–1.55 (2H, m, 2 × C2-H), 1.25–1.16 (2H, m, 2 × C1-H), 1.09–1.01 (2H, m, 2 × C2-H), 0.94–
0.87 (2H, m, 2 × C3-H); 13C NMR (CDCl3, 100 MHz): δ 140.7 (C6), 128.3, 128.3, 126.8 (C7, C8, C9), 
53.6 (C5), 42.3 (C4), 23.0 (C2), 21.8 (C1), 18.8 (C3); HRMS: (ESI+) Calculated for C14H20N: 202.1590. 
Found [M + H]+: 202.1589. 
1,3-Dibenzyl-1-((1R*,6S*,7S*)-bicyclo[4.1.0]heptan-7-yl)urea (cis-222) 
 
General procedure A: Amine cis-232 (750 mg, 3.73 mmol) was employed and the residue was purified 
by FCC (15–20% EtOAc/hexane) to provide the title compound (1.16 g, 93%) as a colourless solid; 
m.p. 105–107 °C (CHCl3/hexane); νmax / cm-1: 2924 (w), 1632 (s), 1504 (s), 1278 (m), 1231 (m); 1H 
NMR (DMSO-d6, 500 MHz, 70 °C): δ 7.32–7.19 (10H, m, 2 × C8-H, 2 × C9-H, C10-H, 2 × C13-H, 2 
× C14-H, 2 × C15-H), 6.63 (1H, m, NH), 4.53 (2H, br. s, C11-H2), 4.33 (2H, d, J  = 5.9 Hz, C6-H2), 
2.23 (1H, t, J = 7.4 Hz, C4-H), 1.82 (2H, m, 2 × C2-H), 1.56 (2H, m, 2 × C2-H), 1.30–1.17 (4H, m, C1-
H), 1.10 (2H, m, C3-H); 13C NMR (CDCl3, 100 MHz): δ 159.2 (C5), 140.2 (C7), 138.5 (C12), 127.6, 
127.5, 127.3, 126.8, 126.2, 125.9 (C8, C9, C10, C13, C14, C15), 49.8 (C11), 43.5 (C6), 34.1 (C4), 20.7 
(C1), 18.5 (C2), 13.9 (C3); HRMS: (ESI+) Calculated for C22H26N2NaO: 357.1937. Found [M + Na]+: 
357.1937. 






General Procedure B: Urea cis-222 (50.2 mg, 0.150 mmol) and [Rh(cod)2]BARF (10.0 mol%) were 
employed, and the reaction was stirred for 96 h at 90 °C. The crude mixture was purified by FCC (10% 
EtOAc/hexane) to yield the title compound (28.2 mg, 54%) as a colourless oil; νmax / cm-1: 2934 (w), 
2863 (w), 1697 (s), 1645 (s), 1404 (s); 1H NMR (CDCl3, 400 MHz): δ 7.33–7.24 (8H, m, 2 × C9-H, 
C10-H, 2 × C13-H, 2 × C14-H, C15-H), 7.07–7.05 (2H, m, C8-H), 5.82 (1H, s, C5-H), 5.24 (1H, d, J = 
14.5 Hz, C11-H), 4.92–4.84 (2H, m, 1 × C6-H, 1 × C11-H), 4.59 (1H, d, J = 15.0 Hz, C6-H), 3.16 (1H, 
m, C3-H), 2.39 (1H, m, C16-H), 2.27 (1H, m, C18-H), 2.13 (1H, m, C16-H), 1.81–1.67 (3H, m, 1 × 
C17-H, C18-H, C19-H), 1.50 (1H, m, C19-H), 1.33 (1H, m, C17-H); 13C NMR (CDCl3, 100 MHz): δ 
171.7 (C2), 154.5 (C1), 138.0 (C12), 136.4 (C7), 128.8, 128.5, 128.4, 128.2, 127.7, 127.2 (C8, C9, C10, 
C13, C14, C15), 123.2 (C5), 52.8 (C6), 47.7 (C11), 41.2 (C3), 27.0 (C16), 23.1 (C17), 22.7 (C19), 22.1 
(C18); HRMS: (ESI+) Calculated for C23H24N2NaO2: 383.1730. Found [M + Na]+: 383.1739. 
1-Benzyl-3-((1R*,6S*,7S*)-bicyclo[4.1.0]heptan-7-yl)urea (cis-233) and 1-Benzyl-3-
((1R*,6S*,7S*)-bicyclo[4.1.0]heptan-7-yl)urea (trans-233) 
 
General procedure A: Amine·hydroiodide salt cis-232 (480 mg, 3.73 mmol, 3:1 d.r.) was employed 
and the residue was purified by FCC (50% EtOAc/hexane) to provide the title compound (378 mg, 77%, 
4:1 d.r.,) as a colourless oil. Data for the mixture of diastereomers: νmax / cm-1: 3316 (s), 2924 (s), 
2850 (s), 1629 (s), 1565 (s), 1249 (s); m/z (ESI+) HRMS: Calculated for C15H21N2O: 245.1648. Found 
[M + H]+: 245.1646. Data for major diastereomer cis-233: 1H NMR (CDCl3, 400 MHz): δ 7.36–7.25 
(5H, m, 2 × C8-H, 2 × C9-H, C10-H), 5.23 (1H, br. s, NH), 4.47 (2H, d, J = 6.0 Hz, C6-H2) 2.33 (1H, 
t, J = 7.0 Hz, C4-H), 1.87 (2H, m, 2 × C2-H), 1.44–1.34 (2H, m, 2 × C2-H), 1.27–1.18 (4H, m, 4 × 
C1-H), 1.08–1.03 (2H, m, 2 × C3-H); 13C NMR (CDCl3, 100 MHz): δ 159.3 (C5), 139.5 (C7), 128.7, 
127.6, 127.3 (C8, C9, C10), 44.4 (C6), 29.0 (C4), 21.8 (C1), 18.0 (C2), 12.2 (C3). The relative 
stereochemistry of this compound was corroborated by nOe experiments (as indicated on the compound 
structure). A strong nOe was observed between C4-H to C3-H. Data for minor diastereomer 




trans-233: Characteristic signals only:  1H NMR (CDCl3, 400 MHz): δ 5.05 (1H, br. s, NH), 4.66 (1H, 
br. s, NH), 2.11 (1H, m, C4-H), 1.66–1.58 (2H, m, 2 × C2-H); 13C NMR (CDCl3, 100 MHz): δ 159.3 
(C5), 139.6 (C7), 128.7, 127.2, (ArCH), 44.1 (C6), 34.0 (C4), 22.3 (C2), 21.3 (C1), 19.7 (C3). 
(5aS*,9aR*)-2-Benzyloctahydro-1H-benzo[e][1,3]diazepine-1,3(2H)-dione (235) and 2-Benzyl-
4,5,6,7,8,9-hexahydro-1H-benzo[e][1,3]diazepine-1,3(2H)-dione (234) 
 
General Procedure B: Urea cis-233 (36.7 mg, 0.150 mmol, 4:1 d.r.) and [Rh(cod)2]BARF (7.5 mol%) 
were employed, and the reaction was stirred for 48 h at 110 °C. The crude mixture was purified by FCC 
(15–25% EtOAc/hexane) to yield title compound 235 (20.7 mg, 51%) as a pale brown oil and 234 
(6.80 mg, 17%) as a colourless oil. Analysis of the crude reaction mixture by 1H NMR revealed a 3:1 
(234:235) mixture of products. Data for major product 235: νmax / cm-1: 3304 (m), 2929 (m), 1707 (s), 
1536 (s), 1380 (s), 1247 (s); 1H NMR (CDCl3, 500 MHz): δ 8.76 (1H, br. s, NH), 7.35–7.24 (5H, m, 2 
× C8-H, 2 × C9-H, C10-H), 4.53 (1H, ddd, J = 15.0, 5.5 Hz, 1 × C6-H), 4.47 (1H, dd, J = 15.0, 5.5 Hz, 
1 × C6-H), 3.67 (1H, dd, J = 11.0, 6.0 Hz, 1 × C5-H), 3.61 (1H, dd, J = 11.0, 2.0 Hz, 1 × C5-H), 2.69 
(1H, td, J = 7.0, 4.0 Hz, C3-H), 2.33 (1H, m, C4-H), 2.04 (1H, m, 1 × C14-H), 1.76 (1H, m, 1 × C11-H), 
1.64–1.50 (3H, m, 1 × C12-H, 1 × C13-H, 1 × C14-H), 1.27–1.13 (3H, m, 1 × C11-H, 1 × C12-H, 1 × 
C13-H); 13C NMR (CDCl3, 125 MHz): δ 178.1 (C2), 153.5 (C1), 138.2 (C7), 128.6, 127.6, 127.3 (C8, 
C9, C10), 49.3 (C5), 44.2 (C3), 43.8 (C6), 31.2 (C4), 27.7 (C11), 23.4 (C12), 22.9 (C14), 22.6 (C13); 
HRMS: (ESI+) Calculated for C16H20N2NaO2: 295.1417. Found [M + Na]+: 295.1424. Data for minor 
product 234: νmax / cm-1: 3298 (m), 2930 (m), 1699 (s), 1679 (m), 1537 (s), 1356 (s), 1250 (s); 1H NMR 
(CDCl3, 500 MHz): δ 8.75 (1H, br. s, NH), 7.35–7.22 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 4.53 (2H, 
d, J = 6.0 Hz, C6-H2), 4.26 (2H, s, C5-H2), 2.35–2.32 (2H, m, C14-H2), 2.21–2.17 (2H, m, C11-H2), 
1.79–1.70 (4H, m, C12-H3, C13-H3); 13C NMR (CDCl3, 125 MHz): δ 172.2 (C2), 154.8 (C4), 152.7 
(C1), 138.5 (C7), 131.3 (C3), 128.6, 127.5, 127.2 (C8, C9, C10), 51.5 (C5), 43.6 (C6), 24.4 (C14), 21.7, 









3-Benzyl-1,3-diazepane-2,4-dione (d-204a) and 1-Benzyl-3,6-dihydro-1H-1,3-diazepine-2,7-dione 
(203a) 
 
d-202a was initially prepared by repeatedly dissolving 202a in MeOD-d4 and concentrating the resulting 
solution in-vacuo. 97% deuterium incorporation at N1 and 90% deuterium incorporation at N2 was 
measured by 1H NMR. Data for d-202a: 1H NMR (CDCl3, 400 MHz): δ 7.37-7.25 (2 × C6-H, 2 × C7-H, 
C8-H), 5.31 (0.03H, br. s, NH), 4.79 (0.10H, br. s, NH), 4.47 (2H, d, J = 6.0 Hz, C4-H2), 2.46 (1H, tt, 
J = 7.0, 3.5 Hz, C2-H), 0.76-0.71 (2H, m, 2 × C1-H), 0.60-0.57 (2H, m, 2 × C1-H). CDCl3 was base 
filtered (K2CO3 plug) prior to use. 
General Procedure B: Urea d-202a (28.5 mg, 0.150 mmol) and [Rh(cod)2]BARF (5.0 mol%) were 
employed, and the reaction was stirred for 24 h at 90 °C. The crude mixture was purified by FCC (30% 
EtOAc/hexane) to yield the title compound (20.5 mg, 63%, 2.5:1, d-204a:203a) as a yellow oil. Analysis 
of the product revealed 56% deuterium incorporation at C5, 16% at C4 and 40% at C3. No deuterium 
incorporation was observed in 8l. Data for product d-204a: 1H NMR (CDCl3, 400 MHz): δ 8.79 (1H, 
br. s, NH), 7.35–7.21 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 4.50 (2H, d, J = 6.0 Hz, C6-H2), 3.89 
(1.44H, t, J = 7.0 Hz, C5-H2), 2.61 (1.60H, t, J = 7.0 Hz, C3-H2), 2.04 (1.84H, tt, J = 7.0, 7.0 Hz, 
C4-H2); 2H NMR (CHCl3, 500 MHz): δ 3.89 (0.56D, br. s, C5-D), 2.60 (0.49D, br. s, C3-D), 2.02 
(0.06D, br. s, C4-D).  
3-Benzyl-6-butyl-1,3-diazepane-2,4-dione (d-221b) and 3-Benzyl-5-butyl-1,3-diazepane-2,4-dione 
(219b) 
 
d-cis-215b was initially prepared by repeatedly dissolving cis-215b in MeOD-d4 and concentrating the 
resulting solution in-vacuo. 92% deuterium incorporation at N1 and 90% deuterium incorporation at 
N2 was measured by 1H NMR. Data for d-cis-215b: 1H NMR (CDCl3, 500 MHz): δ 7.31–7.22 (5H, m, 
2 × C11-H, 2 × C12-H, C13-H), 5.44 (0.08H, br. s, NH), 4.92 (0.10H, br. s, NH), 4.40 (2H, d, J = 
6.0 Hz, C9-H2), 2.45 (1H, m, C7-H), 1.45 (1H, m, 1 × C4-H), 1.37–1.28 (4H, m, C2-H2, C3-H2), 1.19 




(1H, m, 1 × C4-H), 0.89–0.84 (4H, m, C1-H3, 1 × C6-H), 0.13 (1H, m, 1 × C6-H). CDCl3 was base 
filtered (K2CO3 plug) prior to use. 
General Procedure B: Urea d-cis-215b (37.0 mg, 0.150 mmol) and [Rh(cod)2]BARF (7.5 mol%) were 
employed, and the reaction was stirred for 43 h at 90 °C. The crude mixture was purified by FCC (20% 
EtOAc/hexane) to yield the title compound d-221b (19.2 mg, 47%) as a yellow oil. Analysis of the 
product revealed 23% and 19% deuterium incorporation at the diastereotopic C5 positions. <5% 
deuterium incorporation was measured at C4. 219b could not be isolated in a pure form and therefor 
deuterium incorporation could not be confirmed. Data for product d-221b: 1H NMR (CDCl3, 
400 MHz): δ 8.75 (1H, br. s, NH), 7.39–7.20 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 4.50 (2H, d, J = 
6.0 Hz, C6-H2), 4.04 (0.81H, dd, J = 11.0, 7.5 Hz, 1 × C5-H), 3.44 (0.77H, dd, J = 11.0, 7.0 Hz, 1 × 
C5-H), 2.69 (1H, m, 1 × C3-H), 2.35–2.26 (1.96H, m, 1 × C3-H, C4-H), 1.52–1.26 (6H, m, C11-H2, 
C12-H2, C13-H2), 0.91 (3H, t, J = 7.0 Hz, C14-H3). 2H NMR (CHCl3, 500 MHz): δ 8.74 (0.34 D, br. s, 
ND), 4.05 (0.71D, br. s, 1 × C5-D), 3.44 (1D, br. s, 1 × C5-D), 2.28 (0.04D, br. m, C4-D). 
Ethyl methyl(2-methylprop-1-en-1-yl)carbamate (248a) and Ethyl methylcarbamate (248b) 
 
Carbamate trans-174a was synthesised by McCreanor103: An oven dried reaction tube, fitted with a 
magnetic stirrer, was charged with [Rh(cod)2]BF4 (3.10 mg, 0.00750 mmol) and PPh3 (5.90 mg, 
0.0225 mmol). The tube was fitted with a rubber septum and purged with argon. Carbamate trans-174a 
(23.6 mg, 0.150 mmol, single diastereomer) in argon sparged anhydrous toluene (0.75 mL) was added 
via syringe before aging the catalyst for ca. 5 minutes. The reaction was heated at 100 °C with stirring 
for 6 h. The mixture was cooled to room temperature, concentrated in vacuo and purified by FCC (5% 
EtOAc/hexane) to yield the title compounds (15.1 mg, 64%, 10:1, 248a:248b) as a colourless oil. The 
presence of 248b is attributed to hydrolysis of enamine I under the reaction conditions. None of the 
linear β-hydride elimination products resulting from insertion into bond b were observed by NMR of 
the crude reaction mixture. Data for the mixture of compounds: νmax / cm-1: 2978 (w), 1698 (s), 1447 
(m), 1382 (m), 1147 (s); HRMS: (ESI+) Calculated for C8H15NNaO2: 180.1000. Found [M + Na]+: 
180.0988. Data for major compound 248a: 1H NMR (CDCl3, 400 MHz): δ 4.86 (1H, br. s, C2-H), 
4.77 (1H, br. s, C2-H), 4.14 (2H, q, J = 7.0 Hz, C6-H2), 3.80 (2H, m, C4-H2), 2.82 (3H, m, C8-H3), 1.67 
(3H, s, C1-H3), 1.26 (3H, m, C7-H3); 13C NMR (CDCl3, 100 MHz): δ 111.9 (C2), 61.4 (C6), 54.7 (C4), 




33.3 (C8), 19.9 (C1), 14.9 (C7). Data for minor compound 248b: Characteristic signals only: 1H 
NMR (CDCl3, 400 MHz): δ 2.98 (3H, s, C1-H3). Proton signals corresponding to C3 and C4 closely 
overlap C6 and C7 of compound 248b. 
Benzyl ((1R*,2S*)-2-butylcyclopropyl)carbamate 
 
Amine I was synthesised by McCreanor103: To a stirring solution of amine (100 mg, 0.880 mmol) and 
NEt3 (0.150 mL, 1.06 mmol) in CH2Cl2 (4.4 mL) was added benzyl chloroformate (150 μL, 1.06 mmol) 
dropwise at 0 °C over 10 minutes under an atmosphere of nitrogen. The reaction mixture was warmed 
to room temperature and stirred for 16 h. The mixture was diluted with water (10 mL) and extracted 
with CH2Cl2 (3 × 10 mL). The organic extracts were combined, washed with brine (10 mL), dried over 
Na2SO4 and concentrated in vacuo. The crude mixture was purified by FCC (20% EtOAc/hexane) to 
yield the title compound (145 mg, 67%) as a colourless oil; νmax / cm-1: 3324 (m), 1700 (s), 1525 (s), 
1453 (m), 1259 (s), 1075 (s); 1H NMR (CDCl3, 400 MHz): δ 7.36–7.27 (5H, m, 2 × C11-H, 2 × C12-H, 
C13-H), 5.16–5.09 (2H, m, C9-H2), 4.73 (1H, m, NH), 2.69 (1H, m, C7-H), 1.49–1.18 (6H, m, C2-H2, 
C3-H2, C4-H2), 0.98–0.83 (5H, m, C1-H3, C5-H, 1 × C6-H), 0.16 (1H, m, 1 × C6-H); 13C NMR (CDCl3, 
100 MHz): δ 157.3 (C8), 136.7 (C10), 128.4, 128.0 (C11, C12, C13), 66.7 (C9), 31.7 (C3), 27.6 (C7), 
27.3 (C4), 22.5 (C2), 17.4 (C5), 13.9 (C1), 12.3 (C6); HRMS: (ESI+) Calculated for C15H22NO2: 
248.1645. Found [M + H]+: 248.1642. 
Benzyl ((1R*,2S*)-2-butylcyclopropyl)(methyl)carbamate (cis-174b) 
 
To a solution of NaH (58.0 mg, 2.40 mmol) in THF (1.6 mL) was added a solution of carbamate I (120 
mg, 0.485 mmol) in THF (0.25 mL) and the reaction was stirred at 0 °C for 1 h. Methyl iodide (150 μL, 
2.40 mmol) was added dropwise at 0 °C and the reaction was stirred at room temperature for 18 h. 
Water (5 mL) was added to the reaction mixture and the solution was extracted with Et2O (3 × 5 mL). 
The organic extracts were combined, washed with brine (5 mL), dried over Na2SO4 and concentrated 
in vacuo. The crude mixture was purified by FCC (10% EtOAc/hexane) to yield the title compound 
(99.2 mg, 78%) as a colourless oil; νmax / cm-1: 2927 (s), 1701 (s), 1455 (m), 1391 (s), 1344 (s), 1150 
(s); 1H NMR (CDCl3, 400 MHz): δ 7.39–7.28 (5H, m, 2 × C11-H, 2 × C12-H, C13-H), 5.19–5.09 (2H, 
m, C9-H2), 2.91 (3H, s, C14-H3), 2.68 (1H, ddd, J = 7.5, 7.0, 4.5 Hz, C7-H), 1.58 (1H, m, 1 × C4-H), 




1.37–1.25 (4H, m, C2-H2, C3-H2), 0.99–0.81 (6H, m, C1-H3, 1 × C4-H, C5-H, 1 × C6-H), 0.32 (1H, m, 
1 × C6-H); 13C NMR (CDCl3, 100 MHz): δ 158.0 (C8), 136.9 (C10), 128.4, 127.9 (C11, C12, C13), 
67.0 (C9), 35.8 (C14), 35.4 (C7), 31.7 (C3), 27.6 (C4), 22.6 (C2), 19.7 (C5), 14.1 (C1), 11.9 (C6); 
HRMS: (ESI+) Calculated for C16H23NNaO2: 284.1621. Found [M + Na]+: 284.1623. 
Benzyl (E)-hept-1-en-1-yl(methyl)carbamate (247bI) and Benzyl hept-2-en-1-
yl(methyl)carbamate (247bII) 
 
An oven dried reaction tube, fitted with a magnetic stirrer, was charged with [Rh(cod)2]BF4 (3.70 mg, 
9.00 mol) and PPh3 (7.10 mg, 0.0270 mmol). The tube was fitted with a rubber septum and purged 
with argon. Carbamate cis-174b (47.0 mg, 0.180 mmol) in argon sparged anhydrous toluene (2 mL) 
was added via syringe before aging the catalyst for ca. 5 minutes. The reaction was heated at 100 °C 
with stirring for 3 h. The mixture was cooled to room temperature, concentrated in vacuo and purified 
by FCC (5% EtOAc/hexane) to yield regioisomer 247bI (31.1 mg, 66%, 1:1, mixture of rotamers A:B) 
as a colourless oil and regioisomer 247bII (9.40 mg, 20%, tentatively assigned mixture of E/Z 
diastereomers) as a colourless oil. Data for the major regioisomer 247bI: νmax / cm-1: 2928 (m), 1693 
(s), 1403 (m), 1214 (m), 1153 (s); 1H NMR (CDCl3, 400 MHz): δ 7.38–7.30 (5H, m, 2 × C11-H, A+B, 
2 × C12-H, A+B, C13-H, A+B), 7.01 (0.50H, d, J = 14.0 Hz, C7-H, A), 6.89 (0.50H, d, J = 14.0 Hz, 
C7-H, B), 5.19 (2H, s, C9-H2, A+B), 4.85 (1H, dt, J = 14.0, 7.5 Hz, C6-H, A+B), 3.07–3.05 (3H, m, 
C14-H3, A+B), 2.08–1.99 (2H, m, C5-H2, A+B), 1.40–1.25 (6H, m, C2-H2, A+B, C3-H2, A+B, C4-H2, 
A+B), 0.89 (3H, t, J = 7.0 Hz, C1-H3, A+B); 13C NMR (CDCl3, 100 MHz): δ 154.3, 153.9 (C8, A+B), 
136.4 (C10, A+B), 128.5, 128.2, 128.0 (C11, A+B, C12, A+B, C13, A+B), 127.5 (C7, A+B), 110.0 (C6, 
A+B), 67.8, 67.6 (C9, A+B), 31.5 (CH2, A+B), 31.0 (C14, A+B), 30.2 (CH2, A+B, C5, A+B), 22.5 (CH2, 
A+B), 14.1 (C1, A+B). C2, C3 and C4 could not be assigned. Aldehyde peaks appear due to 
decomposition of the product; HRMS: (ESI+) Calculated for C16H23NNaO2: 284.1621. Found [M + 
Na]+: 284.1618. Data for the minor regioisomer 247bII: νmax / cm-1: 2929 (m), 1705 (s), 1397 (m), 
1324 (m), 1256 (s), 1136 (s); 1H NMR (400 MHz, CDCl3): δ 7.38–7.28 (5H, m, 2 × C11-H, 2 × C12-H, 
C13-H), 5.55 (1H, m, C5-H), 5.39 (1H, m, C6-H), 5.13 (2H, s, C9-H2), 3.87–3.79 (2H, m, C7-H2), 2.88–
2.82 (3H, m, C14-H3), 2.06–1.97 (2H, m, C4-H2), 1.37–1.23 (4H, m, C2-H2, C3-H2), 0.90 (3H, t, J = 
C1-H3); 13C NMR (100 MHz, CDCl3): δ 156.2 (C8), 137.0 (C10), 133.9 (C5), 128.4, 127.8, 127.8 (C11, 




C12, C13), 124.6 (C6), 67.0 (C9), 50.6 (C7), 33.1 (C14), 31.8 (C4), 31.3 (CH2), 22.2 (CH2), 13.9 (C1). 
C2 and C3 could not be assigned; HRMS: (ESI+) Calculated for C16H23NNaO2: 284.1621. Found [M + 
Na]+: 284.1619. 
1,3-Dibenzyl-1-(2-methylprop-1-en-1-yl)urea (250a) and 1,3-Dibenzyl-1-(2-methylallyl)urea 
(250b) 
 
Urea trans-206a was synthesised by McCreanor103: Urea trans-206a (58.9 mg, 0.20 mmol) in 
anhydrous toluene (2 mL) was added to a resealable tube containing [Rh(cod)2]BF4 (4.00 mg, 
0.010 mmol) and PPh3 (7.90 mg, 3.00 mol) under an atmosphere of argon. The tube was sealed and 
heated at 100 °C and stirred for 2 h. The mixture was cooled to room temperature and concentrated in 
vacuo. The crude mixture was purified by FCC (25% EtOAc/hexane) to yield title compounds 250a 
and 250b (50.7 mg, 86%, 2:1, r.r.) as a colourless oil. The isomers could not be separated by FCC. 
Analysis of the crude reaction mixture by 1H NMR revealed a 2:1 (250a:250b) mixture of products. 
Data for the mixture of compounds: νmax / cm-1: 3355 (m), 1643 (s), 1510 (s), 1496 (s), 1434 (m), 
1264 (s); HRMS: (ESI+) Calculated for C19H23N2O: 295.1805. Found [M + H]+: 295.1804. Data for 
compound 250a: 1H NMR (CDCl3, 400 MHz): δ 7.37–7.23 (10H, m, 2 × C8-H, 2 × C9- H, C10-H, 2 
× C13-H, 2 × C14-H, C15-H), 5.67 (1H, s, C4-H), 5.11 (1H, t, J = 6.0 Hz, NH), 4.62 (2H, s, C11-H2), 
4.47 (2H, d, J = 6.0 Hz, C6-H2), 1.66 (3H, s, C1/2-H3), 1.50 (3H, s, C1/2-H3); 13C NMR (CDCl3, 
100 MHz): δ 157.0 (C5), 139.8 (C7), 138.4 (C12), 137.9 (C3), 128.6, 128.5. 128.3. 127.5, 127.4, 127.0 
(C8, C9, C10, C13, C14, C15), 122.3 (C4), 51.1 (C11), 44.8 (C6), 21.9, 17.6 (C1, C2). Data for 
compound 250b: 1H NMR (CDCl3, 400 MHz): δ 7.37–7.23 (10H, m, 2 × C8-H, 2 × C9-H, C10-H, 2 × 
C13-H, 2 × C14-H, C15-H), 4.92 (1H, s, C2-H), 4.89 (1H, s, C2-H), 4.86 (1H, br. s, NH), 4.54 (2H, s, 
C11-H2), 4.46 (2H, d, J = 6.0 Hz, C6-H2), 3.79 (2H, s, C4-H2), 1.70 (3H, s, C1-H3); 13C NMR (CDCl3, 
100 MHz): δ 158.5 (C5), 141.3 (C3), 139.6 (C7), 138.0 (C12), 128.7, 128.5, 128.4, 127.5, 127.3, 127.1 









(E)-1,3-Dibenzyl-1-(but-1-en-1-yl)urea (249) and 1,3-Dibenzyl-1-(2-methylprop-1-en-1-yl)urea 
(250) 
 
Urea cis-206a was synthesised by McCreanor103: To a resealable tube containing [Rh(cod)2]BF4 
(4.00 mg, 10.0 mol) and PPh3 (7.90 mg, 30.0 mol) under an atmosphere of argon was added urea 
cis-206a (58.9 mg, 0.200 mmol) in anhydrous toluene (2 mL). The tube was sealed and heated at 100 °C 
and stirred for 2 h. The mixture was cooled to room temperature and concentrated in vacuo. The crude 
mixture was purified by FCC (25% EtOAc/hexane) to yield title compound 249 (21.8 mg, 37%) as a 
colourless oil. Analysis of the crude reaction mixture by 1H NMR revealed an 11:1 (249:250) mixture 
of products. Data for compound 249: νmax / cm-1: 3322 (s), 1628 (s), 1531 (s), 1452 (s), 1248 (s); 1H 
NMR (CDCl3, 400 MHz): δ 7.35–7.21 (10H, m, 2 × C8-H, 2× C9-H, C10-H, 2 × C13-H, 2 × C14-H, 
C15-H), 6.81 (1H, d, J = 14.0 Hz, C4-H), 5.03–4.93 (2H, m, C3-H, NH), 4.73 (2H, s, C11-H2), 4.44 
(2H, d, J = 5.5 Hz, C6-H2), 2.02 (2H, dq, J = 7.0, 7.0 Hz, C2-H2), 0.95 (3H, t, J = 7.0 Hz, C1-H3); 13C 
NMR (CDCl3, 100 MHz): δ 156.0 (C5), 139.1 (C7), 137.3 (C12), 128.7, 128.6, 127.5, 127.3, 127.2, 
126.8, 126.5 (C4, C8, C9, C10, C13, C14, C15), 114.8 (C3), 48.7 (C11), 44.9 (C6), 23.5 (C2), 14.7 
(C1); HRMS: (ESI+) Calculated for C19H23N2O: 295.1805. Found [M + H]+: 295.1808.  
  




4.3 Experimental procedures for the studies in Section 2.2 
1,3-Dibenzyl-1-(cyclopropylmethyl)urea (263a) 
 
Amine I was synthesised by McCreanor359: To a stirring solution of amine I (1.77 g, 11.0 mmol) in 
CH2Cl2 (33 mL), was added benzyl isocyanate (1.24 mL, 10.0 mmol). The reaction mixture was stirred 
for 2 h before being diluted with CH2Cl2 (100 mL) and washed with 1M aq. HCl (50 mL), sat. aq. 
NaHCO3 (50 mL) and brine (50 mL). The organic layer was dried over Na2SO4 and concentrated in 
vacuo. Purification by FCC (50% EtOAc/hexane) provided the title compound (2.46 g, 83%) as a 
colourless solid; m.p. (CH2Cl2/ hexane); 86–88 °C; νmax / cm-1: 3305 (s), 1616 (s), 1540 (s), 1454 (s), 
1266 (s); 1H NMR (CDCl3, 400 MHz): δ 7.32–7.17 (10H, m, 2 × C7-H, 2 × C8-H, C9-H, 2 × C12-H, 2 
× C13-H, C14-H), 4.82 (1H, t, J = 5.5 Hz, NH), 4.57 (2H, s, C10-H2), 4.40 (2H, d, J = 5.5 Hz, C5-H2), 
3.21 (2H, d, J = 6.5 Hz, C3-H2), 0.96 (1H, m, C2-H), 0.50–0.45 (2H, m, 2 × C1-H2), 0.18–0.14 (2H, m, 
2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 158.2 (C4), 139.6 (C6), 138.1 (C11), 128.7, 128.5, 127.4, 
127.3, 127.1, 126.9 (C7, C8, C9, C12, C13, C14), 51.6 (C3), 50.6 (C10), 44.9 (C5), 10.2 (C2), 3.8 (C1); 
HRMS: (ESI+) Calculated for C19H23N2O: 295.1805. Found [M + H]+: 295.1808. 
1,3-Dibenzyl-1-(but-3-en-1-yl)urea (267a) and (E)-1,3-Dibenzyl-1-(but-2-en-1-yl)urea (267b) 
 
General procedure B: [Rh(cod)2]BARF (13.3 mg, 0.0113 mmol), dppe (4.48 mg, 0.0113 mmol) and 
urea 263a (44.2 mg, 0.150 mmol) were employed in 1,2-DCB (0.75 mL) at 140 °C for 18 h. Purification 
by FCC (30% EtOAc/ hexane) provided title compounds 267 (22.0 mg, 50%, 1:2.5 mixture of 
regioisomers 267a (A) and 267b (B)) as a colourless oil; νmax / cm-1: 3342 (br.), 1626 (s), 1529 (s), 1495 
(m), 1244 (m); 1H NMR (CDCl3, 400 MHz): δ 7.37–7.14 (20H, m, 4 × C8-H, 4 × C9-H, 2 × C10-H, 4 
× C13-H, 4 × C14-H, 2 × C15-H, A+B), 5.79 (1H, ddt, J = 17.0, 10.0, 7.0 Hz, C2-H, A), 5.58 (1H, m, 
C2-H, B), 5.41 (1H, m, C3-H, B), 5.10–5.01 (2H, m, C1-H2, A), 4.78 (1H, NH, A), 4.68 (1H, NH, B), 
4.51–4.51 (4H, m, 4 × C11-H2, A+B), 4.44–4.41 (4H, m, 4 × C6-H2, A+B), 3.80 (2H, d, J = 6.0 Hz, 
C4-H2, B), 3.39 (2H, t, J = 7.0 Hz, C4-H2, A), 2.33 (2H, m, C3-H2, A), 1.67 (3H, ddt, J = 6.5, 1.5, 




1.5 Hz, C1-H3, B); 13C NMR (CDCl3, 100 MHz): δ 158.4 (C5, A+B), 139.7, 139.7 (C7, A+B), 138.3 
(C12, A+B), 135.4 (C2, A), 128.9, 128.9, 128.8, 128.6 (ArC-H, A+B), 128.5 (C2, B), 127.6, 127.5, 
127.4, 127.2, 127.0 (ArC-H, A+B), 126.8 (C3, B), 117.1 (C1, A), 50.3 (C11, A+B), 49.0 (C4, B), 47.4 
(C4, A), 45.0 (C6, A+B), 33.0 (C3, A), 17.7 (C1, B); HRMS: (ESI+) Calculated for C19H23N2O: 
295.1732. Found [M + H]+: 295.1811. 
1-Benzyl-3-(cyclopropylmethyl)urea (263b) 
 
To a stirring solution of cyclopropylmethylamine (0.870 mL, 10.0 mmol) and NEt3 (3.50 mL, 
25.0 mmol) in CH2Cl2 (33 mL), was added benzyl isocyanate (1.20 mL, 9.95 mmol). The reaction 
mixture was stirred for 2 h during which time a colourless solid had formed. The reaction mixture was 
diluted with CH2Cl2 (100 mL) and washed with aq. 1M HCl (50 mL), sat. aq. NaHCO3 (50 mL) and 
brine (50 mL) before being dried over Na2SO4 and concentrated in vacuo to provide the title compound 
(1.87 g, 92%) as a colourless solid; m.p. 110–111 °C (CH2Cl2/hexane); νmax / cm-1: 3344 (m), 3301 (m), 
1614 (s), 1571 (s), 1453 (m), 1242 (s); 1H NMR (CDCl3, 400 MHz): δ 7.31–7.21 (5H, m, 2 × C7-H, 2 
× C8-H, C9-H), 5.10 (1H, br. m, N2-H), 4.87 (1H, br. m, N1-H), 4.31 (2H, d, J = 5.5 Hz, C5-H2), 2.99 
(2H, dd, J = 6.5, 4.5 Hz, C3-H2), 0.89 (1H, m, C2-H), 0.43 (2H, m, 2 × C1-H2), 0.12 (2H, m, 2 × C1-H2); 
13C NMR (CDCl3, 100 MHz): δ 158.5 (C4), 139.5 (C6), 128.7, 127.6 (C7, C8), 127.3 (C9), 45.4 (C3), 




To a flame dried reaction tube equipped with a stir bar was added [Rh(cod)2]OTf (3.51 mg, 
0.00750 mmol), PPh3 (5.90 mg, 0.0225 mmol) and 263b (30.6 mg, 0.150 mmol). The tube was sealed 
with a rubber septum and purged with argon for 30 minutes. Dry toluene (0.75 mL) was added by 
syringe and the reaction mixture was stirred for 10 seconds. The tube was sealed and heated at 140 °C 
for 20 h. The crude reaction mixture was concentrated in vacuo and purified by FCC (40% 
EtOAc/hexane) to provide the title compound (7.00 mg, 36% assuming 2 eq. of substrate required) as 
a pale yellow solid; νmax / cm-1: 3214 (w), 3085 (w), 2924 (m), 1697 (m), 1660 (s), 1450 (s), 1434 (s), 




1277 (m); 1H NMR (CDCl3, 400 MHz): δ 7.35–7.32  (5H, m, 2 × C12-H, 2 × C13-H, C14-H), 5.67 (1H, 
t, J = 1.5 Hz, C2-H), 4.80 (1H, br. s, NH), 4.68 (1H, d, J = 15.5 Hz, C10-H), 4.54 (1H, d, J = 15.5 Hz, 
C10-H), 3.94 (1H, m, C4-H), 1.94 (2H, m, C8-H2), 1.58–1.30 (4H, m, C5-H2, C6-H2), 0.98 (3H, t, J = 
7.5 Hz, C9-H3), 0.92 (3H, t, J = 7.5 Hz, C7-H3); 13C NMR (CDCl3, 100 MHz): δ 154.5 (C1), 138.3 
(C11), 128.7, 127.6 (C12, C13), 127.4 (C14), 122.6 (C2), 116.7 (C3), 54.8 (C4), 49.6 (C10), 37.9 (C5), 
23.5 (C8), 17.3 (C6), 14.1 (C7), 12.1 (C9); HRMS: (ESI+) Calculated for C16H23N2O: 259.1805. Found 
[M + H]+: 259.1801. 
1-(tert-Butyl)-3-(cyclopropylmethyl)urea (263c) 
 
To a stirring solution of cyclopropylmethylamine (0.870 mL, 10.0 mmol) in CH2Cl2 (33 mL), was added 
tert-butyl isocyanate (1.08 mL, 9.50 mmol). The reaction was stirred for 2 h during which time a 
colourless solid formed. The suspension was diluted with CH2Cl2 (100 mL) and washed with aq. 1M 
HCl (50 mL), sat. aq. NaHCO3 (50 mL) and brine (50 mL) before being dried over Na2SO4 and 
concentrated in vacuo to provide the title compound (1.21 g, 75%) as a colourless solid; m.p. 147–
149 °C (CH2Cl2/hexane); νmax / cm-1: 3355 (m), 3317 (m), 2963 (m), 1629 (s), 1559 (s), 1269 (m), 1216 
(m); 1H NMR (CDCl3, 400 MHz): δ 4.55 (1H, br. m, N1-H), 4.46 (1H, br. s, N2-H), 2.98 (2H, dd, J = 
6.5, 5.5 Hz, C3-H2), 1.32 (9H, s, C6-H3), 0.92 (1H, m, C2-H), 0.45 (2H, m, 2 × C1-H2), 0.15 (2H, m, 2 
× C1-H2); 13C NMR (CDCl3, 100 MHz): δ 157.8 (C4), 50.4 (C5), 45.3 (C3), 29.7 (C6), 11.3 (C2), 3.4 
(C1); HRMS: (ESI+) Calculated for C9H19N2O: 171.1492. Found [M + H]+: 171.1495. 
1-(Cyclopropylmethyl)-3-mesitylurea (263d) 
 
To a stirring solution of cyclopropylmethylamine (0.870 mL, 10.0 mmol) in CH2Cl2 (20 mL), was added 
mesityl isocyanate (1.53 g, 9.50 mmol). The reaction was stirred for 2 h during which time a colourless 
solid formed. The suspension was diluted with CH2Cl2 (200 mL) and washed with aq. 1M HCl (50 mL), 
sat. aq. NaHCO3 (50 mL) and brine (50 mL) before being dried over Na2SO4 and concentrated in vacuo 
to provide the title compound (1.73 g, 78%) as a colourless solid; m.p. 206–208 °C (CHCl3); νmax / cm-1: 
3318 (m), 2919 (w), 1631 (s), 1609 (m), 1563 (s), 1519 (m), 1476 (m), 1237 (m); 1H NMR (CDCl3, 
400 MHz): δ 6.93 (2H, s, 2 × C7-H), 5.73 (1H, br. s, N2-H), 4.36 (1H, br. m, N1-H), 3.06 (2H, dd, J = 
6.5, 6.0 Hz, C3-H2), 2.29 (3H, s, C10-H3), 2.25 (6H, s, C9-H3), 0.89 (1H, m, C2-H), 0.41 (2H, m, 2 × 




C1-H2), 0.12 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 157.2 (C4), 137.8 (C8), 137.2 (C6), 
131.4 (C5), 129.6 (C7), 45.0 (C3), 21.1 (C10), 18.3 (C8), 11.6 (C2), 3.3 (C1); HRMS: (ESI+) Calculated 
for C14H21N2O: 233.1648. Found [M + H]+: 233.1656. 
N-Benzyl-N-cyclopropyl-2-phenylacetamide (272a) 
 
To a stirring solution of N-benzylcyclopropanamine354 (294 mg, 2.00 mmol) and NEt3 (0.56 mL, 
4.00 mmol) in CH2Cl2 (4 mL) at 0 °C was added phenylacetyl chloride (0.400 mL, 3.00 mmol) over 
1 minute. The reaction was warmed to room temperature and stirred for 4 h before being quenched by 
the addition of water (10 mL) and CH2Cl2 (10 mL). The organic layer was separated, washed with 1 M 
aq. NaOH (10 mL), 1 M aq. HCl (10 mL), sat. aq. NaHCO3 (10 mL) and brine (10 mL). The organic 
phase was dried over Na2SO4 and concentrated in vacuo before purification by FCC (20% 
EtOAc/hexane) to provide the title compound 25a (531 mg, 51%) as a colourless oil; νmax / cm-1: 3027 
(w), 1648 (s), 1495 (m), 1453 (m), 1396 (s); 1H NMR (CDCl3, 400 MHz): δ 7.43–7.07 (10H, m, 2 × 
C6-H, 2 × C7-H, C8-H, 2 × C11-H, 2 × C12-H, C13-H), 4.62 (2H, s, C9-H2), 3.97 (2H, s, C4-H2), 2.47 
(1H, m, C2-H), 0.84 (4H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 174.0 (C3), 138.4 (C10), 
135.4 (C5), 129.3, 128.6, 128.5, 128.0, 127.2, 126.8 (C6, C7, C8, C11, C12, C13), 50.1 (C9), 41.6 (C4), 
30.4 (C2), 9.7 (C1); HRMS: (ESI+) Calculated for C18H20NO: 266.1539. Found [M + H]+: 266.1549. 
(E)-N-Benzyl-2-phenyl-N-(prop-1-en-1-yl)acetamide (277a) and (Z)-N-Benzyl-2-phenyl-N-(prop-
1-en-1-yl)acetamide (277b) 
 
To a flame dried reaction tube, equipped with a stir bar, was added [Rh(cod)2]BARF (8.87 mg, 
7.50 mol), PPh3 (3.93 mg, 0.0150 mmol) and 25a (39.8 mg, 0.150 mmol). The reaction tube was sealed 
with a rubber septum and purged with argon for 30 minutes. Dry 1,2-DCB (0.75 mL) was added by 
syringe and the reaction mixture was stirred for 10 seconds before being heated at 100 °C for 2 h. The 
reaction was transferred to a flask and concentrated in vacuo before being purified by FCC (25% 
EtOAc/hexane) to provide the title compounds (33.7 mg, 85% 2:1 mixture of diastereomers 277a (A) 
and 277b (B)) as a yellow oil; νmax / cm-1: 3285 (s), 3032 (w), 1636 (s), 1547 (s), 1491 (m), 1453 (m); 




1H NMR (CDCl3, 400 MHz): δ 7.42–7.14 (20H, m, 4 × C7-H, 4 × C8-H, 2 × C9-H, 4 × C12-H, 4 × 
C13-H, 2 × C14-H, A+B), 6.61 (1H, dd, J = 14.0, 1.5 Hz, C3-H, A), 6.00 (1H, dd, J = 7.5, 1.5 Hz, 
C3-H, B), 5.55 (1H, dq, J = 7.0, 6.0 Hz, C2-H, B), 5.05 (1H, dq, J = 14.0, 6.5 Hz, C2-H, A), 4.86 (2H, 
s, C10-H2, A), 4.64 (2H, s, C10-H2, B), 3.92 (2H, s, C5-H2, A), 3.66 (2H, s, C5-H2, B), 1.60 (3H, dd, J 
= 6.5, 1.5 Hz, C1-H3, A), 1.41 (3H, dd, J = 7.0, 1.5 Hz, C1-H3, B); 13C NMR (CDCl3, 100 MHz): δ 
170.8 (C4, B), 169.9 (C4, A), 137.4 (C11, A), 137.2 (C11, B), 135.2 (C6, B), 134.6 (C6, A), 129.3 
(ArC-H), 128.9 (C3, B), 128.7, 128.7, 128.4, 128.4, 128.3 (ArC-H), 128.1 (C3, A), 127.3, 127.1, 127.0, 
126.9, 126.6, 125.5 (ArC-H), 110.7 (C2, A), 50.6 (C10, B), 47.4 (C10, A), 41.3 (C5, A), 40.9 (C5, B), 




To a stirring solution of cyanoacetic acid (391 mg, 4.60 mmol) and N-benzylcyclopropanamine 
(615 mg, 4.18 mmol) in CH2Cl2 (12 mL) at 0 °C was added a solution of DCC (906 mg, 4.39 mmol) 
and DMAP (26.0 mg, 0.210 mmol) in CH2Cl2 (8 mL). The reaction mixture was warmed to room 
temperature and stirred for 4 h before being filtered over a short pad of celite. The filtrate was 
concentrated in vacuo and purified by FCC (25% EtOAc/hexane) to provide the title compound 
(476 mg, 53%) as a colourless solid; m.p. 56–58 °C (CH2Cl2); νmax / cm-1: 3029 (w), 1649 (s), 1417 (m), 
1249 (m); 1H NMR (CDCl3, 400 MHz): δ 7.35–7.25 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 4.61 (2H, s, 
C6-H2), 3.73 (2H, s, C4-H2), 2.63 (1H, m, C2-H), 0.95 (2H, m, 2 × C1-H2), 0.85 (2H, m, 2 × C1-H2); 
13C NMR (CDCl3, 100 MHz): δ 164.6 (C3), 137.1 (C7), 128.9, 128.1, 127.8 (C8, C9, C10), 114.3 (C5), 
50.7 (C6), 30.4 (C2), 26.0 (C4), 9.5 (C1); HRMS: (ESI+) Calculated for C13H15N2O: 215.1179. Found 
[M + H]+: 215.1179. 
N-Benzyl-N-cyclopropyl-3-oxo-3-phenylpropanamide (272c) 
 
A solution of N-benzylcyclopropanamine (353 mg, 2.40 mmol), ethyl benzoylacetate (0.340 mL, 
2.00 mmol) and DMAP (1.22 g, 10.0 mmol) in toluene (20 mL) was heated at reflux for 18 h. The 




reaction mixture was cooled to room temperature and concentrated in vacuo before being redissolved 
in Et2O (40 mL) and washed with 1 M aq. HCl (30 mL), water (30 mL) and brine (30 mL). The organic 
phase was dried over Na2SO4 and concentrated in vacuo and purified by FCC (10% EtOAc/hexane) to 
provide the title compound (532 mg, 91%) as an orange oil; νmax / cm-1: 2983 (w), 1622 (s), 1567 (s), 
1460 (s), 1434 (s), 1358 (s), 1211 (s), 767 (s); The product appears as a 4:5 mixture of tautomers (A:B) 
in CDCl3 at room temperature:  1H NMR (CDCl3, 400 MHz): δ 15.15 (1H, s, OH, B), 7.98 (2H, d, J = 
8.0 Hz, 2 × C7-H, A), 7.82 (2H, d, J = 7.0 Hz, 2 × C7-H, B), 7.60 (1H, m, C9-H, A), 7.50–7.40 (5H, 
m, 4 × C8-H (A+B), 1 × C9-H (B)), 7.35–7.24 (10H, m, 4 × C12-H, (A+B), 4 × C13-H (A+B), 2 × 
C14-H, (A+B)), 6.31 (1H, s, C4-H, B), 4.71 (2H, s, C10-H2, B), 4.67 (2H, s, C10-H2, A), 4.36 (2H, s, 
C4-H2, A), 2.67-2.58 (2H, m, 2 × C2-H, A+B), 0.95–0.78 (8H, m, C1-H2, A+B); 13C NMR (CDCl3, 
100 MHz): δ 194.5 (C5, A), 174.6 (C3, B), 171.3 (C5, B), 170.4 (C3, A), 138.1 (C11, B), 137.9 (C11, 
A), 136.7 (C6, A), 135.1 (C6, B), 133.6 (C9, A), 130.8, 128.8, 128.7, 128.6, 128.6, 128.0, 127.7, 127.3, 
127.2 (C7 (A), C8 (A+B), C9 (A+B), C12 (A+B), C13 (A+B), C14 (A+B)), 126.1 (C7, B), 86.9 (C4, 
B), 50.1 (C10, A), 49.5 (C10, B), 46.5 (C4, A), 30.5, 29.7 (C2, A+B), 9.3, 9.3 (C1, A+B); HRMS: 
(ESI+) Calculated for C19H20NO2: 294.1489. Found [M + H]+: 294.1489. 
tert-Butyl 1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide (283) 
 
Hydroxycarbamate I was prepared according to a literature procedure360. The synthesis of sulfamidate 
283 was carried out according to a literature procedure361: To a flame dried three-necked flask fitted 
with a rubber septum and pressure equalising dropping funnel was added imidazole (8.90 g, 131 mmol) 
and the reaction vessel was sealed and placed under a nitrogen atmosphere. Dry CH2Cl2 (327 mL) was 
added by cannula which was followed by NEt3 (10.0 mL, 71.9 mmol) and thionyl chloride (2.60 mL, 
36.0 mmol) and then the rubber septum was replaced with a thermometer. The reaction mixture was 
cooled to between -50 and -60 °C in a dry ice/acetone bath. Hydroxycarbamate I (1.61 g, 10.0 mmol) 
in CH2Cl2 (82 mL) was then added by dropping funnel over 30 minutes. The reaction mixture was 
warmed to room temperature and stirred for 16 h before being concentrated in vacuo to provide the 
crude sulfamidite II as a brown liquid. The crude sulfamidite was immediately dissolved in acetonitrile 
(77 mL) and cooled to 0 °C. Sodium periodate (2.31 g, 10.8 mmol), RuCl3 (20.7 mg, 0.100 mmol) and 
water (63 mL) were added in single portions, and the reaction was stirred whilst following closely by 
TLC. On consumption of the sulfamidite (typically 15 min) the reaction was diluted with water 
(100 mL) and extracted with Et2O (3 × 100 mL). The combined organics were washed with brine 
(100 mL), dried over Na2SO4 and concentrated in vacuo. Purification by FCC (25% EtOAc/Hex, dry 
loaded on silica) provided the title compound (1.52 g, 68%) as a colourless solid; m.p. 116–118 °C 




(CH2Cl2/hexane); νmax / cm-1: 2989 (w), 1720 (s), 1370 (m), 1357 (s), 1343 (s), 1323 (s), 1151 (s); 1H 
NMR (CDCl3, 400 MHz): δ 4.60 (2H, t, J = 6.5 Hz, C1-H2), 4.04 (2H, t, J = 6.5 Hz, C2-H2), 1.55 (9H, 
s, C5-H3). The spectroscopic properties of this compound were consistent with the data available in the 
literature.361  
Benzyl (2-((tert-butoxycarbonyl)amino)ethyl)(cyclopropyl)carbamate (284a) 
 
Cyclopropylcarbamate I was prepared according to a literature procedure102: To a stirring solution of 
NaH (340 mg, 8.50 mmol, 60% suspension in mineral oil) in DMF (16.5 mL), at room temperature 
under an atmosphere of argon, was added cyclopropylcarbamate I (1.43 g, 7.50 mmol) in two portions 
over 2 minutes. The resulting suspension was stirred for 30 minutes during which time the solution 
became clear. Sulfamidate 283 (1.12 g, 5.00 mmol) was added to the reaction in two portions over 
2 minutes at room temperature. The reaction mixture was stirred for 30 minutes before being 
concentrated in vacuo. The residue was redissolved in 1,4-dioxane (10 mL) and conc. HCl (4 mL) and 
stirred for 15 minutes. The reaction was neutralised by the addition of sat. aq. NaHCO3 (30 mL) and 
the aqueous layer was extracted with EtOAc (3 × 30 mL). The combined organics were washed with 
brine (50 mL), dried over Na2SO4 and concentrated in vacuo before being purified by FCC (25% 
EtOAc/hexane) to provide the title compound (1.44 g, 86%) as a pale yellow oil which crystallised upon 
standing; m.p. 57–59 °C (CHCl3); νmax / cm-1: 3354 (br.), 2975 (w), 2930 (w), 1691 (s), 1512 (m), 1409 
(m), 1167 (m); 1H NMR (CDCl3, 400 MHz): δ 7.38–7.28 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 5.14 
(2H, s, C6-H2), 4.81 (1H, br. s, NH), 3.40 (2H, m, C3-H2), 3.29 (2H, m, C4-H2), 2.65 (1H, m, C2-H), 
1.42 (9H, s, C13-H3), 0.78 (2H, m, 2 × C1-H2), 0.66 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): 
δ 157.6 (C5), 156.1 (C11), 136.8 (C7), 128.6, 128.0, 127.8 (C8, C9, C10), 79.4 (C12), 67.3 (C6), 47.5 
(C3), 39.7 (C4), 28.5 (C13), 8.2 (C1); HRMS: (ESI+) Calculated for C18H26N2NaO4: 357.1785. Found 
[M + Na]+: 357.1803. 
Benzyl (2-aminoethyl)(cyclopropyl)carbamate (284b) 
 




To a stirring solution of carbamate 284a (1.44 g, 4.31 mmol) in CH2Cl2 (5.0 mL) was added 
trifluoroacetic acid (3.20 mL, 43.1 mmol) and the reaction was stirred for 1 h at room temperature. The 
reaction was diluted with CH2Cl2 (50 mL) before the addition of sat. aq. NaHCO3 (50 mL). The organic 
layer was removed and the aqueous layer was extracted with CH2Cl2 (2 × 50 mL). The combined 
organics were dried over Na2SO4 and concentrated in vacuo to provide the title compound (965 mg, 
96%) as a yellow oil; νmax / cm-1: 3323 (br.), 2958 (s), 1689 (s), 1454 (m), 1413 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.40–7.27 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 5.15 (2H, s, C6-H2), 3.35 (2H, t, J = 
6.5 Hz, C3-H2), 2.88 (2H, t, J = 6.5 Hz, C4-H2), 2.62 (1H, tt, J = 7.0, 4.0 Hz, C2-H), 1.64 (2H, br. s, 
NH2), 0.83–0.74 (2H, m, 2 × C1-H2), 0.69–0.61 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 
155.4 (C5), 136.7 (C7), 128.5, 128.5, 127.9 (C8, C9, C10), 67.2 (C6), 52.9 (C3), 40.5 (C4), 30.1 (C2), 
8.1 (C1); HRMS: (ESI+) Calculated for C13H19N2O2: 235.1441. Found [M + H]+: 235.1450. 
Benzyl cyclopropyl(2-((4-methylphenyl)sulfonamido)ethyl)carbamate (284c) 
 
To a stirring solution of amine 284b (460 mg, 1.96 mmol) and NEt3 (0.330 mL, 2.35 mmol) in CH2Cl2 
(10 mL) at 0 °C was added p-toluenesulfonyl chloride (448 mg, 2.35 mmol). The reaction was stirred 
for 16 h before being quenched by the addition of water (20 mL). The aqueous layer was extracted with 
CH2Cl2 (2 × 20 mL) and the combined organics were dried over Na2SO4 and concentrated in vacuo. 
Purification by FCC (20% EtOAc/hexane) provided the title compound (442 mg, 50%) as a colourless 
oil; νmax / cm-1: 3249 (br.), 1683 (s), 1411 (m), 1329 (m), 1302 (m), 1156 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.68 (2H, d, J = 8.0 Hz, 2 × C12-H), 7.42–7.29 (5H, m, 2 × C8-H, 2 × C9-H, C10-H), 7.25 
(2H, d, J = 8.0 Hz, 2 × C13-H), 5.13 (2H, s, C6-H2), 5.03 (1H, br. s, NH), 3.39 (2H, t, J = 6.0 Hz, 
C3-H2), 3.12 (2H, dt, J = 6.0, 6.0 Hz, C4-H2), 2.50 (1H, tt, J = 7.0, 4.0 Hz, C2-H), 2.40 (3H, s, C15-H3), 
0.73 (2H, m, 2 × C1-H2), 0.55 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 158.0 (C5), 143.5 
(C11), 137.1 (C14), 136.6 (C7), 129.8 (C13), 128.7, 128.2, 127.9 (C8, C9, C10), 127.2 (C12), 67.5 
(C6), 47.6 (C3), 42.6 (C4), 29.6 (C2), 21.6 (C15), 8.2 (C1); HRMS: (ESI+) Calculated for C20H25N2O4S: 









Benzyl (E)-(2-((4-methylphenyl)sulfonamido)ethyl)(prop-1-en-1-yl)carbamate (286c) 
 
General procedure B: [Rh(cod)2]BARF (8.87 mg, 7.50 mol), AsPh3 (4.59 mg, 0.0150 mmol) and  
284c (58.3 mg, 0.150 mmol) were employed in 1,2-DCB (1.5 mL) at 140 °C for 24 h. Purification by 
FCC (30% EtOAc/hexane) provided the title compound (21.3 mg, 37%) as a pale yellow oil; νmax / cm-1: 
2970 (br.), 2901 (br.), 1701 (s), 1411 (s), 1346 (s), 1163 (s); The product appears as a 1:1 mixture of 
rotamers (A:B) in CDCl3 at room temperature; 1H NMR (CDCl3, 400 MHz): δ 7.71 (2H, d, J = 7.5 Hz, 
2 × C13-H, A), 7.60 (2H, d, J = 7.5 Hz, 2 × C13-H, B), 7.43–7.33 (8H, m, 4 × C9-H, 4 × C10-H, A+B), 
7.23–7.21 (4H, m, 2 × C11-H (A+B), 2 × C14-H (A)), 7.08 (2H, d, J = 7.5 Hz, 2 × C14-H, B), 5.42–
5.32 (2H, m, 2 × C3-H, A+B), 5.11–4.91 (4H, m, 4 × C7-H2, A+B), 3.75 (2H, m, 2 × C1/2-H2, A/B), 
3.53 (2H, m, 2 × C1/2-H2, A/B), 3.18 (2H, m, 2 × C1/2-H2, A/B), 2.91 (1H, m, C1/2-H2, A/B), 2.76 
(1H, m, C1/2-H2, A/B), 2.37 (3H, s, C16-H3, B), 2.33 (3H, s, C16-H3, A), 1.81 (2H, m, C4-H2, A/B), 
1.64 (2H, m, C4-H2, A/B), 1.00 (6H, m, C5-H3, A+B); 13C NMR (CDCl3, 100 MHz): δ 153.4, 153.0 
(C6, A+B), 144.5, (C15, B), 144.3 (C15, A), 136.3, 136.3 (C8, A+B), 134.8 (C12, A), 134.5 (C12, B), 
130.0, 130.0 (C15, A+B), 128.8, 128.6, 128.5, 128.4, 128.3, 128.0, (C9, C10, C11, A+B), 127.7 (C14, 
A), 127.4 (C14, B), 75.6, 74.9 (C3, A+B), 67.5, 67.0 (C7, A+B), 45.9, 45.1, 43.6, 43.4 (C1, C2, A+B), 
28.3, 27.7 (C4, A+B), 21.7, 21.7, (C16, A+B), 9.5, 9.4 (C5, A+B). HRMS: (ESI+) Calculated for 
C20H24N2NaO4S: 411.1354. Found [M + Na]+: 411.1380. 
N-Cyclopropylaniline (301) 
 
Pd2(dba)3 (45.7 mg, 0.0500 mmol), rac-BINAP (93.4 mg, 0.150 mmol) and sodium pentoxide (826 mg, 
7.50 mmol) were added to a flame dried sealable reaction tube which was then fitted with a rubber 
septum and purged with argon. Degassed toluene (10 mL) was added followed by cyclopropylamine 
(0.550 mL, 8.00 mmol) and bromobenzene (0.530 mL, 5.00 mmol). The rubber septum was quickly 
replaced with a screw cap and the sealed reaction tube was heated at 130 °C for 16 h. The reaction 
mixture was cooled to room temperature before being filtered through a short pad of celite and 
concentrated in vacuo. Purification by FCC (3% EtOAc/hexane) provided the title compound (433 mg, 




65%) as a bright orange oil; νmax / cm-1: 3389 (br.), 3009 (s), 1601 (s), 1501 (s), 1364 (m), 1312 (s), 
1266 (m), 1019 (m); 1H NMR (CDCl3, 400 MHz): δ 7.20 (2H, m, 2 × C5-H), 6.80 (2H, m, 2 × C4-H), 
6.75 (1H, m, C6-H), 4.16 (1H, br. s, NH), 2.43 (1H, m, C2-H), 0.74 (2H, m, 2 × C1-H2), 0.52 (2H, m, 
2 × C1-H2). The spectroscopic properties of this compound were consistent with the data available in 
the literature.362 
tert-Butyl (2-(cyclopropyl(phenyl)amino)ethyl)carbamate (302a) 
 
N-Cyclopropylaniline (1.20 g, 9.0 mmol) and THF (20 mL) were transferred to a flask under an 
atmosphere of N2 which was then cooled to -78 °C. n-BuLi (6.50 mL, 1.6 M, 10.5 mmol) was added 
dropwise over 30 minutes, forming an orange suspension. The reaction was stirred for 15 minutes before 
the addition of sulfamidate 283 (1.67 g, 7.5 mmol) in THF (15 mL) dropwise over 10 minutes, which 
caused the formation of an orange homogenous solution. After a further 15 minutes the reaction was 
warmed to room temperature and quenched with 2 M aq. HCl (20 mL) then stirred for a further 
30 minutes. The biphasic solution was neutralised with sat. aq. NaHCO3 (100 mL), separated and the 
aqueous layer was further extracted with Et2O (2 × 50 mL). The combined organics were washed with 
brine (20 mL), dried over Na2SO4 and concentrated in vacuo. Purification by FCC (10% EtOAc/hexane) 
provided the title compound (1.67 g, 81%) as an orange oil; νmax / cm-1: 3347 (br.), 2975 (w), 1694 (s), 
1598 (m), 1500 (s), 1366 (s), 1248 (m), 1169 (s); 1H NMR (CDCl3, 400 MHz): δ 7.24 (2H, m, 2 × 
C7-H), 7.01 (2H, m, 2 × C6-H), 6.76 (1H, t, J = 7.5 Hz, C8-H), 4.58 (1H, s, NH), 3.53 (2H, t, J = 6.5 
Hz, C3-H2), 3.32 (2H, m, C4-H2), 2.48 (1H, tt, J = 7.0, 4.0 Hz, C2-H), 1.43 (9H, s, C11-H3), 0.84 (2H, 
m, 2 × C1-H2), 0.61 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 156.0 (C9), 149.5 (C5), 129.1 
(C7), 117.8 (C8), 114.3 (C6), 79.4 (C10), 51.0 (C3), 38.6 (C4), 32.2 (C2), 28.5 (C11), 9.3 (C1); HRMS: 
(ESI+) Calculated for C16H25N2O2: 277.1911. Found [M + H]+: 277.1918. 
tert-Butyl 2-ethyl-3-phenylimidazolidine-1-carboxylate (304a) and tert-Butyl (2-
(phenylamino)ethyl)carbamate (I) 
 




General procedure B: [Rh(cod)2]BARF (13.3 mg, 0.0113 mmol), PPh3 (5.90 mg, 0.0225 mmol) and 
302a (41.5 mg, 0.150 mmol) were employed in 1,2-DCB (1.5 mL) at 150 °C for 18 h. Purification by 
FCC (10–30% EtOAc/hexane) provided 304a (21.5 mg, 52%) as an orange oil and decyclopropanated 
product I (1.9 mg, 5%) as a colourless oil; Data for major compound 304a: νmax / cm-1: 2971 (br.), 
1696 (s), 1599 (m), 1505 (m), 1406 (s), 1365 (s), 1335 (s); The compound appears as a 1:1 mixture of 
rotamers (A/B) in CDCl3 at room temperature; 1H NMR (CDCl3, 400 MHz): δ 7.25 (4H, m, 4 × C8-H, 
A+B), 6.76 (2H, t, J = 7.5 Hz, 2 × C9-H, A+B), 6.62 (4H, d, J = 8.0 Hz, C7-H, A+B), 5.41–5.28 (2H, 
br. m, C3-H, A+B), 4.01–3.87 (2H, br. m, 2 × C1/2-H, A+B), 3.61–3.53 (4H, m, 2 × C1-H, 2 × C2-H, 
A+B), 3.46–3.42 (2H, br. m, 2 × C1/2-H, A+B), 1.94 (2H, br. m, C4-H2, A/B), 1.80 (2H, br. m, C4-H2, 
A/B), 1.49 (18H, s, 18 × C12-H3, A+B), 0.87 (6H, br. m, 6 × C5-H3, A+B); 13C NMR (CDCl3, 
100 MHz): δ 153.5 (C10, A+B), 145.8 (C6, A+B), 129.4 (C8, A+B), 117.3 (C9, A+B), 112.9 (C7, 
A+B), 73.0 (C3, A+B), 46.2 (C1/2, A+B) 43.5 (C1/2, A+B), 28.6 (C12, A+B), 25.8 (C4, A+B), 8.5 
(C5, A+B); HRMS: (ESI+) Calculated for C16H25N2O2: 277.1911. Found [M + H]+: 277.1913. Data for 
minor compound I: νmax / cm-1: 3366 (br.), 2975 (w), 1689 (s), 1602 (s), 1506 (s), 1366 (m), 1251 (s), 
1167 (s); 1H NMR (CDCl3, 400 MHz): δ 7.17 (2H, m, 2 × C5-H), 6.71 (1H, t, J = 7.5 Hz, C6-H), 6.62 
(2H, d, J = 8.0 Hz, C4-H), 4.79 (1H, br. s, NH), 3.37 (2H, m, C2-H2), 3.26 (2H, t, J = 5.5 Hz, C1-H2), 
1.45 (9H, s, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 156.5 (C7), 147.9 (C3), 129.4 (C5), 117.8 (C6), 
112.9 (C4), 79.7 (C8), 44.5 (C1), 40.2 (C2), 28.5 (C9); HRMS: (ESI+) Calculated for C13H21N2O2: 
237.1598. Found [M + H]+: 237.1592. 
N-(2-(Cyclopropyl(phenyl)amino)ethyl)-4-methylbenzenesulfonamide (302b) 
 
Trifluoroacetic acid (5.6 mL, 73.4 mmol) was added to a stirring solution of carbamate 302a (2.03 g, 
7.34 mmol) in CH2Cl2 (24 mL) at 0 °C. The reaction mixture was warmed to room temperature and 
stirred for 6 h before being concentrated in vacuo. The residue was redissolved in CH2Cl2 (30 mL) and 
neutralised with sat. aq. NaHCO3 (30 mL). The organic layer was separated, and the aqueous layer was 
extracted with CH2Cl2 (30 mL). The combined organics were dried over Na2SO4 and concentrated in 
vacuo to provide the crude diamine. The crude diamine and NEt3 (1.19 mL, 8.51 mmol) were dissolved 
in CH2Cl2 (9.5 mL) and cooled to 0 °C. p-Toluenesulfonyl chloride (1.08 g, 5.67 mmol) was added in 
one portion and the reaction was warmed to room temperature and stirred for 3 h. The reaction mixture 
was diluted in CH2Cl2 (30 mL) and washed with water (30 mL) and brine (30 mL) before being dried 
over Na2SO4 and concentrated in vacuo. Purification by FCC (15% EtOAc/hexane) provided the title 
compound (371 mg, 15%) as a colourless oil; νmax / cm-1: 3285 (br.), 2955 (br.), 1599 (m), 1500 (m), 




1327 (m), 1159 (s); 1H NMR (CDCl3, 400 MHz): δ 7.72 (2H, d, J = 8.5 Hz, 2 × C10-H), 7.28 (2H, d, J 
= 8.5 Hz, 2 × C11-H), 7.20 (2H, m, 2 × C7-H), 6.91 (2H, m, 2 × C6-H), 6.78 (1H, m, C8-H), 4.55 (1H, 
t, J = 6.0 Hz, NH), 3.51 (2H, t, J = 7.0 Hz, C3-H2), 3.14 (2H, td, J = 7.0, 6.0 Hz, C4-H2), 2.42 (3H, s, 
C13-H3), 2.38 (1H, m, C2-H), 0.79 (2H, m, C1-H), 0.52 (2H, m, C1-H); 13C NMR (CDCl3, 100 MHz): 
δ 149.2 (C5), 143.7 (C12), 137.0 (C9), 129.9 (C11), 129.2 (C7), 127.2 (C10), 118.5 (C8), 114.9 (C6), 
51.6 (C3), 40.6 (C4), 32.2 (C2), 21.7 (C13), 9.2 (C1); HRMS: (ESI+) Calculated for C18H23N2O2S: 
331.1475. Found [M + H]+: 331.1474. 
2-Ethyl-1-phenyl-3-tosylimidazolidine (304b) 
 
General procedure B: [Rh(cod)2]BARF (13.3 mg, 0.0113 mmol), PPh3 (5.90 mg, 0.0225 mmol) and 
302b (49.6 mg, 0.150 mmol) were employed in 1,2-DCB (1.5 mL) at 140 °C for 16 h. Purification by 
FCC (30% EtOAc/hexane) provided the title compound (18.4 mg, 37%) as a yellow oil; νmax / cm-1: 
2969 (w), 1598 (m), 1504 (m), 1343 (s), 1162 (s); 1H NMR (CDCl3, 400 MHz): δ 7.57 (2H, d, J = 
8.5 Hz, 2 × C11-H), 7.16 (2H, m, 2 × C8-H), 7.04 (2H, d, J = 8.5 Hz, 2 × C12-H), 6.71 (1H, t, J = 
7.5 Hz, C9-H), 6.32 (2H, d, J = 8.0 Hz, 2 × C7-H), 5.22 (1H, dd, J = 8.5, 3.5 Hz, C3-H), 3.85 (1H, ddd, 
J = 12.5, 8.0, 3.0 Hz, C2-H2), 3.67 (1H, ddd, J = 12.5, 9.0, 7.5 Hz, C2-H2), 3.16 (1H, ddd, J = 8.5, 7.5, 
3.0 Hz, C1-H2), 2.54 (1H, q, J = 8.5 Hz, C1-H2), 2.28 (3H, s, C14-H3), 1.87 (1H, dqd, J = 15.0, 7.5, 
3.5 Hz, C4-H2), 1.66 (1H, m, C4-H2), 1.08 (3H, t, J = 7.5 Hz, C5-H3); 13C NMR (CDCl3, 100 MHz): δ 
145.3 (C6), 144.1 (C13), 134.9 (C10), 129.7 (C12), 129.2 (C8), 127.5 (C11), 117.4 (C9), 112.1 (C7), 
77.0 (C3), 45.7 (C2), 45.5 (C1), 27.2 (C4), 21.6 (C14), 9.5 (C5); HRMS: (ESI+) Calculated for 
C18H23N2O2S: 331.1475. Found [M + H]+: 331.1464. 
2-(Benzyl(cyclopropyl)amino)ethan-1-ol (303) 
 
To a stirring solution of benzylcyclopropylamine (736 mg, 5.00 mmol) in THF (10 mL) under an 
atmosphere of argon was added ethylene oxide (4 ml, 10.0 mmol, 2.5-3.3 M in THF) followed by ZnCl2 
(136 mg, 1.0 mmol). The reaction was stirred for 19 h during which time a colourless precipitate had 




formed. The suspension was diluted with Et2O (30 mL) and washed with water (40 mL). The aqueous 
phase was further extracted with Et2O (2 × 30 mL) and the combined organics were dried over Na2SO4, 
filtered and concentrated in vacuo to provide the title compound (800 mg, 84%) as a colourless oil; νmax 
/ cm-1: 3384 (br.), 2923 (m), 2820 (m), 1495 (m), 1453 (s), 1350 (m), 1018 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.33–7.24 (5H, m, 2 × C7-H, 2 × C8-H, C9-H), 3.77 (2H, s, C5-H2), 3.58 (2H, t, J = 
5.5 Hz, C4-H2), 2.75 (2H, t, J = 5.5 Hz, C3-H2), 2.35 (1H, br. s, OH), 1.84 (1H, m, C2-H), 0.52 (2H, m, 
2 × C1-H2), 0.43 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 138.2 (C6), 129.5, 128.3 (C7, 
C8), 127.3 (C9), 59.9 (C5), 58.5 (C4), 56.5 (C3), 36.9 (C2), 7.4 (C1); HRMS: (ESI+) Calculated for 
C12H18NO: 192.1383. Found [M + H]+: 192.1378. 
2-(Benzyl(propyl)amino)ethan-1-ol (307) 
 
General procedure B: [Rh(cod)2]BARF (8.87 mg, 0.0075 mmol), PPh3 (3.93 mg, 0.015 mmol) and  
303 (28.7 mg, 0.150 mmol) were employed in 1,2-DCB (0.75 mL) at 120 °C for 15 h. Purification by 
FCC (20% EtOAc/hexane) provided the title compound (8.41 mg, 29%) as a colourless oil; νmax / cm-1: 
3359 (br.), 2957 (m), 2872 (m), 1631 (m), 1453 (m), 1052 (s); 1H NMR (CDCl3, 400 MHz): δ 7.34-7.23 
(5H, m, 2 × C8-H, 2 × C9-H, C10-H), 3.63 (2H, s, C6-H2), 3.56 (2H, t, J = 5.5 Hz, C5-H2), 2.64 (2H, t, 
J = 5.5 Hz, C4-H2), 2.45 (2H, m, C3-H2), 1.52 (2H, tt, J = 7.5, 7.5 Hz, C2-H2), 0.87 (3H, t, J = 7.5 Hz, 
C1-H3); 13C NMR (CDCl3, 100 MHz): δ 138.7 (C7), 129.1 128.5 (C8, C9), 127.3 (C10), 58.5 (C6), 58.5 
(C5), 55.8 (C3), 55.3 (C4), 20.2 (C2), 11.9 (C1); HRMS: (ESI+) Calculated for C12H20NO: 194.1539. 
Found [M + H]+: 194.1546. 
6-Hydroxyhexanoic acid  
 
KOH pellets (6.70 g, 120 mmol) were added to a stirring solution of methyl 6-hydroxyhexanoate 
(6.40 g, 40.0 mmol) in MeOH (80 mL) in one portion. The reaction mixture was stirred for 4 h before 
being concentrated in vacuo. The residue was dissolved in EtOAc (200 mL) and 2 M aq. NaHSO4 
(200 mL). The organic layer as washed with brine (100 mL), dried over Na2SO4 and concentrated in 
vacuo to provide 6-hydroxyhexanoic acid (4.90 g, 93%) as a colourless oil; νmax / cm-1: 3247 (br.), 2938 
(m), 2522 (br.), 1675 (s), 1416 (m), 1303 (s), 1046 (s), 985 (s); 1H NMR (CDCl3, 400 MHz): δ 5.90 
(1H, br. s, CH2OH), 3.66 (2H, td, J = 6.5, 1.0 Hz, C6-H2), 2.37 (2H, t, J = 7.5 Hz, C2-H2), 1.67 (2H, m, 
C3-H2), 1.59 (2H, m, C5-H2), 1.42 (2H, m, C4-H2); 13C NMR (CDCl3, 100 MHz): δ 179.2 (C1), 62.8 




(C6), 34.0 (C2), 32.3 (C5), 25.3 (C4), 24.5 (C3); HRMS: (ESI+) Calculated for C6H12NaO3: 155.0679. 
Found [M + Na]+: 155.0677. 
N-Benzyl-N-cyclopropyl-6-hydroxyhexanamide (314) 
 
EDCI (2.20 g, 11.5 mmol) and DMAP (122 mg, 1.0 mmol) were added to a flask which was sealed with 
a rubber septum and purged with argon for 10 minutes. CH2Cl2 (20 mL) and N-benzylcyclopropanamine 
(1.47 g, 10.0 mmol) were added by syringe and the mixture was cooled to 0 °C. 6-Hydroxyhexanoic 
acid (1.45 g, 11.0 mmol) in CH2Cl2 (5 mL) was added and the reaction mixture was warmed to room 
temperature and stirred for 16 h. The resulting solution was concentrated in vacuo and dissolved in 
water (40 mL) and EtOAc (40 mL). The organic layer was washed with 1 M aq. NaOH (20 mL), 1 M 
aq. HCl (20 mL) and brine (20 mL) before being dried over Na2SO4 and concentrated in vacuo. 
Purification by FCC (30% EtOAc/hexane) provided the title compound (2.19 g, 84%) as a colourless 
oil; νmax / cm-1: 3403 (br.), 2931 (m), 2860 (m), 1631 (s), 1409 (s), 1373 (m); 1H NMR (CDCl3, 
400 MHz): δ 7.34–7.24 (5H, m, 2 × C11-H, 2 × C12-H, C13-H), 4.63 (2H, s, C9-H2), 3.69 (2H, t, J = 
6.5 Hz, C8-H2), 2.62 (2H, t, J = 7.5 Hz, C4-H2), 2.56 (1H, m, C2-H), 1.75 (2H, m, C5-H2), 1.63 (2H, 
m, C7-H2), 1.46 (2H, m, C6-H2), 0.86 (2H, m, 2 × C1-H2), 0.79 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 
100 MHz): δ 176.1 (C3), 138.6 (C10), 128.6, 127.9 (C11, C12), 127.1 (C13), 62.7 (C8), 49.9 (C9), 34.2 
(C4), 32.6 (C7), 30.1 (C1), 25.7 (C6), 24.7 (C5), 9.4 (C1); HRMS: (ESI+) Calculated for C16H24NO2: 
262.1802. Found [M + H]+: 262.1801. 
1-Cyclopropyl-1-(6-hydroxyhexyl)-3,3-dimethylurea (315) 
 
A stirring solution of cyclopropylamine (0.69 mL, 10 mmol), K2CO3 (1.04 g ,7.50 mmol) and 6-
bromohexan-1-ol (905 mg, 5.00 mmol) in MeCN (10 mL) was heated at 80 °C for 16 h. The reaction 
mixture was dissolved in water (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organics 
were dried over Na2SO4 and concentrated in vacuo to yield the crude aminoalcohol intermediate as a 
pale brown oil which was carried through without further purification. To a stirring solution of crude 
aminoalcohol and NEt3 (0.84 mL, 6.00 mmol) in CH2Cl2 (17 mL) at 0 °C under argon was added 




dimethylcarbamoyl chloride (0.55 mL, 6.00 mmol). The reaction mixture was stirred for 3 h before 
being quenched by the addition of water (5 mL) and 1 M aq. HCl (20 mL). The organic layer was 
separated, and the aqueous layer was further extracted with CH2Cl2 (2 × 20 mL). The combined organics 
were washed with brine (30 mL), dried over Na2SO4 and concentrated in vacuo. Purification by FCC 
(5% MeOH/EtOAc) provided the title compound (361 mg, 32%) as a colourless oil; νmax / cm-1: 3392 
(br.), 2928 (m), 2858 (m), 1613 (s), 1496 (m), 1400 (s), 1370 (m); 1H NMR (CDCl3, 400 MHz): δ 3.62 
(2H, t, J = 6.5 Hz, C8-H2), 3.20 (2H, t, J = 7.5 Hz, C3-H2), 2.85 (6H, s, C10-H3), 2.57 (1H, m, C2-H), 
1.62–1.52 (4H, m, C4-H2, C7-H2), 1.41–1.27 (4H, m, C5-H2, C6-H2), 0.72 (2H, m, 2 × C1-H2), 0.56 
(2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 164.4 (C9), 62.8 (C8), 49.0 (C3), 38.1 (C10), 32.8 
(C7), 30.6 (C2), 28.1 (C4), 26.7 (C5), 25.5 (C6), 8.8 (C1); HRMS: (ESI+) Calculated for C12H25N2O2: 
229.1911. Found [M + H]+: 229.1900. 
(E)-2-((Cyclopropylimino)methyl)phenol (316a) 
 
Cyclopropylamine (0.35 mL, 5.10 mmol) was added to a stirring solution of salicylaldehyde (0.53 mL, 
5.00 mmol) in EtOH (5 mL) at room temperature causing the immediate formation of a bright yellow 
colour. The reaction was stirred for 16 h before being concentrated in vacuo and purified by FCC (5% 
EtOAc/hexane) to afford the title compound (780 mg, 97%) as an orange oil; νmax / cm-1: 2885 (w), 1621 
(s), 1575 (m), 1487 (m), 1395 (m), 1271 (s); 1H NMR (CDCl3, 400 MHz): δ 12.75 (1H, s, OH), 8.49 
(1H, s, C3-H), 7.26 (1H, m, C7-H), 7.22 (1H, m, C5-H), 6.93 (1H, d, J = 8.0 Hz, C8-H), 6.87 (1H, m, 
C6-H), 2.97 (1H, m, C2-H), 1.00–0.94 (4H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 162.1 (C3), 
160.5 (C9), 131.7 (C7), 130.7 (C5), 119.2 (C4), 118.8 (C6), 116.9 (C8), 40.4 (C2), 9.5 (C1); HRMS: 
(ESI+) Calculated for C10H12NO: 162.0913. Found [M + H]+: 162.0920. 
(2-Aminophenyl)(cyclopropyl)methanone 
 
To a stirring solution of 2-aminobenzonitrile 323 (1.18 g, 10.0 mmol) in THF (20 mL) at 0 °C, under 
an atmosphere of argon, was added cyclopropylmagnesium bromide (60 mL, 30.0 mmol, 0.5 M in THF) 
dropwise over 30 minutes. The reaction was warmed to room temperature and stirred for 6 h before 
being quenched by the careful addition of 2 M aq. HCl (40 mL). The resulting biphasic solution was 




stirred for 16 h before being basified by the addition of 4 M aq. NaOH (pH ~14). The organic layer was 
removed and the aqueous layer was further extracted with Et2O (3 × 50 mL). The combined organics 
were dried over Na2SO4 and concentrated in vacuo. Purification by FCC (10% EtOAc/hexane) provided 
the title compound (451 mg, 28%) as a pale yellow oil; νmax / cm-1: 3461 (m), 3341 (m), 3005 (w), 1634 
(m), 1614 (s), 1581 (s), 1547 (m), 1392 (m), 1222 (s), 1160 (m); 1H NMR (CDCl3, 400 MHz): δ 7.96 
(1H, d, J = 8.0 Hz, C5-H), 7.26 (1H, m, C7-H), 6.69 (1H, m, C6-H), 6.65 (1H, d, J = 8.5 Hz, C8-H), 
6.13 (2H, br. s, NH2), 2.64 (1H, m, C2-H), 1.17 (2H, m, 2 × C1-H2), 0.96 (2H, m, 2 × C1-H2); 13C NMR 
(CDCl3, 100 MHz): δ 202.0 (C3), 149.5 (C9), 133.9 (C7), 131.2 (C5), 119.2 (C4), 117.2 (C8), 115.9 




To a stirring solution of aniline I (226 mg, 1.4 mmol) and NEt3 (0.23 mL, 1.68 mmol) in CH2Cl2 (7 mL) 
at 0 °C was added acetyl chloride (0.12 mL, 1.68 mmol). The reaction was stirred for 3 h before being 
quenched by the addition of water (10 mL). The aqueous layer was extracted with CH2Cl2 (2 × 10 mL) 
and the combined organics were dried over Na2SO4 and concentrated in vacuo. Purification by FCC 
(15% EtOAc/hexane) provided the title compound (215 mg, 75%) as a yellow oil; νmax / cm-1: 3249 (w), 
1694 (m), 1639 (m), 1582 (s), 1519 (s), 1449 (s), 1379 (s), 1302 (s), 1208 (s); 1H NMR (CDCl3, 
400 MHz): δ 11.54 (1H, br. s, NH), 8.69 (1H, d, J = 8.5 Hz, C8-H), 8.11 (1H, d, J = 8.0 Hz, C5-H), 
7.54 (1H, dd, J = 8.5, 7.5 Hz, C7-H), 7.15 (1H, dd, J = 8.0, 7.5 Hz, C6-H), 2.69 (1H, m, C2-H), 2.20 
(3H, s, C11-H3), 1.26 (2H, m, 2 × C1-H2), 1.09 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 
204.4 (C3), 169.5 (C10), 140.3 (C9), 134.6 (C7), 130.9 (C5), 123.2 (C4), 122.5 (C6), 121.0 (C8), 25.7 








To a stirring solution of aniline I (226 mg, 1.40 mmol) and NEt3 (0.46 mL, 3.36 mmol) in CH2Cl2 
(7 mL) at 0 °C was added p-toluenesulfonyl chloride (640 mg, 3.36 mmol). The reaction was stirred for 
16 h before being quenched by the addition of water (10 mL). The aqueous layer was extracted with 
CH2Cl2 (2 × 10 mL) and the combined organics were dried over Na2SO4 and concentrated in vacuo. 
Purification by FCC (20% EtOAc/hexane) provided the title compound (222 mg, 50%) as a colourless 
oil; νmax / cm-1: 3008 (br. w), 1634 (m), 1492 (m), 1337 (m), 1159 (s), 1090 (m); 1H NMR (CDCl3, 
400 MHz): δ 11.19 (1H, br. s, NH), 7.98 (1H, d, J = 8.0 Hz, C5-H), 7.68 (2H, d, J = 8.5 Hz, 2 × C11-H), 
7.67 (1H, d, J = 8.5 Hz, C8-H), 7.45 (1H, dd, J = 8.5 ,7.5 Hz, C7-H), 7.21 (2H, d, J = 8.5 Hz, C12-H), 
7.11 (1H, dd, J = 8.0 ,7.5 Hz, C6-H), 2.51 (1H, m, C2-H), 2.36 (3H, s, C14-H3), 1.18 (2H, m, 2 × 
C1-H2), 1.02 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 203.8 (C3), 143.8 (C13), 139.3 (C9), 
136.8 (C10), 134.3 (C7), 131.0 (C5), 129.7 (C12), 127.4 (C11), 124.3 (C4), 123.0 (C6), 120.1 (C8), 




KOH pellets (8.42 g, 150 mmol) were dissolved in water (100 mL) before the addition of 
cyclopropylacetonitrile 326 (9.11 mL, 100 mmol) at room temperature. The reaction mixture was heated 
at reflux for 5 h before being cooled to room temperature. The reaction mixture was washed with Et2O 
(50 mL), acidified (pH 1) with conc. HCl and extracted with Et2O (3 × 50 mL). The combined organics 
were dried over MgSO4 and concentrated in vacuo to provide the title compound (10.6 g, 99%) as a 
colourless liquid; νmax / cm-1: 2918 (br.), 2675 (br.), 1708 (s), 1413 (m), 1222 (m); 1H NMR (CDCl3, 
400 MHz): δ 11.41 (1H, br. s, OH), 2.27 (2H, d, J = 7.0 Hz, C3-H2), 1.06 (1H, m, C2-H), 0.57 (2H, m, 
2 × C1-H2), 0.19 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 179.5 (C4), 39.2 (C3), 6.8 (C2), 
4.5 (C1); HRMS: (Negative ion) Calculated for C5H7O2: 99.0452. Found [M - H]-: 99.0455. 
N-Benzyl-2-cyclopropylacetamide (328a) 
 
To a stirring solution of carboxylic acid 327 (5.01 g, 50.0 mmol), DCC (11.3 g, 55.0 mmol) and DMAP 
(61 mg, 0.50 mmol) in dry CH2Cl2 (167 mL) at 0 °C was added benzylamine (5.73 mL, 52.5 mmol). 
The reaction mixture was warmed to room temperature and stirred for 2 h before being filtered over a 




short pad of celite. The filtrate was concentrated in vacuo and purified by FCC (40–50% EtOAc/hexane) 
to provide the crude product contaminated with dicyclohexylurea. The crude product was dissolved in 
the minimum amount of EtOAc and filtered to provide the title compound (4.40 g, 46%) as a colourless 
solid; m.p. (CH2Cl2/hexane); 56–58 °C; νmax / cm-1: 3298 (s), 3081 (w), 1632 (s), 1548 (s), 1452 (m), 
1326 (m), 1229 (s), 1021 (m); 1H NMR (CDCl3, 400 MHz): δ 7.36–7.26 (5H, m, 2 × C7-H, 2 × C8-H, 
C9-H), 6.18 (1H, br. s, NH), 4.49 (2H, d, J = 5.5 Hz, C5-H2), 2.21 (2H, d, J = 7.0 Hz, C3-H2), 0.98 (1H, 
m, C2-H), 0.61 (2H, m, 2 × C1-H2), 0.21 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 172.4 
(C4), 138.6 (C6), 128.9 (C8), 127.8 (C7), 127.6 (C9), 43.6 (C5), 41.7 (C3), 7.3 (C2), 4.8 (C1); HRMS: 
(ESI+) Calculated for C12H16NO: 190.1226. Found [M + H]+: 190.1230. 
(E)-N-Benzylpent-3-enamide (329a) and (Z)-N-Benzylpent-3-enamide (329b) and N-Benzylpent-
4-enamide (329c) 
 
General procedure B: [Rh(cod)2]BARF (8.87 mg, 0.0113 mmol), PPh3 (3.93 mg, 0.0225 mmol) and 
328a (28.4 mg, 0.150 mmol) were employed in 1,4-dioxane (1.5 mL) at 120 °C for 24 h. Purification 
by FCC (20% EtOAc/hexane) provided 329a, 329b and 329c (20.2 mg, 71%, 3:1.4:1 mixture of 
regioisomers and diastereomers A:B:C) as a pale yellow oil; Data for the mixture of compounds 329a 
(A), 329b (B) and 329c (C): νmax / cm-1: 3287 (s), 2917 (w), 1636 (s), 1543 (s), 1453 (m), 1235 (m); 1H 
NMR (CDCl3, 400 MHz): δ 7.36–7.25 (15H, m, 6 × C8-H, 6 × C9-H, 3 × C10-H, A+B+C), 5.94 (1H, 
br. s, NH, B), 5.89 (1H, br. s, NH, A), 5.89–5.51 (6H, m, 1 × NH (C), 3 × C2-H (A+B+C), 2 × C3-H 
(A+B)), 5.07 (1H, dq, J = 17.0, 1.5 Hz, C1-H, C), 5.01 (1H, dq, J = 10.0, 1.5 Hz, C1-H, C), 4.45 (6H, 
m, 6 × C6-H2, A+B+C), 3.08 (2H, d, J = 7.5 Hz, C4-H2, B) 2.99 (2H, d, J = 7.0 Hz, C4-H2, A), 2.43 
(2H, m, C3-H2, C), 2.31 (2H, m, C4-H2, C), 1.72 (3H, dd, J = 6.0, 1.5 Hz, C1-H3, A), 1.65 (3H, m, 
C1-H3, B); 13C NMR (CDCl3, 100 MHz): δ 176.2 (C5, C), 171.3 (C5, A), 171.2 (C5, B), 138.5, 138.4, 
137.2 (C7, A+B+C), 131.4, 130.0, (C2/3, A), 129.7 (C2/3, B), 128.9, 127.9, 127.8, 127.6 (ArC-H, 
A+B+C), 123.8 (C2/3, A), 122.7 (C2/3, B), 115.8 (C1, C), 43.8, 43.8, 43.7 (C6, A+B+C), 40.7 (C4, A), 
36.0 (C4, C), 35.0 (C4, B), 29.8 (C3, C), 18.2 (C1, A), 13.1 (C1, B); HRMS: (ESI+) Calculated for 
C13H16NO2: 218.1176. Found [M + H]+: 218.1176. 
 




1-Benzyl-3,6-dihydro-1H-azepine-2,7-dione (331a) and 1-Benzylazepane-2,7-dione (330a) and 1-
Benzyl-3,4-dihydro-1H-azepine-2,7-dione (C) 
 
General procedure B: [Rh(cod)2]BARF (8.87 mg, 0.0075 mmol), P(C6F5)3 (7.98 mg, 0.015 mmol), 
60a (28.4 mg, 0.150 mmol) and pyridine (0.015 mL, 0.5 M stock solution in 1,2-DCB) were employed 
in 1,2-DCB (2.0 mL) at 130 °C for 46 h. Purification by FCC (25% EtOAc/hexane) provided 330a and 
331a (31.1 mg, 95%, 5.7:1, 330a:331a) as a colourless oil; Separated samples of 330a and 331a could 
be obtained by FCC (20% EtOAc/hexane); C is typically formed in >5% yield as determined by 1H 
NMR analysis of the crude reaction against 1,4-DCB as an internal standard. Data for “saturated” 
compound 330a: νmax / cm-1: 2948 (br.), 1710 (m), 1658 (s), 1339 (m), 1161 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.31–7.19 (5H, m, 2 × C6-H, 2 × C7-H, C8-H), 4.91 (2H, s, C4-H2), 2.77 (4H, m, 4 × 
C2-H2), 1.85 (4H, m, 4 × C3-H2); 13C NMR (CDCl3, 100 MHz): δ 175.8 (C1), 137.9 (C8), 128.5, 128.5, 
127.4 (C6, C7, C8), 46.5 (C4), 36.2 (C2), 20.8 (C3); HRMS: (ESI+) Calculated for C13H16NO2: 
218.1176. Found [M + H]+: 218.1176. Data for “unsaturated” compound 331a: νmax / cm-1: 3032 (w), 
1708 (m), 1659 (s), 1322 (m), 1227 (m), 1154 (m); 1H NMR (CDCl3, 400 MHz): δ 7.27–7.18 (5H, m, 
2 × C6-H, 2 × C7-H, C8-H), 6.03 (2H, t, J = 5.0 Hz, 2 × C3-H), 4.95 (2H, s, C4-H2), 3.55 (4H, d, J = 
5.0 Hz, 4 × C2-H2); 13C NMR (CDCl3, 100 MHz): δ 170.6 (C1), 137.7 (C5), 128.4 (C6), 128.3 (C7), 
127.3 (C8), 126.0 (C3), 45.6 (C4), 38.9 (C2); HRMS: (ESI+) Calculated for C13H14NO2: 216.1019. 
Found [M + H]+: 216.1025. Data for the minor product C: (Characteristic signals only)  1H NMR 
(CDCl3, 400 MHz): δ 6.63 (1H, dt, J = 12.0, 5.0 Hz, C5-H), 6.16 (1H, d, J = 12.0 Hz, C6-H), 4.95 (2H, 
s, C7-H2), 2.88 (2H, m, C3-H2), 2.54 (2H, m, C4-H2); 13C NMR (CDCl3, 100 MHz): δ 173.2 (C2), 170.6 
(C1), 144.5 (C5), 137.7 (C8), 127.8 (C6), 45.6 (C7), 37.6 (C3), 24.6 (C4);  
2-Cyclopropyl-N-phenylacetamide (328b) 
 




To a flame dried flask containing EDCI (1.05 g, 5.50 mmol) and DMAP (61.1 mg, 0.50 mmol) under 
an atmosphere of argon was added CH2Cl2 (10 mL) and aniline (0.46 mL, 5.00 mmol). The flask was 
cooled to 0 °C before the addition of carboxylic acid 327 (551 mg, 5.50 mmol). The reaction mixture 
was stirred for 66 h before being concentrated in vacuo. The resulting solid dissolved in 1 M aq. NaOH 
(20 mL) and extracted with EtOAc (3 × 20 mL). The combined organics were washed with 1 M aq. 
HCl (30 mL), dried over MgSO4 before being concentrated in vacuo. Purification by FCC (20% 
EtOAc/hexane) provided the title compound (703 mg, 80%) as a colourless solid; m.p. 
(CH2Cl2/hexane); 100–101 °C; νmax / cm-1: 3246 (w), 1656 (s), 1596 (s), 1540 (s), 1442 (s); 1H NMR 
(CDCl3, 400 MHz): δ 7.74 (1H, br. s, NH), 7.53 (2H, m, 2 × C6-H), 7.31 (2H, m, 2 × C7-H), 7.10 (1H, 
t, J = 8.0 Hz, C8-H), 2.31 (2H, d, J = 7.0 Hz, C3-H2), 1.08 (1H, m, C2-H), 0.68 (2H, m, 2 × C1-H2), 
0.28 (2H, m, 2 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 170.8 (C4), 138.0 (C5), 129.1 (C7), 124.4 
(C8), 120.0 (C6), 42.6 (C3), 7.4 (C2), 4.9 (C1); HRMS: (ESI+) Calculated for C11H14NO: 176.1070. 
Found [M + H]+: 176.1069. 
1-Phenylazepane-2,7-dione (330b) and 1-Phenyl-3,6-dihydro-1H-azepine-2,7-dione (331b) 
 
General procedure B: [Rh(cod)2]BARF (13.3 mg, 0.0113 mmol), P(C6F5)3 (12.0 mg, 0.0225 mmol), 
328b (26.3 mg, 0.150 mmol) and pyridine (0.015 mL, 0.5 M stock solution in 1,2-DCB) were employed 
in 1,2-DCB (2.0 mL) at 130 °C for 46 h. Purification by FCC (50% EtOAc/hexane) provided the title 
compounds (6.7 mg, 22%, 2:1 A:B) as a pale yellow oil; Data for the mixture of compounds 330b 
(A) and 331b (B): νmax / cm-1: 2938 (w), 1715 (m), 1670 (s), 1491 (m), 1339 (m), 1248 (m); 1H NMR 
(CDCl3, 400 MHz): δ 7.48–7.30 (6H, m, ArCH, A+B), 7.11–7.02 (4H, m, ArCH, A+B), 6.15 (2H, m, 
C3-H, B), 3.68 (4H, d, J = 4.5 Hz, C2-H2, B), 2.93 (4H, m, C2-H2, A), 2.04 (4H, m, C3-H2); 13C NMR 
(CDCl3, 100 MHz): δ 175.9 (C1, A), 169.7 (C1, B), 138.4, 138.0 (C4, A+B), 129.4, 129.4, 128.5, 128.4, 
128.4, 128.2, (ArCH, A+B), 126.1 (C3, B), 39.2 (C2, B), 36.2 (C2, A), 20.9 (C3, A). Data for the 
saturated product 330b:  δ; HRMS: (ESI+) Calculated for C12H14NO2: 204.1019. Found [M + H]+: 
204.1024: Data for the unsaturated product 331b:  δ; HRMS: (ESI+) Calculated for C12H12NO2: 










To a flame dried flask containing EDCI (1.05 g, 5.50 mmol) and DMAP (61.1 mg, 0.50 mmol) under 
an atmosphere of argon was added CH2Cl2 (10 mL) and cyclohexylamine (0.57 mL, 5.00 mmol). The 
flask was cooled to 0 °C before the addition of carboxylic acid 327 (551 mg, 5.50 mmol). The reaction 
mixture was stirred for 66 h before being concentrated in vacuo. The resulting solid dissolved in 1 M 
aq. NaOH (20 mL) and extracted with EtOAc (3 × 20 mL). The combined organics were washed with 
1 M aq. HCl (30 mL), dried over MgSO4 before being concentrated in vacuo. Purification by FCC (30% 
EtOAc/hexane) provided the title compound (413 mg, 46%) as a colourless solid; m.p. 
(CH2Cl2/hexane); 92–94 °C; νmax / cm-1: 3291 (m), 2978 (s), 2852 (m), 1632 (s), 1551 (s); 1H NMR 
(CDCl3, 400 MHz): δ 5.77 (1H, br. s, NH), 3.78 (1H, m, C5-H), 2.11 (2H, d, J = 7.0 Hz, C3-H2), 1.90 
(2H, m, 2 × C6-H2), 1.68 (2H, m, 2 × C7-H2), 1.59 (1H, m, C8-H2), 1.37 (2H, m, 2 × C7-H2), 1.21–1.08 
(3H, m, 2 × C6-H2, C8-H2), 0.91 (1H, m, C2-H), 0.58 (2H, m, 2 × C1-H2), 0.17 (2H, m, C1-H2); 13C 
NMR (CDCl3, 100 MHz): δ 171.6 (C4), 48.0 (C5), 41.8 (C3), 33.3 (C6), 25.7 (C8), 24.9 (C7), 7.3 (C2), 
4.7 (C1); HRMS: (ESI+) Calculated for C11H20NO: 182.1539. Found [M + H]+: 182.1533. 
1-Cyclohexylazepane-2,7-dione (330c) and 1-Cyclohexyl-3,6-dihydro-1H-azepine-2,7-dione 
(331c) 
 
General procedure B: [Rh(cod)2]BARF (13.3 mg, 0.0113 mmol), P(C6F5)3 (12.0 mg, 0.0225 mmol), 
328c (27.2 mg, 0.150 mmol) and pyridine (0.015 mL, 0.5 M stock solution in 1,2-DCB) were employed 
in 1,2-DCB (2.0 mL) at 130 °C for 46 h. Purification by FCC (20% EtOAc/hexane) provided the title 
compounds (7.9 mg, 23%, 2:1 A:B) as a pale yellow oil; Data for the mixture of compounds 330c 
and 331c: νmax / cm-1: 2928 (m), 2854 (m), 17100 (m), 1661 (s), 1338 (m), 1320 (m), 1142 (m); 1H 
NMR (CDCl3, 400 MHz): δ 6.00 (2H, m, 2 × C3-H, B), 4.47–4.33 (2H, m, 2 × C4-H, A+B), 3.46 (4H, 
m, 4 × C2-H2, B), 2.67 (4H, t, J = 6.5 Hz, 4 × C2-H2, A), 2.18–2.03 (4H, m, 4 × C5-H2, A+B), 1.82 
(4H, t, J = 6.5 Hz, 4 × C3-H2, A), 1.78–1.74 (4H, m, 4 × C6-H2, A+B), 1.62–1.57 (2H, m, 2 × C7-H2, 
A+B), 1.55–1.52 (4H, m, 4 × C5-H2, A+B), 1.35–1.23 (4H, m, 4 × C6-H2, A+B), 1.21–1.12 (2H, m, 2 
× C7-H2, A+B); 13C NMR (CDCl3, 100 MHz): δ 176.6 (C1, A), 171.6 (C1, B), 126.3 (C3, B), 56.5 (C4, 




B), 56.4 (C4, A), 39.7 (C2, B), 37.0 (C2, A), 29.9 (C5, A), 29.4 (C5, B), 26.7 (C6, B), 26.6 (C6, A), 
25.5 (C7, B), 25.5 (C7, A), 21.0 (C3, A); HRMS: (ESI+) Calculated for C12H20NO2: 210.1489. Found 
[M + H]+: 210.1495. 
2-Cyclopropyl-3-phenylpropanoic acid (332) 
 
To a flame-dried flask containing diisopropylamine (1.41 mL, 10.0 mmol) and THF (7 mL) under an 
atmosphere of argon at 0 °C was added n-BuLi (6.25 mL, 10.0 mmol, 1.6 M in THF) over 2 minutes 
before being stirred for 30 minutes. The resulting solution of LDA was transferred to a flask containing 
carboxylic acid 327 in THF (26 mL) at -78 °C over 10 minutes. After 20 minutes the reaction was 
warmed to 0 °C for 10 minutes and then 35 °C for 10 minutes. The reaction was then cooled to room 
temperature before the addition of benzyl chloride (575 mg, 5.00 mmol). After 30 minutes the reaction 
was quenched by the addition of water (20 mL). The organic phase was removed and the aqueous layer 
was washed with Et2O (20 mL). The aqueous layer was acidified by the addition of 1 M HCl (5 mL) 
before being extracted with Et2O (3 × 20 mL). The combined organics were dried over MgSO4 and 
concentrated in vacuo. Purification by FCC (10% EtOAc/hexane) provided the title compound (780 mg, 
82%) as a colourless oil; νmax / cm-1: 2923 (m), 1704 (s), 1290 (w), 1229 (w); 1H NMR (CDCl3, 
400 MHz): δ 10.22 (1H, br. s, OH), 7.34–7.24 (5H, m, 2 × C7-H, 2 × C8-H, C9-H), 3.15 (1H, dd, J = 
13.5, 8.5 Hz, C5-H2), 3.01 (1H, dd, J = 13.5, 6.0 Hz, C5-H2), 1.95 (1H, m, C3-H), 1.05 (1H, m, C2-H), 
0.60–0.58 (2H, m, 2 × C1-H2), 0.41 (1H, m, C1-H2), 0.12 (1H, m, C1-H2); 13C NMR (CDCl3, 100 MHz): 
δ 181.2 (C4), 139.2 (C6), 129.1, 128.5 (C7, C8), 126.5 (C9), 52.6 (C3), 38.5 (C5), 13.8 (C2), 5.0 (C1), 
3.8 (C1); HRMS: (ESI+) Calculated for C12H14NaO2: 213.0886. Found [M + Na]+: 213.0886. 
N-Benzyl-2-cyclopropyl-3-phenylpropanamide (333a) 
 
To a stirring solution of carboxylic acid 332 (700 g, 3.68 mmol), DCC (836 mg, 4.05 mmol) and DMAP 
(spatula tip) in dry CH2Cl2 (12 mL) at 0 °C was added benzylamine (0.42 mL, 3.86 mmol). The reaction 
mixture was warmed to room temperature and stirred for 2 h before being filtered over a short pad of 
celite. The filtrate was concentrated in vacuo and purified by FCC (15–20% EtOAc/hexane) to provide 




the title compound (261 mg, 26%) as a colourless solid; m.p. 111–113 °C (CH2Cl2/hexane); νmax / cm-
1: 3295 (m), 1637 (s), 1541 (s), 1452 (m), 1220 (m); 1H NMR (CDCl3, 400 MHz): δ 7.33–7.24 (8H, m, 
8 × ArCH), 7.10–7.08 (2H, m, 2 × ArCH), 5.76 (1H, br. m, NH), 4.48 (1H, dd, J = 15.0, 6.0 Hz, C5-H2), 
4.49 (1H, dd, J = 15.0, 5.5 Hz, C5-H2), 3.19 (1H, dd, J = 13.5, 9.0 Hz, C10-H2), 3.07 (1H, dd, J = 13.5, 
5.0 Hz, C10-H2), 1.67 (1H, m, C3-H), 1.09 (1H, m, C2-H), 0.64 (2H, m, 2 × C1-H2), 0.30 (1H, m, 
C1-H2), 0.18 (1H, m, C1-H2); 13C NMR (CDCl3, 100 MHz): δ 174.2 (C4), 139.9 (C11), 138.3 (C6), 
129.4, 128.7, 128.5, 127.7 (C7, C8, C12, C13), 127.4, 126.3 (C9, C14), 55.2 (C3), 43.5 (C5), 38.9 
(C10), 13.7 (C2), 5.0 (C1), 4.4 (C1); HRMS: (ESI+) Calculated for C19H22NO: 280.1696. Found [M + 
H]+: 280.1698. 
1,3-Dibenzylazepane-2,7-dione (335a) and 1,3-Dibenzyl-3,6-dihydro-1H-azepine-2,7-dione (336a) 
 
General procedure B: [Rh(cod)2]BARF (13.3 mg, 0.0113 mmol), P(C6F5)3 (12.0 mg, 0.0225 mmol), 
amide 333a (41.9 mg, 0.150 mmol) and pyridine (0.015 mL, 0.5 M stock solution in 1,2-DCB) were 
employed in 1,2-DCB (2.0 mL) at 130 °C for 46 h. 1H NMR analysis of the crude reaction against 1,4-
DNB as an internal standard suggests 335a and 336a (45%, 1.8:1 mixture of 69:70). Analytical samples 
of 335a and 336a were obtained in an impure form by FCC (15% EtOAc/hexane); Data for the 
saturated product 335a: νmax / cm-1: 2936 (w), 1661 (s), 1341 (m), 1330 (m), 1168 (m); 1H NMR 
(CDCl3, 400 MHz): δ 7.27–7.12 (10H, m, 2 × C9-H, 2 × C10-H, C11-H, 2 × C14-H, 2 × C15-H, C16-H), 
5.00 (1H, d, J = 14.0 Hz, C7-H2), 4.89 (1H, d, J = 14.0 Hz, C7-H2), 3.27 (1H, dd, J = 14.0, 7.0 Hz, 
C12-H2), 2.99 (1H, m, C6-H), 2.84 (1H, dd, J = 18.0, 5.0 Hz, C3-H2), 2.72 (1H, dd, J = 14.0, 7.0 Hz, 
C12-H2), 2.64 (1H, m, C3-H2), 1.91–1.66 (4H, m, C4-H2, C5-H2); 13C NMR (CDCl3, 100 MHz): δ 
176.9, 176.9 (C1, C2), 139.4 (C13), 137.8 (C8), 129.2, 128.6, 128.5, 128.3 (C9, C10, C14, C15), 127.3, 
126.5 (C11, C16), 47.1 (C7), 46.9 (C6), 37.6 (C12), 37.0 (C3), 28.8 (C5), 20.1 (C4); HRMS: (ESI+) 
Calculated for C20H21NNaO2: 330.1465. Found [M + Na]+: 330.1455. Data for the unsaturated 
product 336a: νmax / cm-1: 2925 (w), 1710 (m), 1662 (s), 1454 (m), 1305 (m); 1H NMR (CDCl3, 
400 MHz): δ 7.31–7.18 (10H, m, ArCH), 5.94 (1H, m, C4-H), 5.81 (1H, m, C5-H), 5.04 (1H, d, J = 
14.5 Hz, C7-H2), 4.96 (1H, d, J = 14.5 Hz, C7-H2), 3.89 (1H, m, C6-H), 3.66 (1H, m, C3-H2), 3.50 (1H, 
dd, J = 17.0, 7.5 Hz, C3-H2), 3.44 (1H, dd, J = 14.5, 6.0 Hz, C12-H2), 3.00 (1H, dd, J = 14.5, 9.0 Hz, 
C12-H2); 13C NMR (CDCl3, 100 MHz): δ 172.1 (C1), 171.0 (C2), 138.8 (C13), 137.8 (C8), 132.1 (C5), 
129.2, 128.7, 128.4, 128.3, 127.3, 126.7 (C9, C10, C11, C14, C15, C16), 125.1 (C4), 48.2 (C6), 46.0 
(C7), 39.8 (C3), 35.7 (C12); HRMS: (ESI+) Calculated for C20H19NNaO2: 328.1308. Found [M + Na]+: 
328.1320. 






LiAlH4 powder (569 mg, 15.0 mmol) was added to a flask which was sealed with a rubber septum and 
purged with argon for 20 minutes. The flask was cooled to 0 °C before adding conc. H2SO4 (0.41 mL, 
7.50 mmol) dropwise over 15 minutes (gas evolved). The flask was warmed to room temperature and 
stirred for 1 h. To the resulting grey suspension was added cyclopropylacetonitrile 326 (0.46 mL, 
5.00 mmol) in THF (5 mL) over 10 minutes. The reaction mixture was warmed to 40 °C for 2 h and 
then cooled to 0 °C, diluted with Et2O (20 mL) and quenched by the dropwise addition of water (20 mL) 
over 2 minutes. KOH pellets (~1 g) were added and the mixture was stirred for 15 minutes causing the 
grey suspension to separate into a colourless aqueous suspension and a clear colourless organic layer. 
The organic phase was separated and the aqueous was extracted with CH2Cl2 (3 × 10 mL). The 
combined organics were dried over MgSO4 and filtered. trifluoroacetic acid (3.5 mL) was added to the 
organic phase allowing the intermediate amine to be isolated as a brown liquid trifluoroacetic acid salt 
(1.81 g) after being concentrated in vacuo. Half of the amine salt (0.90 g, assumed ~2.50 mmol) was 
added to solution of NaOH (250 mg, 6.25 mmol) in water (63 mL, 0.04 M). Benzoyl chloride (0.32 mL, 
2.75 mmol) was then added to the solution causing the formation of a colourless solid. The reaction 
mixture was extracted with CH2Cl2 (3 × 30 mL) and the combined organic phase was dried over MgSO4 
before being concentrated in vacuo. The resulting crude product was purified by FCC (25% 
EtOAc/hexane) to provide the title compound (340 mg, 72% over 2 steps on a 2.50 mmol scale) as a 
colourless solid; m.p. 56–57 °C (CH2Cl2); νmax / cm-1: 3302 (br.), 3075 (w), 3000 (w), 2925 (w), 1635 
(s), 1539 (s), 1490 (m), 1310 (m); 1H NMR (CDCl3, 400 MHz): δ 7.77–7.75 (2H, m, C7-H), 7.47 (1H, 
m, C9-H), 7.42 (2H, m, C8-H), 6.29 (1H, br. s, NH), 3.55 (2H, td, J = 7.0, 6.5 Hz, C4-H2), 1.53 (2H, 
dt, J = 7.0, 7.0 Hz, C3-H2), 0.74 (1H, m, C2-H), 0.50 (2H, m, C1-H), 0.12 (2H, m, C1-H); 13C NMR 
(CDCl3, 100 MHz): δ 167.5 (C5), 135.0 (C6), 131.4 (C9), 128.7 (C8), 126.9 (C7), 40.5 (C4), 34.6 (C3), 
8.8 (C2), 4.3 (C1); HRMS: (ESI+) Calculated for C12H16NO: 190.1226. Found [M + H]+: 190.1235. 
2-Cyclopropyl-3-phenylpropanamide (333b)  
 




To a stirring solution of carboxylic acid 332 (3.80 g, 20.0 mmol) in dry CH2Cl2 (20 mL), at 0 °C was 
added a drop of DMF and then oxalyl chloride (1.88 mL, 22.0 mmol) over 5 minutes. The resulting 
solution was stirred for 30 minutes before being added to a stirring solution of aq. ammonia (40 mL) 
resulting in immediate formation of a colourless precipitate. After 30 minutes the aqueous layer was 
extracted with CH2Cl2 (3 × 20 mL). The combined organics were dried over MgSO4, filtered and 
concentrated in vacuo. The resulting solid was purified by FCC (50% EtOAc/hexane) to provide the 
title compound (2.87 g, 76%) as a colourless solid; m.p. 107–108 °C (CH2Cl2); νmax / cm-1 3398 (s), 
3189 (m), 1653 (s), 1621 (s), 1409 (m), 1284 (w); 1H NMR (CDCl3, 400 MHz): δ 7.33–7.21 (5H, m, 2 
× C7-H, 2 × C8-H, 1 × C9-H), 5.79 (1H, br. s, 1 × NH), 5.59 (1H, br. s, 1 × NH), 3.14 (1H, dd, J = 13.5, 
8.0 Hz, 1 × C5-H2), 3.02 (1H, dd, J = 13.5, 5.5 Hz, 1 × C5-H2), 1.71 (1H, m, C3-H), 0.63–0.60 (2H, m, 
2 × C1-H2), 0.31 (1H, m, 1 × C1-H2), 0.13 (1H, m, 1 × C1-H2); 13C NMR (CDCl3, 100 MHz): δ 177.2 
(C4), 139.8 (C6), 129.3, 128.4 (C7, C8), 126.3 (C9), 54.0 (C3), 38.9 (C5), 13.6 (C2), 5.1 (C1), 4.3 (C1); 
HRMS: (ESI+) Calculated for C12H15NNaO: 212.1046. Found [M + Na]+: 212.1052. 
3-Benzylazepane-2,7-dione (335b) and 3-Benzyl-3,6-dihydro-1H-azepine-2,7-dione and 6-Benzyl-
3,4-dihydro-1H-azepine-2,7-dione (336b) 
 
General procedure B: [Rh(cod)2]BARF (8.9 mg, 0.0075 mmol), P(C6F5)3 (8.0 mg, 0.015 mmol), 
amide 333b (28.4 mg, 0.150 mmol) and pyridine (0.015 mL, 0.5 M stock solution in 1,2-DCB) were 
employed in 1,2-DCB (2.0 mL) at 130 °C for 46 h. 1H NMR analysis of the crude reaction against 1,4-
DNB as an internal standard suggests 335b and 336b (79%, 2:1 mixture of 335b:336b). Analytical 
samples of 335b and 336b were obtained in an impure form by FCC (15% EtOAc/hexane); Data for 
the saturated product 335b: νmax / cm-1 3228 (br.), 2923 (w), 1696 (s), 1271 (m), 1198 (w); 1H NMR 
(CDCl3, 400 MHz): δ 8.02 (1H, br. s, NH), 7.31–7.19 (5H, m, 2 × C9-H, 2 × C10-H, 1 × C11-H), 3.30 
(1H, dd, J = 14.0, 5.5 Hz, 1 × C7-H2), 2.97 (1H, m, C6-H), 2.76–2.61 (3H, m, 2 × C3-H2, 1 × C7-H2), 
1.95–1.79 (3H, m, 2 × C4-H2, 1 × C5-H2), 1.69 (1H, m, 1 × C5-H2); 13C NMR (CDCl3, 100 MHz): δ 
175.6 (C1), 175.2 (C2), 139.1 (C8), 129.2, 128.6 (C9, C10), 126.6 (C11), 45.0 (C6), 36.9 (C7), 35.1 
(C3), 27.5 (C5), 20.0 (C4); HRMS: (ESI+) Calculated for C13H15NNaO2: 240.0995. Found [M + Na]+: 
240.0997. Data for the unsaturated product 336b: νmax / cm-1 3217 (br.), 2935 (w), 1684 (s), 1353 
(m), 1260 (m), 1203 (m); 1H NMR (CDCl3, 400 MHz): δ 7.72 (1H, br. s, NH), 7.31 (2H, m, 2 × C10-H), 
7.26–7.21 (3H, m, 2 × C9-H, C11-H), 5.93 (1H, m, C4-H), 5.78 (1H, m, C5-H), 3.78 (1H, m, C6-H), 
3.51 (1H, m, 1 × C3-H2), 3.44 (1H, dd, J = 14.5, 5.5 Hz, 1 × C7-H2), 3.35 (1H, dd, J = 16.5, 8.0 Hz, 1 
× C3-H2), 2.96 (1H, dd, J = 14.5, 9.0 Hz, 1 × C7-H2); 13C NMR (CDCl3, 100 MHz): δ 171.5 (C1), 170.5 




(C2), 138.5 (C8), 131.6 (C5), 129.2 (C9), 128.8 (C10), 126.6 (C11), 124.6 (C4), 47.0 (C6), 37.8 (C3), 
34.9 (C7); HRMS: (ESI+) Calculated for C13H13NNaO2: 238.0838. Found [M + Na]+: 238.0845.  
2-((1S*,2R*)-2-Ethylcyclopropyl)acetic acid (342)  
 
Ethyl ester I (0.80 mL, 5.00 mmol) and CH2I2 (2.42 mL, 30.0 mmol) were added by syringe to a flame-
dried flask containing dry CH2Cl2 (20 mL). The flask was cooled to -10 °C. Et2Zn (15 mL, 15.0 mmol, 
1 M Hex) was then added by syringe over 5 minutes and the resulting mixture was stirred for 2 h. Sat. 
aq. EDTA (10 mL) was added and the resulting mixture was filtered through celite. The organic layer 
was separated, washed with brine (20 mL), dried over MgSO4, and concentrated in vacuo. 1H NMR 
analysis of the crude reaction mixture showed complete consumption of the starting material. 0.5 M aq. 
NaOH (20 mL) was added and the mixture was heated at reflux for 1 h. Once cooled, the aqueous layer 
was washed with Et2O (20 mL), acidified with conc. HCl and extracted with Et2O (3 × 20 mL). The 
product containing organics were dried over Mg2SO4, filtered and concentrated in vacuo to provide the 
title compound (499 mg, 78%, single diastereomer) as a pale yellow oil; νmax / cm-1 2922 (s), 2851 (m), 
1707 (s), 1458 (m); 1H NMR (CDCl3, 400 MHz): δ 2.27 (2H, dd, J = 7.0, 2.0 Hz, C2-H2), 1.26 (2H, m, 
C6-H2), 0.95 (2H, t, J = 7.5 Hz, C7-H3), 0.79 (1H, m, C3-H), 0.54 (1H, m, C5-H), 0.33 (2H, m, C4-H2); 
13C NMR (CDCl3, 100 MHz): δ 179.7 (C1), 39.0 (C2), 27.0 (C6), 20.6 (C5), 13.9 (C3), 13.6 (C7), 11.5 
(C4); HRMS: 342 was not observed by +ESI or -ESI. 
N-Benzyl-2-((1S*,2R*)-2-ethylcyclopropyl)acetamide (343a)  
 
To a flame dried flask containing EDCI (449 mg, 2.34 mmol) and DMAP (24 mg, 0.20 mmol) under 
an atmosphere of argon was added CH2Cl2 (10 mL) and benzylamine (0.43 mL, 3.90 mmol). The flask 
was cooled to 0 °C before the addition of carboxylic acid 342 (250 mg, 1.95 mmol). The reaction 
mixture was stirred for 24 h before being concentrated in vacuo. The resulting solid dissolved in 1 M 
aq. NaOH (10 mL) and extracted with EtOAc (3 × 10 mL). The combined organics were washed with 
1 M aq. HCl (10 mL), dried over MgSO4 before being concentrated in vacuo. Purification by FCC (25% 
EtOAc/hexane) provided the title compound (161 mg, 38%) as a colourless solid; m.p. 41–42 °C 
(CH2Cl2); νmax / cm-1 3293 (m), 2961 (m), 1631 (s), 1549 (s), 1453 (m); 1H NMR (CDCl3, 400 MHz): δ 
7.36–7.28 (5H, m, C10-H, C11-H, C12-H), 6.13 (1H, br. s, NH), 4.47 (2H, d, J = 5.5 Hz, C8-H2), 2.26 




(1H, dd, J = 16.0, 7.0 Hz, C2-H2), 2.15 (1H, dd, J = 16.0, 7.5 Hz, C2-H2), 1.24 (2H, m, C6-H2), 0.92 
(3H, t, J = 7.5 Hz, C7-H3), 0.70 (1H, m, C3-H), 0.56 (1H, m, C5-H), 0.35 (2H, m, C4-H2); 13C NMR 
(CDCl3, 100 MHz): δ 172.6 (C1), 138.5 (C9), 128.8, 127.8 (C10, C11), 127.6 (C12), 43.6 (C8), 41.3 
(C2), 26.9 (C6), 20.8 (C3), 14.5 (C5), 13.7 (C7), 11.8 (C4); HRMS: (ESI+) Calculated for C14H20NO: 
218.1539. Found [M + H]+: 218.1536. 
2-((1S*,2R*)-2-Ethylcyclopropyl)acetamide (343b)  
 
To a stirring solution of carboxylic acid 342 (250 mg, 1.95 mmol) in dry CH2Cl2 (2 mL), at 0 °C was 
added a drop of DMF and then oxalyl chloride (0.19 mL, 2.15 mmol) over 5 minutes. The resulting 
solution was stirred for 30 minutes before being added to a stirring solution of aq. ammonia (5 mL) 
resulting in immediate formation of a colourless precipitate. After 30 minutes the aqueous layer was 
extracted with CH2Cl2 (3 × 5 mL). The combined organics were dried over MgSO4, filtered and 
concentrated in vacuo. The resulting solid was purified by FCC (70% EtOAc/hexane) to provide the 
title compound (170 mg, 69%) as a colourless solid; m.p. 86–89 °C (CH2Cl2); νmax / cm-1 3349 (br. m), 
3175 (br. m), 2960 (m), 1660 (s), 1630 (s), 1415 (s), 1278 (m); 1H NMR (CDCl3, 400 MHz): δ 5.80 
(2H, br. m, NH2), 2.24 (1H, dd, J = 16.0, 7.0 Hz, C2-H2), 2.11 (1H, dd, J = 16.0, 7.5 Hz, C2-H2), 1.27 
(2H, m, C6-H2), 0.96 (3H, t, J = 7.5 Hz, C7-H3), 0.71 (1H, m, C3-H), 0.57 (1H, m, C5-H), 0.36 (2H, m, 
C4-H2); 13C NMR (CDCl3, 100 MHz): δ 175.6 (C1), 40.9 (C2), 27.0 (C6), 20.8 (C3), 14.6 (C5), 13.7 
(C7), 11.8 (C4); HRMS: (ESI+) Calculated for C7H13NO: 128.1070. Found [M + H]+: 128.1070k. 
3-Ethylazepane-2,7-dione (344b), 3-Ethyl-3,6-dihydro-1H-azepine-2,7-dione (345b) and 4-
Ethylazepane-2,7-dione (346b) 
 
General procedure B: [Rh(cod)2]BARF (8.87 mg, 0.0075 mmol), P(C6F5)3 (8.0 mg, 0.015 mmol), 
amide 343b (19.1 mg, 0.150 mmol) and pyridine (0.015 mL, 0.5 M stock solution in 1,2-DCB) were 
employed in 1,2-DCB (2.0 mL) at 130 °C for 46 h. 1H NMR analysis of the crude reaction against 1,4-




DNB as an internal standard suggests a 43% yield (5:1:1 mixture of 344b:345b:346b). Analytical 
samples of 344b and 345b were obtained in an impure form by FCC (15% EtOAc/hexane); Data for 
the saturated (C6-substituted) 344b: νmax / cm-1 3183 (br. w), 1698 (s), 1669 (s), 1363 (s), 1208 (s); 
1H NMR (CDCl3, 400 MHz): δ 7.74 (1H, br. s, NH), 2.82–2.67 (2H, m, 2 × C3-H2), 2.61 (1H, m, C6-H), 
2.05–1.90 (4H, m, 2 × C4-H2, 1 × C5-H2, 1 × C7-H2), 1.69 (1H, m, 1 × C5-H2), 1.50 (1H, m, 1 × C7-H2), 
0.98 (3H, t, J = 7.5 Hz, C8-H3); 13C NMR (CDCl3, 100 MHz): δ 175.8 (C1), 175.1 (C2), 44.8 (C6), 35.2 
(C3), 27.9 (C5), 24.1 (C7), 20.2 (C4), 12.0 (C8); HRMS: (APCI+) Calculated for C8H13NO2: 156.1019. 
Found [M + H]+: 156.1019. Data for the unsaturated (C6-substituted) 345b: νmax / cm-1 3223 (br. w), 
1690 (s), 1276 (m), 1201 (m); 1H NMR (CDCl3, 400 MHz): δ 7.62 (1H, br. s, NH), 5.99 (1H, m, C4-H), 
5.74 (1H, m, C5-H), 3.55 (1H, m, 1 × C3-H2), 3.41–3.31 (2H, m, 1 × C3-H2, 1 × C6-H), 2.07 (1H, m, 
1 × C7-H2), 1.71 (1H, m, 1 × C7-H2), 1.02 (3H, t, J = 7.5 Hz, C8-H3); 13C NMR (CDCl3, 100 MHz): δ 
171.8 (C1), 170.7 (C2), 132.2 (C5), 124.4 (C4), 47.2 (C6), 37.9 (C3), 22.2 (C7), 11.7 (C8); HRMS: 
(APCI+) Calculated for C8H11NO2: 154.0863. Found [M + H]+: 154.0865. Data for the saturated 
(C5-substituted) 346b: νmax / cm-1 3334 (br. w), 3185 (br. w), 1666 (s), 1695 (s), 1460 (w), 1203 (m); 
1H NMR (CDCl3, 400 MHz): δ 8.02 (1H, br. s, NH), 2.79–2.69 (3H, m, 2 × C3-H2, 1 × C6-H2), 2.58 
(1H, dd, J = 14.5, 8.0 Hz, 1 × C6-H2), 2.10 (1H, m, 1 × C4-H2), 1.96 (1H, m, C5-H), 1.55 (1H, m, 1 × 
C4-H2), 1.40 (2H, m, 2 × C7-H2), 0.94 (3H, t, J = 7.5 Hz, C8-H3); 13C NMR (CDCl3, 100 MHz): δ 175.1 
(C2), 173.7 (C1), 40.3 (C6), 34.2 (C5), 34.2 (C3), 29.2 (C7), 27.0 (C4), 11.5 (C8); HRMS: (APCI+) 
Calculated for C8H13NO2: 156.1019. Found [M + H]+: 156.1021.  




4.4 Experimental procedures for the studies in Section 3.2 
tert-Butyl ((1R*,2R*)-2-methylcyclopropyl)carbamate (trans-213a) 
 
General Procedure D: Carboxylic acid trans-212a (10.0 g, 100 mmol) was employed and the reaction 
was heated for 72 h. FCC (5% EtOAc/hexane) provided the title compound (15.0 g, 88%, 8:1 d.r. A:B) 
as a colourless oil; 1H NMR (CDCl3, 400 MHz): δ 4.68 (2H, br. s, NH, A+B), 2.53 (1H, m, C4-H, B), 
2.19 (1H, m, C4-H, A), 1.40 (18H, s, C7-H3, A+B), 1.07–1.05 (6H, m, C1-H3, A+B), 0.96–0.78 (3H, 
m, 2 × C2-H (A+B), 1 × C3-H2, A), 0.60 (1H, m, C3-H2, A), 0.44 (C3-H2, A), 0.05 (1H, m, C3-H2, B); 
13C NMR (CDCl3, 100 MHz): δ 155.0 (C5, A), 79.4 (C6, A+B), 30.4 (C4, A), 28.5 (C7, A), 28.5 (C7, 
B), 17.3 (C1, A), 15.2 (C2, A), 15.0 (C3, A), 12.4 (C1, B). The spectroscopic properties of this 
compound were consistent with the data available in the literature99 
tert-Butyl methyl((1R*,2R*)-2-methylcyclopropyl)carbamate (401) 
 
General Procedure G: Carbamate trans-213a (3.42 g, 20.0 mmol) was employed in THF (67 mL) 
using NaH (1.20 g, 30.0 mmol) and MeI (3.74 mL, 60.0 mmol). The reaction was run for 16 h at room 
temperature. FCC (3% EtOAc/hexane) provided the title compound (2.54 g, 69%, 8:1 d.r., A:B) as a 
pale yellow oil; νmax / cm-1: 2973 (m), 1697 (s), 1364 (s), 1153 (s); 1H NMR (CDCl3, 400 MHz): δ 2.83 
(3H, s, C10-H3, B), 2.79 (3H, s, C8-H3, A), 2.55 (1H, m, C4-H, B), 2.12 (1H, m, C4-H, A), 1.46 (18H, 
s, C7-H3, A+B), 1.05 (3H, d, J = 6.0 Hz, C1-H3, A), 1.02 (3H, d, J = 5.5 Hz, C1-H3, B), 0.99–0.89 (2H, 
m, 2 × C2-H, A+B), 0.82 (1H, m, C3-H2, B), 0.69 (1H, m, C3-H2, A), 0.43 (1H, m, C3-H2, A), 0.22 
(1H, m, C3-H2, B); 13C NMR (CDCl3, 100 MHz): δ 158.0 (C5), 79.1 (C6), 37.9 (C4), 28.5 (C7), 28.4 








General Procedure H: Carbamate 401 (7.20 g, 38.9 mmol) was employed. FCC (20% EtOAc/hexane) 
provided the title compound (4.89 g, 90%, 8:1 d.r.) as a pale yellow oil; νmax / cm-1: 3485 (br.), 2956 
(m), 1653 (s), 1615 (s), 1428 (m), 1402 (s); 1H NMR (CDCl3, 400 MHz): δ 6.82 (1H, dd, J = 17.0, 
10.5 Hz, C6-H), 6.31 (1H, dd, J = 17.0, 2.0 Hz, C7a-H), 5.64 (1H, dd, J = 10.5, 2.0 Hz, C7b-H), 2.94 
(3H, s, C8-H3), 2.37 (1H, m, C4-H), 1.11 (3H, d, J = 5.5 Hz, C1-H3), 1.09–1.00 (1H, m, C2-H), 0.85 
(1H, m, C3-H2), 0.63 (1H, m, C3-H2); 13C NMR (CDCl3, 100 MHz): δ 168.1 (C5), 129.0 (C6), 127.1 
(C7), 38.5 (C4), 34.2 (C8), 17.5 (C2), 17.0 (C1), 16.7 (C3); HRMS: (ESI+) Calculated for C8H14NO: 
140.1070. Found [M + H]+: 140.1058. 
(Z)-1,6-Dimethyl-1,3,4,6-tetrahydroazocine-2,5-dione (403a) 
 
General Procedure I: (Screening conditions for optimum yield) Acrylamide 402 (20.3 mg, 
0.150 mmol),  [Rh(cod)2]BARF (17.7 mg, 0.0150 mmol), P(p-CNC6H4)3 (12.7 mg, 0.0375 mmol) and 
N-methyltrifluoroacetamide (19.1 mg, 0.150 mmol) were employed, and the reaction was  heated at 
150 °C for 72 h. 1H NMR analysis of the crude reaction mixture against 1,4-DNB as an internal standard 
indicated formation of the title compound (51% yield).  
General Procedure I: (Multi-mmol scale reaction for material throughput) Acrylamide 402  (696 mg, 
5.00 mmol), [Rh(cod)2]BARF (296 mg, 0.250 mmol), P(p-CNC6H4)3 (169 mg, 0.500 mmol) and N-
methyltrifluoroacetamide (317 mg, 2.50 mmol) were employed and the reaction was  heated at 150 °C 
for 72 h. FCC (50% EtOAc/hexane) was followed by further FCC (50% Et2O/hexane) to provide the 
title compound (406 mg, 49%) as a pale yellow oil which solidified on standing; m.p. 35–38 °C 
(CHCl3); νmax / cm-1: 2942 (w), 1705 (m), 1652 (s), 1640 (s), 1449 (m), 1382 (m), 1028 (m); 1H NMR 
(CDCl3, 400 MHz): δ 6.15 (1H, dd, J = 7.5, 1.0 Hz, C7-H), 5.16 (1H, dd, J = 9.0, 7.5 Hz, C6-H), 3.49 
(1H, m, C5-H), 3.07 (3H, s, C8-H3), 2.86–2.61 (2H, m, 1 × C2-H2, 1 × C3-H2), 2.56–2.43 (2H, m, 1 × 
C2-H2, 1 × C3-H2), 1.15 (3H, d, J = 6.5 Hz, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 207.6 (C4), 173.0 
(C1), 131.9 (C7), 125.9 (C6), 43.8 (C5), 38.9 (C3), 34.1 (C8), 32.6 (C2), 15.2 (C9); HRMS: (ESI+) 
Calculated for C9H14NO2: 168.1019. Found [M + H]+: 168.1017. 
2-((Benzyloxy)methyl)oxirane (404) 
 




To a stirring solution of allyl ether I (12.6 g, 85.0 mmol) at 0 °C in CH2Cl2 (260 mL), was added m-
CPBA (22.4 g, 130 mmol) in one portion. The resulting suspension was stirred at room temperature for 
16 h. The reaction mixture was diluted with CH2Cl2 (250 mL), washed with sat. aq. Na2SO3 (250 mL), 
sat. aq. NaHCO3 (3 × 250 mL) and brine (250 mL) before drying over Na2SO4 and concentrating in 
vacuo to provide the title compound (13.1 g, 94%) as a colourless oil; νmax / cm-1: 2862 (w), 1453 (m), 
1253 (m), 1094 (s); 1H NMR (CDCl3, 400 MHz): δ 7.38–7.27 (5H, m, C1-H, 2 × C2-H, 2 × C3-H), 4.63 
(1H, d, J = 12.0 Hz, C5-H2), 4.57 (1H, d, J = 12.0 Hz, C5-H2), 3.77 (1H, dd J = 11.5, 3.0 Hz, C6-H2), 
3.45 (1H, dd, J = 11.5, 6.0 Hz, C6-H2), 3.20 (1H, m, C7-H), 2.81 (1H, dd, J = 5.0, 4.5 Hz, C8-H2), 2.63 
(1H, dd, J = 5.0, 2.5 Hz, C8-H2); 13C NMR (CDCl3, 100 MHz): δ 138.0 (C4), 128.6, 127.9 (C1, C2, 
C3), 73.5 (C5), 71.0 (C6), 51.0 (C7), 44.5 (C8); HRMS: (ESI+) Calculated for C10H12NaO2: 187.0730. 
Found [M + Na]+: 187.0737. 
Ethyl (1R*,2R*)-2-((benzyloxy)methyl)cyclopropane-1-carboxylate (405a) 
 
A flame-dried, two-necked flask containing NaH (3.72 g, 93.0 mmol, 60% dispersion in mineral oil) 
was fitted with a reflux condenser and placed under an atmosphere of nitrogen before the addition of 
anhydrous 1,2-DME (70 mL). While stirring, triethyl phosphonoacetate (24.0 mL, 121 mmol) was 
added to the resulting suspension over 1 h using a syringe pump. The resulting solution was stirred for 
1 h before the dropwise addition of epoxide 404 (11.5 g, 70.0 mmol) over 1.5 h using a syringe pump. 
The reaction mixture was heated at 60 °C for 2 h then at reflux for 22 h before being cooled to room 
temperature. The reaction mixture was quenched with sat. aq. NH4Cl (150 mL) and extracted with 
EtOAc (2 × 150 mL). The combined organics were washed with brine (150 mL), dried over Na2SO4 
and concentrated in vacuo. Purification by FCC (10% EtOAc/hexane) provided the title compound 
(8.57 g, 52%) as a pale yellow oil. The product was assigned as the trans-diastereomer in accordance 
with the reported selectivity of the cyclopropanation; νmax / cm-1: 2980 (w), 2863 (w), 1722 (s), 1453 
(w), 1182 (s), 1092 (m); 1H NMR (CDCl3, 400 MHz): δ 7.37–7.27 (5H, m, C1-H, 2 × C2-H, 2 × C3-H), 
4.52 (2H, s, C5-H2), 4.12 (2H, q, J = 7.0 Hz, C11-H2), 3.45 (1H, dd, J = 10.5, 6.0 Hz, C6-H2), 3.37 (1H, 
dd, J = 10.5, 6.0 Hz, C6-H2), 1.74 (1H, m, C7-H), 1.56 (1H, m, C9-H), 1.26 (3H, t, J = 7.0 Hz, C12-H3), 
1.21 (1H, m, C8-H2), 0.86 (1H, m, C8-H2); 13C NMR (CDCl3, 100 MHz): δ 174.0 (C10), 138.3 (C4), 
128.6, 127.8, (C2, C3), 127.8 (C1), 72.8 (C5), 71.7 (C6), 60.7 (C11), 21.7 (C7), 18.7 (C9), 14.4 (C12), 
13.1 (C8); HRMS: (ESI+) Calculated for C14H18NaO3: 257.1148. Found [M + Na]+: 257.1151. 
 




(1R*,2R*)-2-((Benzyloxy)methyl)cyclopropane-1-carboxylic acid (406a) 
 
General Procedure C: Ester 405a (10.5 g, 45.0 mmol) was employed and the reaction was stirred at 
room temperature for 16 h. The title compound (9.04 g, 97%) was isolated as a colourless oil; νmax / 
cm-1: 2861 (w), 2664 (br.), 1692 (s), 1454 (m), 1229 (m), 1081 (s); 1H NMR (CDCl3, 400 MHz): δ 7.32–
7.27 (5H, m, C1-H, 2 × C2-H, 2 × C3-H), 4.53 (2H, s, C5-H2), 3.48 (1H, dd, J = 10.5, 6.0 Hz, C6-H2), 
3.37 (1H, dd, J = 10.5, 6.5 Hz, C6-H2), 1.80 (1H, m, C7-H), 1.58 (1H, m, C9-H), 1.28 (1H, m, C8-H2), 
0.95 (1H, m, C8-H2); 13C NMR (CDCl3, 100 MHz): δ 179.8 (C10), 138.2 (C4), 128.6, 127.9, 127.8 (C1, 
C2, C3), 72.9 (C5), 71.3 (C6), 22.7 (C7), 18.4 (C9), 13.8 (C8); HRMS: (ESI+) Calculated for 
C12H14NaO3: 229.0835. Found [M + Na]+: 229.0829. 
tert-Butyl ((1R*,2R*)-2-((benzyloxy)methyl)cyclopropyl)carbamate (407a) 
 
General Procedure D: Carboxylic acid 406a (9.28 g, 45.0 mmol) was employed and the reaction was 
heated for 22 h. FCC (10% EtOAc/hexane) provided the title compound (9.60 g, 77%) as a colourless 
oil; νmax / cm-1: 3353 (w), 2977 (w), 1688 (m), 1509 (m), 1365 (m), 1160 (s), 1096 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.36–7.25 (5H, m, C1-H, 2 × C2-H, 2 × C3-H), 4.69 (1H, br. s, NH), 4.53 (2H, d, J = 
1.5 Hz, C5-H2), 3.47 (1H, dd, J = 10.5, 6.5 Hz, C6-H2), 3.30 (1H, dd, J = 10.5, 7.0 Hz, C6-H2), 2.42 
(1H, br. m, C9-H), 1.44 (9H, s, C12-H3), 1.23 (1H, m, C7-H), 0.78–0.69 (2H, m, C8-H2); 13C NMR 
(CDCl3, 100 MHz): δ 156.5 (C10), 138.5 (C4), 128.5, 127.9 (C2, C3), 127.7 (C1), 79.5 (C11), 72.9 
(C5), 72.0 (C6), 28.5 (C12), 28.3 (C9), 20.3 (C7), 12.3 (C8); HRMS: (ESI+) Calculated for 
C16H23NNaO3: 300.1576. Found [M + Na]+: 300.1580. 
tert-Butyl ((1R*,2R*)-2-((benzyloxy)methyl)cyclopropyl)(methyl)carbamate (408a) 
 
General Procedure G: Carbamate 407a (9.60 g, 34.0 mmol) was employed in DMF using NaH (1.47 g, 
102 mmol) and MeI (10.6 mL, 170 mmol). The reaction was run for 1 h at room temperature. FCC (5% 
EtOAc/hexane) provided the title compound (6.67 g, 67%) as a colourless oil; νmax / cm-1: 2974 (w), 
2856 (w), 1695 (s), 1364 (s), 1152 (s); The product appears as a 5:2 mixture of rotamers (A:B) in CDCl3 




at room temperature; 1H NMR (CDCl3, 400 MHz): δ 7.37–7.27 (10H, m, 2 × C1-H, 4 × C2-H, 4 × 
C3-H, A+B), 4.52 (2H, s, C5-H2, A), 4.51 (2H, s, C5-H2, B), 3.69 (1H, dd, J = 10.0, 6.0 Hz, C6-H2, B), 
3.57 (1H, dd, J = 10.0, 6.0 Hz, C6-H2, A), 3.25–3.19 (2H, m, 2 × C6-H2, A+B), 2.85 (3H, s, C13-H3, 
B), 2.83 (3H, s, C13-H3, A), 2.66 (1H, m, C9-H, B), 2.36 (1H, m, C9-H, A), 1.44 (9H, s, C12-H3, A), 
1.43 (9H, s, C12-H3, B), 1.37–1.28 (2H, m, 2 × C7-H, A+B), 1.01 (1H, m, C8-H2, B), 0.87 (1H, m, 
C8-H2, A), 0.76 (1H, m, C8-H2, A), 0.63 (1H, m, C8-H2, B); 13C NMR (CDCl3, 100 MHz): δ 156.9 
(C10, A), 138.5 (C4, A), 128.5, 127.9, 127.7 (C1, C2, C3, A), 79.6 (C11, A), 72.8 (C5, A), 71.9 (C6, 
A), 35.3 (C13, A), 34.8 (C9, A), 28.6 (C12, A), 28.5 (C12, B), 19.1 (C7, A), 13.3 (C8, A); HRMS: 
(ESI+) Calculated for C17H26NO3: 292.1907. Found [M + H]+: 292.1911. 
N-((1R*,2R*)-2-((Benzyloxy)methyl)cyclopropyl)-N-methylacrylamide (409a) 
 
General Procedure H: Carbamate 408a (6.67 g, 22.9 mmol) was employed. FCC (10% 
EtOAc/hexane) provided the title compound (4.21 g, 75%) as a pale yellow oil; νmax / cm-1: 2860 (w), 
2228 (m), 1623 (s), 1614 (m), 1447 (m), 1402 (m), 1073 (m); 1H NMR (CDCl3, 400 MHz): δ 7.38–7.28 
(5H, m, C1-H, 2 × C2-H, 2 × C3-H), 7.07 (1H, dd, J = 17.0, 10.0 Hz, C11-H), 6.33 (1H, dd, J = 17.0, 
2.0 Hz, C12a-H), 5.61 (1H, dd, J = 10.0, 2.0 Hz, C12b-H), 4.57 (1H, d, J = 12.0 Hz, C5-H2), 4.51 (1H, 
d, J = 12.0 Hz, C5-H2), 3.62 (1H, m, C6-H2), 3.23 (1H, m, C6-H2), 2.99 (3H, s, C13-H3), 2.65 (1H, m, 
C9-H), 1.48 (1H, m, C7-H), 0.95 (1H, m, C8-H2), 0.86 (1H, m, C8-H2); 13C NMR (CDCl3, 100 MHz): 
δ 168.2 (C10), 138.3 (C4), 129.0 (C11), 127.8 , 127.6, 127.6,  (C1, C2, C3), 127.4 (C12), 73.0 (C5), 
71.5 (C6), 36.3 (C9), 34.4 (C13), 22.5 (C7), 13.6 (C8); HRMS: (ESI+) Calculated for C15H19NNaO2: 
268.1308. Found [M + Na]+: 268.1311. 
(Z)-6-((Benzyloxy)methyl)-1-methyl-1,3,4,6-tetrahydroazocine-2,5-dione (410a) and (Z)-1-
Methyl-6-methylene-1,3,4,6-tetrahydroazocine-2,5-dione (411) 
 
To a flame dried reaction tube equipped with a stir bar was added [Rh(cod)2]BARF (17.7 mg, 
0.015 mmol) and P(p-CNC6H4)3 (10.1 mg, 0.300 mmol). The reaction tube was sealed with a rubber 
septum and purged with argon (balloon) for 30 minutes. Acrylamide 409a (36.8 mg, 0.150 mmol) in 




dry benzonitrile (1.5 mL) was added by syringe and the reaction mixture was stirred for 10 seconds. 
The reaction tube was then purged with CO for 2 minutes and the reaction mixture was sparged for a 
further 10 seconds before the reaction tube was sealed and heated at 140 °C for 26 h. The resulting 
solution was transferred to a flask and concentrated in vacuo before being analysis by 1H NMR against 
1,4-DNB as an internal standard. Purification by FCC (60% EtOAc/hexane) provided the title 
compound 410a (11.7 mg, 29%, contains a number of unidentified impurities) as a pale brown oil; Data 
for major compound 410a: νmax / cm-1: 3417 (w), 2927 (w), 1712 (m), 1642 (s), 1389 (s), 1169 (s), 
1108 (s); 1H NMR (CDCl3, 400 MHz): δ 7.35–7.27 (5H, m, 2 × C12-H, 2 × C13-H, C14-H), 6.21 (1H, 
dd, J = 7.5, 1.0 Hz, C7-H), 5.20 (1H, dd, J = 9.0, 7.5 Hz, C6-H), 4.51 (1H, d, J = 12.0 Hz, C10-H2), 
4.45 (1H, d, J = 12.0 Hz, C10-H2), 3.87 (1H, dd, J = 9.5, 7.5 Hz, C9-H2), 3.73 (1H, m, C5-H), 3.52 (1H, 
dd, J = 9.5, 6.5 Hz, C9-H2), 3.06 (3H, s, C8-H3), 2.78–2.69 (2H, m, 1 × C2-H2, 1 × C3-H2), 2.57 (1H, 
m, C2-H2), 2.47 (1H, m, C3-H2); 13C NMR (CDCl3, 100 MHz): δ 205.9 (C4), 172.7 (C1), 138.0 (C11), 
133.3 (C7), 128.5, 127.9, 127.8 (C12, C13, C14), 121.5 (C6), 73.5 (C10), 68.8 (C9), 49.9 (C5), 39.3 
(C3), 34.2 (C8), 32.4 (C2); HRMS: (ESI+) Calculated for C16H19NNaO3: 296.1257. Found [M + Na]+: 
296.1267. Data for minor compound 411: Characteristic signals: 1H NMR (CDCl3, 400 MHz): δ 5.92 
(1H, d, J = 9.0 Hz, C7-H), 5.84 (1H, d, J = 9.0 Hz, C6-H), 5.33 (1H, s, C9-H2), 5.31 (1H, s, C9-H2). 
(1R*,2R*)-2-(Ethoxycarbonyl)cyclopropane-1-carboxylic acid (413)  
 
NaOH (4.00g, 100 mmol) in water (100 mL), was added to a stirring solution of diester (17.6 mL, 
100 mmol) in EtOH (125 mL) at 0 °C over 15 min. The reaction was warmed to room temperature and 
stirred for 4 h. The resulting solution was washed with EtOAc (200 mL), acidified with conc. HCl 
(pH ~2) and extracted with EtOAc (3 × 100 mL). The combined organics were dried over MgSO4 and 
concentrated in vacuo to provide the title compound (13.4 g, 85%) as a pale yellow solid; m.p. 54–55 
°C (CHCl3) (lit. 56–57 °C)363; νmax / cm-1: 2922 (br.), 2632 (w), 1732 (m), 1684 (s), 1379 (m), 1319 (s), 
1179 (s); 1H NMR (CDCl3, 400 MHz): δ 4.16 (2H, q, J = 7.0 Hz, C2-H2), 0.22 (1H, m, 1 × C5-H2), 2.17 
(1H, m, 1 × C5-H2), 1.53–1.45 (2H, m, 1 × C4-H, 1 × C6-H), 1.27 (3H, t, J = 7.0 Hz, C1-H3); HRMS: 
(ESI+) Calculated for C7H10NaO4: 181.0471. Found [M + Na]+: 181.0466. 
Ethyl (1R*,2R*)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropane-1-carboxylate (405b)  
 




BH3·THF (70 mL, 70.0 mmol, 1M THF) was added to a stirring solution of carboxylic acid 413 (7.43 g, 
47.0 mmol) in THF (67 mL) at 0 °C, over 30 minutes. The resulting solution was warmed to room 
temperature and stirred for 16 h. The complete reaction mixture was quenched by the careful addition 
of MeOH until no more effervescence was observed and stirred for 30 minutes. The quenched reaction 
was concentrated in vacuo to provide the crude alcohol. The crude alcohol was dissolved in DMF 
(47 mL) before the addition of imidazole (3.84 g, 56.4 mmol) and TBSCl (7.44 g, 49.4 mmol). The 
reaction mixture was stirred for 3 h at room temperature. Water (200 mL) was added and the mixture 
was extracted with EtOAc (3 × 150 mL). The combined organics were then washed with brine (5 × 
150 mL) before being dried over MgSO4 and concentrated in vacuo. Purification by FCC (2% 
EtOAc/hexane) provided the title compound (10.5 g, 86%) as a colourless oil; νmax / cm-1: 2930 (m), 
2857 (m), 1728 (s), 1316 (m), 1254 (m), 1178 (s), 1092 (s); 1H NMR (CDCl3, 400 MHz): δ 4.12 (2H, 
q, J = 7.0 Hz, C6-H2), 3.66 (1H, dd, J = 11.0, 5.0 Hz, 1 × C1-H2), 3.59 (1H, dd, J = 11.0, 5.0 Hz, 1 × 
C1-H2), 1.62 (1H, m, C4-H), 1.56 (1H, m, C2-H), 1.25 (3H, t, J = 7.0 Hz, C7-H3), 1.13 (1H, m, 1 × 
C3-H2), 0.92–0.88 (10H, m, 1 × C3-H2, 9 × C8-H3), -0.04 (6H, s, C8-H3); 13C NMR (CDCl3, 100 MHz): 
δ 174.4 (C5), 63.5 (C1), 60.5 (C6), 26.0 (C10), 24.2 (C4), 18.4 (C9), 17.8 (C2), 14.4 (C7), 12.4 
(C3), -5.2 (C8); HRMS: (ESI+) Calculated for C13H26NaO3Si: 281.1543. Found [M + Na]+: 281.1549. 
Ethyl (1R*,2R*)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropane-1-carboxylate (414)  
 
General Procedure D: Carboxylic acid 413 (4.74 g, 30.0 mmol) was employed and the reaction was 
heated for 24 h. FCC (10% EtOAc/hexane) provided the title compound (3.89 g, 57%) as a pale yellow 
oil; νmax / cm-1: 3366 (m), 2990 (m), 1717 (s), 1686 (s), 1511 (s), 1183 (s), 1156 (s); 1H NMR (CDCl3, 
400 MHz): δ 4.70 (1H, br s, NH), 4.17–4.09 (2H, m, C8-H2), 3.02 (1H, m, C4-H), 1.71 (1H, m, C2-H), 
1.44 (9H, s, C7-H3), 1.39 (1H, m, 1 x C3-H2), 1.26 (3H, t, J = 7.0 Hz, C9-H3), 1.09 (1H, m, 1 x C3-H2); 
13C NMR (CDCl3, 100 MHz): δ 172.5 (C1), 156.0 (C5), 80.1 (C6), 60.8 (C8), 31.9 (C4), 28.4 (C7), 22.6 
(C2), 15.8 (C3), 14.3 (C9); HRMS: (ESI+) Calculated for C11H19NNaO4: 252.1206. Found [M + Na]+: 
252.1212. 
tert-Butyl ((1R*,2R*)-2-(hydroxymethyl)cyclopropyl)carbamate (415)  
 




DIBAL-H (19.6 mL, 19.6 mmol, 1 M Hexanes) was added over 10 minutes to a stirring solution of 
ester 414 (900 mg, 3.93 mmol) in anhydrous PhMe (39 mL) at -78 °C. The reaction was stirred for 3 h 
before the sequential addition of 10 v% MeOH/PhMe (0.5 ml), MeOH (0.5 mL) and water (10 mL). 
The reaction was warmed to room temperature and stirred for 30 minutes before being filtered through 
celite. The organic layer was separated, dried over MgSO4, filtered and concentrated in vacuo. FCC 
(50% EtOAc/hexane) provided the title compound (605 mg, 82%) as a colourless oil; νmax / cm-1: 3318 
(br.), 2978 (w), 1686 (s), 1512 (m), 1366 (m), 1164 (s); 1H NMR (CDCl3, 400 MHz): δ 4.88 (1H, br., 
NH), 3.81 (1H, br. m, 1 × C1-H2), 3.09 (1H, br. m, 1 × C1-H2), 2.90 (1H, br., OH), 2.31 (1H, br., C4-H), 
1.44 (9H, s, C7-H3), 1.22 (1H, m, C2-H), 0.79 (1H, m, 1 × C3-H2), 0.70 (1H, m, 1 × C3-H2); 13C NMR 
(CDCl3, 100 MHz): δ 157.2 (C5), 80.0 (C6), 65.0 (C1), 28.6 (C4), 28.5 (C7), 24.1 (C2), 11.4 (C3); 
HRMS: (ESI+) Calculated for C9H17NNaO3: 210.1101. Found [M + Na]+: 210.1108. 
tert-Butyl ((1R*,2R*)-2-(((tert-butyldimethylsilyl)oxy)methyl)cyclopropyl)carbamate (407b) 
 
Imidazole (321 mg, 4.72 mmol) and TBSCl (622 mg, 4.13 mmol) were added to a stirring solution of 
alcohol 415 (737 mg, 3.94 mmol) in DMF (4.0 mL). On completion, as determined by TLC, the reaction 
mixture was diluted with sat. aq. NaHCO3 (50 mL) and extracted with Et2O (3 × 50 mL). The combined 
organics were dried over MgSO4, filtered and concentrated in vacuo. FCC (15% EtOAc/hexane) 
provided the title compound (703 mg, 59%) as a colourless oil; νmax / cm-1: 3330 (br.), 2929 (m), 2857 
(m), 1697 (s), 1366 (m), 1252 (s), 1171 (s), 1097 (s); 1H NMR (CDCl3, 400 MHz): δ 4.69 (1H, br., NH), 
3.64 (1H, dd, J = 11.0, 5.5 Hz, 1 × C1-H2), 3.53 (1H, dd, J = 11.0, 5.5 Hz, 1 × C1-H2), 2.41 (1H, m, 
C4-H), 1.44 (9H, s, C7-H3), 1.12 (1H, m, C2-H), 0.88 (9H, s, C10-H3), 0.76–0.65 (2H, m, 2 × C3-H2), 
0.04 (6H, s, C8-H3); 13C NMR (CDCl3, 100 MHz): δ 155.3 (C5), 79.5 (C6), 64.1 (C1), 28.5 (C7), 27.6 
(C4), 26.1 (C10), 25.8 (C9), 22.8 (C2), 11.7 (C3), -5.1 (C8); HRMS: (ESI+) Calculated for 




General Procedure G: Carbamate 407b (603 mg, 2.00 mmol) was employed in THF using NaH 
(120 mg, 3.00 mmol) and MeI (0.199 mL, 3.20 mmol). The reaction was run for 16 h at room 




temperature. FCC (2–5% EtOAc/hexane) provided the title compound (400 mg, 63%) as a colourless 
oil; νmax / cm-1: 2955 (m), 2929 (m), 2860 (m), 1700 (s), 1365 (s), 1252 (m), 1155 (s); Product 408b 
appears as a mixture of rotamers A:B (4:1); 1H NMR (CDCl3, 400 MHz): δ 3.63–3.53 (2H, m, 2 × 
C1-H2), 2.82 (3H, s, C5-H3), 2.34 (1H, m, C4-H), 1.46–1.45 (9H, m, 9 × C8-H3, A+B), 1.25–1.16 (1H, 
m, C2-H, A+B), 0.91–0.88 (9H, m, 9 × C11-H3, A+B), 0.81–0.65 (2H, m, 2 × C3-H2), 0.09–0.04 (6H, 
m, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 157.0 (C6), 80.3 (C7, A), 79.5 (C7, B), 64.0 (C1), 35.5 
(C4), 34.8 (C5), 28.7 (C8), 26.1 (C11), 24.0 (C2), 18.5 (C10), 12.6 (C3), -3.4 (C9, A), -5.1 (C9, B); 
HRMS: (ESI+) Calculated for C16H33NNaO3Si: 338.2122. Found [M + Na]+: 338.2135. 
(1R*,2R*)-2-(((tert-Butyldimethylsilyl)oxy)methyl)-N-methylcyclopropan-1-amine (416) and tert-
Butyl ((1R*,2R*)-2-(hydroxymethyl)cyclopropyl)(methyl)carbamate (417)  
 
ZnBr2 (2.34 g, 10.4 mmol) was added to a stirring solution of carbamate 408b (410 mg, 1.30 mmol) in 
CH2Cl2 (13 mL). The reaction mixture was stirred for 16 h before the addition of 1 M aq. NaOH 
(10 mL). The aqueous layer was extracted with CH2Cl2 (3 × 10 mL) and the combined organics were 
dried over MgSO4, filtered and concentrated in vacuo. FCC (50% EtOAc/Hex then 2% MeOH/EtOAc) 
provided alcohol 417 (51 mg, 19%) as a yellow oil and amine 416 (44 mg, 15%) as a pale yellow oil; 
Data for compound 416: νmax / cm-1: 3413 (br.), 2974 (w), 1674 (s), 1366 (s), 1157 (s); 1H NMR 
(CDCl3, 400 MHz): δ 3.88–3.67 (2H, br. m, 1 × C1-H2, OH), 3.01 (1H, br. m, 1 × C1-H2), 2.80 (3H, s, 
C5-H3), 2.33 (1H, m, C4-H), 1.44 (9H, s, C8-H3), 1.44 (1H, m, C2-H), 0.83 (1H, m, 1 × C3-H2), 0.67 
(1H, m, 1 × C3-H2); 13C NMR (CDCl3, 100 MHz): δ 157.4 (C6), 80.2 (C7), 65.1 (C1), 36.2 (C2), 34.8 
(C5), 28.5 (C8), 25.0 (C4), 11.4 (C3); HRMS: (ESI+) Calculated for C10H19NNaO3: 224.1257. Found 
[M + Na]+: 224.1265. Data for compound 417: νmax / cm-1: 2953 (s), 2959 (s), 2856 (s), 1472 (m), 1253 
(m), 1098 (s), 836 (s); 1H NMR (CDCl3, 400 MHz): δ 3.62 (1H, dd, J = 11.0, 5.5 Hz, 1 × C1-H2), 3.32 
(1H, dd, J = 11.0, 7.5 Hz, 1 × C1-H2), 2.45 (3H, s, C5-H3), 1.97 (1H, m, C4-H), 1.02 (1H, m, C2-H), 
0.89 (9H, s, C8-H3), 0.55 (1H, m, 1 × C3-H2), 0.41 (1H, m, 1 × C3-H2), 0.05 (6H, s, C6-H3); 13C NMR 
(CDCl3, 100 MHz): δ 65.4 (C2), 38.1 (C4), 36.0 (C5), 26.1 (C8), 22.7 (C2), 18.5 (C7), 11.2 (C3), -5.0 
(C8); HRMS: (ESI+) Calculated for C11H26NOSi: 216.1778. Found [M + Na]+: 216.1773.  
(1R*,2R*)-2-(((tert-Butyldimethylsilyl)oxy)methyl)-N-methylcyclopropan-1-amine (409b)  
 




K2CO3 (53 mg, 0.380 mmol) and then acryloyl chloride (0.031 mL, 0.380 mmol) were added to a stirring 
solution of amine 416 (41 mg, 0.190 mmol) in acetone (0.50 mL) and water (0.11 mL) at 0 °C. The 
reaction was stirred for 6 h before the acetone was removed in vacuo. The aqueous layer was diluted 
with water (4 mL) and extracted with CH2Cl2 (3 × 4 mL). The combined organics were washed with 
sat. aq. NaHCO3 (5 mL) and brine (5 mL) before being dried over MgSO4, filtered and concentrated in 
vacuo. FCC (20% EtOAc/hexane) provided the title compound (32.1 mg, 63%) as a colourless oil; νmax 
/ cm-1: 2953 (m), 2928 (m), 2856 (m), 1658 (s), 1402 (m), 1256 (m), 1075 (s), 839 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.12 (1H, dd, J = 17.0, 10.0 Hz, C2-H), 6.34 (1H, dd, J = 17.0, 2.0 Hz, C1a-H), 5.64 (1H, 
dd, J = 10.0, 2.0 Hz, C1b-H), 3.90 (1H, dd, J = 11.0, 4.5 Hz, 1 × C7-H2), 3.26 (1H, dd, J = 11.0, 8.0 Hz, 
1 × C7-H2), 2.98 (3H, s, C8-H3), 2.63 (1H, m, C4-H), 1.39 (1H, m, C6-H), 0.90–0.85 (10H, m, 1 × 
C5-H2, 9 × C11-H3), 0.81 (1H, m, 1 × C5-H2), 0.07 (3H, s, 3 × C9-H3), 0.06 (3H, s, 3 × C9-H3); 13C 
NMR (CDCl3, 100 MHz): δ 168.1 (C3), 129.0 (C2), 127.2 (C1), 64.0 (C7), 35.9 (C4), 34.3 (C8), 25.9 
(C11), 24.8 (C6), 18.3 (C10), 12.6 (C5), -5.4 (C9); HRMS: (ESI+) Calculated for C14H27NNaO2Si: 
292.1703. Found [M + Na]+: 292.1716. 
N-Benzyl-N-cyclopropylpropiolamide (420) 
 
To a stirring solution of benzylcyclopropylamine (1.47 g, 10.0 mmol), DCC (2.27 g, 11.0 mmol) and 
DMAP (1.2 mg, 0.01 mmol) in CH2Cl2 (30 mL) at 0 °C was added propiolic acid (0.67 mL, 10.8 mmol) 
in CH2Cl2 (10 mL). The reaction was stirred for 2 h before being filtered through a pad of celite, washing 
with CH2Cl2 (2 × 10 mL). The organic solution was concentrated in vacuo. FCC (15% EtOAc/hexane) 
provided the title compound (2.19 g, 110%) as a pale yellow oil; m.p. 102–105 °C (CHCl3); νmax / cm-1: 
3206 (m), 2096 (m), 1615 (s), 1395 (m), 1303 (m); Product appears as a 3:1 mixture of rotamers (A:B) 
in CDCl3; 1H NMR (CDCl3, 400 MHz): δ 7.38–7.25 (10H, m, C8-H, C9-H, C10-H, A+B), 4.77 (2H, s, 
C6-H2, B), 4.60 (2H, s, C6-H2, A), 3.20 (1H, s, C5-H, A), 3.08 (1H, s, C5-H, B), 2.66 (1H, m, C2-H, 
A), 2.52 (1H, m, C2-H, B), 0.88–0.87 (4H, m, C1-H2, A), 0.82 (2H, m, C1-H2, B), 0.69 (2H, m, C1-H2, 
B); 13C NMR (CDCl3, 100 MHz): δ 156.0 (C3, A), 155.3 (C3, B), 137.0 (C7, A), 136.9 (C7, B), 128.9, 
128.7, 128.2, 127.9, 127.6, 127.4 (C8, C9, C10, A+B), 80.1 (C5, A), 78.7 (C4, A), 77.2 (C5, B), 76.7 
(C4, B), 53.6 (C6, B), 49.9 (C6, A), 30.4 (C2, A), 28.2 (C2, B), 9.33 (C1, A), 7.2 (C1, B); HRMS: 
(ESI+) Calculated for C13H14NO: 200.1070. Found [M + H]+: 200.1064. 
 
 






To a stirring solution of AgOTf (5.1 mg, 0.020 mmol) in BnOH (0.5 mL) in a flame-dried flask under 
an atmosphere of argon was added amide 420 (300 mg, 2.00 mmol) in BnOH (0.3 mL). The reaction 
mixture was heated at 70 °C for 3 h before being purified by FCC (30% EtOAc/hexane) to afford the 
title compound (401 mg, 65%) as a yellow oil. The Z-geometry of the product alkene was determined 
by comparison of the coupling constants of the C4-H and C5-H protons with those measured in 
compound E-421 (see below); νmax / cm-1: 1655 (s), 1614 (s), 1454 (m), 137 (m), 1263 (m), 1105 (m); 
1H NMR (CDCl3, 400 MHz): δ 7.37–7.20 (10H, m, C8-H, C9-H, C10-H, C13-H, C14-H, C15-H), 6.46 
(1H, d, J = 7.0 Hz, C5-H), 5.47 (1h, d, J = 7.0 Hz, C4-H), 5.03 (2H, s, C6-H2), 4.64 (2H, s, C11-H2), 
2.53 (1H, m, C2-H), 0.75–0.73 (4H, m, C1-H2); 13C NMR (CDCl3, 100 MHz): δ 167.7 (C3), 154.3 (C5), 
138.7 (C12), 136.6 (C7), 128.8, 128.5, 128.4, 128.2, 127.7, 127.0 (C8, C9, C10, C13, C14, C15), 99.2 
(C4), 75.8 (C6), 49.5 (C11), 29.8 (C2), 9.5 (C1); HRMS: (ESI+) Calculated for C20H22NO2: 308.1645. 
Found [M + H]+: 308.1649. 
(E)-N-Benzyl-3-(benzyloxy)-N-cyclopropylacrylamide (E-421) 
 
General Procedure I: Acrylamide Z-421 (46.1 mg, 0.150 mmol) and  [Rh(cod)2]BARF (17.7 mg, 
0.015 mmol), P(p-CNC6H4)3 (5.06 mg, 0.015 mmol) were employed, and the reaction was  heated at 
150 °C for 4 h. The reaction mixture was concentrated in vacuo and purified by FCC (25% 
EtOAc/hexane) afforded the title compound (27 mg, 59%) as an orange oil; νmax / cm-1: 1652 (s), 1596 
(s), 1403 (m), 1372 (m), 1164 (s); 1H NMR (CDCl3, 400 MHz): δ 7.69 (1H, d, J = 12.0 Hz, C5-H), 
7.38–7.18 (10H, m, C8-H, C9-H, C10-H, C13-H, C14-H, C15-H), 6.13 (1H, d, J = 12.0 Hz, C4-H), 
4.93 (2h, s, C6-H2), 4.62 (2H, s, C11-H2), 2.51 (1H, m, C2-H), 0.80–0.69 (4H, m, C1-H2); 13C NMR 
(CDCl3, 100 MHz): δ 169.3 (C3), 160.9 (C5), 138.5 (C12), 135.7 (C7), 128.7, 128.4, 128.4, 127.7, 
127.7, 126.9 (C8, C9, C10, C13, C14, C15), 98.6 (C4), 73.4 (C6), 49.8 (C11), 29.5 (C2), 9.4 (C1); 
HRMS: (ESI+) Calculated for C20H22NO2: 308.1645. Found [M + H]+: 308.1653. 




(4E,7Z)-5-((tert-Butyldimethylsilyl)oxy)-1,6-dimethyl-3,6-dihydroazocin-2(1H)-one (427a) and 
(5E,7Z)-5-((tert-Butyldimethylsilyl)oxy)-1,6-dimethyl-3,4-dihydroazocin-2(1H)-one (427b) 
 
Freshly prepared LDA (3.94 mL, 0.5 M, 1.97 mmol), DMPU (0.24 mL, 1.97 mmol) and THF (0.82 mL) 
were added to a flame-dried flask fitted with a septum under an atmosphere of argon. The mixture was 
cooled to -78 °C before the addition of ketone 403a (220 mg, 1.32 mmol) in THF (2 mL) over 1 minute. 
After 15 minutes, TBSCl (995 mL, 6.60 mmol) in THF (1 mL) was added and the reaction was warmed 
to room temperature. Upon consumption of the starting material by TLC (after approximately 2 h) the 
reaction was quenched with water (10 mL). The aqueous was extracted with EtOAc (3 × 15 mL) and 
the combined organics were dried over MgSO4 and concentrated in vacuo.  Purification by FCC (20% 
EtOAc/hexane) provided the title compound (260 mg, 70%, 8:1 mixture of regioisomers 427a:427b) as 
a pale yellow oil; Data for the major regioisomer 427a: νmax / cm-1: 2955 (m), 2929 (m), 2857 (m), 
1648 (s), 1340 (m); 1H NMR (CDCl3, 400 MHz): 6.12 (1H, d, J = 7.5 Hz, C7-H), 5.15 (1H, dd, J = 8.5, 
7.5 Hz, C6-H), 4.88 (1H, dd, J = 7.0, 7.0 Hz, C3-H), 3.08 (1H, m, C5-H), 3.04–2.96 (2H, m, C2-H2), 
2.94 (3H, s, C8-H3), 1.16 (3H, d, J = 7.0 Hz, C9-H3), 0.91 (9H, s, C12-H3), 0.15 (3H, s, C10-H3), 0.14 
(3H, s, C10-H3); 13C NMR (CDCl3, 100 MHz): δ 170.5 (C1), 151.7 (C4), 130.3 (C7), 124.5 (C6), 100.0 
(C3), 35.4 (C5), 34.3 (C2), 33.1 (C8), 25.9 (C12), 18.3 (C11), 17.5 (C9), -4.4 (C10), -4.5 (C10); HRMS: 
(ESI+) Calculated for C15H28NO2Si: 282.1884. Found [M + H]+: 282.1897. Data for the minor 
regioisomer 427b: Characteristic signals only; 1H NMR (CDCl3, 400 MHz): δ 5.76 (1H, d, J = 9.0 Hz, 
C7-H), 5.50 (1H, d, J = 9.0 Hz, C6-H), 2.99 (3H, s, C8-H3), 1.67 (3H, s, C9-H3), 0.94 (9H, s, C12-H3), 
0.15 (6H, s, C10-H3);  
 (Z)-4-((tert-Butyldimethylsilyl)oxy)-1,6-dimethyl-1,3,4,6-tetrahydroazocine-2,5-dione (429) and 
(R*,Z)-5-((tert-butyldimethylsilyl)oxy)-4-hydroxy-1,6-dimethyl-2-oxo-1,2,3,4,5,6-
hexahydroazocin-5-yl 3-chlorobenzoate (430) 
 




NaHCO3 (33.0 mg, 0.390 mmol) was added to a flame-dried reaction tube which was sealed and purged 
with argon. Silyl enol ether 427a (100 mg, 0.350 mmol) in CH2Cl2 (3.5 mL) was added by syringe and 
the reaction mixture was cooled to 0 °C. m-CPBA (67.4 mg, 0.390 mmol) in CH2Cl2 (1.0 mL) was 
added by syringe in one portion. The reaction was stirred for 45 minutes before being diluted with 
CH2Cl2 (5 mL) and washed with sat. aq. NaHCO3 (5 mL) and brine (5 mL). The organic layer was dried 
over Na2SO4 and concentrated in vacuo before purification by FCC (15% EtOAc/hexane) provided the 
title compounds (41 mg, 39%, 4:1 mixture of 429:430) as a colourless oil; Data for product 429: The 
relative stereochemistry of product 429 was not determined;  νmax / cm-1: 2956 (m), 2928 (m), 2855 (m), 
1732 (s), 1649 (s), 1254 (s); 1H NMR (CDCl3, 400 MHz): δ 6.10 (1H, dd, J = 7.5, 1.0 Hz, C7-H, A), 
5.94 (1H, dd, J = 8.0, 1.0 Hz, C7-H, B), 5.24 (1H, d, J = 7.5 Hz, C6-H, B), 5.22 (1H, d, J = 7.5 Hz, 
C6-H, A), 5.02 (1H, d, J = 9.0 Hz, C3-H, B), 4.48 (1H, dd, J = 12.0, 3.5 Hz, C3-H, A), 3.47 (1H, dqd, 
J = 9.0, 6.5, 1.0 Hz, C5-H, A), 3.23 (1H, d, J = 13.0 Hz, C2-H2, B), 3.12 (1H, dd, J = 12.0, 12.0 Hz, 
C2-H2, A), 3.05 (6H, s, 6 × C8-H3, A+B), 2.83 (1H, dd, J = 13.0, 9.0 Hz, C2-H2, B), 2.70 (1H, m, J = 
7.5 Hz, C5-H, B), 2.67 (1H, dd, J = 12.0, 3.5 Hz, C2-H2, A), 1.17 (3H, d, J = 6.5 Hz, C9-H3, A), 1.12 
(3H, d, J = 7.5 Hz, C9-H3, B), 0.92 (9H, s, C12-H3, A), 0.90 (9H, s, C12-H3, B), 0.24 (3H, s, C10-H3, 
B), 0.22 (3H, s, C10-H3, B), 0.16 (3H, s, C10-H3, A), 0.06 (3H, s, C10-H3 A); 13C NMR (CDCl3, 
100 MHz): δ 206.2 (C4, A), 171.0, 168.5 (C1, A+B), 131.6 (C7, A), 130.0 (C6, B), 128.4 (C7, B), 126.7 
(C6, A), 74.5 (C3, B), 74.1 (C3, A), 43.2 (C2, A), 40.8 (C5, A), 36.5 (C5, B), 34.2 (C2, B), 34.2, 34.1 
(C8, A+B), 26.0 (C12, B), 25.9 (C12, A), 18.6 (C11, A), 18.2 (C11, B), 15.4 (C9, A), 15.2 (C9, B), -2.2 
(C10, B), -2.4 (C10, B), -4.5 (C10, A), -5.4 (C10, A); HRMS: (ESI+) Calculated for C15H28NO3Si: 
298.1833. Found [M + H]+: 298.1832. Data for acetal 430: The relative stereochemistry of product 
430 was not determined; m.p. 120–121 °C (CH2Cl2); νmax / cm-1: 3367 (br.), 2929 (w), 1731 (m), 1633 
(s), 1251 (s), 1069 (s), 1027 (m); 1H NMR (CDCl3, 400 MHz): δ 8.05 (1H, s, C15-H), 8.00 (1H, d, J = 
8.0 Hz, C17/19-H), 7.54 (1H, m, C17/19-H), 7.40 (1H, dd, J = 8.0, 8.0 Hz, C18-H), 5.93 (1H, d, J = 8.0 
Hz, C7-H), 5.23 (1H, dd, J = 8.5, 8.0 Hz, C6-H), 5.02 (1H, d, J = 9.0 Hz, C3-H), 3.58 (1H, s, OH), 3.23 
(1H, d, J = 13.0 Hz, 1 × C2-H2), 3.05 (3H, s, C8-H3), 2.83 (1H, dd, J = 13.0, 9.0 Hz, 1 × C2-H2), 2.70 
(1H, m, C5-H), 1.12 (3H, d, J = 7.0 Hz, C9-H3), 0.90 (9H, s, C12-H3), 0.24 (3H, s, C10-H3), 0.22 (3H, 
s, C10-H3); 13C NMR (CDCl3, 100 MHz): δ 168.5 (C1), 166.9 (C13), 134.7, 133.6, 131.6, 130.3, 130.0, 
129.9, 128.5, 128.4 (ArC, C6, C7), 97.9 (C4), 74.5 (C3), 36.5 (C5), 34.2 (C2), 34.1 (C8), 26.0 (C12), 
18.2 (C11), 15.2 (C9), -2.2 (C10), -2.4 (C10); HRMS: (ESI+) Calculated for C22H32ClNNaO5Si: 









(Z)-1,6-Dimethyl-2,5-dioxo-1,2,3,4,5,6-hexahydroazocin-4-yl 3-chlorobenzoate (432) 
 
DBU (0.10 mL, 0.65 mmol) was added to a stirring solution of acetal 430 (150 mg, 4:1 429:430, 0.090 
mmol of acetal 430) in CH2Cl2 (1.1 mL) at 0 °C. The reaction was stirred for 15 minutes by which time 
the starting material had been consumed as determined by TLC. The reaction was concentrated in vacuo 
and purified by FCC (25% EtOAc/hexane) to provide the title compound (22.5 mg, 77%) as a colourless 
oil. The relative stereochemistry of product 432 was not determined; νmax / cm-1: 2938 (w), 1722 (s), 
1658 (s), 1645 (s), 1384 (m), 1289 (s), 1253 (s); 1H NMR (CDCl3, 400 MHz): δ 8.02 (1H, dd, J = 2.0, 
2.0 Hz, C12-H), 7.93 (1H, d, J = 8.0 Hz, C14/16-H), 7.54 (1H, m, C14/16-H), 7.38 (1H, dd, J = 8.0, 8.0 
Hz, C15-H), 6.17 (1H, d, J = 7.5 Hz, C7-H), 5.64 (1H, dd, J = 12.5, 3.0 Hz, C3-H), 5.30 (1H, dd, J = 
8.5, 7.5 Hz, C6-H), 3.62 (1H, m, C5-H), 3.30 (1H, dd, J = 12.5, 12.0 Hz, 1 × C2-H2), 3.10 (3H, s, C8-
H3), 2.90 (1H, dd, J = 12.0 3.0 Hz, 1 × C2-H2), 1.23 (3H, d, J = 6.5 Hz, C9-H3); 13C NMR (CDCl3, 100 
MHz): δ 201.1 (C4), 169.5 (C1), 164.3 (C10), 134.7 (C11), 133.5 (C14/16), 131.8 (C7), 131.1 (C13), 
130.0, 129.9 (C12, C15), 128.2 (C14/16), 126.5 (C6), 74.5 (C3), 41.0 (C5), 38.6 (C2), 34.5 (C8), 24.0 
(C9); HRMS: (ESI+) Calculated for C16H16ClNNaO4: 344.0660. Found [M + Na]+: 3440.0661. 
(Z)-9,12-Dimethyl-1,4-dioxa-9-azaspiro[4.7]dodec-10-en-8-one (434) 
 
BF3·Et2O (0.22 mL, 0.18 mmol) was added to a stirring solution of ketone 403a (200 mg, 1.20 mmol) 
and ethylene glycol (0.22 mL, 1.80 mmol) in CH2Cl2 (2.4 mL) at 0 °C. The reaction was warmed to 
room temperature and stirred for 2 h before the addition of water (5 mL). The aqueous layer was 
extracted with CH2Cl2 (3 × 5 mL) and the combined organics were dried over Na2SO4, filtered and 
concentrated in vacuo to provide the title compound (234 mg, 92%) as an orange oil; νmax / cm-1: 2893 
(w), 1634 (s), 1388 (m), 1161 (m), 1072 (m), 1044 (s); 1H NMR (CDCl3, 400 MHz): δ 5.96 (1H, dd, J 
= 8.0, 1.0 Hz, C7-H), 5.22 (1H, m, C6-H), 4.00 (2H, m, 1 × C10a-H2, 1 × C10b-H2), 3.83 (2H, m, 1 × 
C10a-H2, 1 × C10b-H2), 2.97 (3H, s, C8-H3), 2.70 (1H, m, 1 × C3-H2), 2.52 (1H, m, C5-H), 2.33 (1H, 
m, 1 × C3-H2), 1.95–1.79 (2H, m, 2 × C2-H2), 1.01 (3H, d, J = 7.0 Hz, C9-H3); 13C NMR (CDCl3, 




100 MHz): δ 173.9 (C1), 129.5 (C7), 129.4 (C6), 110.1 (C4), 65.6, 64.6 (C10a, C10b), 39.1 (C5), 34.5 
(C2), 33.7 (C8), 31.2 (C3), 15.1 (C9); HRMS: (ESI+) Calculated for C11H18NO3: 212.1281. Found [M 
+ H]+: 212.1284. 
(E)-4-((tert-Butyldimethylsilyl)oxy)-5-methyl-6-((methylimino)methyl)cyclohex-3-en-1-ol (438) 
 
LiAlH4 (0.039 mL, 2 M in THF, 0.078 mmol) was added to amide 427a (20 mg, 0.071 mmol) in 
anhydrous THF (0.7 mL) at 0 °C, over 30 seconds. TLC indicated the reaction was complete after 
5 minutes. The reaction was diluted with Et2O (1.0 mL), before being quenched by the addition of water 
(0.1 mL) then 3 M aq. NaOH (0.1 mL) and then water (0.3 mL). The reaction was stirred for 15 minutes 
before being diluted with water (1 mL) and extracted with Et2O (3 × 2 mL). The combined organics 
were dried over MgSO4 and concentrated in vacuo to afford the title compound (19.0 mg, 95%) as a 
pale yellow oil. The relative stereochemistry of product was not determined; νmax / cm-1: 3342 (br.), 
2930 (m), 1665 (w), 1345 (m), 1192 (s), 1181 (s); 1H NMR (CDCl3, 400 MHz): δ 7.82 (1H, m, C7-H), 
4.66 (1H, dd, J = 4.0, 4.0 Hz, C3-H), 4.08 (1H, m, C1-H), 3.28 (3H, m, C8-H3), 2.41–2.30 (6H, m, 1 × 
C2-H2, 1 × C5-H, 1 × C6-H), 2.16 (1H, m, 1 × C2-H2), 1.19 (3H, d, J = 6.5 Hz, C9-H3), 0.92 (9H, s, 
C12-H3), 0.14 (6H, s, C10-H3); 13C NMR (CDCl3, 100 MHz): δ 169.2 (C7), 152.6 (C4), 99.7 (C3), 65.8 
(C1), 49.8 (C6), 47.8 (C8), 36.2 (C5), 30.6 (C2), 25.7 (C12), 18.2 (C11), 17.5 (C10); HRMS: (ESI+) 
Calculated for C15H30NO2Si: 284.2040. Found [M + H]+: 284.2044. 
11-Bromo-10-methoxy-9,12-dimethyl-1,4-dioxa-9-azaspiro[4.7]dodecan-8-one (449) 
 
NBS (18.7 mg, 0.105 mmol) was added to a stirring solution of enamide 434 (20.0 mg, 0.095 mmol) 
and MeOH (0.080 mL, 0.190 mmol) in THF (0.50 mL) at -78 °C. The reaction was warmed to room 
temperature after 1 h before being concentrated in vacuo. FCC (90% EtOAc/hexane) provided the title 
compound (26.0 mg, 86%, 6:1 d.r.) as a pale yellow oil; Data for the mixture of diastereomers: νmax 
/ cm-1: 2889 (w), 1623 (s), 1395 (m), 1076 (s); Data for the major diastereomer: The relative 
stereochemistry of the major diastereomer was not determined; 1H NMR (CDCl3, 400 MHz): δ 5.87 




(1H, d, J = 10.0 Hz, C7-H), 4.18 (1H, m, 1 × C10a-H2), 4.05 (1H, d, J = 10.0 Hz, C6-H), 3.99–3.90 
(3H, m, 1 × C10a-H2, 2 × C10b-H2), 2.89 (1H, m, 1 × C2-H2), 2.81 (3H, s, C8-H3), 2.75 (1H, m, C5-H), 
2.75 (3H, s, C11-H3), 2.41 (1H, ddd, J = 13.5, 6.5, 2.0 Hz, 1 × C2-H2), 2.20 (1H, ddd, J = 16.5, 14.5, 
2.0 Hz, 1 × C3-H2), 1.75 (1H, m, 1 × C3-H2), 0.97 (3H, d, J = 8.0 Hz, C9-H3); 13C NMR (CDCl3, 
100 MHz): δ 172.8 (C1), 111.8 (C4), 80.6 (C7), 66.0, 64.4 (C10a, C10b), 57.1 (C5), 34.3 (C3), 30.8 
(C2), 29.7 (C11), 26.2 (C8), 17.7 (C9); HRMS: (ESI+) Calculated for C11H17BrNO3: 290.0386. Found 
[M + H]+: 290.0407. 
6,9-Dimethyl-1,4-dioxa-9-azaspiro[4.7]dodecan-7-ol (451)  
 
BH3·THF (1.42 mL, 1.42 mmol) was added to a stirring solution of enamide 434 (100 mg, 0.47 mmol) 
in THF (2.35 mL) at -78 °C. The reaction was stirred for 10 minutes before warming to room 
temperature and stirring for a further 1.5 h by which time enamide 434 had been consumed by TLC. 
The reaction was cooled to 0 °C and quenched by the addition of water (1 mL) followed by 2 M aq. 
NaOH (1.5 mL) and 30% aq. H2O2 (1.0 mL). After 30 minutes the aqueous layer was saturated by the 
addition of K2CO3 and then extracted with Et2O (3 × 5 mL). The combined organics were dried over 
Na2SO4, filtered and concentrated in vacuo. FCC (40% EtOAc/hexane) provided the major diastereomer 
of the title compound (23 mg, 22%) as a pale yellow oil and the minor diastereomer (18 mg, 18%) as 
pale yellow oil; The product diastereomers are formed in a 1:1 ratio and are easily separated by FCC; 
Data for the first diastereomer (A) to elute by FCC: The relative stereochemistry of diastereomer A 
was not determined; νmax / cm-1: 3488 (br.), 2349 (m), 1455 (m), 1167 (s), 1058 (s); 1H NMR (CDCl3, 
400 MHz): δ 3.96–3.79 (6H, m, 1 × C6-H, 1 × C7-H2, 2 × C10a-H2, 2 × C10b-H2), 3.20 (1H, dd, J = 
15.0, 10.0 Hz, 1 × C1-H2), 2.90 (1H, dd, J = 15.0, 7.0 Hz, 1 × C1-H2), 2.71 (1H, d, J = 14.0 Hz, 1 × 
C7-H2), 2.55 (3H, s, C8-H3), 1.94–1.82 (3H, m, 1 × C2-H2, 1 × C3-H2, 1 × C5-H), 1.75–1.61 (2H, m, 1 
× C2-H2, 1 × C3-H2), 1.14 (3H, d, J = 7.0 Hz, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 111.0 (C4), 69.6 
(C6), 65.1 (C7), 64.6, 63.7 (C10a, C10b), 61.4 (C1), 51.7 (C8), 46.1 (C5), 34.7 (C2), 18.5 (C3), 14.3 
(C9); HRMS: (ESI+) Calculated for C11H22NO3: 216.1594. Found [M + H]+: 216.1594. Data for the 
second diastereomer (B) to elute by FCC: The relative stereochemistry of diastereomer B was not 
determined; νmax / cm-1: 3277 (br.), 2376 (m), 1446 (m), 1161 (s), 1066 (s), 1034 (s), 1019 (s); 1H NMR 
(CDCl3, 400 MHz): δ 3.98–3.82 (5H, m, 1 × C7-H2, 2 × C10a-H2, 2 × C10b-H2), 3.56 (1H, d, J = 9.5 Hz, 
C6-H), 3.13 (1H, dd, J = 13.5, 7.0 Hz, 1 × C1-H2), 2.94 (1H, d, J = 15.0 Hz, 1 × C7-H2), 2.85 (1H, dd, 
J = 13.5, 10.5 Hz, 1 × C1-H2), 2.63 (3H, s, C8-H3), 2.20 (1H, m, 1 × C2-H2), 1.95 (1H, m, C5-H), 1.82–
1.77 (2H, m, 2 × C3-H2), 1.65 (1H, m, 1 × C2-H2), 1.12 (3H, d, J = 6.5 Hz, C9-H3); 13C NMR (CDCl3, 




100 MHz): δ 110.6 (C4), 69.69 (C6), 64.7, 64.5 (C10a, C10b), 63.9 (C7), 60.8 (C1), 51.8 (C8), 48.2 
(C5), 35.4 (C3), 19.5 (C2), 13.7 (C9); HRMS: (ESI+) Calculated for C11H22NO3: 216.1594. Found [M 
+ H]+: 216.1589. 
6,9-Dimethyl-1,4-dioxa-9-azaspiro[4.7]dodecan-7-yl acetate (454) 
 
Acetic anhydride (0.019 mL, 0.20 mmol) was added to a stirring solution of alcohol 451 (21 mg, 
0.10 mmol, 1:1 d.r.), DMAP (1.2 mg, 0.010 mmol) and NEt3 (0.035 mL, 0.25 mmol) in CH2Cl2 (1.0 
mL). Water (2 mL) was added after 16 h and the aqueous layer was extracted with CH2Cl2 (3 × 2 mL). 
The combined organics were dried over Na2SO4, filtered and concentrated in vacuo. FCC (30% 
EtOAc/hexane) provided the minor diastereomer of the title compound (8.0 mg, 31%) and the major 
diastereomer (12.3 mg, 48%) as colourless oils; Data for the first diastereomer (A) to elute by FCC: 
νmax / cm-1: 2888 (m), 2388 (m), 2362 9m), 1730 (s), 1374 (m), 1256 (s), 1181 (s); 1H NMR (CDCl3, 
400 MHz): δ 5.10 (1H, ddd, J = 11.0, 5.0, 2.0 Hz, C6-H), 4.10 (1H, dd, J = 16.0, 5.0 Hz, 1 × C7-H2), 
3.99–3.84 (4H, m, 2 × C10a-H2, 2 × C10b-H2), 3.08–2.94 (2H, m, 2 × C1-H2), 2.78 (1H, d, J = 16.0 Hz, 
1 × C7-H2), 2.61 (3H, s, C8-H3), 2.32 (1H, m, 1 × C2-H2), 2.09 (3H, s, C12-H3), 2.01 (1H, m, C5-H), 
1.94–1.82 (2H, m, 2 × C3-H2), 1.66 (1H, m, 1 × C2-H2), 0.93 (3H, d, J = 7.0 Hz, C9-H3); 13C NMR 
(CDCl3, 100 MHz): δ 170.0 (C11), 110.4 (C4), 69.6 (C6), 64.8, 64.4 (C10a, C10b), 63.2 (C7), 60.0 
(C1), 51.5 (C8), 46.7 (C5), 34.4 (C3), 21.2 (C12), 20.1 (C2), 13.0 (C9); HRMS: (ESI+) Calculated for 
C13H23NNaO4: 280.1519. Found [M + Na]+: 280.1532. Data for the second diastereomer (B) to elute 
by FCC: νmax / cm-1: 2944 (m), 2372 (m), 1745 (s), 1372 (m), 1231 (s), 1166 (s); 1H NMR (CDCl3, 
400 MHz): δ 5.14 (1H, m, C6-H), 3.97–3.86 (4H, m, 2 × C10a-H2, 2 × C10b-H2), 3.55 (1H, d, J = 
15.0 Hz, 1 × C7-H2), 3.30–3.20 (2H, m, 1 × C1-H2, 1 × C7-H2), 2.95 (1H, m, 1 × C1-H2), 2.63 (3H, s, 
C8-H3), 2.17 (1H, m, C5-H), 2.08 (3H, s, C12-H3), 1.96 (1H, m, 1 × C3-H2), 1.91–1.85 (2H, m, 2 × 
C2-H2), 1.72 (1H, m, 1 × C3-H2), 0.97 (3H, d, J = 7.0 Hz, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 
169.7 (C11), 110.6 (C4), 72.8 (C6), 64.6, 64.6 (C10a, C10b), 61.5 (C7), 60.3 (C1), 52.4 (C8), 45.8 
(C5), 35.7 (C3), 21.4 (C12), 18.9 (C2), 13.7 (C9); HRMS: (ESI+) Calculated for C13H23NNaO4: 
280.1519. Found [M + Na]+: 280.1527. 
 
 




(5E,7Z)-5-Ethoxy-1,6-dimethyl-3,4-dihydroazocin-2(1H)-one (458) and (Z)-5,5-Diethoxy-1,6-
dimethyl-3,4,5,6-tetrahydroazocin-2(1H)-one (459) 
 
p-TSA (5.2 mg, 0.030 mmol) was added to a stirring solution of ketone 403a (50 mg, 0.30 mmol) and 
triethyl orthoformate (0.15 mL, 0.90 mmol) in EtOH (0.6 mL) at room temperature. The reaction was 
stirred for 16 h before being concentrated in vacuo. The crude reaction mixture was dissolved in water 
(5 mL) and extracted with EtOAc (3 × 5 mL). The combined organics were dried over MgSO4, filtered 
and concentrated in vacuo to provide title compounds (32 mg, 2:1 458:459, 34% yield for 458, 17% 
yield for 459) as a pale yellow oil; Data for the enol ether 458: νmax / cm-1: 2924 (w), 1734 (s), 1435 
(m), 1165 (m); 1H NMR (CDCl3, 400 MHz): δ 5.78 (1H, d, J = 9.0 Hz, C7-H), 5.50 (1H, d, J = 9.0 Hz, 
C6-H), 3.74 (2H, q, J = 7.0 Hz, C10-H2), 2.98 (3H, s, C8-H3), 2.71–2.62 (4H, m, 2 × C2-H2, 2 × C3-H2), 
1.69 (3H, d, J = 1.5Hz, C9-H3), 1.23 (3H, t, J = 7.0 Hz, C11-H3); 13C NMR (CDCl3, 100 MHz): δ 173.7 
(C1), 151.0 (C4), 126.7 (C7), 122.9 (C6), 112.7 (C5), 64.3 (C10), 33.9 (C8), 30.6, 28.7 (C2, C3), 18.7 
(C9), 15.6 (C11); HRMS: (ESI+) Calculated for C11H18NO2: 196.1332. Found [M + H]+: 196.1334. Data 
for the diethyl acetal 459: Characteristic signals only; 1H NMR (CDCl3, 400 MHz): δ 5.90 (1H, br. 
m, C7-H), 2.95 (3H, s, C8-H3).  
(Z)-5-Benzyl-2,5,7,8-tetrahydro-1,5-oxazonine-6,9-dione (462) 
 
m-CPBA (151 mg, 0.66 mmol) was added to a stirring solution of enamide 441 (50.4 mg, 0.022 mmol) 
and NaHCO3 (92 mg, 1.10 mmol) in CH2Cl2 (2.2 mL). The reaction was stirred for 16 h. Sat. aq. Na2SO3 
(5 mL) was added and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The combined organics 
were dried over MgSO4, filtered and concentrated in vacuo. FCC (50% EtOAc/hexane) provided the 
title compound (47.8 mg, 89%) as a colourless oil; νmax / cm-1: 3440 (br.), 2953 (w), 1746 (s), 1635 (s), 
1447 (s), 1266 (s), 1167 (s); 1H NMR (CDCl3, 400 MHz): δ 7.37 (2H, m, ArCH), 7.32–7.26 (3H, m, 
ArCH), 6.12 (1H, dt, J = 8.0, 1.0 Hz, C7-H), 5.79 (1H, dt, J = 8.0, 5.0 Hz, C6-H), 5.21 (1H, d, J = 
14.0 Hz, 1 × C8-H2), 4.58 (1H, dd, J = 13.5, 6.0 Hz, 1 × C5-H2), 4.04 (1H, d, J = 14.0 Hz, 1 × C8-H2), 
3.34 (1H, d, J = 13.5 Hz, 1 × C5-H2), 2.89 (1H, m, 1 × C2/3-H2), 2.62–2.58 (2H, m, 2 × C2/3-H2), 2.49 




(1H, m, 1 × C2/3-H2); 13C NMR (CDCl3, 100 MHz): δ 173.7 (C4), 171.7 (C1), 137.2 (C9), 132.1 (C7), 
130.7 (C6), 129.3, 128.6 (C10, C11), 127.9 (C12), 60.8 (C5), 50.8 (C8), 34.5, 32.2 (C2, C3); HRMS: 
(ESI+) Calculated for C14H16NO3: 246.1125. Found [M + H]+: 246.1126. 
1-Benzyl-7-bromo-8-methoxyazocane-2,5-dione (464a) and 2-Benzyl-8-bromo-6-methoxy-9-oxa-
2-azabicyclo[4.2.1]nonan-3-one (465) 
 
Bromine (0.223 mL, 4.36 mmol) was added to a stirring solution of enamide 441 (500 mg, 2.18 mmol) 
and NaHCO3 (549 mg, 6.54 mmol) in MeOH (11 mL) under an atmosphere of argon. After 30 minutes, 
sat. aq. Na2SO3 (10 mL) was added and the aqueous layer was diluted with water (50 mL) and extracted 
with CH2Cl2 (3 × 20 mL). The combined organics were dried over MgSO4, filtered and concentrated in 
vacuo. The products were formed in a 3.3:1 ratio of 464a (1:1 d.r.):465. Note: It is convenient to 
proceed to the next step as the diastereomers are inconsequential and the ketal side product cannot be 
separated at this point. FCC (25% EtOAc/PhMe) provided the title aminal 464a and title ketal 465 as 
an inseparable mixture (737 mg, 100%, 3:1 464a:465) as a colourless oil. The relative stereochemistry 
of the products was not determined; Data for the mixture of compounds 464a and 465: νmax / cm-1: 
2944 (w), 1709 (m), 1645 (s), 1453 (m), 1430 (m), 1076 (s); 1H and 13C NMR spectra for diastereomer 
B of 464a was very broad and could not be assigned at this point. 1H NMR (CDCl3, 400 MHz): δ 7.37–
7.26 (10H, m, ArCH), 5.46 (1H, s, C7-H, C), 4.92 (1H, d, J = 15.0 Hz, 1 × C8-H2, C), 4.69 (1H, d, J = 
15.0 Hz, 1 × C8-H2, A), 4.63 (1H, d, J = 2.0 Hz, C7-H, A), 4.75 (1H, d, J = 15.0 Hz, 1 × C8-H2, C), 
4.35 (1H, br. d, J = 15.0 Hz, 1 × C8-H2, A), 4.25 (1H, m, C6-H, C), 3.96 (1H, br. m, C6-H, A), 3.59 
(1H, br. m, 1 × C5-H2, A), 3.40 (3H, s, C9-H3, C), 3.16 (3H, s, C9-H3, A), 2.89 (1H, m, 1 × C2-H2, C), 
2.71-2.55 (5H, m, 2 × C2-H2, 2 × C3-H2, 1 × C5-H2, A), 2.46 (1H, m, 1 × C2-H2, C), 2.14 (1H, m, 1 × 
C3-H2, C), 1.81 (1H, m, 1 × C3-H2, C); 13C NMR (CDCl3, 100 MHz): δ 207.2 (C4, A), 172.4 (C1, A), 
172.1 (C1, C), 137.2 (C10, C), 136.9 (C10, A), 129.1, 129.0, 128.8, 128.4, 128.2, 127.8 (C11, C12, 
C13, A+C), 112.6 (C4, C), 95.9 (C7, C), 91.3 (C7, A), 57.2 (C9, A), 51.7 (C8, C), 50.9 (C8, A), 50.3 
(C9, C), 48.0 (C6, C), 47.7 (C6, A), 44.7 (C2, C), 44.1 (C2/3, A), 43.8 (C5, A), 42.0 (C2/3, A), 33.7 
(C2, C), 33.3 (C3, C); HRMS: (ESI+) Calculated for C15H19BrNO3: 340.0543. Found [M + H]+: 
340.0549. 
 




(Z)-1-Benzyl-8-methoxy-1,3,4,8-tetrahydroazocine-2,5-dione (467)  
 
General Procedure K: -Bromoketone 464a (150 mg, 0.44 mmol, 3:1 464a:465) and DBU (0.13 mL, 
0.88 mmol) were employed. The reaction was quenched after approximately 20 minutes. CH2Cl2 
(10 mL) was added and the organic layer was washed with 10 wt% aq. citric acid (2 × 5 mL) and sat. 
aq. NaHCO3 (5 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo 
providing the title compound and ketal as a mixture (109 mg, 84%, 1.2:1 aminal:ketal) as a colourless 
oil. Note: On a larger scale, aminal 467 was found to degrade rapidly on silica; νmax / cm-1: 2928 (w), 
1654 (s), 1454 (m), 1349 (m), 1074 (m); 1H NMR (CD2Cl2, 400 MHz): δ 7.35–7.23 (5H, m, 2 × C11-H, 
2 × C12-H, C13-H), 5.98 (1H, dd, J = 13.0, 5.0 Hz, C6-H), 5.83 (1H, dd, J = 13.0, 1.0 Hz, C5-H), 5.02 
(1H, dd, J = 5.0, 1.0 Hz, C7-H), 4.76 (1H, d, J = 15.0 Hz, 1 × C8-H2), 4.40 (1H, d, J = 15.0 Hz, 1 × 
C8-H2), 3.43 (1H, m, 1 × C2-H2), 3.19 (3H, s, C9-H2), 2.90 (1H, m, 1 × C3-H2), 2.78–2.66 (2H, m, 1 × 
C2-H2, 1 × C3-H2); 13C NMR (CD2Cl2, 100 MHz): δ 203.7 (C4), 174.0 (C1), 137.2 (C10), 134.2 (C6), 
129.1 (ArC), 129.0 (C5), 128.7 (ArC), 127.9 (C13), 87.9 (C7), 57.1 (C9), 50.4 (C8), 43.6 (C3), 31.0 
(C2); HRMS: (ESI+) Calculated for C15H17NNaO3: 282.1101. Found [M + Na]+: 282.1112. 
6-Benzyl-2-methoxy-1-oxa-6-azaspiro[4.4]non-3-en-7-one (468)  
 
BF3·Et2O (0.096 mL, 0.77 mmol) was added to a stirring solution of aminal 467 (100 mg, 0.39 mmol) 
and triethylsilane (0.06 mL, 0.386 mmol) in CH2Cl2 (3.8 mL) at -78 °C. TLC indicated consumption of 
aminal after 15 minutes. The reaction was quenched by the addition of sat. aq. NaHCO3 (5 mL) and the 
aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The combined organics were dried over MgSO4, 
filtered and concentrated in vacuo. FCC (40% EtOAc/hexane) provided the title compound (16 mg, 
16%, 2:1 d.r., A:B) as a colourless oil. The relative stereochemistry of product diastereomers was not 
determined; Data for the mixture of diastereomers A and B: νmax / cm-1: 2929 (w), 1697 (s), 1396 
(m), 1192 (m), 1019 (s); 1H NMR (CD2Cl2, 400 MHz): δ 7.17–6.99 (10H, m, 5 × ArCH, A+B), 5.75 




(1H, dd, J = 6.0, 1.0 Hz, C5-H, B), 5.71 (1H, dd, J = 6.0, 1.0 Hz, C5-H, A), 5.55 (1H, dd, J = 6.0, 
1.0 Hz, C6-H, B), 5.43 (1H, m, C6-H, A), 5.30 (1H, dd, J = 1.0, 1.0 Hz, C7-H, A), 5.13 (1H, dd, J = 
1.0, 1.0 Hz, C7-H, B), 4.43 (1H, d, J = 16.0 Hz, 1 × C8-H2, A), 4.26 (1H, d, J = 15.5 Hz, 1 × C8-H2, 
B), 3.92 (1H, d, J = 16.0 Hz, 1 × C8-H2, A), 3.82 (1H, d, J = 15.5 Hz, C8-H2, B), 3.21 (3H, s, C9-H3, 
A), 3.15 (3H, s, C9-H3, B), 2.48–2.38 (2H, m, 1 × C2-H2, A+B), 2.27–2.18 (2H, m, 1 × C2-H2, A+B), 
2.12–1.93 (4H, m, 2 × C3-H2, A+B); 13C NMR (CD2Cl2, 100 MHz): δ 175.0 (C1, B), 174.8 (C1, A), 
138.9 (C10, A), 138.4 (C10, B), 134.4 (C6, B), 133.8 (C6, A), 130.8 (C5, B), 130.3 (C5, A), 128.2, 
128.1, 127.9, 127.8, 126.9, 126.7 (C11, C12, C13, A+B), 107.7 (C7, B), 107.3 (C7, A), (C4, B), 104.4 
(C4, A), 56.0 (C9, A), 54.5 (C9, B), 42.6 (C8, B), 42.0 (C8, A), 32.5 (C3, B), 31.6 (C3, A), 28.8 (C2, 
B), 28.8 (C2, A); The structure was assigned based on HMBC correlation between C8 and C4 as well 
as C9 and C7, shown in blue. HRMS: (ESI+) Calculated for C15H17NNaO3: 282.1101. Found [M + Na]+: 
282.1104. 
1-Benzyl-7-bromoazocane-2,5-dione (471) and 1-Benzyl-7-bromo-5-hydroxyazocan-2-one (472) 
 
General Procedure J: Enamide 441 (170 mg, 0.74 mmol) was employed. FCC (60–90% 
EtOAc/hexane) provided ketone (106 mg, 46%) as a colourless oil and the alcohol (88 mg, 38%) as a 
yellow foam; Data for ketone 471: νmax / cm-1: 2963 (w), 1706 (s), 1642 (s), 1452 (m), 1417 (m), 1102 
(s); 1H NMR (CDCl3, 400 MHz): δ 7.36–7.29 (3H, m, ArCH), 7.23 (2H, m, ArCH), 4.64–4.55 (2H, m, 
2 × C8-H2), 3.92 (1H, m, C6-H), 3.87 (1H, dd, J = 15.0, 10.0 Hz, 1 × C7-H2), 3.64 (1H, dd, J = 15.0, 
2.0 Hz, 1 × C7-H2), 3.20 (1H, m, 1 × C2-H2), 3.15 (1H, dd, J = 12.0, 11.0 Hz, 1 × C5-H2), 2.95 (1H, 
dd, J = 12.0, 4.0 Hz, 1 × C5-H2), 2.80–2.72 (2H, m, 2 × C3-H2), 2.62 (1H, dt, J = 13.5, 5.0 Hz, 1 × 
C2-H2); 13C NMR (CDCl3, 100 MHz): δ 206.1 (C4), 172.3 (C1), 136.5 (C9), 129.0, 128.6 (C10, C11), 
128.2 (C12), 55.4 (C7), 50.4 (C8), 49.4 (C5), 44.2 (C6), 44.0 (C3), 29.4 (C2); HRMS: (ESI+) Calculated 
for C14H16BrNO2: 310.0437. Found [M + H]+: 310.0438. Data for alcohol 472: The relative 
stereochemistry of product 472 was not determined; νmax / cm-1: 3358 (br.), 2403 (w), 2254 (w), 1626 
(s), 1452 (m), 1101 (m); 1H NMR (CDCl3, 400 MHz): δ 7.34–7.26 (5H, m, ArCH), 4.73 (1H, d, J = 
14.5 Hz, C8-H2), 4.55 (1H, d, J = 14.5 Hz, C8-H2), 4.16–4.05 (2H, m, C4-H, C6-H), 3.72 (1H, dd, J = 
15.5, 10.5 Hz, C7-H2), 3.61 (1H, dd, J = 15.5, 5.0 Hz, C7-H2), 2.70–2.58 (2H, m, 2 × C2-H2), 2.26–
2.11 (2H, m, 1 × C3-H2, 2 × C5-H2), 1.95 (1H, m, C3-H2); 13C NMR (CDCl3, 100 MHz): δ 174.3 (C1), 
137.2 (C9), 128.9, 128.4 (C10, C11), 128.0 (C12), 68.0 (C4), 53.0 (C7), 49.3 (C8), 47.5 (C6), 42.5 (C5), 




36.7 (C3), 31.1 (C2); HRMS: (ESI+) Calculated for C14H19BrNO2: 312.0594. Found [M + H]+: 
312.0596. 
(Z)-1-Benzyl-1,3,4,8-tetrahydroazocine-2,5-dione (473)  
 
General Procedure K: Bromoketone 471 (106 mg, 0.34 mmol) and NEt3 (0.24 mL, 1.71 mmol) were 
employed. The reaction was quenched after approximately 3 h. FCC (80% EtOAc/hexane) provided the 
title compound (63 mg, 81%) as a colourless oil; νmax / cm-1: 2923 (w), 1681 (s), 1648 (s), 1454 (m), 
1416 (m), 1176 (m); 1H NMR (CDCl3, 400 MHz): δ 7.34–7.24 (3H, m, ArCH), 7.21 (2H, m, ArCH), 
6.00–5.93 (2H, m, C5-H, C6-H), 4.54 (2H, s, C8-H2), 3.95 (2H, d, J = 2.5 Hz, C7-H2), 2.95 (2H, m, 
C3-H2), 2.87 (2H, m, C2-H2); 13C NMR (CDCl3, 100 MHz): δ 203.7 (C4), 174.0 (C1), 136.7 (C9), 134.3 
(C5), 130.6 (C6), 128.8, 128.5 (C10, C11), 127.9 (C12), 51.2 (C8), 48.5 (C7), 44.8 (C3), 30.0 (C2); 
HRMS: (ESI+) Calculated for C14H16NO2: 230.1176. Found [M + H]+: 230.1183. 
7-Bromo-1,6-dimethylazocane-2,5-dione (474a) 
 
General Procedure J: Enamide 403a (167 mg, 1.00 mmol) was employed. FCC (80% EtOAc/hexane) 
provided ketone (161 mg, 65%) as a colourless oil. The relative stereochemistry of product 474a was 
not determined; νmax / cm-1: 2935 (w), 1709 (s), 1633 (s), 1470 (m), 1401 (m), 1104 (m); The 
1H and 
13C NMR spectra of the product are broad in both CDCl3 and MeOD-d3. As a result, the signals for C8 
could not be identified. The proposed structure was confirmed upon E1cB elimination of the bromide. 
1H NMR (CD3OD, 400 MHz): δ 4.16 (1H, br. m, C7-H2), 4.03 (1H, ddd, J = 12.0, 9.0, 3.0 Hz, C6-H), 
3.78 (1H, br. d, J = 16.0 Hz, C7-H2), 3.21 (1H, m, C5-H), 2.98–2.88 (2H, m, C3-H2), 2.46 (2H, m, 
C2-H2), 1.28 (3H, d, J = 6.5 Hz, C9-H3); 13C NMR (CD3OD, 100 MHz): δ 211.3 (C4), 173.9 (C1), 57.7 
(C7), 53.4 (C6), 50.3 (C5), 43.0, 43.0 (C2, C3), 17.5 (C9); HRMS: (ESI+) Calculated for C9H15BrNO2: 
248.0281. Found [M + H]+: 248.0290. 
 






General Procedure K: Bromoketone 474a (50.0 mg, 0.20 mmol) and DBU (0.06 mL, 0.40 mmol) 
were employed. The reaction was quenched after approximately 30 minutes. FCC (100% EtOAc) 
provided the title compound (22.0 mg, 66%) as a colourless oil; νmax / cm-1: 2922 (w), 1684 (s), 1629 
(s), 1452 (m), 1400 (m), 1254 (w), 1085 (m); 1H NMR (CD3OD, 400 MHz): δ 5.97 (1H, m, C6-H), 4.10 
(2H, m, C7-H2), 2.88–2.80 (7H, m, C2-H2, C3-H2, C8-H3), 1.86 (3H, m, C9-H3); 13C NMR (CD3OD, 
100 MHz): δ 209.0 (C4), 175.9 (C1), 140.8 (C5), 128.6 (C6), 50.9 (C7), 43.6 (C3), 35.7 (C8), 31.6 (C2), 
20.8 (C9); HRMS: (ESI+) Calculated for C9H14NO2: 168.1019. Found [M + H]+: 168.1027. 
(5E,7Z)-1-Benzyl-5-(methoxyimino)-6-methyl-3,4,5,6-tetrahydroazocin-2(1H)-one (483a) 
 
General Procedure L: Ketone 403b (200 mg, 0.82 mmol), methoxyamine hydrochloride (103 mg, 
1.23 mmol) and NaOAc (101 mg, 1.23 mmol) were employed. The reaction was carried out at room 
temperature for 1 h. The title compound (231 mg, 104%, 3:1 d.r., A+B) was afforded as a colourless 
oil. The oxime diastereomers were not separated at this stage; νmax / cm-1: 2933 (w), 1647 (s), 1442 (m), 
1391 (m), 1047 (s); 1H NMR (CDCl3, 400 MHz): δ 7.33–7.23 (5H, m, ArCH), 5.98 (1H, dd, J = 7.5, 
1.0 Hz, C7-H), 5.17 (1H, dd, J = 8.5, 7.5 Hz, C6-H), 5.01 (1H, d, J = 14.0 Hz, 1 × C8-H2), 4.25 (1H, d, 
J = 14.0 Hz, 1 × C8-H2), 3.80 (3H, s, C10-H3), 3.32 (1H, ddd, J = 16.0, 7.0, 2.5 Hz, 1 × C3-H2), 2.68–
2.49 (3H, m, 2 × C2-H2, C5-H), 2.17 (1H, ddd, J = 16.0, 13.0, 3.5 Hz, 1 × C3-H2), 0.96 (3H, d, J = 
7.0 Hz, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 172.8 (C1), 157.4 (C4), 136.6 (C11), 130.0 (C6), 128.9, 
128.6 (C12, C13), 128.2 (C7), 127.7 (C14), 61.5 (C10), 50.0 (C8), 36.5 (C5), 32.5 (C2), 22.9 (C3), 16.9 
(C9); HRMS: (ESI+) Calculated for C16H21N2O2: 273.1598. Found [M + H]+: 273.1599. 
 
 







General Procedure N: Oxime 485a (100 mg, 0.37 mmol), Pd(OAc)2 (8.30 mg, 0.037 mmol) and 
PhI(OAc)2 (131 mg, 0.41 mmol) were employed in AcOH:Ac2O (3.7 mL, 1:1). The reaction was heated 
at 80 °C for 16 h. FCC (60% EtOAc/hexane) provided the title compound (54 mg, 45%, >15:1 d.r.) as 
a yellow oil and oxime (29 mg, 29%); νmax / cm-1: 3360 (br.), 2937 (w), 1738 (m), 1649 (s), 1440 (m), 
1231 (s), 1043 (s); 1H NMR (CDCl3, 400 MHz): δ 7.33–7.22 (5H, m, ArCH), 6.12 (1H, dd, J = 7.5, 
1.0 Hz, C7-H), 5.23 (1H, dd, J = 8.5, 7.5 Hz, C6-H), 5.02 (1H, d, J = 14.5 Hz, 1 × C8-H2), 4.27 (1H, d, 
J = 14.5 Hz, 1 × C8-H2), 4.22–4.19 (2H, m, 2 × C9-H2), 3.79 (3H, s, C10-H3), 3.42 (1H, ddd, J = 16.5, 
6.0, 3.5 Hz, 1 × C3-H2), 2.97 (1H, q, J = 7.5 Hz, C5-H), 2.61–2.53 (2H, m, 2 × C2-H2), 2.14 (1H, m, 1 
× C3-H2), 1.85 (3H, s, C12-H3); 13C NMR (CDCl3, 100 MHz): δ 172.6 (C1), 170.9 (C11), 154.2 (C4), 
136.8 (C13), 130.9 (C7), 128.8, 128.7 (C14, C15), 127.8 (C16), 125.2 (C6), 64.1 (C9), 61.8 (C10), 50.6 
(C8), 41.3 (C5), 32.5 (C2), 22.8 (C3), 21.0 (C12); HRMS: (ESI+) Calculated for C18H23N2O4: 331.1652. 
Found [M + H]+: 331.1630. 
1-Benzyl-7-bromo-6-methylazocane-2,5-dione (474b)  
 
General Procedure J: Enamide 403b (1.00 g, 4.11 mmol) was employed. FCC (50–60–90% 
EtOAc/hexane) provided ketone (895 mg, 67%) as a colourless oil. The relative stereochemistry of the 
product was not determined; νmax / cm-1: 3301 (br.), 2970 (w), 2933 (w), 1710 (s), 1645 (s), 1453 (s), 
1418 (m), 1120 (m); 1H NMR (CD3OD, 400 MHz): δ 7.37–7.27 (3H, m, ArCH), 7.23 (2H, m, ArCH), 
4.66 (1H, d, J = 15.0 Hz, 1 × C8-H2), 4.40 (1H, br. m, 1 × C8-H2), 4.14 (1H, dd, J = 16.0, 10.5 Hz, 1 × 
C7-H2), 3.77 (1H, m, C6-H), 3.65 (1H, dd, J = 16.0, 3.0 Hz, 1 × C7-H2), 3.53 (1H, m, 1 × C2-H2), 3.26 
(1H, qd, J = 6.5, 4.5 Hz, C5-H), 2.97 (1H, m, 1 × C3-H2), 2.56–2.47 (2H, m, 1 × C2-H2, 1 × C3-H2), 




1.23 (3H, d, J = 6.5 Hz, C9-H3); 13C NMR (CD3OD, 100 MHz): δ 212.1 (C4), 175.4 (C1), 137.8 (C10), 
129.7, 129.5, 128.8 (ArC), 56.4 (C7), 55.2 (C6), 51.7 (C5), 50.8 (C8), 44.4 (C3), 29.6 (C2), 19.4 (C9); 
HRMS: (ESI+) Calculated for C15H18BrNNaO2: 346.0413. Found [M + Na]+: 346.0409. 
(Z)-1-Benzyl-6-methyl-1,3,4,8-tetrahydroazocine-2,5-dione (439b)  
 
General Procedure K: Bromoketone 474b (60.0 mg, 0.190 mmol) and DBU (0.100 mL, 0.756 mmol) 
were employed. The reaction was quenched after approximately 30 minutes. FCC (60% EtOAc/hexane) 
provided the title compound (31.0 mg, 67%) as a colourless oil; νmax / cm-1: 3316 (br.), 2919 (w), 1686 
(s), 1638 (s), 1453 (s), 1418 (m); 1H NMR (CDCl3, 400 MHz): δ 7.27–7.14 (5H, m, ArCH), 5.59 (1H, 
m, C6-H), 4.44 (2H, s, C8-H2), 3.75 (2H, m, C7-H2), 2.82–2.78 (4H, m, C2-H2, C3-H2), 1.76 (3H, m, 
C9-H3); 13C NMR (CDCl3, 100 MHz): δ 207.1 (C4), 173.3 (C1), 140.1 (C5), 136.9 (C10), 128.7, 128.4 
(C11, C12), 127.7 (C13), 126.4 (C6), 50.7 (C8), 46.9(C7), 42.8 (C3), 31.1 (C2), 20.9 (C9); HRMS: 
(ESI+) Calculated for C15H18NO2: 244.1332. Found [M + H]+: 244.1330. 
 (5E,6Z)-1-Benzyl-5-(methoxyimino)-6-methyl-3,4,5,8-tetrahydroazocin-2(1H)-one (485)  
 
General Procedure L: Ketone 439b (81.0 mg, 0.33 mmol), methoxyamine hydrochloride (42.0 mg, 
0.50 mmol) and NaOAc (41.0 mg, 0.50 mmol) were employed. The reaction was carried out at room 
temperature for 6 h. The title compound (91 mg, 100%, 2:1 d.r., A+B) was afforded as a pale yellow 
oil; νmax / cm-1: 2936 (w), 1633 (s), 1453 (m), 1421 (m), 1045 (s); 1H NMR (CDCl3, 400 MHz): δ 7.33–
7.22 (10H, m, ArCH, A+B), 5.66 (1H, tq, J = 7.5, 1.5 Hz, C6-H, A), 5.45 (1H, br. m, C6-H, B), 4.54 
(2H, s, C8-H2, A), 3.90 (3H, s, C10-H3, A), 3.84 (3H, s, C10-H3, B), 3.73 (2H, d, J = 7.5 Hz, C7-H2, 
A), 3.68 (2H, br. m, C7-H2, B), 2.86 (2H, m, C2-H2, A), 2.76 (2H, m, C3-H2, A), 1.88 (3H, s, C9-H3, 
A), 1.84 (3H, s, C9-H3, B); 13C NMR (CDCl3, 100 MHz): δ 170.0 (C1, A), 158.6 (C4, A), 140.2 (C5, 
A), 137.5 (C11, A), 137.5 (C11, B), 128.7, 128.4 (C12 (A), C13 (A)), 128.3 (C12/13, B), 127.6 (C14, 




A), 125.0 (C6, A), 62.0 (C10, A), 49.8 (C8, A), 45.1 (C7, A), 33.4 (C2, A), 25.1 (C3, A), 22.6 (C9, A); 
HRMS: (ESI+) Calculated for C16H20N2NaO2: 295.1417. Found [M + Na]+: 295.1429. 
 (E)-1-Benzyl-7-bromo-5-(methoxyimino)-6-methylazocan-2-one (487a)  
 
General Procedure L: Ketone 474b (162 mg, 0.50 mmol), methoxyamine hydrochloride (63.0 mg, 
0.75 mmol) and NaOAc (62.0 mg, 0.75 mmol) were employed. The reaction was carried out at room 
temperature for 16 h. The title compound (158 mg, 89%, >15:1 d.r.) was afforded as a colourless oil; 
νmax / cm-1: 2936 (w), 1644 (s), 1452 (s), 1412 (m), 1164 (m), 1045 (s); 1H NMR (CDCl3, 400 MHz): δ 
7.35–7.24 (5H, m, ArCH), 5.05 (1H, br., C8-H2), 4.74 (1H, d, J = 14.5, C8-H2), 3.97 (1H, m, C6-H), 
3.86–3.79 (4H, m, 1 × C7-H2, 3 × C10-H3), 3.71 (1H, dd, J = 16.5, 5.5 Hz, C7-H2), 3.47 (1H, m, C2-H2), 
2.80 (1H, m, C3-H2), 2.68–2.54 (2H, m, 1 × C3-H2, C5-H), 2.01 (1H, m, C2-H2), 1.40 (3H, d, J = 
7.0 Hz, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 173.5 (C1), 160.9 (C4), 137.1 (C11), 128.8, 128.6 
(C12, C13), 127.7 (C14), 61.9 (C7), 61.6 (C10), 57.7 (C6), 49.7 (C8), 44.8 (C5), 31.8 (C3), 27.0 (C2), 
20.0 (C9); HRMS: (ESI+) Calculated for C16H22BrN2O2: 353.0859. Found [M + H]+: 353.0869. 
(E)-(1-Benzyl-3-bromo-5-(methoxyimino)-8-oxoazocan-4-yl)methyl acetate (488a) 
 
General Procedure N: Oxime 487a (80.0 mg, 0.226 mmol), Pd(OAc)2 (5.10 mg, 0.0230 mmol) and 
PhI(OAc)2 (109 mg, 0.340 mmol) were employed in AcOH:Ac2O (2.3 mL, 1:1). The reaction was 
heated at 100 °C for 3 h. FCC (60% EtOAc/hexane) provided the title compound (37.0 mg, 40%, >15:1 
d.r.) as an orange oil; νmax / cm-1: 2936 (w), 1739 (s), 1637 (s), 1453 (s), 1226 (s), 1045 (s); 1H NMR 
(CDCl3, 400 MHz): δ 7.34–7.24 (5H, m, ArCH), 5.05 (1H, br. m, C8-H2), 4.75–4.63 (2H, m, 1 × C8-H2, 
1 × C9-H2), 4.34 (1H, dd, J = 10.0, 10.0 Hz, C9-H2), 3.98 (1H, m, C6-H), 3.86–3.72 (5H, m, 2 × C7-H2, 
C10-H3), 3.53 (1H, m, C2-H2), 2.93 (1H, m, C5-H), 2.81 (1H, m, C3-H2), 2.58 (1H, m, C3-H2), 2.08–




1.98 (4H, m, 1 × C2-H2, C12-H3); 13C NMR (CDCl3, 100 MHz): δ 173.3 (C1), 170.7 (C11), 157.0 (C4), 
136.9 (C13), 128.8, 128.6 (C14, C15), 127.8 (C16), 67.3 (C9), 62.2 (C10), 49.9 (C8), 49.1 (C5), 31.9 
(C3), 27.2 (C2), 21.0 (C12); HRMS: (ESI+) Calculated for C18H23BrN2NaO4: 433.0733. Found [M + 
Na]+: 433.0720. 
(5E,7Z)-1-Benzyl-5-(hydroxyimino)-6-methyl-3,4,5,6-tetrahydroazocin-2(1H)-one (483b)  
 
General Procedure L: Ketone 403b (444 mg, 1.72 mmol), hydroxylamine hydrochloride (191 mg, 
2.75 mmol) and NaOAc (222 mg, 2.75 mmol) were employed. The reaction was carried out at room 
temperature for 4 h. The title compound (450 mg, 96%, 3:1 d.r.) was afforded as a colourless oil. The 
oxime diastereomers were separated by FCC (50% EtOAc/hexane) for analysis; Data for the first 
diastereomer (A) to elute by FCC: νmax / cm-1: 3253 (br.), 2970 (w), 1620 (s), 1445 (s), 1389 (m), 
1186 (m); 1H NMR (CDCl3, 400 MHz): δ 8.35 (1H, br. s, OH), 7.34–7.23 (5H, m, ArCH), 6.01 (1H, dd, 
J = 7.5, 1.0 Hz, C7-H), 5.16 (1H, dd, J = 8.5, 7.5 Hz, C6-H), 5.02 (1H, d, J = 14.0 Hz, 1 × C8-H2), 4.25 
(1H, d, J = 14.0 Hz, 1 × C8-H2), 2.68 (1H, m, C5-H), 2.64–2.54 (2H, m, C3-H2), 2.18 (1H, ddd, J = 
16.0, 12.0, 4.0 Hz, 1 × C2-H2), 0.94 (3H, d, J = 6.5 Hz, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 172.7 
(C1), 158.7 (C4), 136.6 (C10), 129.7 (C6), 129.0, 128.6 (C11, C12), 128.6 (C7), 127.8 (C13), 50.0 (C8), 
36.5 (C5), 32.4 (C2), 22.4 (C3), 16.8 (C9); HRMS: (ESI+) Calculated for C15H19N2O2: 259.1441. Found 
[M + H]+: 259.1443; Data for the second diastereomer (B) to elute by FCC: νmax / cm-1: 3253 (br.), 
1625 (s), 1445 (s), 1389 (s), 1183 (m), 939 (s); 1H NMR (CDCl3, 400 MHz): δ 7.78 (1H, br. s, OH), 
7.31–7.22 (5H, m, ArCH), 5.81 (1H, dd, J = 8.5, 2.0 Hz, C7-H), 5.33 (1H, dd, J = 8.5, 5.5 Hz, C6-H), 
4.96 (1H, d, J = 14.5 Hz, 1 × C8-H2), 4.28 (1H, d, J = 14.5 Hz, 1 × C8-H2), 3.85 (1H, m, C5-H), 2.89 
(1H, m, 1 × C2-H2), 2.63–2.48 (3H, m, 1 × C2-H2, 2 × C3-H2), 1.13 (3H, d, J = 7.5 Hz, C9-H3); 13C 
NMR (CDCl3, 100 MHz): δ 172.0 (C1), 159.4 (C4), 136.8 (C10), 128.9, 128.5 (C11, C12), 127.9 (C7), 
127.5 (C13), 126.9 (C6), 50.5 (C8), 32.7 (C3), 30.9 (C5), 28.7 (C2), 17.1 (C9); HRMS: (ESI+) 
Calculated for C15H19N2O2: 259.1441. Found [M + H]+: 259.1447. 
 
 








General Procedure N: Oxime 483b (250 mg, 0.194 mmol), Pd(OAc)2 (4.3 mg, 0.019 mmol) and 
PhI(OAc)2 (93.5 mg, 0.290 mmol) were employed in AcOH:Ac2O (1.93 mL, 1:1). The reaction was 
heated at 100 °C for 6 h. FCC (40% EtOAc/hexane) provided acetyl oxime 483c (27 mg, 46%) as a 
yellow oil and oxidised product 484c as a mixture with both non-oxidised diastereomers (16 mg, 
2:1.5:1, 10%) as a yellow oil; Data for acetyl oxime 483c: νmax / cm-1: 2930 (w), 1765 (s), 1740 (s), 
1647 (s), 1365 (m), 1201 (s); 1H NMR (CDCl3, 400 MHz): δ 7.29–7.22 (5H, m, ArCH), 6.04 (1H, d, J 
= 7.5 Hz, C7-H), 5.20 (1H, dd, J = 8.5, 7.5 Hz, C6-H), 5.01 (1H, d, J = 14.0 Hz, 1 × C8-H2), 4.20 (1H, 
d, J = 14.0 Hz, 1 × C8-H2), 3.29 (1H, m, 1 × C3-H2), 2.78 (1H, m, C5-H), 2.67–2.52 (2H, m, 2 × C2-H2), 
2.35 (1H, m, 1 × C3-H2), 2.12 (3H, s, C11-H3), 1.02 (3H, d, J = 7.0 Hz, C9-H3); 13C NMR (CDCl3, 
100 MHz): δ 171.9 (C1), 168.8 (C10), 166.0 (C4), 136.3 (C12), 129.2 (C7), 128.9, 128.6 (C13, C14), 
128.6 (C6), 127.9 (C15), 50.0 (C8), 37.2 (C5), 32.1 (C2), 24.6 (C3), 19.9 (C11), 16.7 (C9); HRMS: 
(ESI+) Calculated for C17H20N2NaO3: 323.1366. Found [M + Na]+: 323.1365; Data for the C-H 
acetoxylated product 484c: νmax / cm-1: 2934 (w), 1764 (s), 1747 (s), 1648 (s), 1366 (m), 1204 (s); 1H 
NMR (CDCl3, 400 MHz): δ 7.32–7.25 (5H, m, ArCH), 6.19 (1H, dd, J = 7.5, 1.0 Hz, C7-H), 5.29 (1H, 
dd, J = 8.5, 7.5 Hz, C6-H), 5.01 (1H, d, J = 14.5 Hz, 1 × C8-H2), 4.32 (1H, dd, J = 11.0, 6.0 Hz, 1 × 
C9-H2), 4.29 (1H, dd, J = 14.5 Hz, 1 × C8-H2), 4.22 (1H, dd, J = 11.0, 8.0 Hz, 1 × C9-H2), 3.41 (1H, 
ddd, J = 15.5, 6.0 3.5 Hz, 1 × C3-H2), 3.15 (1H, m, C5-H), 2.65–2.62 (2H, m, 2 × C2-H2), 2.40 (1H, m, 
1 × C3-H2), 2.16 (3H, s, C11-H3), 1.86 (3H, s, C13-H3); 13C NMR (CDCl3, 100 MHz): δ 171.8 (C1), 
170.6 (C12), 168.7 (C10), 163.0 (C4), 136.4 (C14), 131.8 (C7), 128.8, 128.8 (C15, C16), 127.9 (C17), 
123.4 (C6), 63.3 (C9), 50.6 (C8), 42.1 (C5), 32.2 (C2), 24.7 (C3), 20.9 (C13), 20.0 (C11); HRMS: 











General Procedure K: Bromoketone 488a (50.1 mg, 0.122 mmol) and DBU (0.091 mL, 0.608 mmol) 
were employed. The reaction was quenched after approximately 16 h. FCC (80% EtOAc/hexane) 
provided the title compound (21 mg, 52%) as a pale yellow; νmax / cm-1: 2936 (w), 1739 (s), 1638 (s), 
1453 (m), 1421 (m), 1226 (s), 1045 (s); 1H NMR (CDCl3, 400 MHz): δ 7.33–7.23 (5H, m, ArCH), 5.83 
(1H, tt, J = 6.5, 2.5 Hz, C6-H), 4.65 (2H, s, C9-H2), 4.55 (2H, s, C8-H2), 3.90 (3H, s, C10-H3), 3.85–
3.81 (2H, m, C7-H2), 2.86–2.81 (4H, m, C2-H2, C3-H2), 2.06 (3H, s, C12-H3); 13C NMR (CDCl3, 
100 MHz): δ 173.0 (C1), 170.5 (C11), 155.3 (C4), 137.6 (C5), 137.4 (C13), 128.7, 128.5 (C14, C15), 
127.7 (C16), 127.4 (C6), 66.1 (C9), 62.3 (C10), 50.2 (C8), 45.2 (C7), 32.9 (C2), 25.8 (C3), 21.0 (C12); 




Ketone 429 (412 mg, 4.94 mmol) was added to a stirring solution of ketone (147 mg, 0.49 mmol) in 
pyridine (5.6 mL). The reaction was stirred for 16 h at room temperature before being concentrated in 
vacuo. The residue was dissolved in Et2O (10 mL) and washed with 1 M aq. HCl (10 mL) and brine 
(10 mL). The organics were dried over MgSO4, filtered and concentrated in vacuo to provide the title 
compound (154 mg, 96%) as a colourless oil; νmax / cm-1: 2929 (m), 2956 (m), 1644 (s), 1462 (m), 1390 
(m), 1040 (s); 1H NMR (CDCl3, 400 MHz): δ 5.79 (1H, dd, J = 8.5, 2.5 Hz, C7-H), 5.29 (1H, dd, J = 
8.5, 4.0 Hz, C6-H), 4.57 (1H, dd, J = 10.5, 6.5 Hz, C3-H), 4.08 (1H, m, C5-H), 3.79 (3H, s, C13-H3), 
3.20 (1H, m, 1 × C2-H2), 2.90 (3H, s, C8-H3), 2.61 (1H, dd, J = 11.5, 6.5 Hz, 1 × C2-H2), 1.34 (3H, d, 
J = 7.5 Hz, C9-H3), 0.87 (9H, s, C12-H3), 0.10 (3H, s, C10-H3), 0.06 (3H, s, C10-H3); 13C NMR (CDCl3, 
100 MHz): δ 169.1 (C7), 158.9 (C4), 128.9 (C7), 128.1 (C6), 72.6 (C3), 61.8 (C13), 42.5 (C2), 34.1 




(C8), 29.7 (C5), 25.9 (C12), 19.2 (C9), 18.2 (C11), -4.6 (C10), -5.0 (C10); HRMS: (ESI+) Calculated 
for C16H31N2O3Si: 327.2098. Found [M + Na+]: 327.2113. 
(5Z,7Z)-4-Hydroxy-5-(methoxyimino)-1,6-dimethyl-3,4,5,6-tetrahydroazocin-2(1H)-one (490) 
 
TBAF (0.153 mL, 0.153 mmol, 1 M THF) was added to a stirring solution of silyl ether 489 (50 mg, 
0.153 mmol) in THF (1.5 mL). The reaction was stirred at room temperature for 2 h before the addition 
of water (5 mL). The aqueous layer was extracted with Et2O (3 × 5 mL). The combined organics were 
dried over MgSO4, filtered and concentrated in vacuo. FCC (75% EtOAc/hexane) provided the title 
compound (29 mg, 89%) as a pale yellow oil; νmax / cm-1: 3363 (br.), 2936 (w), 1631 (s), 1455 (m), 1388 
(m), 1041 (s); 1H NMR (CDCl3, 400 MHz): δ 5.94 (1H, dd, J = 7.5, 1.5 Hz, C7-H), 5.50 (1H, dd, J = 
8.0, 7.5 Hz, C6-H), 4.46 (1H, dd, J = 10.5, 3.5 Hz, C3-H), 3.83 (3H, s, C10-H3), 3.58 (1H, br. s, OH), 
3.12 (1H, m, C5-H), 2.95 (3H, s, C8-H3), 2.83 (1H, dd, J = 11.5, 3.5 Hz, 1 × C2-H2), 2.73 (1H, m, 1 × 
C2-H2), 1.39 (3H, d, J = 7.0 Hz, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 170.2 (C1), 157.3 (C4), 129.8 
(C7), 125.9 (C6), 69.0 (C3), 62.4 (C10), 44.3 (C2), 34.5 (C8), 33.6 (C5), 17.4 (C9); HRMS: (ESI+) 
Calculated for C10H16N2NaO3: 235.1053. Found [M + Na+]: 235.1052. 
(5Z,7Z)-5-(Methoxyimino)-1,6-dimethyl-2-oxo-1,2,3,4,5,6-hexahydroazocin-4-yl acetate (491) 
 
General Procedure N: Oxime 490 (29.2 mg, 0.137 mmol), Pd(OAc)2 (5.1 mg, 0.023 mmol) and 
PhI(OAc)2 (109 mg, 0.34 mmol) were employed in AcOH:Ac2O (2.3 mL, 1:1). The reaction was heated 
at 100 °C for 3 h. FCC (60% EtOAc/hexane) provided the title compound (37 mg, 40%) as an orange 
oil; νmax / cm-1: 2939 (w), 1744 (s), 1646 (s), 1372 (m), 1224 (s), 1044 (s); 1H NMR (CDCl3, 400 MHz): 
δ 5.91 (1H, dd, J = 8.5, 2.0 Hz, C7-H), 5.55 (1H, dd, J = 10.0, 5.5, Hz, C3-H), 5.42 (1H, dd, J = 8.5, 
6.0 Hz, C6-H), 3.97 (1H, m, C5-H), 3.83 (3H, s, C10-H3), 3.19 (1H, dd, J = 12.0, 10.0 Hz, 1 × C2-H2), 
2.94 (3H, s, C8-H3), 2.83 (1H, dd, J = 12.0, 5.5 Hz, 1 × C2-H2), 2.05 (3H, s, C12-H3), 1.31 (3H, d, J = 
7.5 Hz, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 169.3 (C11), 168.2 (C1), 155.4 (C4), 130.1 (C7), 127.4 




(C6), 71.7 (C3), 62.2 (C10), 39.2 (C2), 34.1 (C8), 30.3 (C5), 21.1 (C12), 17.2 (C9); HRMS: (ESI+) 
Calculated for C12H18N2NaO4: 277.1159. Found [M + Na+]: 277.1146. 
2-((((5E,7Z)-1,6-Dimethyl-2-oxo-1,3,4,6-tetrahydroazocin-5(2H)-ylidene)amino)oxy)-2-
methylpropanoic acid (492) 
 
General Procedure M: Ketone 403a (100 mg, 0.60 mmol), oxime hydrochloride (140 mg, 0.90 mmol) 
and NaOAc (147 mg, 1.80 mmol) were employed. The reaction was carried out at reflux for 1 h. The 
title compound (161 mg, 100%, 8:1 d.r.) was afforded as a pale yellow oil which solidified upon 
standing; Data for the major diastereomer: m.p. 107–109 °C (CH2Cl2);; νmax / cm-1: 3437 (br.), 2982 
(w), 2935 (w), 1722 (m), 1605 (s), 1455 (m), 1386 (m), 1155 (s); 1H NMR (CDCl3, 400 MHz): δ 8.73 
(1H, br., OH), 6.01 (1H, dd, J = 8.0, 1.5 Hz, C7-H), 5.21 (1H, dd, J = 8.0, 8.0 Hz, C6-H), 3.29 (1H, 
ddd, J = 15.5, 6.5, 4.0 Hz, 1 × C3-H2), 3.08–3.00 (4H, m, C5-H, C8-H3), 2.64–2.61 (2H, m, C2-H2), 
2.33 (1H, ddd, J = 15.5, 10.5, 5.5 Hz, 1 × C3-H2), 1.50 (3H, s, C11-H3), 1.49 (3H, s, C11-H3), 1.20 (3H, 
d, J = 7.0 Hz, C9-H3); 13C NMR (CDCl3, 100 MHz): δ 177.5 (C12), 173.3 (C1), 159.9 (C4), 130.0 (C7), 
128.3 (C6), 81.6 (C10), 37.0 (C5), 34.2 (C8), 32.0 (C2), 24.2 (C11), 22.9 (C3), 17.4 (C9); HRMS: 
(ESI+) Calculated for C13H21N2O4: 269.1496. Found [M + H+]: 269.1492; Data for the major 
diastereomer: Characteristic signals only: 1H NMR (CDCl3, 400 MHz): δ 5.85 (1H, dd, J = 8.5, 2.0 Hz, 
C7-H), 5.33 (1H, dd, J = 8.5, 6.0 Hz, C6-H), 4.00 (1H, m, C5-H).  
 (E)-2-(((7-Bromo-1,6-dimethyl-2-oxoazocan-5-ylidene)amino)oxy)-2-methylpropanoic acid (494) 
 
General Procedure M: Ketone 474a (50.3 mg, 0.20 mmol), oxime hydrochloride (94.4 mg, 
0.60 mmol) and NaOAc (115 mg, 1.40 mmol) were employed. The reaction was carried out at reflux 
for 1 h. The title compound (65 mg, 93%) was afforded as a colourless foam; νmax / cm-1: 3125 (br.), 
2936 (w), 1722 (m), 1600 (s), 1465 (m), 1158 (s); 1H NMR (CDCl3, 400 MHz): δ 10.36 (1H, br. s, OH), 
4.17 (1H, br. m, C7-H2), 3.94 (1H, ddd, J = 10.5, 3.5, 3.5 Hz, C6-H), 3.66 (1H, br. m, C7-H2), 3.45 (1H, 




m, C3-H2), 3.15 (3H, s, C8-H3), 2.74–2.65 (2H, m, C2-H2), 2.53 (1H, m, C5-H), 1.99 (1H, br. m, C3-H2), 
1.53 (3H, s, C11-H3), 1.48 (3H, s, C11-H3), 1.37 (3H, d, J = 7.0 Hz, C9-H3); 13C NMR (CDCl3, 100 
MHz): δ 176.9 (C1), 174.5 (C12), 160.4 (C4), 81.6 (C10), 56.3 (C7), 53.6 (C6), 45.6 (C5), 37.8 (C8), 
31.9 (C2), 27.5 (C3), 24.6, 23.5 (C11), 19.3 (C9); HRMS: (ESI+) Calculated for C13H21BrN2NaO4: 
371.0577. Found [M + Na+]: 371.0613. 
(E)-2-(((6-(Acetoxymethyl)-7-bromo-1-methyl-2-oxoazocan-5-ylidene)amino)oxy)-2-
methylpropanoic acid (495) 
 
General Procedure N: Oxime 494 (100 mg, 0.286 mmol), Pd(OAc)2 (6.4 mg, 0.029 mmol) and 
PhI(OAc)2 (92 mg, 0.286 mmol) were employed in AcOH:Ac2O (2.9 mL, 1:1). The reaction was heated 
at 80 °C for 16 h. The crude reaction mixture was dissolved in Et2O (5 mL) and extracted with 10% aq. 
K2CO3 (3 × 5 mL). The aqueous layer was acidified to pH 1 with conc. HCl and extracted with Et2O 
(3 × 10 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo to 
provide the title compound (129 mg, 92%) as a yellow foam; νmax / cm-1: 3445 (br.), 2985 (w), 1732 (s), 
1604 (s), 1466 (s), 1232 (s), 1164 (s); 1H NMR (CDCl3, 400 MHz): δ 7.02 (1H, br. s, OH), 4.56 (1H, 
dd, J = 10.5, 4.0 Hz, C9-H2), 4.35 (1H, dd, J = 10.5, 10.0 Hz, C9-H2), 4.24 (1H, br. m, C7-H2), 4.00 
(1H, ddd, J = 11.0, 3.5, 3.0 Hz, C6-H), 3.64 (1H, br. m, C7-H2), 3.51 (1H, ddd, J = 13.0, 6.0, 5.5 Hz, 
C3-H2), 3.16 (3H, br. s, C8-H3), 2.81 (1H, br. m, C5-H), 2.75–2.63 (2H, br. m, C2-H2), 2.00 (3H, s, 
C14-H3), 1.97 (1H, br. m, C3-H2), 1.51 (3H, s, C11-H3), 1.48 (3H, s, C11-H3); The 
13C signal for C1 
was not visible because the signal was broad. 13C NMR (CDCl3, 100 MHz): δ 176.7 (C12), 171.0 (C13), 
158.2 (C4), 81.8 (C10), 66.8 (C9), 51.4 (C6), 49.0 (C5), 37.8 (C8), 32.1 (C2), 27.9 (C3), 24.4 (C11), 
23.5 (C11), 20.8 (C14); HRMS: (ESI+) Calculated for C15H22N2O6Br: 405.0661. Found [M + H+]: 
405.0665. 
((1R,4R,E)-2-(Methoxyimino)-7,7-dimethylbicyclo[2.2.1]heptan-1-yl)methyl acetate (497a) 
 




General Procedure N: Oxime 496a was prepared according to a literature procedure301: Oxime 496a 
(90.7 mg, 0.500 mmol), Pd(OAc)2 (5.60 mg, 0.0250 mmol) and PhI(OAc)2 (322 mg, 1.00 mmol) were 
employed in AcOH:Ac2O (5 mL, 1:1). The reaction was heated at 80 °C for 3 h and a separate identical 
reaction was heated at 90 °C for 9 h. The crude reaction mixtures were concentrated in vacuo and a 
yield of product 497a (<10% yield obtained at 80 °C for 3 h; 60% yield obtained at 90 °C for 9 h) was 
measured by analysis of the 1H NMR of the crude material against an internal standard (1,4-DNB). A 
pure sample of product 497a was obtained by Ambler, the spectroscopic properties of which were 
consistent with that available in the literature.301   
2-((((1S,4R,E)-1,7,7-Trimethylbicyclo[2.2.1]heptan-2-ylidene)amino)oxy)acetic acid (496b) 
 
General Procedure M: Camphor (305 mg, 2.00 mmol), oxime hydrochloride (328 mg, 3.00 mmol) 
and NaOAc (493 mg, 6.00 mmol) were employed. The reaction was carried out at reflux for 1 h. The 
title compound (207 mg, 92%) was afforded as a colourless foam; νmax / cm-1: 3036 (br. s), 2957 (s), 
1731 (s), 1239 (m); 1H NMR (CDCl3, 400 MHz): δ 4.62–4.53 (2H, m, C11-H2), 2.58 (1H, dd, J = 18.0, 
4.0 Hz, C6-H2), 2.07 (1H, d, J = 18.0 Hz, C6-H2), 1.91 (1H, m, C5-H), 1.84 (1H, m, C5-H2), 1.72 (1H, 
ddd, J = 12.5, 12.0, 4.0 Hz, C4-H2), 1.45 (1H, m, C4-H2), 1.24 (1H, m, C3-H2), 0.99 (3H, s, C10-H3), 
0.92 (3H, s, C8/9-H3), 0.80 (3H, s, C8/9-H3); 13C NMR (CDCl3, 100 MHz): δ 174.1 (C12), 173.4 (C1), 
70.0 (C11), 52.4 (C7), 48.5 (C2), 43.8 (C5), 34.1 (C6), 32.7 (C3), 27.3 (C4), 19.5, 18.6 (C8, C9), 11.1 




General Procedure N: Oxime 496b (113 mg, 0.500 mmol), Pd(OAc)2 (5.60 mg, 0.0250 mmol) and 
PhI(OAc)2 (322 mg, 1.00 mmol) were employed in AcOH:Ac2O (5 mL, 1:1). The reaction was heated 
at 80 °C for 3 h and a separate identical reaction was heated at 90 °C for 9 h. The crude reaction mixtures 
were concentrated in vacuo and a yield of product 497b (75% yield obtained at 80 °C for 3 h; 75% yield 
obtained at 90 °C for 9 h) was measured by analysis of the 1H NMR of the crude material against an 
internal standard (1,4-DNB). A purer sample of product 497b was obtained by dissolving the crude 




reaction mixture in Et2O (5 mL) and extracting with 10% aq. K2CO3 (3 × 5 mL). The aqueous layer was 
acidified to pH 1 with conc. HCl and extracted with Et2O (3 × 10 mL). The combined organics were 
dried over MgSO4, filtered and concentrated in vacuo to provide the title compound in a suitable purity 
for analysis; νmax / cm-1: 3125 (br.), 2923 (m), 1739 (s), 1243 (s), 1073 (m); 1H NMR (CDCl3, 400 MHz): 
δ 4.60 (1H, d, J = 17.0 Hz, C13-H2), 4.54 (1H, d, J = 17.0 Hz, C13-H2), 4.31 (1H, d, J = 12.0 Hz, 
C10-H2), 4.22 (1H, d, J = 12.0 Hz, C10-H2), 2.62 (1H, m, C6-H2), 2.08–2.00 (4H, s, 1 × C6-H2, 3 × 
C12-H3), 2.00–1.83 (3H, m, 1 × C3-H2, 1 × C4-H2, 1 × C5-H), 1.48 (1H, m, C3-H2), 1.28 (1H, m, 
C4-H2), 1.01 (3H, s, C8/9-H3), 0.91 (3H, s, C8/9-H3); 13C NMR (CDCl3, 100 MHz): δ 175.3 (C14), 
171.4 (C11), 169.2 (C1), 70.0 (C13), 61.7 (C10), 54.6 (C7), 48.7 (C2), 44.7 (C5), 33.8 (C6), 28.3 (C3), 
26.9 (C4), 20.1, 19.7 (C8/9); HRMS: (ESI+) Calculated for C14H22NO5: 284.1492. Found [M + H]+: 
284.1491. 
(E)-2-(((2-(Acetoxymethyl)cyclohexylidene)amino)oxy)-2-methylpropanoic acid (507) 
 
General Procedure N: Oxime 506 was prepared by Ambler according to a literature procedure305: 
Oxime305 (53.3 mg, 0.25 mmol), Pd(OAc)2 (2.8 mg, 0.0125 mmol) and PhI(OAc)2 (121 mg, 
0.375 mmol) were employed in AcOH:Ac2O (2.5 mL, 1:1). The reaction was heated at 60 °C for 16 h. 
The crude reaction mixture was concentrated in vacuo and analysed by 1H NMR against 1,4-DNB as 
an internal standard which revealed that the desired product (76%, 5:1 d.r.) had been formed. A purified 
sample of the title compound was obtained by dissolving the crude reaction mixture in Et2O (5 mL) and 
extracting with 10% aq. K2CO3 (3 × 5 mL). The aqueous layer was acidified to pH 1 with conc. HCl 
and extracted with Et2O (3 × 10 mL). The combined organics were dried over MgSO4, filtered and 
concentrated in vacuo to provide the title compound for characterisation purposes; Data for the major 
diastereomer: νmax / cm-1: 2933 (m), 2860 (w), 1735 (s), 1303 (m), 1169 (m), 1087 (m); 1H NMR 
(CDCl3, 400 MHz): δ 8.84 (1H, br. s, OH), 4.31 (1H, dd, J = 11.0, 7.0 Hz, 1 × C7-H2), 4.10 (1H, dd, J 
= 11.0, 6.0 Hz, 1 × C7-H2), 3.00 (1H, m, 1 × C6-H2), 2.56 (1H, m, C2-H), 2.07–1.92 (5H, m, 1 × C3-H2, 
1 × C6-H2, 3 × C9-H3), 1.82–1.74 (2H, m, 1 × C4-H2, 1 × C5-H2), 1.60–1.37 (9H, m, 1 × C3-H2, 1 × 
C4-H2, 1 × C5-H2, 6 × C11-H3); 13C NMR (CDCl3, 100 MHz): δ 177.3 (C12), 171.2 (C8), 162.0 (C1), 
81.1 (C10), 64.3 (C7), 41.7 (C2), 30.3 (C3), 26.0 (C5), 24.9 (C6), 24.2 (C4), 24.2 (C11), 21.0 (C9); 
HRMS: (ESI+) Calculated for C13H21NNaO5: 294.1312. Found [M + Na]+: 294.1318; Data for the 
minor diastereomer: Characteristic signals only: 1H NMR (CDCl3, 400 MHz): δ 3.17 (1H, m, C2-H). 




Method for the methanolysis of crude reaction mixtures: When the reaction was run in solvents 
other than AcOH:Ac2O, a methanolic work-up was required to break up PhI(OAc)2 based side products. 
The crude reaction mixture was dissolved in MeOH (5 mL), to which K2CO3 (100 mg) was added. The 
mixture was stirred for 15 minutes before being concentrated in vacuo. The resulting residue was 
dissolved in water (10 mL) and extracted with Et2O (5 mL). The aqueous phase was acidified (pH ~1) 
with conc. HCl and extracted with Et2O (3 × 5 mL). The resulting organic extracts were combined and 
dried over MgSO4, filtered and concentrated in vacuo to provide -oxygenation products. 
 (E)-2-(((2-(Methoxymethyl)cyclohexylidene)amino)oxy)-2-methylpropanoic acid (508a) 
 
General Procedure N: Oxime 506 (32.0 mg, 0.15 mmol), Pd(OAc)2 (3.40 mg, 0.015 mmol) and 
PhI(OAc)2 (72.5 mg, 0.225 mmol) were employed in MeOH (1.5 mL, 1:1). The reaction was heated at 
80 °C for 16 h. The crude reaction mixture was concentrated in vacuo and analysed by 1H NMR against 
1,4-DNB as an internal standard which revealed that the desired product (75%, 5:2 d.r., A:B) had been 
formed. A purified sample of the title compound was obtained by dissolving the crude reaction mixture 
in Et2O (5 mL) and extracting with 10% aq. K2CO3 (3 × 5 mL). The aqueous layer was acidified to pH 1 
with conc. HCl and extracted with Et2O (3 × 10 mL). The combined organics were dried over MgSO4, 
filtered and concentrated in vacuo to provide the title compound for characterisation purposes; νmax / 
cm-1: 2930 (m), 1714 (s), 1449 (w), 1171 (s); 1H NMR (CDCl3, 400 MHz): δ 3.83 (1H, m, C2-H, B), 
3.64–3.59 (2H, m, 1 × C7-H2, A+B), 3.49 (1H, dd, J = 9.0, 5.5 Hz, C7-H2, B), 3.37 (1H, dd, J = 9.5, 
6.5 Hz, C7-H2, A), 3.34 (3H, s, C8-H3, B), 3.32 (3H, s, C8-H3, A), 2.99 (1H, m, C6-H2, A), 2.50 (1H, 
m, C2-H, A), 2.34 (1H, m, C6-H2, B), 2.17 (1H, m, C6-H2, B), 2.02–1.95 (2H, m, 1 × C3-H2, 1 × C6-H2, 
A), 1.89 (1H, m, C5-H2, B), 1.83–1.71 (4H, m, 1 × C3-H2 (B), 2 × C4-H2 (A), 1 × C5-H2 (B), 1.64–
1.53 (5H, m, 1 × C3-H2 (B), 1 × C4-H2 (B), 3 × C10-H3 (B)), 1.53–1.33 (11H, m, 1 × C3-H2 (A), 1 × 
C4-H2 (B), 6 × C10-H3 (A), 3 × C10-H3 (B)); 13C NMR (CDCl3, 100 MHz): δ 176.9 (C11, A), 176.6 
(C11, B), 81.4 (C9, B), 81.2 (C9, A), 73.6 (C7, B), 72.7 (C7, A), 59.0 (C8, B), 58.9 (C8, A), 42.7 (C2, 
A), 33.5 (C2, B), 30.5 (C3, A), 28.8 (C6, B), 27.0 (C3, B), 26.3 (C5, B), 26.1 (C5, A), 25.4 (C10, B), 
25.1 (C6, A), 24.4, 24.4 (C4 (A), C10 (A), C10 (A)), 22.9 (C10, B), 21.6 (C4, B); HRMS: (ESI+) 
Calculated for C12H22NO4: 244.1543. Found [M + H]+: 244.1540. 
 




Preliminary procedure for the removal of carboxylic acid oximes under photoredox catalysed 
conditions 
 
The procedure for the removal of carboxylic acid oximes under photoedox catalysed conditions was 
adapted from a literature procedure288: A flame-dried, 1.7 mL vial, equipped with a stir bar, was 
charged with IMes-Acr catalyst Acr-BF4 (2.0 mg, 0.005 mmol), sealed with a rubber septum and cooled 
to 0 °C before being purged with argon for 5 minutes. Carboxylic acid oxime 492 (27.0 mg, 
0.100 mmol) in anhydrous 1,2-DCE (0.5 mL), 2,6-lutidine (0.030 mL, 0.025 mmol) and thiophenol 
(0.020 mL, 0.020 mmol) were added by syringe. The stirring reaction was irradiated with two 15 W, 
royal blue, PAR38 LED floodlamps (Caution: the lamps were only turned on when suitably shaded so 
as to avoid shining the light into eyes) for 24 h at room temperature. The reaction mixture was 
concentrated in vacuo and analysed by 1H NMR where the product 403a was measured by integration 
to be in an approximately 1:1 molar ratio with starting material 492. 
Allyl(benzyl)dimethylsilane (516) 
 
Magnesium ribbon (2.92 g, 120 mmol) was added to a flame-dried three-necked flask fitted with a 
250 mL dropping funnel, rubber septum and attached to a Schlenk line. The flask was evacuated and 
refilled with nitrogen three times before the addition of dry Et2O (44 mL) and a crystal of iodine. The 
suspension was stirred until colourless and then benzylchloride (2.90 mL, 120 mmol) in Et2O (100 mL) 
was added dropwise at such a rate as to maintain reflux. Meanwhile, allylchlorodimethylsilane 
(11.2 mL, 74.0 mmol) and Et2O (200 mL) were added to a separate flask under argon, which was cooled 
to 0 °C. The  benzylmagnesium chloride solution was transferred to the silane solution by canula over 
5 minutes. The reaction mixture was warmed to room temperature then heated at reflux for 5 h. The 
reaction was cooled to room temperature then quenched by the addition of sat. aq. NH4Cl (100 mL). 
The aqueous layer was extracted with Et2O (3 × 100 mL) and the combined organics were dried over 
MgSO4, filtered and concentrated in vacuo. FCC (Hexane) provided the title compound (10.6 g, 75%) 




as a colourless oil; 1H NMR (CDCl3, 400 MHz): δ 7.22 (2H, dd, J = 7.5, 7.5 Hz, C8-H), 7.08 (1H, t, J 
= 7.5 Hz, C9-H), 7.00 (2H, d, J = 7.5 Hz, C7-H), 5.77 (1H, m, C2-H), 4.87 (1H, m, 1 × C1-H2), 4.84 
(1H, m, 1 × C1-H2), 2.11 (2H, s, C5-H2), 1.53 (2H, m, C3-H2), 0.02 (6H, s, C4-H3); 13C NMR (CDCl3, 
100 MHz): δ 140.1 (C6), 134.8 (C2), 128.3, 128.3 (C7, C8), 124.1 (C9), 113.4 (C1), 25.2 (C5), 22.9 
C3), -3.9 (C4). The spectroscopic properties of this compound were consistent with the data available 
in the literature364 
Ethyl (1R*,2R*)-2-((benzyldimethylsilyl)methyl)cyclopropane-1-carboxylate (519) 
 
Allylsilane 516 (10.6 g, 55.8 mmol) in CH2Cl2 (56 mL, 1.0 M) was added to a flask containing 
Rh2(OAc)4 (246 mg, 0.558 mmol) under argon. Ethyl diazoacetate (8.80 mL, 83.7 mmol) in CH2Cl2 
(8.80 mL) was added dropwise over 14 h. The resulting solution was concentrated in vacuo. FCC (4–
6% EtOAc/hexane) provided the title compound (8.87 g, 57%, 5:2 d.r., A:B) as a pale orange oil; νmax / 
cm-1: 2956 (w), 1722 (s), 1493 (m), 1248 9m), 1193 (m), 1162 (s), 837 (s); 1H NMR (CDCl3, 400 MHz): 
Some signals for the minor diastereomer B could not be assigned: δ 7.23–7.20 (4H, m, C10-H, A+B), 
7.10–7.05 (2H, m, C11-H, A+B), 7.02–6.98 (4H, m, C9-H, A+B), 4.17–4.09 (4H, m, C12-H2, A+B), 
2.13–2.12 (4H, m, C7-H2, A+B), 1.30–1.19 (9H, m, 1 × C2-H (A), 1 × C3-H2 (A), 1 × C4-H (A), 6 × 
C13-H3 (A+B), 1.04 (1H, m, C3-H2, B), 0.87–0.82 (3H, m, 1 × C3-H2 (B), 2 × C5-H2 (B)), 0.77 (1H, 
dd, J = 14.5, 5.0 Hz, C5-H2, A), 0.63 (1H, m, C3-H2, A), 0.44 (1H, dd, J = 14.5, 7.5 Hz, C5-H2, A); 13C 
NMR (CDCl3, 100 MHz): δ 174.6 (C1, A), 173.1 (C1, B), 140.2 (C8, B), 140.0 (C8, A), 128.3, (C10, 
A), 128.3 (C10, B), 128.2 (C9, B), 128.2 (C9, A), 124.2 (C11, A), 124.1 (C11, B), 60.4 (C12, A), 60.3 
(C12, B), 25.6, 25.6 (C7, A+B), 22.3 (C4, A), 19.2 (C5, A), 19.1 (C4, B), 18.9 (C2, A), 17.7 (C2, B), 
17.4 (C3, A), 15.0 (C3, B), 14.5 (C13, B), 14.5 (C13, A), 12.4 (C5, B), -3.3 (C6, A), -3.4 (C6, A), -3.4 
(C6, B), -3.5 (C6, B); HRMS: (ESI+) Calculated for C16H24NaO2Si: 299.1438. Found [M + Na]+: 
299.1441. 
(1R*,2R*)-2-((Benzyldimethylsilyl)methyl)cyclopropane-1-carboxylic acid (520) 
 
Ethyl ester 519 (6.39 g, 23.1 mmol) was dissolved in MeOH (56 mL) and 4 M aq. NaOH (29 mL, 
116 mmol). The reaction was heated at reflux for 2 h at which point it was complete by TLC. MeOH 
was removed in vacuo and the aqueous phase was washed with Et2O (30 mL). The aqueous phase was 




acidified with conc. HCl and extracted with Et2O (3 × 30 mL). The combined organic extracts were 
dried over MgSO4, filtered and concentrated in vacuo to provide the title compound (971 mg, 99%, 
5:2 d.r., A:B) as a pale yellow oil; νmax / cm-1: 3300 (br.), 2959 (w), 1688 (s), 1450 (m), 1231 (m), 837 
(s); 1H NMR (CDCl3, 400 MHz): δ 7.23–7.19 (4H, m, C10-H, A+B), 7.09–7.05 (2H, m, C11-H, A+B), 
7.01–6.98 (4H, m, C9-H, A+B), 2.14–2.12 (4H, s, C7-H2, A+B), 1.68 (1H, m, 1 × C4-H, B), 1.41–1.25 
(4H, m, 2 × C2-H (A+B), 1 × C3-H2 (A), 1 × C4-H (A)), 1.12 (1H, m, 1 × C3-H2, B), 0.91–0.77 (4H, 
m, 1 × C3-H2 (B), 1 × C5-H2 (A), 2 × C5-H2 (B)), 0.72 (1H, m, C3-H2, A), 0.43 (1H, dd, J = 14.5, 8.5 
Hz, C5-H2, A), 0.05 (3H, s, C6-H3, A), 0.04 (3H, s, C6-H3, A), 0.02 (3H, s, C6-H3, B), 0.02 (3H, s, 
C6-H3, B); 13C NMR (CDCl3, 100 MHz): δ 181.1 (C1, A), 179.8 (C1, B), 140.1 (C8, B), 139.9 (C8, A), 
128.4, (C10, A), 128.3 (C10, B), 128.2 (C9, B), 128.2 (C9, A), 124.2 (C11, A), 124.1 (C11, B), 25.7 
(C7, B), 25.6 (C7, A), 22.1 (C2, A), 20.2 (C4, A), 19.3 (C5, A), 19.2, 19.1 (C2, C4, B), 18.4 (C3, A), 
16.0 (C3, B), 12.4 (C5, B), -3.31- -3.37 (4 × C6, A+B); HRMS: (ESI+) Calculated for C14H20NaO2Si: 
271.1125. Found [M + Na]+: 271.1138. 
tert-Butyl ((1R*,2R*)-2-((benzyldimethylsilyl)methyl)cyclopropyl)carbamate (521) 
 
General Procedure D: Carboxylic acid 520 (7.44 g, 30.0 mmol, 5:2 d.r.) was employed and the 
reaction was heated for 72 h. FCC (10% EtOAc/hexane) provided the major diastereomer (4.98 g, 67%) 
of title compound as a colourless oil and the minor diastereomer (2.15 g, 29%) as a colourless oil; Note: 
The two diastereomers could be separated at this point by FCC (10% Et2O/hexane) but were typically 
carried on as a mixture to aid material throughput;  Data for the trans-diastereomer trans-521: νmax 
/ cm-1: 3333 (br.), 2975 (w), 1703 (s), 1493 (m), 1366 (m), 1248 (s), 1169 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.20 (2H, m, C9-H), 7.06 (1H, m, C10-H), 6.99 (2H, d, J = 7.5 Hz, C8-H), 4.60 (1H, br. 
s, NH), 2.17 (1H, br. m, C1-H), 2.12 (2H, s, C6-H2), 1.44 (9H, s, C13-H3), 0.81 (1H, dd, J = 14.5, 
5.5 Hz, C4-H2), 0.71 (1H, br. m, C3-H), 0.64 (1H, m, C2-H2), 0.42 (1H, m, C2-H2), 0.30 (1H, br. m, 
C4-H2), 0.02 (3H, s, C5-H3), 0.01 (3H, s, C5-H3); 13C NMR (CDCl3, 100 MHz): δ 156.6 (C11), 140.3 
(C7), 128.3 (C9), 128.2 (C8), 124.1 (C10), 79.4 (C12), 31.0 (C1), 28.5 (C13), 25.8 (C6), 18.3 (C4), 
16.1 (C2), 15.9 (C3), -3.2 (C5), -3.3 (C5); HRMS: (ESI+) Calculated for C18H29NNaO2Si: 342.1860. 
Found [M + Na]+: 342.1853; Data for the cis-diastereomer cis-521: νmax / cm-1: 3318 (br.), 2975 (w), 
1700 (s), 1493 (s), 1365 (m), 1248 (m), 1169 (s); 1H NMR (CDCl3, 400 MHz): δ 7.20 (2H, m, C9-H), 
7.06 (1H, t, J = 7.5 Hz, C10-H), 7.00 (2H, m, C8-H), 4.53 (1H, br. s, NH), 2.53 (1H, m, C1-H), 2.13 
(2H, s, C6-H2), 1.46 (9H, s, C13-H3), 0.91–0.77 (3H, m, 1 × C2-H2, 1 × C3-H, 1 × C4-H2), 0.24 (1H, 
dd, J = 15.0, 11.0 Hz, C4-H2), 0.03 (3H, s, C5-H3), 0.02 (3H, s, C5-H3), -0.01 (1H, m, 1 × C2-H2); 13C 
NMR (CDCl3, 100 MHz): δ 157.0 (C11), 140.2 (C7), 128.3 (C9), 128.2 (C8), 124.1 (C10), 79.4 (C12), 




28.5 (C13), 27.3 (C1), 25.8 (C6), 13.9 (C2), 12.7 (C3), 12.5 (C4), -3.2 (C5), -3.3 (C5); HRMS: (ESI+) 
Calculated for C18H29NNaO2Si: 342.1860. Found [M + Na]+: 342.1869. 
tert-Butyl ((1R*,2R*)-2-((benzyldimethylsilyl)methyl)cyclopropyl)(methyl)carbamate (trans-522) 
 
General Procedure G: Carbamate trans-521 (4.98 g, 15.6 mmol) was employed in THF using NaH 
(300 mol%) and MeI (500 mol%). The reaction was run for 3 h at 50 °C. FCC (6% EtOAc/hexane) 
provided the title compound (4.43 g, 85%) as a colourless oil. Note: This reaction was typically carried 
out as a mixture of diastereomers to aid material throughput; νmax / cm-1: 2973 (w), 1697 (s), 1364 (s), 
1152 (s), 837 (m); 1H NMR (CDCl3, 400 MHz): δ 7.20 (2H, m, C9-H), 7.06 (1H, m, C10-H), 6.99 (2H, 
m, C8-H), 2.76 (3H, s, C11-H3), 2.14–2.08 (3H, m, C1-H, 2 × C6-H2), 1.44 (9H, s, C14-H3), 1.06 (1H, 
dd, J = 14.5, 4.0 Hz, C4-H2), 0.85 (1H, m, C3-H), 0.75 (1H, m, C2-H2), 0.42 (1H, m, C2-H2), 0.11 (1H, 
dd, J = 14.5, 11.5 Hz, C4-H2), 0.03 (3H, s, C5-H3), 0.02 (3H, s, C5-H3); 13C NMR (CDCl3, 100 MHz): 
δ 157.1 (C12), 140.2 (C7), 128.3 (C9), 128.2 (C8), 124.1 (C10), 79.3 (C13), 38.6 (C1), 34.5 (C11), 28.7 
(C14), 25.6 (C6), 18.5 (C4), 17.6 (C1), 16.4 (C2), -3.8 (C5), -3.2 (C5); HRMS: (ESI+) Calculated for 
C19H31NNaO2Si: 356.2016. Found [M + Na]+: 356.2022. 
tert-Butyl ((1R*,2S*)-2-((benzyldimethylsilyl)methyl)cyclopropyl)(methyl)carbamate (cis-522) 
 
General Procedure G: Carbamate cis-521 (2.14 g, 6.70 mmol) was employed in THF using NaH 
(1.40 g, 33.5 mmol) and MeI (4.17 mL, 67.0 mmol). The reaction was run for 72 h at 50 °C. FCC (10% 
EtOAc/hexane) provided the title compound (1.71 g, 77%) as a pale yellow oil; νmax / cm-1: 2973 (w), 
1697 (s), 1363 (s), 1248 (m), 1152 (s); 1H NMR (CDCl3, 400 MHz): δ 7.20 (2H, m, C9-H), 7.06 (1H, 
m, C10-H), 6.99 (2H, m, C8-H), 2.82 (3H, s, C11-H3), 2.52 (1H, m, C1-H), 2.13 (2H, m, C6-H2), 1.45 
(9H, s, C14-H3), 1.00–0.84 (3H, m, 1 × C2-H2, 1 × C3-H, 1 × C4-H2), 0.15 (1H, m, C2-H2), 0.07–0.01 
(7H, m, 1 × C4-H2, 6 × C6-H3); 13C NMR (CDCl3, 100 MHz): δ 157.7 (C12), 140.3 (C7), 128.3 (C9), 
128.2 (C8), 124.1 (C10), 79.3 (C13), 35.7 (C11), 35.3 (C1), 28.5 (C14), 25.6 (C6), 15.2 (C3), 13.3 (C2), 
13.0 (C4), -3.1 (C6), -3.3 (C6); HRMS: (ESI+) Calculated for C19H31NNaO2Si: 356.2016. Found [M + 
Na]+: 356.2027. 
 






General Procedure H: Carbamate trans-522 (2.62 g, 7.85 mmol) was employed. FCC (40% 
EtOAc/hexane) provided the title compound (2.06 g, 92%) as a golden oil; νmax / cm-1: 2954 (w), 1656 
(s), 1616 (m), 1400 (m), 1248 (m), 839 (s); 1H NMR (CDCl3, 400 MHz): δ 7.21 (2H, m, C9-H), 7.08 
(1H, t, J = 7.5 Hz, C10-H), 6.99 (2H, m, C8-H), 6.80 (1H, dd, J = 17.0, 10.5 Hz, C13-H), 6.33 (1H, dd, 
J = 17.0, 2.0 Hz, C14-Ha), 5.65 (1H, dd, J = 10.5, 2.0 Hz, C14-Hb), 2.93 (3H, s, C11-H3), 2.36 (1H, m, 
C1-H), 2.13 (2H, s, C6-H2), 1.08 (1H, dd, J = 14.5, 4.0 Hz, C4-H2), 0.99–0.87 (2H, m, 1 × C3-H, 1 × 
C2-H2), 0.59 (1H, m, C2-H2), 0.14 (1H, dd, J = 14.5, 10.0 Hz, C2-H2), 0.05 (3H, s, C6-H3),0.03 (3H, s, 
C6-H3); 13C NMR (CDCl3, 100 MHz): δ 168.2 (C12), 139.9 (C7), 129.1 (C13), 128.4 (C9), 128.2 (C8), 
127.2 (C14), 124.3 (C10), 39.1 (C1), 34.1 (C11), 25.8 (C6), 18.7 (C3), 18.1 (C4), 17.5 (C2), -3.1 (C5), 
-3.2 (C5); HRMS: (ESI+) Calculated for C17H26NOSi: 288.1778. Found [M + H]+: 288.1786. 
N-((1R*,2S*)-2-((Benzyldimethylsilyl)methyl)cyclopropyl)-N-methylacrylamide (cis-517)  
 
General Procedure H: Carbamate cis-522 (1.71 g, 5.11 mmol) was employed. FCC (55% 
EtOAc/hexane) provided the title compound (1.27 g, 86%) as a pale yellow oil; νmax / cm-1: 2958 (w), 
1655 (s), 1614 (m), 1399 (m), 1248 (m), 839 (s); 1H NMR (CDCl3, 400 MHz): δ 7.20 (2H, m, C9-H), 
7.06 (1H, m, C10-H), 6.97 (2H, m, C8-H), 6.80 (1H, dd, J = 17.0, 10.5 Hz, C13-H), 6.39 (1H, dd, J = 
17.0, 2.0 Hz, C14-H2), 5.65 (1H, dd, J = 10.5, 2.0 Hz, C14-H2), 2.97 (3H, s, C11-H3), 2.77 (1H, m, 
C1-H), 2.11 (2H, m, C6-H2), 1.10–0.95 (2H, m, 1 × C2-H2, 1 × C3-H), 0.89 (1H, d, J = 14.5 Hz, C4-H2), 
0.31 (1H, m, C2-H2), 0.03 (3H, s, C5-H3), 0.01 (3H, s, C5-H3), -0.05 (1H, dd, J = 14.5, 12.0 Hz, C4-H2); 
13C NMR (CDCl3, 100 MHz): δ 168.8 (C12), 139.9 (C7), 128.8 (C13), 128.3 (C9), 128.2 (C8), 127.6 
(C14), 124.2 (C10), 35.5 (C1), 35.1 (C11), 25.7 (C6), 16.6 (C3), 14.4 (C2), 13.6 (C4), -3.1 (C5), -3.3 











General Procedure I for the (7+1) carbonylative cycloaddition of trans-517: (Screening conditions 
for optimum yield) Acrylamide (28.7 mg, 0.10 mmol), [Rh(cod)2]OTf (3.5 mg, 0.0075 mmol), 
As(PPh3)3 (4.6 mg, 0.015 mmol) and fumaric acid (5.8 mg, 0.050 mmol) were employed, and the 
reaction was  heated at 140 °C for 48 h. 1H NMR analysis of the crude reaction mixture against 1,4-
DNB as an internal standard indicated formation of the title compound (35%).  
General Procedure I for the (7+1) carbonylative cycloaddition of trans-517: (Multi-mmol scale 
reaction for material throughput) Acrylamide (1.14 g, 3.96 mmol), [Rh(cod)2]OTf (139 mg, 
0.30 mmol), As(PPh3)3 (182 mg, 0.59 mmol) and fumaric acid (230 mg, 1.98 mmol) were employed, 
and the reaction was heated at 140 °C for 48 h. FCC (30% EtOAc/hexane) was followed by further FCC 
(30% Et2O/hexane) to provide the title compound as an orange oil indicating the presence of residual 
rhodium. The crude product was treated with a single drop of DMSO and purified by FCC (10% 
EtOAc/CH2Cl2) to provide the title compound (387 mg, 31%) as a light yellow oil; νmax / cm-1: 2955 
(w), 1710 (s), 1656 (s), 1379 (m), 833 (m); 1H NMR (CDCl3, 400 MHz): δ 7.20 (2H, m, C14-H), 7.07 
(1H, m, C15-H), 6.95 (2H, m, C13-H), 6.10 (1H, dd, J = 7.5, 1.0 Hz, C7-H), 5.08 (1H, dd, J = 9.0, 
7.5 Hz, C6-H), 3.41 (1H, m, C5-H), 3.07 (3H, s, C8-H3), 2.74 (1H, ddd, J = 13.5, 12.0, 1.5 Hz, 1 × 
C2-H2), 2.63 (1H, m, 1 × C3-H2), 2.54 (1H, m, 1 × C2-H2), 2.45 (1H, m, 1 × C3-H2), 2.04 (2H, s, 
C11-H2), 1.08 (1H, dd, J = 15.0, 6.0 Hz, 1 × C11-H2), 0.83 (1H, dd, J = 15.0, 8.0 Hz, 1 × C11-H2), -0.07 
(3H, s, C10-H3), -0.07 (3H, s, C10-H3); 13C NMR (CDCl3, 100 MHz): δ 207.8 (C4), 172.9 (C1), 139.6 
(C12), 131.5 (C7), 128.4, 128.2 (C13, C14), 127.0 (C6), 124.4 (C15), 45.4 (C5), 38.8 (C3), 34.0 (C8), 
32.8 (C2), 26.1 (C11), 15.6 (C9), -2.6, -2.9 (C10, C10); HRMS: (ESI+) Calculated for C18H25NNaO2Si: 
338.1547. Found [M + Na]+: 338.1542. 
 




General Procedure I for the (7+1) carbonylative cycloaddition of cis-517: Acrylamide (144 mg, 
0.50 mmol), [Rh(cod)2]OTf (17.6 mg, 0.0375 mmol), As(PPh3)3 (23.0 mg, 0.0375 mmol) and fumaric 
acid (29.2 mg, 0.25 mmol) were employed, and the reaction was  heated at 140 °C for 48 h. 1H NMR 
analysis of the crude reaction mixture against 1,4-DNB as an internal standard indicated formation of 
the title compound (30% yield).  
(Z)-6-(Hydroxymethyl)-1-methyl-1,3,4,6-tetrahydroazocine-2,5-dione (526)  
 
TBAF (0.16 mL, 0.160 mmol) was added to a stirring solution of silane 518 (34 mg, 0.055 mmol) in 
THF (0.2 mL) at 0 °C. Upon consumption of silane 518, as determined by TLC, MeOH (0.18 mL), aq. 
30% H2O2 (0.088 mL) and KHCO3 (11 mg, 0.110 mmol) were added. The reaction was stirred for 
30 minutes before being diluted with water (1 mL) and extracted with EtOAc (5 × 1.5 mL). The 
combined organics were dried over MgSO4, filtered and concentrated in vacuo. FCC (90% 
EtOAc/hexane) provided the title compound (10 mg, 50%) as a colourless oil; νmax / cm-1: 3300 (br.), 
2960 (s), 2932 (s), 2874 (s), 1708 (m), 1643 (s), 1462 (s), 1381 (s); 1H NMR (CDCl3, 400 MHz): δ 6.28 
(1H, dd, J = 7.5, 1.0 Hz, C7-H), 5.45 (1H, dd, J = 8.5, 7.5 Hz, C6-H), 3.80–3.79 (2H, m, C9-H2), 3.55 
(1H, m, C5-H), 3.08 (3H, s, C8-H3), 2.84–2.72 (2H, m, 1 × C2-H2, 1 × C3-H2), 2.60–2.48 (2H, m, 1 × 
C2-H2, 1 × C3-H2); 13C NMR (CDCl3, 100 MHz): δ 208.7 (C4), 172.6 (C1), 133.7 (C7), 120.2 (C6), 
61.8 (C9), 51.3 (C5), 39.3 (C2/3), 33.9 (C8), 32.2 (C2/3); HRMS: (ESI+) Calculated for C9H14NO3: 
184.0968. Found [M + H]+: 184.0975. 
(E)-6-((Benzyldimethylsilyl)methyl)-1-methyl-1,3,4,8-tetrahydroazocine-2,5-dione (528)  
 
General Procedure J: Enamide 518 (96.2 mg, 0.30 mmol) was employed. FCC (35% EtOAc/hexane) 
provided ketone (94.0 mg, 68%) as a colourless oil. The intermediate -bromide was not characterised 
at this point. General Procedure K: Bromoketone 527 (23.1 mg, 0.058 mmol) and DBU (0.043 mL, 
0.29 mmol) were employed. The reaction was quenched after approximately 30 minutes. FCC (90% 




EtOAc/hexane) provided the title compound (10.3 mg, 56%) as a pale yellow oil; νmax / cm-1: 2959 (w), 
1681 (m), 1642 (s), 1246 (s), 1057 (s), 831 (s); 1H NMR (CDCl3, 400 MHz): δ 7.21 (2H, m, C14-H), 
7.08 (1H, m, C15-H), 6.98 (2H, m, C13-H), 5.73 (1H, t, J = 6.5 Hz, C6-H), 3.88 (2H, d, J = 6.5 Hz, 
C7-H2), 2.91 (3H, s, C8-H3), 2.84–2.78 (4H, m, C2-H2, C3-H2), 2.12 (2H, s, C11-H2), 1.67 (2H, s, 
C9-H2); 13C NMR (CDCl3, 100 MHz): δ 206.7 (C4), 172.4 (C1), 144.8 (C5), 139.6 (C12), 128.4 (C14), 
128.3 (C13), 124.4 (C15), 124.2 (C6), 48.9 (C7), 41.8 (C2/3), 35.2 (C8), 32.1 (C2/3), 25.9 (C11), 23.0 
(C9), -3.0 (C10); HRMS: (ESI+) Calculated for C18H25NNaO2Si: 338.1547. Found [M + Na]+: 338.1554. 
1-Methyl-6-methyleneazocane-2,5-dione (530)  
 
TBAF (0.16 mL, 0.16 mmol) was added to a stirring solution of silane 528 (10.3 mg, 0.033 mmol) in 
THF (0.11 mL) at 0 °C. Upon consumption of silane 528, as determined by TLC, MeOH (0.066 mL), 
aq. 30% H2O2 (0.053 mL) and KHCO3 (9.9 mg, 0.099 mmol) were added. The reaction was stirred for 
30 minutes before being diluted with water (1 mL) and extracted with EtOAc (5 × 1.5 mL). The 
combined organics were dried over MgSO4, filtered and concentrated in vacuo. No further purification 
was carried out. The reaction provided a mixture of several species resulting from proto-desilylation, 
which were not identified; νmax / cm-1: 2924 (m), 2858 (w), 1694 (s), 1633 (s), 1398 (m), 1156 (m); 1H 
NMR (CDCl3, 400 MHz): δ 5.26 (1H, s, 1 × C9-H2), 5.21 (1H, s, 1 × C9-H2), 3.47 (2H, t, J = 6.0 Hz, 
C7-H2), 2.90 (3H, s, C8-H3), 2.88 (2H, m, C3-H2), 2.71 (2H, m, C2-H2), 2.56 (2H, t, J = 6.0 Hz, C6-H2); 
13C NMR (CDCl3, 100 MHz): δ 209.0 (C4), 172.8 (C1), 148.0 (C5), 116.9 (C9), 48.7 (C7), 43.2 (C3), 
33.6 (C8), 33.6 (C6), 31.6 (C2); HRMS: (ESI+) Calculated for C9H14NO2: 168.1019. Found [M + H]+: 
168.1021. 
(Z)-6-((Benzyldimethylsilyl)methyl)-4-((tert-butyldimethylsilyl)oxy)-1-methyl-1,3,4,6-
tetrahydroazocine-2,5-dione (535a) and (Z)-6-((Benzyldimethylsilyl)methyl)-1-methyl-2,5-dioxo-
1,2,3,4,5,6-hexahydroazocin-4-yl 3-chlorobenzoate (536) 
 




Freshly prepared LDA (0.96 mL, 0.5 M, 0.48 mmol), DMPU (0.058 mL, 0.48 mmol) and THF (1.6 mL 
mL) were added to a flame-dried flask fitted with a septum under an atmosphere of argon. The mixture 
was cooled to -78 °C before the addition of ketone 518 (100 mg, 0.31 mmol) in THF (1 mL) over 
1 minute. After 15 minutes, TBSCl (140 mg, 0.93 mmol) in THF (1 mL) was added and the reaction 
was warmed to room temperature. After 3 h the reaction was quenched with water (5 mL). The aqueous 
phase was extracted with EtOAc (3 × 5 mL) and the combined organics were dried over MgSO4 and 
concentrated in vacuo.  The crude silyl enol ether was carried through to the Rubottom oxidation step 
without further purification. NaHCO3 (29 mg, 0.35 mmol) was added to a flame-dried reaction tube 
which was sealed and purged with argon. Crude silyl enol ether 534a (presumed 100% yield in the 
previous step, 0.31 mmol) in CH2Cl2 (3.1 mL) was added by syringe and the reaction mixture was 
cooled to 0 °C. m-CPBA (60.0 mg, 0.35 mmol) in CH2Cl2 (1.0 mL) was then added by syringe in one 
portion. The reaction was stirred for 45 minutes before being diluted with CH2Cl2 (5 mL) and washed 
with sat. aq. NaHCO3 (5 mL) and brine (5 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo to provide a mixture of the title compound 535a and a hemiacetal intermediate. 
The crude product mixture was dissolved in CH2Cl2 (2 mL) and treated with DBU (0.046 mL, 
0.031 mmol). The reaction was stirred for 15 minutes before being concentrated in vacuo and purified 
by FCC (30% EtOAc/hexane) to provide the title compounds 535a and 536 (57 mg, 41%, 1:1 535a:536) 
as a colourless oil; Analytical samples of 535a and 536 were obtained by further FCC (30% 
EtOAc/hexane); Data for the TBS-ether 535a: The relative stereochemistry of product 535a was not 
determined; νmax / cm-1: 2927 (m), 2860 (m), 1731 (m), 1658 (s), 1378 (m), 1250 (s), 1144 (s), 836 (s); 
1H NMR (CDCl3, 400 MHz): δ 7.21 (2H, m, C14-H), 7.08 (1H, m, C15-H), 6.95 (2H, d, J = 8.0 Hz, 
C13-H), 6.06 (1H, dd, J = 7.0, 1.0 Hz, C7-H), 5.16 (1H, dd, J = 9.0, 7.0 Hz, C6-H), 4.42 (1H, dd, J = 
12.0, 3.5 Hz, C3-H), 3.38 (1H, m, C5-H), 3.08 (4H, m, 1 × C2-H2, C8-H3), 2.63 (1H, dd, J = 12.0, 
3.5 Hz, 1 × C2-H2), 2,.03 (2H, s, C11-H2), 1.03 (1H, dd, J = 15.0, 6.0 Hz, C9-H2), 0.93–0.90 (10H, m, 
1 × C9-H2, 9 × C18-H3), 0.15 (3H, s, C16-H3), 0.06 (3H, s, C16-H3), -0.07 (3H, s, C10-H3), -0.07 (3H, 
s, C10-H3); 13C NMR (CDCl3, 100 MHz): δ 206.3 (C4), 170.9 (C1), 139.5 (C12), 131.2 (C7), 128.5 
(C14), 128.1 (C13), 127.7 (C6), 124.4 (C15), 73.9 (C3), 43.4 (C2), 42.4 (C5), 34.0 (C8), 26.0 (C11), 
25.9 (C18), 18.6 (C17), 16.0 (C9), -2.6 (C10), -2.8 (C10), -4.5 (C16), -5.3 (C16); HRMS: (ESI+) 
Calculated for C24H39NNaO3Si2: 468.2361. Found [M + Na]+: 468.2354; Data for the benzoate ester 
536: The relative stereochemistry of product 536 was not determined; νmax / cm-1: 2928 (w), 1724 (s), 
1659 (s), 1644 (s), 1380 (m), 1290 (s), 1251 (s); 1H NMR (CDCl3, 400 MHz): δ 8.02 (1H, m, C18-H), 
7.93 (1H, d, J = 8.0 Hz, C22-H), 7.55 (1H, d, J = 8.0 Hz, C20-H), 7.39 (1H, dd, J = 8.0, 8.0 Hz, C21-H), 
7.23 (2H, m, C14-H), 7.09 (1H, m, C15-H), 6.98 (2H, d, J = 8.0 Hz, C13-H), 6.11 (1H, d, J = 7.5 Hz, 
C7-H), 5.58 (1H, dd, J = 13.0, 3.0 Hz, C3-H), 5.21 (1H, dd, J = 9.0, 7.5 Hz, C6-H), 3.47 (1H, m, C5-H), 
3.26 (1H, dd, J = 12.5, 12.0 Hz, 1 × C2-H2), 3.10 (3H, s, C8-H3), 2.85 (1H, dd, J = 12.0, 3.0 Hz, 1 × 
C2-H2), 2.07 (2H, s, C11-H2), 1.14 (1H, dd, J = 15.0, 6.5 Hz, C9-H2), 0.91 (1H, dd, J = 15.0, 8.0 Hz, 
C9-H2), -0.01 (3H, s, C10-H3), -0.02 (3H, s, C10-H3); 13C NMR (CDCl3, 100 MHz): δ 201.4 (C4), 169.3 




(C1), 164.1 (C16), 139.5 (C12), 134.6 (C17/19), 133.5 (C20), 131.3 (C7), 131.2 (C17/19), 130.0 (C18), 
129.9 (C21), 128.5 (C14), 128.1, 128.1 (C13, C22), 127.8 (C6), 124.5 (C15), 74.3 (C3), 42.7 (C5), 38.9 
(C2), 34.3 (C8), 26.1 (C11), 15.9 (C9), -2.6 (C10), -2.9 (C10); HRMS: (ESI+) Calculated for 




Ketone 518 (691 mg, 2.19 mmol) was added to a flame-dried flask equipped with a magnetic stir bar 
which was sealed with a rubber septum and purged with argon. Dry THF (22 mL, 0.1 M) was added 
and the solution was cooled to -78 °C. Freshly distilled (Hickman still) TMSCl (0.83 mL, 6.57 mmol) 
was then added. In a separate flame-dried flask under an atmosphere of argon, n-BuLi (3.1 mL, 5 mmol, 
1.6 M Hex) was added to a solution of diisopropylamine (0.71 mL, 5.0 mmol) in dry THF (6.2 mL) at 
0 °C, over 5 minutes. One equivalent of the freshly prepared LDA solution (4.38 mL, 2.19 mmol, 0.5 M 
THF) was added to the ketone solution by syringe over 5 minutes. Further LDA solution (typically 
0.5 eq.) was then added in 0.1 eq. portions until a suitable end point has been reached as judged by TLC 
(Note: A non-polar side-product begins to form before complete consumption of the starting ketone. 
Therefore, the end point of the reaction is at a time when the starting ketone and unwanted non-polar 
sideproduct are at a minimum). The completed reaction mixture was then transferred by syringe to a 
stirring solution of sat. aq. NaHCO3 (100 mL). The aqueous layer was extracted with Et2O (3 × 50 mL) 
and the combined organics are dried over MgSO4, filtered and concentrated in vacuo. The crude product 
was carried through to the next step without further purification due to the instability of the silyl enol 
ether on silica gel; νmax / cm-1: 2954 (w), 1660 (s), 1375 (m), 1251 (s), 842 (s); 1H NMR (CDCl3, 
400 MHz): δ 7.20 (2H, m, C14-H), 7.06 (1H, m, C15-H), 6.97 (2H, d, J = 7.5 Hz, C13-H), 6.11 (1H, d, 
J = 7.5 Hz, C7-H), 5.06 (1H, dd, J = 9.0, 7.5 Hz, C6-H), 4.88 (1H, m, C3-H), 3.09–2.99 (2H, m, 1 × 
C2-H2, C5-H), 2.96–2.91 (4H, m, 1 × C2-H2, C8-H3), 2.07 (2H, s, C11-H2), 1.10 (1H, dd, J = 15.0, 
4.0 Hz, C9-H2), 0.66 (1H, dd, J = 15.0, 10.5 Hz, C9-H2), 0.17 (9H, s, C16-H3), -0.02 (3H, s, C10-
H3), -0.04 (3H, s, C10-H3); 13C NMR (CDCl3, 100 MHz): δ 170.3 (C1), 151.4 (C4), 140.0 (C12), 129.9 
(C7), 128.4 (C14), 128.2 (C13), 125.0 (C6), 124.2 (C15), 100.4 (C3), 36.2 (C5), 34.7 (C2), 33.0 (C8), 
26.3 (C11), 16.9 (C9), 0.3 (C16), -2.3 (C10), -3.0 (C10); HRMS: (ESI+) Calculated for C21H34NO2Si: 
388.3123. Found [M + H]+: 388.2123. 






4-yl 3-chlorobenzoate (536) 
 
The crude silyl enol ether 534b (assumed 100% yield, 1.37 mmol) was dissolved in CH2Cl2 (14 mL, 
0.1 M) and cooled to 0 °C. m-CPBA (353 mg, 1.58 mmol, >77% purity) was added in a single portion 
and the reaction mixture was warmed to room temperature. On consumption of the starting material as 
determined by TLC (typically 30 minutes) 10 wt% aq. Na2SO3 (10 mL) was added and the mixture was 
stirred for 10 minutes. The aqueous layer was extracted with CH2Cl2 (3 × 10 mL) and the combined 
organics were dried over MgSO4, filtered and concentrated in vacuo. The crude product was redissolved 
in THF (10 mL) and hydrolysed by the addition of 1 M aq. HCl (10 mL) until consumption of the 
intermediate silyl ether (typically 15 minutes) as determined by TLC. The aqueous layer was extracted 
with Et2O (3 × 10 mL), dried over MgSO4, filtered and concentrated in vacuo. Purification by FCC 
(50% EtOAc/hexane) provided the title compound (274 mg, 1:1 d.r., 60%) as a yellow oil and the 
benzoate ester 536 (48 mg, 7%) as a pale yellow oil. Although the product diastereomers 535b are 
separable at this point, they were carried through as a mixture to the next step to facilitate material 
throughput; Data for the first diastereomer of 535b (A) to elute by FCC: The relative 
stereochemistry of product 535b was not determined; νmax / cm-1: 3445 (br.), 2922 (w), 1720 (m), 1657 
(s), 1642 (s), 1378 (m), 1249 (m); 1H NMR (CDCl3, 400 MHz): δ 7.22 (2H, m, C14-H), 7.09 (1H, m, 
C15-H), 6.95 (2H, d, J = 7.5 Hz, C13-H), 6.11 (1H, d, J = 7.5 Hz, C7-H), 5.15 (1H, dd, J = 8.5, 7.5 Hz, 
C6-H), 4.31 (1H, dd, J = 9.5, 4.5 Hz, C3-H), 3.64 (1H, s, OH), 3.44 (1H, m, C5-H), 3.06 (3H, s, C8-H3), 
2.84–2.76 (2H, m, C2-H2), 2.05 (2H, s, C11-H2), 1.10 (1H, dd, J = 15.0, 6.5 Hz, C9-H2), 0.95 (1H, dd, 
J = 15.0, 8.0 Hz, C9-H2), -0.05 (3H, s, C10-H3), -0.06 (3H, s, C10-H3); 13C NMR (CDCl3, 100 MHz): 
δ 209.1 (C4), 170.0 (C1), 139.4 (C12), 132.0 (C7), 128.5 (C14), 128.1 (C13), 126.8 (C6), 124.6 (C15), 
72.1 (C3), 42.3 (C5), 41.8 (C2), 34.2 (C8), 26.0 (C11), 15.7 (C9), -2.5 (C10), -2.8 (C10); HRMS: (ESI+) 
Calculated for C18H26NO3Si: 332.1676. Found [M + H]+: 332.1671; Data for the second diastereomer 
of 535b (B) to elute by FCC: The relative stereochemistry of product 535b was not determined; νmax / 
cm-1: 3341 (br.), 2922 (m), 1717 (m), 1633 (s), 1249 (m); 1H NMR (CDCl3, 400 MHz): δ 7.21 (2H, m, 
C14-H), 7.08 (1H, m, C15-H), 6.97 (2H, d, J = 7.5 Hz, C13-H), 6.02 (1H, d, J = 7.5 Hz, C7-H), 5.28 
(1H, dd, J = 8.0, 7.5 Hz, C6-H), 4.25 (1H, dd, J = 8.0, 1.5 Hz, C3-H), 3.75 (1H, m, C5-H), 3.54 (1H, s, 




OH), 3.04 (3H, s, C8-H3), 2.97 (1H, dd, J = 13.0, 1.5 Hz, C2-H2), 2.81 (1H, dd, J = 13.0, 8.0 Hz, C2-H), 
2.07 (2H, s, C11-H2), 1.15 (1H, dd, J = 15.0, 7.5 Hz, C9-H2), 0.84 (1H, m, C9-H2), -0.03 (6H, s, 
C10-H3); 13C NMR (CDCl3, 100 MHz): δ 208.2 (C4), 169.9 (C1), 139.6 (C12), 130.8 (C7), 129.5 (C6), 
128.5 (C14), 128.2 (C13), 124.4 (C15), 70.2 (C3), 41.1 (C5), 39.4 (C11), 34.4 (C8), 25.8 (C11), 16.1 
(C9), -2.9 (C10), -2.9 (C10); HRMS: (ESI+) Calculated for C18H25NNaO3Si: 354.1496. Found [M + 
Na]+: 354.1489; Data for the benzoate ester 536: The relative stereochemistry of product 536 was not 
determined; νmax / cm-1: 2958 (w), 1731 (s), 1660 (s), 1644 (s), 1380 (m), 1247 (s), 1088 (m); 1H NMR 
(CDCl3, 400 MHz): δ 8.02 (1H, s, C18-H), 7.96 (1H, d, J = 8.0 Hz, C20/22-H), 7.56 (1H, d, J = 8.0 Hz, 
C20/22-H), 7.40 (1H, dd, J = 8.0, 8.0 Hz, C21-H), 7.16 (2H, m, C14-H), 7.05 (1H, m, C15-H), 6.90 
(2H, d, J = 7.5 Hz, C13-H), 6.08 (1H, d, J = 7.5 Hz, C7-H), 5.31–5.27 (2H, m, C3-H, C6-H), 3.80 (1H, 
dt, J = 7.5, 7.5 Hz, C5-H), 3.18 (1H, dd, J = 13.5, 8.5 Hz, C2-H2), 3.08 (3H, s, C8-H3), 2.98 (1H, d, J = 
13.5 Hz, C2-H2), 2.03 (2H, s, C11-H2), 1.16 (1H, dd, J = 15.0, 6.5 Hz, C9-H2), 0.93 (1H, dd, J = 15.0, 
8.0 Hz, C9-H2), -0.08 (3H, s, C10-H3), -0.08 (3H, s, C10-H3); 13C NMR (CDCl3, 100 MHz): δ 203.8 
(C4), 167.7 (C1), 164.1 (C16), 139.4 (C12), 134.9 (C16/17), 133.8 (C20/22), 131.4 (C7), 130.1, 130.1 
(C18, C21), 128.7 (C6), 128.4 (C14), 128.2 (C20/22), 128.1 (C13), 124.4 (C15), 72.2 (C3), 41.9 (C5), 
36.9 (C2), 34.5 (C8), 25.8 (C11), 15.8 (C9), -3.0 (C10), -3.0 (C10); HRMS: (ESI+) Calculated for 




UHP (347 mg, 3.69 mmol) was added to a flame-dried flask equipped with a stir bar, which was sealed 
and purged with argon. Silane 535b (408 mg, 1.23 mmol) in dry THF (6.2 mL, 0.2 M) was added 
followed by TBAF (4.9 mL, 4.92 mmol, 1 M THF) over 10 minutes. The reaction mixture was stirred 
until consumption of the starting material as determined by TLC (10% MeOH/EtOAc). THF (6.2 mL) 
was then added followed by 10 wt% aq. Na2SO3 (5 mL). After 15 minutes solid NaCl was added in 
order to saturate the aqueous layer which was then extracted with CHCl3 (10 × 10 mL). At this point 
TLC suggested that a significant quantity of the product remained dissolved in the aqueous layer. The 
aqueous layer was concentrated in vacuo and filtered through a cotton plug washing with MeOH (5 × 
5 mL). The combined organics and filtrate were dried over MgSO4, filtered and concentrated in vacuo 
to provide the crude product and tetrabutylammonium salts. The crude mixture was redissolved in 




CH2Cl2 (12.4 mL, 0.1 M) before adding imidazole (836 mg, 12.3 mmol), DMAP (30 mg, 0.25 mmol) 
and TBSCl (926 mg, 6.15 mmol). On completion of the reaction as determined by complete 
consumption of the diol and mono-TBS intermediates by TLC, sat. aq. NaHCO3 (10 mL) was added. 
The aqueous layer was extracted with Et2O (3 × 20 mL) and the combined organics were dried over 
MgSO4, filtered and concentrate in vacuo. Purification by FCC (20% EtOAc/hexane) provided the title 
compound (155 mg, 29%, 6:1 d.r., A+B) as a colourless crystalline solid; Data for the 6:1 d.r. mixture 
of products: m.p. 82–84 °C (CH2Cl2); νmax / cm-1: 2928 (m), 2856 (m), 1736 (m), 1659 (s), 1379 (m), 
1252 (m), 1101 (s); HRMS: (ESI+) Calculated for C21H41NO4Si2: 428.2647. Found [M + H]+: 428.2656; 
Data for the major diastereomer of 539 (A): 1H NMR (CDCl3, 500 MHz): δ 6.14 (1H, d, J = 7.5 Hz, 
C7-H), 5.18 (1H, dd, J = 9.0, 7.5 Hz, C6-H), 4.49 (1H, dd, J = 12.0, 3.0 Hz, C3-H), 4.10 (1H, dd, J = 
9.0, 9.0 Hz, 1 × C9-H2), 3.59 (1H, m, C5-H), 3.54 (1H, dd, J = 9.0, 5.5 Hz, C9-H2), 3.06–3.02 (4H, m, 
1 × C2-H2, C8-H3), 2.64 (1H, dd, J = 12.0, 3.0 Hz, C2-H2), 0.90 (9H, s, C12-H3), 0.83 (9H, s, C12-H3), 
0.14 (3H, s, C10-H3), 0.03 (3H, s, C10-H3), 0.02 (3H, s, C10-H3), 0.00 (3H, s, C10-H3); 13C NMR 
(CDCl3, 100 MHz): δ 204.7 (C4), 170.9 (C1), 132.9 (C7), 122.0 (C6), 74.5 (C3), 62.1 (C9), 49.5 (C5), 
43.2 (C2), 34.3 (C8), 25.9, 25.9 (C12), 18.6, 18.3 (C11), -4.5, -5.4, -5.4, -5.5 (C10); Data for the minor 
diastereomer of 539 (B): Characteristic signals only; 1H NMR (CDCl3, 500 MHz): δ 6.05 (1H, d, J = 




Enamide 539 (154 mg, 0.36 mmol) in CH2Cl2 (3.6 mL, 0.1 M) was added to a flame-dried flask 
containing NaHCO3 (91 mg, 1.08 mmol) under an atmosphere of argon. The suspension was cooled to 
0 °C. Bromine (~1.1 equivalent) was added dropwise by syringe until a brown colour persisted whereby 
2,3-dimethylbut-2-ene was added dropwise until the solution became colourless. THF (1.8 mL, 0.2 M) 
was then added followed by NaBH3CN (34 mg, 0.54 mmol). The suspension was warmed to room 
temperature and stirred for 30 minutes before being quenched with sat. aq. NH4Cl (10 mL). The aqueous 
layer was extracted with CH2Cl2 (3 × 10 mL) and the combined organics were dried over MgSO4, 
filtered and concentrated in vacuo. Purification by FCC (25% EtOAc/hexane) provided the intermediate 
hydrobromination products 540 (128 mg, 70%, mixture of diastereomers) as a colourless oil. The 
intermediate hydrobromination products were not characterised at this stage due to them being formed 




as a mixture of diastereomers and the broad nature of the 1H NMR signals. The hydrobromination 
products were dissolved in CH2Cl2 (2.5 mL, 0.1 M) and DBU (0.11 mL, 0.76 mmol) was added. The 
reaction was followed closely by TLC to minimise the amount of enamide formed due to isomerisation. 
The reaction was quenched by the addition of sat. aq. NH4Cl (10 mL) and the aqueous layer was 
extracted with CH2Cl2 (3 × 10 mL). The combined organics were dried over MgSO4, filtered and 
concentrated in vacuo. Purification by FCC (40% EtOAc/hexane) provided the title compound (35 mg, 
32% over 2 steps) as a colourless oil; νmax / cm-1: 2929 (m), 2856 (m), 1699 (m), 1658 (s), 1462 (m), 
1265 (s), 1085 (s); 1H NMR (CDCl3, 500 MHz): δ 6.02 (1H, m, C6-H), 4.44 (1H, dd, J = 8.0, 6.5 Hz, 
C3-H), 4.34–4.25 (2H, m, 1 × C7-H2, 1 × C9-H2), 4.18 (1H, m, C9-H2), 3.78 (1H, dd, J = 20.0, 6.5 Hz, 
C7-H2), 2.94–2.83 (5H, m, C2-H2, C8-H3), 0.91 (9H, s, C12-H3), 0.88 (9H, s, C12-H3), 0.09–0.06 (12H, 
m, C10-H3); 13C NMR (CDCl3, 100 MHz): δ 204.7 (C4), 170.2 (C1), 141.7 (C5), 123.5 (C6), 79.5 (C3), 
64.2 (C9), 50.9 (C7), 40.7 (C2), 35.8 (C8), 26.0, 25.8 (C12), 18.5, 18.3 (C11), -4.7, -4.8, -5.3, -5.3 
(C10); HRMS: (ESI+) Calculated for C21H42NO4Si2: 428.2647. Found [M + H]+: 428.2658. 
(5E,6Z)-1-Benzyl-6-methyl-1,3,4,8-tetrahydroazocin-5(2H)-one O-methyl oxime (541) 
 
BH3·THF (0.44 mL, 0.44 mmol) was added over 5 minutes to a stirring solution of amide 485 (60 mg, 
0.22 mmol) in anhydrous THF (2.2 mL) at -78 °C. TLC indicated the reaction was complete after 1.5 h. 
The reaction was quenched by the addition of sat. aq. NH4Cl (2 mL). The aqueous layer was extracted 
with Et2O (3 × 5 mL) and the combined organics were dried over MgSO4, filtered and concentrated in 
vacuo. FCC (10% EtOAc/hexane) provided the title compound (13 mg, 22%) as a colourless oil; νmax / 
cm-1: 2936 (w), 2379 (br. s), 2279 (w), 1453 (m), 1170 (s), 1034 (s); 1H NMR (CDCl3, 400 MHz): δ 
7.47 (2H, m, 2 × C12-H), 7.39–7.31 (3H, m, 2 × C13-H, C14-H), 5.73 (1H, t, J = 8.5 Hz, C6-H), 3.92–
3.76 (6H, m, 1 × C7-H2, 2 × C8-H2, 3 × C10-H3), 3.31 (1H, dd, J = 14.5, 8.5 Hz, 1 × C7-H2), 3.01 (1H, 
ddd, J = 14.0, 5.5, 5.5 Hz, 1 × C3-H2), 2.90–2.76 (2H, m, C1-H2), 2.51–2.28 (2H, m, 1 × C2-H2, 1 × 
C3-H2), 1.97 (3H, s, C9-H3), 1.76 (1H, m, 1 × C2-H2); 13C NMR (CDCl3, 100 MHz): δ 158.1 (C4), 
142.8 (C5), 133.0 (C12), 131.8 (C11), 129.0 (C14), 128.0 (C13), 121.7 (C6), 66.5 (C8), 62.0 (C10), 
56.3 (C1), 55.2 (C7), 25.6 (C3), 22.3 (C9), 21.0 (C2); HRMS: (ESI+) Mass peak of the borane adduct 
541; Calculated for C16H25BN2NaO: 295.1955. Found [M + Na]+: 295.1967; Mass peak of the tertiary 
amine; Calculated for C16H23N2O: 259.1805. Found [M + H]+: 259.1814. 
 
 




Preliminary data for the product of the reaction of lactam 532a with BH3·THF (542) 
 
Lactam 532a (8.5 mg, 0.020 mmol) was added to a flame-dried flask containing a stir bar. Dry THF 
(0.40 mL, 0.05 M) was added and the reaction was cooled to 0 °C. BH3·THF (0.06 mL, 0.06 mmol), 
was added dropwise over 5 minutes and the reaction progress was monitored by TLC. On consumption 
of the starting material, MeOH (0.4 mL) was added by syringe and the reaction was warmed to room 
temperature before being concentrated in vacuo. FCC provided the unassigned compound (5.1 mg) as 
a colourless oil. The structure of the compound 542 has not been fully assigned. The data shown below 
suggests that the unknown compound contains the structural motif shown above.  νmax / cm-1: 2926 (m), 
2856 (m), 1463 (w), 1254 (m), 1063 (s), 837 (s); 1H NMR (CDCl3, 500 MHz): δ 6.47 (1H, d, J = 2.5 
Hz, C7-H), 5.96 (1H, d, J = 2.5 Hz, C6-H), 5.17 (1H, dd, J = 9.0, 6.5 Hz, C3-H), 4.55 (1H, d, J = 12.0 
Hz, C9-H2), 4.51 (1H, d, J = 12.0 Hz, C9-H2), 3.71 (3H, s, C8-H3), 3.61–3.53 (2H, m, 1 × C1-H2, OH), 
3.32 (1H, m, C1-H2), 2.22 (1H, m, C2-H2), 1.92 (1H, m, C2-H2), 0.91 (9H, s, C12-H3), 0.86 (9H, s, 
C12-H3), 0.14 (3H, s, C10-H3), 0.10 (3H, s, C10-H3), 0.06 (3H, s, C10-H3), -0.21 (3H, s, C10-H3); 13C 
NMR (CDCl3, 100 MHz): δ 130.7 (C4), 122.6 (C7), 120.4 (C5), 107.9 (C6), 65.7 (C3), 59.4 (C1), 58.6 
(C9), 40.5 (C2), 35.4 (C8), 26.2, 25.9 (C12), 18.6, 18.1 (C11), -4.8, -5.1, -5.1, -5.1 (C10); HRMS: 
(ESI+) Calculated for C21H43NNaO3Si2: 436.2674. Found [M + Na]+: 436.2671. 
Preliminary data for the product of the reaction of lactam 439a with BH3·THF (544a)  
 
Lactam 439a (25 mg, 0.15 mmol) was added to a flame-dried flask containing a stir bar. Dry THF 
(3.0 mL) was added and the reaction was cooled to 0 °C. BH3·THF (0.30 mL, 0.30 mmol), was added 
dropwise over 5 minutes and the reaction progress was monitored by TLC. On consumption of the 
starting material, MeOH (0.4 mL) was added by syringe and the reaction was warmed to room 
temperature before being concentrated in vacuo. FCC (30% EtOAc/hexane) provided the title 
compound (11.1 mg, 48%) as a colourless oil; The structure of the compound 544a has not been fully 




assigned. The data shown below suggests that the unknown compound contains the structural motif 
shown above. νmax / cm-1: 3356 (br.), 2923 (s), 2857 (s); 1H NMR (MeOD-d4, 400 MHz): δ 6.40 (1H, d, 
J = 2.5 Hz, C7-H), 5.76 (1H, d, J = 2.5 Hz, C6-H), 3.55 (2H, t, J = 6.5 Hz, C1-H2), 3.51 (3H, s, C8-H3), 
2.61 (2H, t, J = 7.5 Hz, C3-H2), 1.98 (3H, s, C9-H3), 1.68 (2H, m, C2-H2); 13C NMR (MeOD-d4, 100 
MHz): δ 128.3 (C4), 119.3 (C7), 114.1 (C5), 107.4 (C6), 60.9 (C1), 32.5 (C2), 32.4 (C8), 19.8 (C3), 




Alane N,N-dimethylethylamine complex (0.042 mL, 0.021 mmol, 0.5 M PhMe) was added to a stirring 
soultion of lactam 532a (6.0 mg, 0.014 mmol) in anhydrous THF (1.0 mL) at 0 °C. TLC indicated that 
the starting material was consumed in less than 1 minute. The reaction mixture was then quenched by 
addition of THF:water (1:1, 3 mL) and the resulting solution was concentated in vacuo. NMR analysis 
of the crude reaction mixture indicated the formation of alcohol 545. Due to the small quantities 
involved, several crude reaction mixtures containing alcohol 545 were combined to provide sufficient 
quantities for characterisation. The combined crude reactions were purified by FCC (60–100% 
EtOAc/Hex then 30–50% EtOAc/hexane) to provide the title compound of sufficient purity for 
characterisation. The relative stereochemistry of product 545 was not determined; νmax / cm-1: 2956 (s), 
2927 (s), 2856 (s), 1467 (m), 1252 (s), 1074 (s); 1H NMR (CDCl3, 500 MHz): δ 5.69 (1H, m, C6-H), 
4.17–4.05 (2H, m, C9-H2), 3.94 (1H, ddd, J = 10.5, 3.5, 2.5 Hz, C3-H), 3.64 (1H, m, C4-H), 3.31 (1H, 
d, J = 18.5 Hz, C7-H2), 3.00 (1H, dd. J = 18.5, 3.0 Hz, C7-H2), 2.80 (1H, m, C1-H2), 2.35 (3H, s, C8-H3), 
2.27 (1H, m, C1-H2), 1.89 (1H, m, C2-H2), 1.68 (1H, m, C2-H2), 0.91 (9H, s, C12-H3), 0.86 (9H, s, 
C12-H3), 0.07 (3H, s, C10-H3), 0.07 (3H, s, C10-H3), 0.06 (3H, s, C10-H3), 0.04 (3H, s, C10-H3); 13C 
NMR (CDCl3, 100 MHz): δ 122.4 (C6), 76.7 (C3), 73.8 (C4), 67.0 (C9), 57.5 (C7), 55.9 (C1), 46.7 
(C8), 33.2 (C2), 26.1, 25.9 (C12), 18.6, 18.2 (C11), -4.7, -4.7, -5.2, -5.2 (C10); HRMS: (ESI+) 
Calculated for C21H46NO3Si2: 416.3011. Found [M + H]+: 416.3022. 




4.5 Experimental procedures for the studies in Section 3.3 
 (Z)-1,4-Bis((tetrahydro-2H-pyran-2-yl)oxy)but-2-ene (I) 
 
Prepared according to a literature procedure.345 Dihydropyran (4.56 mL, 50.0 mmol, 2.0 eq) was added 
to a stirring solution of diol 601 (2.06 mL, 25 mmol) and p-TSA (28.5 mg, 0.15 mmol) in CH2Cl2 
(25 mL, 1 M) over 15 minutes (exothermic reaction). The resulting solution was stirred for 1.5 h during 
which time a blue colour had developed. NEt3 (0.031 mL, 0.23 mmol) was added by syringe and the 
reaction mixture was concentrated in vacuo. Purification by FCC (50% Et2O/hexane) provided the title 
compound (12.4 g, 97%) as a colourless oil; 1H NMR (CDCl3, 400 MHz): δ 5.74 (2H, t, J = 4.0 Hz, 2 × 
C1-H), 4.63 (2H, t, J = 3.5 Hz, 2 × C3-H), 4.29 (2h, m, 2 × C2-H2), 4.12 (2H, m, 2 × C2-H2), 3.87 (2H, 
m, 2 × C7-H2), 3.51 (2H, m, 2 × C7-H2), 1.87 (2H, m, 2 × C5-H2), 1.71 (2H, m, 2 × C4-H2), 1.62–1.50 
(8H, m, 2 × C4-H2, 2 × C5-H2, 4 × C6-H2); 13C NMR (CDCl3, 100 MHz): δ 129.3 (C1), 98.2 (C3), 63.0 
(C2), 62.4 (C7), 30.8 (C4), 25.6 (C6), 19.6 (C5). The spectroscopic properties of this compound were 
consistent with that available in the literature.345 
tert-Butyl (E)-2-methyl-4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-enoate (E-599a) 
 
Phosphonium ylid II was prepared according to a literature procedure.365 The synthesis of E-599a was 
adapted from a literature procedure.345 A 2-necked Schlenk flask with stopcock was charged with 
alkene I (2.56 g, 10 mmol, 1.0 eq) and DCM (20 mL) and cooled to -78 °C. A tube attached to an ozone 
generator was passed through a rubber septum and submerged into the reaction mixture. Tubing was 
attached to the stopcock to guide exhaust gasses to the top of the fumehood. Ozone was passed through 
the reaction mixture with strong stirring until a faint blue colour appeared or completion was monitored 
by TLC (approximately 5 h). Nitrogen was then bubbled through the resulting solution for 30 minutes 
to remove all ozone. PPh3 (2.62 g, 10.0 mmol) in CH2Cl2 (20 mL) were then added and the reaction was 




warmed to room temperature and stirred for 2 h. The reaction was concentrated in vacuo and purified 
by FCC (20% EtOAc/hexane) to provide the intermediate aldehyde which was used immediately in the 
next step. The intermediate aldehyde was dissolved in CH2Cl2:PhMe (80 mL, 2:1) and tert-butyl ester 
phosphonium ylide II (15.6 g, 40.0 mmol) was added. The reaction was stirred for 16 h before being 
concentrated in vacuo. The crude product was dissolved in Et2O:Hex (1:1) and filtered to remove PPh3O 
and unreacted phosphonium ylide. The filtrate was concentrated in vacuo and purified by FCC (10% 
EtOAc/hexane) to provide the title compound (3.28 g, 64%) as a colourless oil; νmax / cm-1: 2940 (m), 
1706 (s), 1656 (w), 1366 (m), 1252 (m), 1135 (s), 1027 (s); 1H NMR (CDCl3, 400 MHz): δ 6.73 (1H, t, 
J = 6.0 Hz, C4-H), 4.65 (1H, t, J = 3.5 Hz, C8-H), 4.39 (1H, dd, J = 14.0, 6.0 Hz, 1 × C5-H2), 4.15 (1H, 
dd, J = 14.0, 6.0 Hz, 1 × C5-H2), 3.87 (1H, m, 1 × C12-H2), 3.53 (1H, m, 1 × C12-H2), 1.85 (1H, m, 1 
× C10-H2), 1.81 (3H, s, C3-H3), 1.73 (1H, m, 1 × C9-H2), 1.65–1.51 (4H, m, 1 × C9-H2, 1 × C10-H2, 2 
× C11-H2), 1.48 (9H, s, C7-H3); 13C NMR (CDCl3, 100 MHz): δ 167.0 (C1), 136.8 (C4), 131.0 (C2), 
98.5 (C8), 80.5 (C6), 64.1 (C5), 62.3 (C12), 30.7 (C9), 28.2 (C7), 25.6 (C11), 19.5 (C10), 12.9 (C3); 
HRMS: (ESI+) Calculated for C14H24NaO4: 279.1567. Found [M + Na]+: 279.1578. 
tert-Butyl 3-(hydroxymethyl)-2-methyloxirane-2-carboxylate (602)  
 
m-CPBA (25.8 g, 112 mmol, 3.0 eq) was added portion wise over 15 minutes to a stirring solution of 
alkene E-599a (9.55 g, 37.0 mmol, 1.0 eq) in CH2Cl2 (185 mL, 0.2 M). The reaction was stirred for 
48 h by which time TLC (20% Et2O/hexane) showed consumption of the starting material. Water 
(50 mL) and sat. aq. Na2SO3 (50 mL) were added carefully with vigorous stirring. After an additional 
10 minutes of stirring the mixture was transferred to a separating funnel. The organic layer was 
separated and washed with sat. aq. NaHCO3 (2 × 50 mL) and brine (50 mL), dried with MgSO4 and 
concentrated in vacuo to provide the intermediate epoxide. p-TSA (70 mg, 0.01 eq) was added to a 
stirring solution of intermediate epoxide in MeOH (92 mL, 0.4 M). The reaction was stirred for 4 h at 
which point the intermediate epoxide had been consumed by TLC. NEt3 (0.11 mL, 0.74 mmol) was 
added and the reaction was concentrated in vacuo. Purification by FCC (30–50% EtOAc/hexane) 
provided the title compound (4.66 g, 67%) as a colourless oil. νmax / cm-1: 3426 (br.), 2979 (w), 2935 
(w), 1725 (s), 1369 (m), 1317 (m), 1156 (s); 1H NMR (CDCl3, 400 MHz): δ 3.87 (1H, dd, J = 12.5, 
4.5 Hz, 1 × C5-H2), 3.74 (1H, dd, J = 12.5, 6.0 Hz, 1 × C5-H2), 3.37 (1H, dd, J = 6.0, 4.5 Hz, C4-H), 
1.79 (1H, br. s, OH), 1.51 (3H, s, C3-H3), 1.47 (9H, s, C7-H3); 13C NMR (CDCl3, 100 MHz): δ 169.7 
(C1), 82.5 (C6), 61.3 (C4), 60.7 (C5), 58.1 (C2), 28.0 (C7), 13.7 (C3); HRMS: (ESI+) Calculated for 
C9H16NaO4: 211.0941. Found [M + Na]+: 211.0944. 




tert-Butyl (2S*,3S*)-2,4-dihydroxy-2,3-dimethylbutanoate (597a) 
 
A flame dried 3-necked flask was charged with CuI (172 mg, 0.90 mmol) and placed under an 
atmosphere of nitrogen. THF (18 mL, 0.05 M) was added and the suspension was cooled to -15 °C in 
an ice/salt bath. MeMgBr (3.0 mL, 9.00 mmol) was added dropwise over 5 minutes before stirring for 
an additional 30 minutes. Epoxide (170 mg, 0.90 mmol) in THF (3.0 mL) was added dropwise over 
10 minutes. After 15 minutes, TLC indicated the reaction was complete. Sat. aq. NH4Cl (10 mL) was 
added carefully and the reaction was stirred for 30 minutes before being filtered through celite, washing 
with Et2O. The organic layer was separated, and the aqueous layer was extracted with CH2Cl2 (3 × 
20 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. FCC (40% 
Et2O/hexane) provided the title compound (129 mg, 70%) as a colourless oil; νmax / cm-1: 3424 (br.), 
2977 (w), 2933 (w), 1717 (s), 1456 (m), 1369 (s), 1150 (s); 1H NMR (CDCl3, 400 MHz): δ 3.64 (1H, 
dd, J = 11.0, 6.0 Hz, 1 × C6-H2), 3.59 (1H, dd, J = 11.0, 4.5 Hz, 1 × C6-H2), 3.44 (1H, br. s, OH), 2.21 
(1H, br. s, OH), 2.07 (1H, m, C4-H), 1.49 (9H, s, C8-H3), 1.33 (3H, s, C3-H3), 1.04 (3H, d, J = 7.0 Hz, 
C5-H3); 13C NMR (CDCl3, 100 MHz): δ 176.8 (C1), 82.8 (C7), 77.4 (C2), 65.5 (C6), 41.7 (C4), 28.0 
(C8), 24.1 (C3), 11.2 (C5); HRMS: (ESI+) Calculated for C10H20NaO4: 227.1254. Found [M + Na]+: 
227.1257. 
tert-Butyl (2S*,3S*)-2,3-dimethyloxetane-2-carboxylate (604) 
 
MsCl (0.050 mL, 0.65 mmol) was added to a stirring solution of alcohol 597a (111 mg, 0.54 mmol) 
and NEt3 (0.114 mL, 0.82 mmol) in CH2Cl2 (1.6 mL) at 0 °C. TLC indicated consumption of the starting 
material after 15 minutes. Water (5 mL) was added and the aqueous layer was extracted with Et2O (3 × 
5 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. Meanwhile, 
TEPA (0.214 mL, 1.08 mmol) was added dropwise over 10 minutes to a stirring solution of NaH 
(32 mg, 0.81 mmol) in THF (2.16 mL) at 0 °C. The reaction was stirred for 30 minutes before addition 
of the crude mesylate in THF (1.5 mL). The reaction was heated at reflux for 3 h at which point a new 
non-polar spot and the mesylate were visible by TLC. The reaction was cooled to room temperature 




before being quenched by the addition of 1 M aq. HCl (5 mL). The aqueous layer was extracted with 
EtOAc (3 × 5 mL) and the combined organics were dried over MgSO4, filtered and concentrated in 
vacuo. FCC (30% EtOAc/hexane) provided the title oxetane (40 mg, 30%) as a colourless oil; νmax / 
cm-1: 2979 (m), 1744 (s), 1725 (s), 1368 (m), 1167 (m), 1138 (s), 1121 (s); 1H NMR (CDCl3, 400 MHz): 
δ 4.61 (1H, dd, J = 8.0, 5.5 Hz, 1 × C6-H2), 4.07 (1H, dd, J = 6.5, 6.0 Hz, 1 × C6-H2), 3.09 (1H, m, 
C4-H), 1.48 (9H, s, C8-H3), 1.44 (3H, s, C3-H3), 1.18 (3H, d, J = 7.0 Hz, C5-H3); 13C NMR (CDCl3, 
100 MHz): δ 174.1 (C1), 86.6 (C2), 81.3 (C7), 73.6 (C6), 36.0 (C4), 28.1 (C8), 19.2 (C3), 13.7 (C5); 
HRMS: (ESI+) Calculated for C10H18NaO3: 209.1148. Found [M + Na]+: 209.1155. 
tert-Butyl (2S*,3S*)-2-acetoxy-2,3-dimethyl-4-((methylsulfonyl)oxy)butanoate (605)  
 
MsCl (0.149 mL, 1.93 mmol) was added to a stirring solution of alcohol 597a (328 mg, 1.61 mmol) 
and NEt3 (0.336 mL, 2.41 mmol) in CH2Cl2 (5.0 mL) at 0 °C. TLC indicated consumption of the starting 
material after 15 minutes. Water (5 mL) was added and the aqueous layer was extracted with Et2O (3 × 
5 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. Ac2O 
(1.52 mL, 16.1 mmol) was added to a stirring solution of the crude mesylate and DMAP (49 mg, 
0.40 mmol) in pyridine (8.0 mL). The reaction was stirred for 16 h before being diluted with water 
(40 mL). The aqueous layer was extracted with CH2Cl2 (3 × 10 mL) and the combined organics were 
washed with sat. aq. CuSO4 (3 × 20 mL). The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. FCC (40% Et2O/hexane) provided the title compound (255 mg, 49%) as a yellow 
oil; νmax / cm-1: 2979 (w), 1737 (s), 1458 (w), 1357 (s), 1248 (s), 1175 (s), 962 (s); 1H NMR (CDCl3, 
400 MHz): δ 4.44 (1H, dd, J = 10.0, 4.0 Hz, 1 × C6-H2), 4.09 (1H, dd, J = 10.0, 8.0 Hz, 1 × C6-H2), 
3.02 (3H, s, C9-H3), 2.35 (1H, m, C4-H), 1.51 (3H, s, C8-H3), 1.46 (9H, s, C10-H3), 1.06 (3H, d, J = 
7.0 Hz, C5-H3); 13C NMR (CDCl3, 100 MHz): δ 169.7 (C1), 169.6 (C7), 82.5 (C9), 82.2 (C2), 70.5 
(C6), 40.4 (C4), 37.5 (C11), 27.9 (C10), 21.3 (C8), 17.8 (C3), 11.8 (C5); HRMS: (ESI+) Calculated for 
C13H24NaO7S: 347.1135. Found [M + Na]+: 347.1138. 
tert-Butyl (2S*,3R*)-2-hydroxy-4-iodo-2,3-dimethylbutanoate (606a)  
 




Iodine (635 mg, 2.50 mmol) was added to a solution of PPh3 (747 mg, 2.85 mmol) and imidazole 
(464 mg, 6.84 mmol) in CH2Cl2 (6.5 mL) at 0 °C and the mixture was stirred for 10 minutes. Alcohol 
597a (465 mg, 2.28 mmol) in CH2Cl2 (6.5 mL) was added over 10 minutes and the reaction was warmed 
to room temperature and stirred for a further 16 h. The reaction was quenched by the addition of Na2S2O3 
(0.20 g) in water (10 mL) and the organic layer was washed with 1 M aq. HCl (10 mL) and brine 
(10 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. FCC (5% 
Et2O/hexane) provided the title compound (212 mg, 30%) as a colourless oil; νmax / cm-1: 3504 (br.), 
2977 (m), 1718 (s), 1369 (m), 1257 (m), 1151 (s); 1H NMR (CDCl3, 400 MHz): δ 3.23 (1H, m, 1 × 
C6-H2), 2.92 (1H, dd, J = 10.0, 11.0 Hz, 1 × C6-H2), 2.16 (1H, m, C4-H), 1.51 (9H, s, C8-H3), 1.34 
(3H, s, C3-H3), 1.15 (3H, dd, J = 7.0, 0.5 Hz, C5-H3); 13C NMR (CDCl3, 100 MHz): δ 176.1 (C1), 83.3 
(C7), 76.5 (C2), 44.7 (C4), 28.0 (C8), 24.3 (C3), 14.1 (C5), 9.2 (C6); HRMS: (ESI+) Calculated for 
C10H19INaO3: 337.0271. Found [M + Na]+: 337.0263. 
tert-Butyl (2S*,3R*)-2-acetoxy-4-iodo-2,3-dimethylbutanoate (607a) 
 
Ac2O (0.60 mL, 6.30 mmol) was added to a stirring solution of the iodide 606a (197 mg, 0.63 mmol) 
and DMAP (20 mg, 0.16 mmol) in pyridine (3.2 mL). The reaction was stirred for 6 h before being 
diluted with water (50 mL). The aqueous layer was extracted with CH2Cl2 (3 × 10 mL) and the combined 
organics were washed with sat. aq. CuSO4 (3 × 20 mL). The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo. FCC (5% Et2O/hexane) provided the title compound (203 mg, 91%) 
as a colourless oil; νmax / cm-1: 2976 (m), 1737 (s), 1368 (m), 1283 (m), 1246 (s), 1131 (s); 1H NMR 
(CDCl3, 400 MHz): δ 3.63 (1H, m, 1 × C6-H2), 2.86 (1H, dd, J = 11.0, 9.5 Hz, 1 × C6-H2), 2.27 (1H, 
m, C4-H), 2.05 (3H, s, C8-H3), 1.45 (9H, s, C10-H3), 1.08 (3H, dd, J = 7.0, 0.5 Hz, C5-H3); 13C NMR 
(CDCl3, 100 MHz): δ 169.8 (C1), 169.7 (C7), 83.3 (C2), 82.3 (C9), 44.2 (C4), 27.9 (C10), 21.4 (C8), 
14.9 (C5), 8.0 (C6); HRMS: (ESI+) Calculated for C12H21INaO4: 379.0377. Found [M + Na]+: 379.0390. 
2-(Trimethylsilyl)ethyl 2-oxopropanoate (617) 
 
2-(Trimethylsilyl)ethanol (1.28 mL, 10.0 mmol) was added to a stirring solution of pyruvic acid 
(1.04 mL, 15.0 mmol), EDCI (2.88 g, 15.0 mmol) and DMAP (100 mg, 0.10 mmol) in CH2Cl2 (10 mL) 




and the reaction was stirred for 16 h. The reaction was concentrated in vacuo and purification by FCC 
(5% EtOAc/hexane) provided the title compound (1.16 g, 62%) as a pale yellow oil; 1H NMR (CDCl3, 
400 MHz): δ 4.35 (2H, m, C4-H2), 2.46 (3H, s, C1-H3), 1.10 (2H, m, C5-H2), 0.06 (9H, s, C6-H3); 13C 
NMR (CDCl3, 100 MHz): δ 192.3 (C2), 161.1 (C1), 65.2 (C3), 26.8 (C4), 17.5 (C5), -1.4 (C6). The 
spectroscopic properties of this compound were consistent with that available in the literature.366 
2-(Trimethylsilyl)ethyl (2S*,3S*)-2-hydroxy-2,3-dimethylpent-4-enoate (618) 
 
The crotylation of ketone 617 was adapted from a literature procedure.349 Crotyl boron reagent E-
612349 and BINOL-derived catalyst (S)-614367 were prepared according to literature procedures. A 
mixture of BINOL-derived catalyst (S)-614 (15 mg, 0.034 mmol), t-BuOH (0.325 mL, 3.40 mmol) and 
crotyl boron reagent E-612 (364 mg, 2.60 mmol) were stirred in PhMe (1 mL) for 5 minutes before the 
addition of pyruvate ester 617 (320 mg, 1.70 mmol) in PhMe (1 mL). The reaction was stirred at room 
temperature for 3 h before being concentrated in vacuo. FCC (5% EtOAc/hexane) provided the title 
compound (333 mg, 80%, >25:1 d.r., ~70% e.e., the two peaks were not fully resolved) as a colourless 
oil. The relative stereochemistry of product 618 was assigned by comparison of the 13C chemical shifts 
with literature compounds (S*,S*)-618a and (S*,R*)-618a368 (see Table S1 below); νmax / cm-1: 2955 
(w), 1723 (s), 1454 (w), 1250 (s), 1170 (s); 1H NMR (CDCl3, 400 MHz): δ 5.76 (1H, m, C6-H), 5.04 
(1H, m, 1 × C7-H2), 5.00 (1H, m, 1 × C7-H2), 4.23 (2H, m, C8-H2), 3.13 (1H, s, OH), 2.47 (1H, m, 
C4-H), 1.36 (3H, s, C3-H3), 1.07 (3H, d, J = 7.0 Hz, C5-H3), 1.03 (2H, m, C9-H2), 0.06 (9H, s, C10-H3); 
13C NMR (CDCl3, 100 MHz): δ 177.2 (C1), 139.4 (C6), 116.1 (C7), 76.4 (C2), 64.4 (C8), 46.2 (C4), 
23.7 (C3), 17.7 (C9), 13.7 (C5), -1.4 (C10). HRMS: (ESI+) Calculated for C12H24O3Si: 267.1394. Found 
[M + H]+: 267.1388. The enantiopurity of this compound was determined by chiral GC (DETA DM 
Chiraldex G 0605-18, He mobile phase, 0.5 mL/min, 70 °C for 5 min then 5 °C/min to 80 °C then 2 
°C/min to 115 °C then 1 °C/min to 135 °C then 2 °C/min to 150 °C then 5 °C/min to 180 °C) against a 
racemic standard; tR (minor) – 32.19 min and tR (major) – 32.32 min. 
 





Table S1: Comparison of the 13C chemical shifts of alkene 618 with literature compounds (S*,S*)-618a and 
(S*,R*)-618a. 
Ethyl (E)-2-ethylidene-5-phenylpentanoate (624) 
 
-Bromoacrylate E-611 was prepared according to a literature procedure.369 Zinc dust (255 mg, 
3.90 mmol) was added to a flame-dried 5mL flask which was sealed and purged with argon. DMF 
(0.33 mL) and dibromoethane (0.017 mL, 0.20 mmol) were added and the flask was heated at 50 °C for 
20 minutes before being cooled to room temperature. TMSCl (0.005 mL, 0.04 mmol) was added and 
the reaction was stirred for 30 minutes. Alkyl iodide 622 (0.10 mL, 0.65 mmol) was added and the 
mixture was stirred for 2 h or until the iodide had been consumed as determined by TLC. Stirring was 
stopped to allow the solids to settle. Pd2(dba)3 (11 mg, 0.013 mmol) and SPhos (10.3 mg, 0.025 mmol) 
was added to a separate flame-dried flask which was sealed and purged with argon. DMF (0.33 mL), 
-Bromoacrylate E-611 (96.5 mg, 0.50 mmol) was added to the flask containing the Pd(0)-catalyst 
followed by the freshly formed alkyl zinc reagent. The reaction was heated at 40 °C for 16 h before 
being concentrated in vacuo. FCC (3% EtOAc/hexane) provided the title compound (40.6 mg, 35%) as 
a pale yellow oil; νmax / cm-1: 2924 (m), 1707 (s), 1453 (m), 1255 (s), 11645 (m); 1H NMR (CDCl3, 
400 MHz): δ 7.29–7.26 (2H, m, ArCH), 7.20–7.15 (3H, m, ArCH), 6.85 (1H, q, J = 7.0 Hz, C3-H), 4.18 
(2H, q, J = 7.0 Hz, C12-H2), 2.64 (2H, t, J = 8.0 Hz, C7-H2), 2.35 (2H, t, J = 8.0 Hz, C5-H2), 1.77–1.69 
(5H, m, C4-H3, C6-H2), 1.28 (3H, t, J = 7.0 Hz, C13-H3); 13C NMR (CDCl3, 100 MHz): δ 168.0 (C1), 
142.4 (C8), 137.5 (C3), 133.4 (C2), 128.5, 128.4, 125.9 (C9, C10, C11), 60.5 (C12), 35.9 (C7), 30.7 








Ac2O (1.29 mL, 13.6 mmol) was added to a stirring solution of alcohol 618 (333 mg, 1.36 mmol) and 
DMAP (42 mg, 0.34 mmol) in pyridine (6.8 mL). The reaction was stirred for 6 h before being diluted 
with water (50 mL). The aqueous layer was extracted with CH2Cl2 (3 × 20 mL) and the combined 
organics were washed with sat. aq. CuSO4 (3 × 20 mL). The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo. FCC (5% Et2O/hexane) provided the title compound (337 mg, 86%) 
as a colourless oil; νmax / cm-1: 2954 (w), 1737 (s), 1370 (m), 1249 (s), 1110 (m); 1H NMR (CDCl3, 
400 MHz): δ 5.86 (1H, m, C6-H), 5.12 (1H, d, J = 1.0 Hz, 1 × C7-H2), 5.08 (1H, m, 1 × C7-H2), 4.21 
(2H, m, C10-H2), 2.65 (1H, m, C4-H), 2.05 (3H, s, C9-H3), 1.51 (3H, s, C3-H3), 1.01 (3H, d, J = 7.0 Hz, 
C5-H3), 1.00 (2H, m, C11-H2), 0.04 (9H, s, C12-H3); 13C NMR (CDCl3, 100 MHz): δ 171.7 (C1), 170.1 
(C8), 137.9 (C6), 116.5 (C7), 83.0 (C2), 63.7 (C10), 45.0 (C4), 21.4 (C9), 17.9 (C3), 17.4 (C11), 14.1 
(C5), -1.4 (C12); HRMS: (ESI+) Calculated for C14H26NaO4Si: 309.1493. Found [M + Na]+: 309.1506. 
2-(Trimethylsilyl)ethyl (2S*,3S*)-2-acetoxy-4-hydroxy-2,3-dimethylbutanoate (625)  
 
A 2-necked Schlenk flask with stopcock was charged with alkene (168 mg, 0.59 mmol) and 
CH2Cl2:MeOH (20 mL, 1:1) and cooled to -78 °C. A tube attached to an ozone generator was passed 
through a rubber septum and submerged into the reaction mixture. Tubing was attached to the stopcock 
to guide exhaust gasses to the top of the fumehood. Ozone was passed through the reaction mixture 
with strong stirring until a faint blue colour appeared or completion was monitored by TLC. Nitrogen 
was then bubbled through the solution for 30 minutes to remove all ozone. NaBH4 (56 mg, 1.48 mmol) 
was then added and the reaction was warmed to 0 °C and stirred for 30 minutes. The reaction was 
quenched by the addition of sat. aq. NH4Cl (10 mL) and the aqueous layer was extracted with CH2Cl2 
(3 × 10 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. FCC 
(25% EtOAc/hexane) to provide the title compound (139 mg, 86%) as a colourless oil; νmax / cm-1: 3457 




(br.), 2954 (w), 1738 (s), 1370 (m), 1248 (s), 1129 (m), 1026 (m); 1H NMR (CDCl3, 400 MHz): δ 4.28–
4.16 (2H, m, 2 × C9-H2), 3.83 (1H, dd, J = 11.5, 5.5 Hz, 1 × C6-H2), 3.54 (1H, dd, J = 11.5, 6.0 Hz, 1 
× C6-H2), 2.13 (1H, m, C4-H), 2.07 (3H, s, C8-H3), 1.57 (3H, s, C3-H3), 1.03–0.98 (2H, m, C10-H2), 
0.98 (3H, dd, J = 7.0, 1.0 Hz, C5-H3), 0.04 (9H, s, C11-H3); 13C NMR (CDCl3, 100 MHz): δ 172.0 (C1), 
169.8 (C7), 83.2 (C2), 64.3 (C6), 64.1 (C9), 43.1 (C4), 21.5 (C8), 18.0 (C3), 17.4 (C10), 11.9 (C5), -1.4 
(C11); HRMS: (ESI+) Calculated for C13H26NaO5Si: 313.1442. Found [M + Na]+: 313.1453. 
2-(Trimethylsilyl)ethyl (2S*,3S*)-4-acetoxy-2-hydroxy-2,3-dimethylbutanoate (626) 
 
Iodine (127 mg, 0.50 mmol) was added to a solution of PPh3 (149 mg, 0.57 mmol) and imidazole 
(155 mg, 2.28 mmol) in CH2Cl2 (2.3 mL) at 0 °C and the mixture was stirred for 10 minutes. Alcohol 
625 (125 mg, 0.456 mmol) in CH2Cl2 (2.3 mL) was added over 10 minutes and the reaction was warmed 
to room temperature and stirred for a further 16 h. The reaction was quenched by the addition of Na2S2O3 
(0.20 g) in water (10 mL) and the organic layer was washed with 1 M aq. HCl (10 mL) and brine 
(10 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. FCC (15% 
Et2O/hexane) provided the title compound (63 mg, 50%) as a colourless oil; νmax / cm-1: 3506 (br.), 2953 
(m), 1725 (s), 1365 (m), 1249 (s), 1176 (m), 1039 (m); 1H NMR (CDCl3, 400 MHz): δ 4.31 (1H, m, 1 
× C9-H2), 4.22 (1H, m, 1 × C9-H2), 4.07 (1H, dd, J = 11.0, 7.5 Hz, 1 × C6-H2), 3.90 (1H, dd, J = 11.0, 
6.5 Hz, 1 × C6-H2), 3.22 (1H, s, OH), 2.26 (1H, m, C4-H), 2.26 (3H, s, C8-H3), 1.36 (3H, s, C3-H3), 
1.04 (2H, m, C10-H2), 1.00 (3H, d, J = 7.0 Hz, C5-H3), 0.06 (9H, s, C11-H3); 13C NMR (CDCl3, 
100 MHz): δ 177.5 (C1), 170.8 (C7), 74.5 (C2), 65.9 (C6), 64.6 (C9), 39.8 (C4), 24.6 (C3), 21.0 (C8), 
17.5 (C10), 11.2 (C5), -1.4 (C11); HRMS: (ESI+) Calculated for C13H26NaO5Si: 313.1442. Found [M + 
Na]+: 313.1453. 
2-(Trimethylsilyl)ethyl (2S*,3S*)-2,4-dihydroxy-2,3-dimethylbutanoate (597b) 
 
A 2-necked Schlenk flask with stopcock was charged with alkene 618 (150 mg, 0.60 mmol) and 
CH2Cl2:MeOH (20 mL, 1:1) and cooled to -78 °C. A tube attached to an ozone generator was passed 
through a rubber septum and submerged into the reaction mixture. Tubing was attached to the stopcock 
to guide exhaust gasses to the top of the fumehood. Ozone was passed through the reaction mixture 
with strong stirring until a faint blue colour appeared or completion was monitored by TLC. Nitrogen 




was then bubbled through the solution for 30 minutes to remove all ozone. NaBH4 (57 mg, 1.50 mmol) 
was then added and the reaction was warmed to room temperature and stirred for 3 h. The reaction was 
quenched by the addition of sat. aq. NH4Cl (10 mL) and the aqueous layer was extracted with CH2Cl2 
(3 × 10 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. FCC 
(25% EtOAc/hexane) to provide the title compound (40 mg, 27%) as a colourless oil; νmax / cm-1: 3450 
(br. m), 2954 (m), 1721 (s), 1250 (s), 1041 (s); 1H NMR (CDCl3, 400 MHz): δ 4.26 (2H, m, C7-H2), 
3.63 (1H, dd, J = 11.0, 6.5 Hz, C6-H2), 3.57 (1H, dd, J = 11.0, 4.5 Hz, C6-H2), 3.46 (1H, br. s, OH), 
2.11 (1H, m, C4-H), 1.36 (3H, s, C3-H3), 1.05–1.00 (5H, m, C5-H3, C8-H2), 0.05 (9H, s, C9-H3); 13C 
NMR (CDCl3, 100 MHz): δ 177.9 (C1), 76.7 (C2), 65.4 (C6), 64.6 (C7), 41.7 (C4), 24.0 (C3), 17.5 
(C8), 11.0 (C5), -1.4 (C9); HRMS: (ESI+) Calculated for C11H24NaO4Si: 271.1336. Found [M + Na]+: 
271.1327. 
2-(Trimethylsilyl)ethyl (2S*,3R*)-2-hydroxy-4-iodo-2,3-dimethylbutanoate (606b) 
 
Iodine (54mg, 0.213 mmol) was added to a solution of PPh3 (63 mg, 0.242 mmol) and imidazole (40 mg, 
0.582 mmol) in CH2Cl2 (2.0 mL) at 0 °C and the mixture was stirred for 10 minutes. Alcohol 597b 
(24 mg, 0.097 mmol) in CH2Cl2 (0.5 mL) was added over 10 minutes and the reaction was warmed to 
room temperature and stirred for a further 16 h. The reaction was quenched by the addition of sat. aq. 
Na2S2O3 (5 mL) and the organic layer was diluted with CH2Cl2 (10 mL), washed with 1 M aq. HCl 
(5 mL) and brine (5 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. 
FCC (2.5% EtOAc/hexane) provided the title compound (14.7 mg, 42%) as a colourless oil; νmax / cm-1: 
3513 (br.), 2954 (m), 1721 (s), 1249 (s), 1160 (s); 1H NMR (CDCl3, 400 MHz): δ 4.29 (2H, m, C7-H2), 
3.22 (1H, dd, J = 10.0, 3.0 Hz, C6-H2), 2.95 (1H, dd, J = 10.0, 10.0 Hz, C6-H2), 2.17 (1H, m, C4-H), 
1.38 (3H, s, C3-H3), 1.15 (3H, d, J = 7.0 Hz, C5-H3), 1.05 (2H, m, C8-H2), 0.07 (9H, s, C9-H3); 13C 
NMR (CDCl3, 100 MHz): δ 177.0 (C1), 76.5 (C2), 65.0 (C7), 44.4 (C4), 24.1 (C3), 17.6 (C8), 14.4 
(C5), 9.0 (C6), -1.4 (C9); HRMS: (ESI+) Calculated for C11H23INaO3Si: 381.0353. Found [M + Na]+: 
381.0368. 
 




4.6 Computational details 
 The computational studies in Section 3.2.3.2.2 were carried out with guidance from Dr. Natalie 
Fey at Bristol. Alkene isomers were subjected to MM conformation distribution searches using the 
Spartan software to identify low energy conformations. For each alkene isomer, conformations within 
10 kJ/mol of the lowest energy conformation were optimised by DFT (B3LYP-6-31g(d))272-279 using 
Gaussian 09.280 The energies of the resulting optimised conformations were compared to give the results 
shown in Section 3.2.3.2.2. Computed structures were illustrated with Gaussview.370 
Results from the comparison of 403a and 439a 
 
BC-403a 
B3LYP/6-31G(d) Energy  -555.975200272 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          1           0        0.346856    1.237850   -1.673760 
2          6           0        0.503955    1.633392   -0.666554 
3          1           0        0.975066    2.616523   -0.758147 
4          6           0        1.530796    0.808074    0.112040 
5          7           0        1.712561   -0.518134   -0.251663 
6          6           0        0.790940   -1.265912   -1.014535 
7          1           0        1.231369   -1.826669   -1.839075 
8          6           0       -0.523380   -1.341334   -0.764229 
9          1           0       -1.142098   -1.898883   -1.464831 
10          6           0       -1.242404   -0.725270    0.417197 
11          1           0       -0.503117   -0.552041    1.211083 
12          6           0       -0.853683    1.835939    0.043698 
13          1           0       -0.662130    2.090240    1.096639 
14          1           0       -1.383290    2.680548   -0.405654 
15          6           0       -1.805779    0.648067    0.004897 




16          8           0       -2.965944    0.779269   -0.335061 
17          8           0        2.222219    1.332703    0.976266 
18          6           0        2.872353   -1.233547    0.280540 
19          1           0        3.281219   -1.884380   -0.500332 
20          1           0        2.598681   -1.852778    1.143198 
21          1           0        3.620096   -0.504801    0.592289 
22          6           0       -2.354674   -1.649427    0.929426 
23          1           0       -3.123402   -1.786293    0.163722 
24          1           0       -2.840470   -1.219962    1.811420 




B3LYP/6-31G(d) Energy  -555.970355368 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          1           0        1.400928   -2.082591   -1.578758 
2          6           0        0.784278   -1.292725   -1.143735 
3          1           0        0.365607   -0.691405   -1.955220 
4          6           0        1.699043   -0.480350   -0.240759 
5          7           0        1.331424    0.833335    0.032245 
6          6           0        0.342444    1.587137   -0.641972 
7          1           0        0.727834    2.542963   -1.000279 
8          6           0       -0.952338    1.324352   -0.864152 
9          1           0       -1.472216    2.085181   -1.445450 
10          6           0       -1.860841    0.184793   -0.446309 
11          1           0       -2.182535   -0.316904   -1.374845 
12          6           0       -0.335792   -1.928484   -0.291423 
13          1           0       -0.984625   -2.535049   -0.938858 
14          1           0        0.097079   -2.585771    0.467623 
15          6           0       -1.198584   -0.895294    0.423423 
16          8           0       -1.396338   -0.952599    1.621052 
17          8           0        2.682832   -0.992227    0.276232 
18          6           0        2.204428    1.617221    0.910553 
19          1           0        1.626610    2.029281    1.743735 
20          1           0        2.662198    2.445217    0.353604 
21          1           0        2.983870    0.957800    1.288206 
22          6           0       -3.110883    0.751075    0.252621 
23          1           0       -2.836982    1.216109    1.202603 
24          1           0       -3.830743   -0.045539    0.464422 
25          1           0       -3.599475    1.499625   -0.380260 
 
BB-439a 
B3LYP/6-31G(d) Energy  -555.967611771 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          6           0        1.696125   -0.511632   -0.316842 
2          7           0        1.365542    0.764820    0.086812 
3          6           0        0.504959    1.653612   -0.694568 
4          1           0        0.732459    2.673331   -0.363501 
5          1           0        0.802097    1.633069   -1.754813 




6          6           0       -0.992620    1.475490   -0.599102 
7          1           0       -1.534114    2.346140   -0.973916 
8          6           0       -1.728667    0.463854   -0.118609 
9          6           0       -1.194764   -0.827581    0.460970 
10          6           0        0.716184   -1.179207   -1.272833 
11          1           0        0.308640   -0.496616   -2.023643 
12          1           0        1.255314   -1.975019   -1.791804 
13          6           0       -0.421736   -1.795024   -0.434628 
14          1           0       -0.030553   -2.584624    0.213648 
15          1           0       -1.157938   -2.255712   -1.110579 
16          8           0       -1.520248   -1.156061    1.588778 
17          8           0        2.634318   -1.135136    0.164461 
18          6           0        2.151977    1.379448    1.152996 
19          1           0        2.676585    0.589534    1.688596 
20          1           0        1.487482    1.914559    1.839317 
21          1           0        2.893483    2.084637    0.752696 
22          6           0       -3.236395    0.560991   -0.029889 
23          1           0       -3.550428    0.456379    1.014387 
24          1           0       -3.724918   -0.246597   -0.590981 
25          1           0       -3.599845    1.517050   -0.417967 
 
CC-439a 
B3LYP/6-31G(d) Energy  -555.967464790 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          6           0        1.698186    0.761095   -0.143702 
2          7           0        1.705777   -0.504821    0.395784 
3          6           0        0.560642   -1.038413    1.138304 
4          1           0        0.931056   -1.854930    1.767271 
5          1           0        0.190627   -0.271810    1.823248 
6          6           0       -0.561502   -1.544107    0.253815 
7          1           0       -0.534280   -2.599045   -0.017158 
8          6           0       -1.574185   -0.795630   -0.201553 
9          6           0       -1.733318    0.668967    0.150717 
10          6           0        0.654011    1.760240    0.364170 
11          1           0        0.517027    1.712769    1.450076 
12          1           0        1.089898    2.735759    0.137411 
13          6           0       -0.720846    1.696503   -0.354922 
14          1           0       -0.546113    1.527928   -1.426124 
15          1           0       -1.212453    2.667373   -0.240933 
16          8           0       -2.726960    1.028956    0.759076 
17          8           0        2.512051    1.111789   -0.992777 
18          6           0        2.654553   -1.473543   -0.143266 
19          1           0        3.514622   -0.932574   -0.535624 
20          1           0        2.217130   -2.066646   -0.958281 
21          1           0        2.972552   -2.152633    0.655026 
22          6           0       -2.703553   -1.351868   -1.033307 
23          1           0       -2.770655   -0.849800   -2.007640 
24          1           0       -3.657751   -1.183847   -0.521072 
25          1           0       -2.576749   -2.424224   -1.208622 
 








B3LYP/6-31G(d) Energy  -481.932857787 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          7           0       -1.356669   -0.541259    0.260939 
2          6           0        1.574974   -0.227657   -0.539648 
3          1           0        1.882937    0.366087   -1.418032 
4          6           0       -0.968738    1.556426   -1.010945 
5          1           0       -0.555453    1.084102   -1.909361 
6          6           0       -1.995019    0.628373   -0.359205 
7          1           0       -2.509292    1.168937    0.445530 
8          1           0       -2.766500    0.338193   -1.097088 
9          1           0       -1.483475    2.464510   -1.349118 
10          6           0        1.021360    0.786724    0.483537 
11          6           0        0.159162    1.936795   -0.040974 
12          1           0        0.842603    2.636952   -0.545706 
13          1           0       -0.237281    2.458477    0.836930 
14          6           0       -2.241775   -1.261517    1.169068 
15          1           0       -1.676681   -2.042398    1.686115 
16          1           0       -3.098730   -1.735361    0.653868 
17          1           0       -2.633727   -0.569611    1.921383 
18          8           0        1.393410    0.770850    1.642317 
19          6           0        2.823218   -0.935282    0.017219 
20          1           0        2.571213   -1.491380    0.923587 
21          1           0        3.599853   -0.209531    0.276813 
22          1           0        3.232460   -1.632615   -0.722481 
23          6           0       -0.696921   -1.404997   -0.654556 
24          1           0       -1.288115   -2.231202   -1.067463 
25          6           0        0.574425   -1.250824   -1.035651 
26          1           0        0.965477   -1.951386   -1.773158 
 
BC-442 
B3LYP/6-31G(d) Energy  -481.931561334 





Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          7           0       -1.897662   -0.565421   -0.200864 
2          6           0        1.386291   -0.639954   -0.370041 
3          1           0        1.112075   -0.447645   -1.418304 
4          6           0       -0.843507    1.740818   -0.427179 
5          1           0       -0.412599    2.376432   -1.213103 
6          6           0       -1.450622    0.489364   -1.098581 
7          1           0       -2.316457    0.802875   -1.695667 
8          1           0       -0.746549    0.047061   -1.805527 
9          1           0       -1.653087    2.327959    0.024957 
10          6           0        1.485184    0.766210    0.267951 
11          6           0        0.203008    1.486916    0.678741 
12          1           0        0.515765    2.445304    1.103425 
13          1           0       -0.264842    0.904391    1.481816 
14          6           0       -3.163706   -0.351561    0.480885 
15          1           0       -3.506151   -1.293501    0.921374 
16          1           0       -3.919201   -0.020491   -0.240979 
17          1           0       -3.112888    0.397683    1.288474 
18          8           0        2.567616    1.295174    0.444637 
19          6           0        2.764527   -1.315937   -0.393035 
20          1           0        3.111867   -1.522151    0.625527 
21          1           0        3.508052   -0.674273   -0.870419 
22          1           0        2.709232   -2.265428   -0.935853 
23          6           0       -0.992950   -1.450423    0.371512 
24          1           0       -1.499168   -2.213145    0.961870 
25          6           0        0.351843   -1.538180    0.291040 
26          1           0        0.776245   -2.392026    0.813612 
 
CC-443 
B3LYP/6-31G(d) Energy  -481.928840555 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          6           0        0.705645    0.843460    0.314495 
2          6           0        1.583539   -0.296964   -0.172743 
3          6           0        1.084573   -1.467963   -0.585160 
4          1           0        1.760779   -2.255804   -0.921083 
5          6           0       -2.026990    0.119855   -0.700550 
6          1           0       -1.938147   -0.148356   -1.760591 
7          1           0       -3.087547   -0.003474   -0.428151 
8          6           0       -1.579639    1.578032   -0.509263 
9          1           0       -1.807766    1.914248    0.509627 
10          1           0       -2.121019    2.239512   -1.197847 
11          6           0       -0.061220    1.677917   -0.725196 
12          1           0        0.197887    1.359642   -1.742873 
13          1           0        0.262084    2.718681   -0.602931 
14          6           0       -0.392301   -1.796148   -0.589579 
15          1           0       -0.745245   -1.925382   -1.624657 
16          1           0       -0.552333   -2.773417   -0.105619 
17          7           0       -1.172678   -0.766949    0.075921 
18          6           0       -1.579987   -1.046082    1.438609 




19          1           0       -1.907571   -0.122133    1.924978 
20          1           0       -0.723395   -1.418342    2.009222 
21          1           0       -2.398322   -1.786122    1.502058 
22          6           0        3.062883   -0.009740   -0.093402 
23          1           0        3.344275    0.843081   -0.726511 
24          1           0        3.659031   -0.874414   -0.401453 
25          1           0        3.331939    0.258261    0.935378 
26          8           0        0.769384    1.216058    1.479469 
 









B3LYP/6-31G(d) Energy  -557.140891635 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          7           0        2.126336   -0.779828   -0.209708 
2          6           0        1.032823   -1.463294    0.308783 
3          6           0       -1.099518    1.037849    0.188865 
4          6           0       -0.032172    2.083592   -0.104844 
5          1           0       -0.171264    2.404636   -1.149075 
6          1           0       -0.252636    2.943484    0.534774 
7          6           0        1.440143    1.664332    0.089309 
8          1           0        1.603887    1.380030    1.135598 
9          1           0        2.043958    2.563544   -0.080775 
10          6           0        1.969367    0.531060   -0.836227 
11          1           0        1.336757    0.431207   -1.722499 
12          1           0        2.959209    0.809759   -1.210970 
13          1           0        1.341836   -2.301586    0.929745 
14          6           0       -1.093510   -0.265016   -0.618077 
15          1           0       -0.654343   -0.072266   -1.603193 
16          6           0       -0.297046   -1.300957    0.155010 
17          1           0       -0.922121   -1.993059    0.710117 
18          6           0        3.392640   -0.967916    0.489236 
19          1           0        3.484136   -2.009442    0.809574 
20          1           0        3.500861   -0.327238    1.380834 
21          1           0        4.224156   -0.749942   -0.189588 
22          6           0       -2.540722   -0.757342   -0.856420 
23          1           0       -3.095508    0.024824   -1.402356 
24          1           0       -2.510097   -1.647861   -1.493466 
25          8           0       -1.949275    1.250106    1.045577 
26          8           0       -3.208990   -1.128134    0.331068 
27          1           0       -3.139090   -0.346918    0.912262 
 





B3LYP/6-31G(d) Energy  -557.137213254 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          7           0        1.564939   -0.741142    0.254046 
2          6           0        0.614939   -1.522200   -0.461097 
3          6           0       -0.410557    1.128372    0.516379 
4          6           0        0.632352    1.976358   -0.211437 
5          1           0        0.079348    2.780140   -0.721594 
6          1           0        1.246407    2.453973    0.559850 
7          6           0        1.506033    1.241598   -1.237628 
8          1           0        2.165655    1.960063   -1.740146 
9          1           0        0.881884    0.796605   -2.020753 
10          6           0        2.368260    0.161778   -0.581748 
11          1           0        2.943222   -0.385473   -1.352045 
12          1           0        3.098673    0.639680    0.083355 
13          1           0        0.945989   -2.512328   -0.796016 
14          6           0       -1.282826    0.181946   -0.325760 
15          1           0       -1.544841    0.724122   -1.250240 
16          6           0       -0.625392   -1.115144   -0.744697 
17          1           0       -1.267451   -1.777285   -1.319891 
18          6           0        2.372004   -1.545502    1.164818 
19          1           0        1.714794   -2.106246    1.835714 
20          1           0        3.000192   -0.887625    1.773862 
21          1           0        3.029249   -2.265226    0.641080 
22          6           0       -2.607717   -0.100916    0.400111 
23          1           0       -2.408981   -0.699314    1.298846 
24          1           0       -3.055331    0.848646    0.725143 
25          8           0       -0.657382    1.316479    1.695052 
26          8           0       -3.458941   -0.787076   -0.516827 
27          1           0       -4.255372   -1.054700   -0.034938 
 
BB-445 
B3LYP/6-31G(d) Energy  -557.134465464 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          1           0       -2.977864    0.932378   -0.243527 
2          6           0       -2.260422    0.279520   -0.756107 
3          1           0       -2.830280   -0.291024   -1.516319 
4          7           0       -1.670727   -0.596388    0.253152 
5          6           0        1.217168   -0.114101    0.043995 
6          6           0        0.471663    1.092483    0.565154 
7          6           0       -0.366432    1.920352   -0.409880 
8          1           0        0.351903    2.563164   -0.942908 
9          1           0       -0.990599    2.588053    0.195233 
10          6           0       -1.201367    1.149171   -1.436112 
11          1           0       -1.702062    1.855449   -2.110105 
12          1           0       -0.547290    0.532716   -2.063524 
13          6           0       -0.795848   -1.629681   -0.304834 
14          1           0       -0.878986   -2.531249    0.317509 
15          1           0       -1.139219   -1.945160   -1.309426 




16          6           0        0.663597   -1.261761   -0.358964 
17          1           0        1.328586   -2.054344   -0.696495 
18          6           0       -2.662732   -1.126476    1.181471 
19          1           0       -3.214996   -0.297983    1.636634 
20          1           0       -2.160595   -1.674628    1.984556 
21          1           0       -3.395888   -1.804155    0.703812 
22          6           0        2.717180    0.076758    0.101380 
23          1           0        2.984923    0.264004    1.153004 
24          1           0        2.994547    0.986956   -0.460439 
25          8           0        3.385220   -1.061868   -0.419288 
26          1           0        4.334898   -0.930280   -0.283819 
27          8           0        0.719925    1.519772    1.682680 
 









B3LYP/6-31G(d) Energy  -632.350263263 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          1           0       -2.659416    0.193885   -1.719406 
2          6           0       -1.719810    0.235342   -1.152795 
3          1           0       -0.919803   -0.040901   -1.846455 
4          7           0       -1.752699   -0.782362   -0.058759 
5          6           0        1.276829   -0.345487    0.684108 
6          1           0        0.970154   -0.224858    1.732050 
7          6           0        0.877589    0.945210   -0.036471 
8          6           0       -0.372615    1.707014    0.448891 
9          1           0       -0.056274    2.746695    0.593456 
10          6           0       -1.472783    1.659983   -0.636258 
11          1           0       -2.378483    2.081321   -0.184757 
12          1           0       -1.192229    2.297200   -1.482461 
13          6           0        0.576312   -1.573677    0.114245 
14          1           0        1.240238   -2.406800   -0.102181 
15          6           0       -0.723621   -1.766274   -0.146738 
16          1           0       -1.047526   -2.754185   -0.485857 
17          8           0        1.514712    1.385924   -0.983927 
18          8           0       -0.858894    1.251757    1.697070 
19          1           0       -1.312680    0.408265    1.483742 
20          6           0        2.808119   -0.527008    0.629754 
21          1           0        3.290170    0.356277    1.078981 
22          1           0        3.085573   -1.396387    1.236427 
23          8           0        3.286446   -0.774967   -0.676779 
24          1           0        2.994751   -0.006408   -1.200925 
25          6           0       -3.081017   -1.360970    0.154444 
26          1           0       -3.070793   -1.988950    1.049981 
27          1           0       -3.417721   -1.975437   -0.698449 
28          1           0       -3.809201   -0.559695    0.311169 






B3LYP/6-31G(d) Energy  -632.350231093 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          7           0        1.411729   -1.018861    0.176220 
2          6           0        0.716571   -1.536855   -0.954263 
3          6           0       -0.562917    0.680808    0.514899 
4          6           0        0.565996    1.711129    0.336485 
5          1           0        0.984133    1.884126    1.338885 
6          6           0        1.673386    1.303284   -0.629689 
7          1           0        2.390410    2.128286   -0.710441 
8          1           0        1.250608    1.153314   -1.628882 
9          6           0        2.383609    0.039710   -0.145997 
10          1           0        3.130502   -0.291234   -0.889581 
11          1           0        2.928810    0.260167    0.780015 
12          1           0        1.178519   -2.381220   -1.477537 
13          6           0       -1.217447    0.094773   -0.743187 
14          1           0       -1.260029    0.925838   -1.467132 
15          6           0       -0.442595   -1.033204   -1.381602 
16          1           0       -0.897469   -1.468483   -2.270219 
17          6           0        1.962818   -2.075781    1.019719 
18          1           0        1.160833   -2.760357    1.309379 
19          1           0        2.384417   -1.635503    1.928904 
20          1           0        2.755144   -2.659420    0.515923 
21          6           0       -2.677320   -0.325145   -0.446331 
22          1           0       -3.140684   -0.694996   -1.368237 
23          1           0       -3.240458    0.568291   -0.130454 
24          8           0       -0.028945    2.909560   -0.177781 
25          1           0       -0.636339    3.244382    0.501917 
26          8           0       -1.066544    0.540845    1.624312 
27          8           0       -2.770066   -1.363059    0.504334 
28          1           0       -2.358664   -0.992249    1.306809 
 
BC-cis-446 
B3LYP/6-31G(d) Energy  -632.354131721 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          6           0       -0.112199    1.813456    0.349968 
2          1           0       -0.237538    1.959315    1.440426 
3          6           0        1.370559    1.478288    0.084005 
4          1           0        1.911090    2.404225    0.306645 
5          6           0        1.164983   -1.615989   -0.434549 
6          1           0        1.518651   -2.364575   -1.140456 
7          6           0       -0.172681   -1.549222   -0.269761 
8          1           0       -0.762263   -2.209813   -0.896831 
9          6           0       -1.017675   -0.655493    0.622121 
10          1           0       -0.572616   -0.543838    1.617025 
11          6           0       -1.111602    0.714464   -0.030551 
12          1           0        1.498572    1.296932   -0.989140 
13          6           0        1.985429    0.310782    0.900074 




14          1           0        2.961898    0.618866    1.284945 
15          1           0        1.381856    0.091838    1.785889 
16          7           0        2.214287   -0.928213    0.155258 
17          6           0        3.499448   -0.991898   -0.532720 
18          1           0        3.592010   -0.260230   -1.352838 
19          1           0        3.642216   -1.991211   -0.952714 
20          1           0        4.309239   -0.807964    0.181249 
21          8           0       -1.987448    0.992265   -0.846465 
22          6           0       -2.428845   -1.259105    0.823199 
23          1           0       -2.327936   -2.206727    1.362286 
24          1           0       -3.021986   -0.575888    1.453874 
25          8           0       -0.433286    3.001789   -0.329669 
26          1           0       -1.222624    2.786852   -0.866252 
27          8           0       -3.093906   -1.551565   -0.387605 
28          1           0       -3.117959   -0.711907   -0.881710 
 
BB-otonecine 
B3LYP/6-31G(d) Energy  -632.352237540 
B3LYP/6-31G(d) Geometry 
Center     Atomic      Atomic             Coordinates (Angstroms) 
Number     Number       Type             X           Y           Z 
--------------------------------------------------------------------- 
1          1           0        0.893527   -2.762949   -0.741706 
2          6           0        0.407816   -1.849767   -0.395165 
3          6           0       -1.098104   -1.835869   -0.464100 
4          1           0       -1.478756   -2.720164    0.066067 
5          6           0       -0.821828    1.003248   -1.504032 
6          1           0       -1.111649    1.840968   -2.148402 
7          1           0       -0.310908    0.271243   -2.140149 
8          6           0        0.151920    1.513509   -0.439235 
9          1           0        1.092180    1.811126   -0.940106 
10          6           0        0.591981    0.452443    0.582719 
11          6           0        1.157743   -0.855304    0.090574 
12          1           0       -1.420331   -1.968504   -1.512652 
13          6           0       -2.065280    0.397050   -0.852352 
14          1           0       -2.757463    0.006518   -1.621398 
15          1           0       -2.586565    1.187674   -0.305589 
16          7           0       -1.681193   -0.627500    0.115736 
17          6           0       -2.668387   -0.875992    1.157067 
18          1           0       -2.237037   -1.526280    1.924760 
19          1           0       -3.594935   -1.348278    0.781637 
20          1           0       -2.936019    0.071138    1.634930 
21          6           0        2.653376   -0.961162    0.231904 
22          1           0        2.909260   -0.825303    1.292949 
23          1           0        2.994965   -1.959457   -0.080035 
24          8           0        3.256253    0.062504   -0.566125 
25          1           0        4.126360    0.261215   -0.189190 
26          8           0       -0.414767    2.605131    0.252404 
27          1           0       -0.133091    2.472034    1.181373 
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